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A B S T R A C T
Background
Malignant pleural e)usion (MPE) is a common problem for people with cancer and usually associated with considerable breathlessness.
A number of treatment options are available to manage the uncontrolled accumulation of pleural fluid, including administration of a
pleurodesis agent (via a chest tube or thoracoscopy) or placement of an indwelling pleural catheter (IPC). This is an update of a review
published in Issue 5, 2016, which replaced the original, published in 2004.
Objectives
To ascertain the optimal management strategy for adults with malignant pleural e)usion in terms of pleurodesis success and to quantify
di)erences in patient-reported outcomes and adverse e)ects between interventions.
Search methods
We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and three other databases to June 2019. We screened reference lists from other
relevant publications and searched trial registries.
Selection criteria
We included randomised controlled trials of intrapleural interventions for adults with symptomatic MPE, comparing types of sclerosant,
mode of administration and IPC use.
Data collection and analysis
Two review authors independently extracted data on study design, characteristics, outcome measures, potential e)ect modifiers and risk
of bias.
The primary outcome was pleurodesis failure rate. Secondary outcomes were adverse events, patient-reported breathlessness control,
quality of life, cost, mortality, survival, duration of inpatient stay and patient acceptability.
We performed network meta-analyses of primary outcome data and secondary outcomes with enough data. We also performed pair-wise
meta-analyses of direct comparison data. If we deemed interventions not jointly randomisable, or we found insu)icient available data,
we reported results by narrative synthesis. For the primary outcome, we performed sensitivity analyses to explore potential causes of
heterogeneity and to evaluate pleurodesis agents administered via a chest tube only.
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We assessed the certainty of the evidence using GRADE.
Main results
We identified 80 randomised trials (18 new), including 5507 participants. We found all except three studies at high or unclear risk of bias
for at least one domain. Due to the nature of the interventions, most studies were unblinded.
Pleurodesis failure rate
We included 55 studies of 21 interventions in the primary network meta-analysis. We estimated the rank of each intervention's
e)ectiveness. Talc slurry (ranked 6, 95% credible interval (Cr-I) 3 to 10)  is an e)ective pleurodesis agent (moderate certainty for comparison
with placebo) and may result in fewer pleurodesis failures than bleomycin and doxycycline (bleomycin versus talc slurry: odds ratio (OR)
2.24, 95% Cr-I 1.10 to 4.68; low certainty; ranked 11, 95% Cr-I 7 to 15; doxycycline versus talc slurry: OR 2.51, 95% Cr-I 0.81 to 8.40; low
certainty; ranked 12, 95% Cr-I 5 to 18).
There is little evidence of a di)erence between the pleurodesis failure rate of talc poudrage and talc slurry (OR 0.50, 95% Cr-I 0.21 to 1.02;
moderate certainty). Evidence for any di)erence was further reduced when restricting analysis to studies at low risk of bias (defined as
maximum one high risk domain in the risk of bias assessment) (pleurodesis failure talc poudrage versus talc slurry: OR 0.78, 95% Cr-I 0.16
to 2.08).
IPCs without daily drainage are probably less e)ective at obtaining a definitive pleurodesis (cessation of pleural fluid drainage facilitating
IPC removal) than talc slurry (OR 7.60, 95% Cr-I 2.96 to 20.47; rank = 18/21, 95% Cr-I 13 to 21; moderate certainty). Daily IPC drainage or
instillation of talc slurry via IPC are likely to reduce pleurodesis failure rates.
Adverse e)ects
Adverse e)ects were inconsistently reported. We performed network meta-analyses for the risk of procedure-related fever and pain.
The evidence for risk of developing fever was of low certainty, but suggested there may be little di)erence between interventions relative
to talc slurry (talc poudrage: OR 0.89, 95% Cr-I 0.11 to 6.67; bleomycin: OR 2.33, 95% Cr-I 0.45 to 12.50; IPCs: OR 0.41, 95% Cr-I 0.00 to 50.00;
doxycycline: OR 0.85, 95% Cr-I 0.05 to 14.29).
Evidence also suggested there may be little di)erence between interventions in the risk of developing procedure-related pain, relative to
talc slurry (talc poudrage: OR 1.26, 95% Cr-I 0.45 to 6.04; very-low certainty; bleomycin: OR 2.85, 95% Cr-I 0.78 to 11.53; low certainty; IPCs:
OR 1.30, 95% Cr-I 0.29 to 5.87; low certainty; doxycycline: OR 3.35, 95% Cr-I 0.64 to 19.72; low certainty).
Patient-reported control of breathlessness
Pair-wise meta-analysis suggests there is likely no di)erence in breathlessness control, relative to talc slurry, of talc poudrage ((mean
di)erence (MD) 4.00 mm, 95% CI –6.26 to 14.26) on a 100 mm visual analogue scale for breathlessness; studies = 1; participants = 184;
moderate certainty) and IPCs without daily drainage (MD –6.12 mm, 95% CI –16.32 to 4.08; studies = 2; participants = 160; low certainty).
Overall mortality
There may be little di)erence between interventions when compared to talc slurry (bleomycin and IPC without daily drainage; low
certainty) but evidence is uncertain for talc poudrage and doxycycline.
Patient acceptability
Pair-wise meta-analysis demonstrated that IPCs probably result in a reduced risk of requiring a repeat invasive pleural intervention (OR
0.25, 95% Cr-I 0.13 to 0.48; moderate certainty) relative to talc slurry. There is likely little di)erence in the risk of repeat invasive pleural
intervention with talc poudrage relative to talc slurry (OR 0.96, 95% CI 0.59 to 1.56; moderate certainty).
Authors' conclusions
Based on the available evidence, talc poudrage and talc slurry are e)ective methods for achieving a pleurodesis, with lower failure rates
than a number of other commonly used interventions.
IPCs provide an alternative approach; whilst associated with inferior definitive pleurodesis rates, comparable control of breathlessness
can probably be achieved, with a lower risk of requiring repeat invasive pleural intervention.
Local availability, global experience of agents and adverse events (which may not be identified in randomised trials) and patient preference
must be considered when selecting an intervention.
Further research is required to delineate the roles of di)erent treatments according to patient characteristics, such as presence of trapped
lung. Greater attention to patient-centred outcomes, including breathlessness, quality of life and patient preference is essential to inform
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clinical decision-making. Careful consideration to minimise the risk of bias and standardise outcome measures is essential for future trial
design.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for the management of fluid around the lungs (pleural fluid) caused by cancer
Review question
We reviewed the evidence on the e)ectiveness of di)erent methods to manage a build-up of fluid around the lungs in people where this
is caused by cancer. 
Background
Malignant pleural e)usion (MPE) is a condition that a)ects people with cancer of the lining of the lung. This can cause fluid to build up
in the space between the outside of the lungs and rib cage (pleural cavity), oGen resulting in breathlessness. Treatment options focus
on controlling symptoms. These include removal of the fluid using a temporary chest drain, a camera examination of the pleural cavity
(thoracoscopy) or a semi-permanent chest drain tunnelled under the skin (an indwelling pleural catheter). Introducing a chemical into the
pleural cavity can also be used to prevent the fluid coming back (pleurodesis). We wanted to find out which method was the most e)ective
for preventing fluid re-accumulation (pleurodesis failure) and which was best in terms of side e)ects (including pain and fever) and other
important outcomes such as breathlessness and quality of life.
Study characteristics
We collected and analysed relevant studies to answer this question. We were interested in high quality research, so only searched for
randomised controlled trials (in which participants are randomly allocated to the treatments being tested). We analysed most data
using  'network meta-analysis',  which allows lots of di)erent interventions to be compared in one analysis. This analysis ranks the
interventions in order of their e)ectiveness.
Certainty of the evidence
We rated the certainty of the evidence from studies using four levels: very low, low, moderate or high. Very low-certainty evidence means
that we are very uncertain about the results. High-certainty evidence means that we are very confident in the results. Many of the studies
were of low quality and the individual studies were quite di)erent to each other. This made it di)icult to reach definite conclusions.
Key results
From our searches in June 2019, we found 80 studies (18 new) involving 5507 participants (2079 new).
In the network meta-analysis, we found that giving talc through a chest tube aGer draining  the fluid (talc slurry) resulted in fewer
pleurodesis failures than other commonly used methods, such as the medicines doxycycline or bleomycin through a chest tube (low
certainty). Using a thoracoscopy procedure to remove the fluid and blow talc into the chest (talc poudrage) is likely to be as e)ective as
talc slurry (moderate certainty).
We had a low level of certainty that the risk of having a fever is similar between treatments. There may be little di)erence between
treatments in the chance of having pain (low certainty for bleomycin, IPCs and doxycycline; very-low certainty for talc poudrage).
Using an IPC, which allows intermittent drainage of fluid at home, may relieve breathlessness as much as a talc slurry procedure (low
certainty).
There may be little di)erence in the risk of death between treatments when compared to talc slurry (low certainty for bleomycin and IPC
without daily drainage; very low certainty for talc poudrage and doxycycline).
The chance of needing another invasive procedure to remove fluid was lower aGer having an IPC than aGer talc slurry pleurodesis (moderate
certainty).
Conclusions
The available evidence shows that talc poudrage and talc slurry are e)ective ways of managing MPEs, with lower pleurodesis failure
rates than a number of other commonly used methods. However, it is also important to consider global experience of these agents and
knowledge of their safety and side e)ects when selecting the most appropriate pleurodesis method.
IPCs are less likely to prevent pleural fluid from re-accumulating than talc slurry, but may be as good at helping breathlessness. People
who have an IPC are less likely to need another invasive procedure in the future to manage the pleural e)usion.
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Further research is required to look at particular patient groups and explore outcomes such as breathlessness and quality of life in more
detail. Ideally a fuller understanding of the potential harms of the treatments from the patients' perspective would also be beneficial.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Pleurodesis failure rate in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion
Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo 
Comparator (reference): talc slurry
Outcome: pleurodesis failure rate
Setting: inpatient and outpatients
Data: based on network meta-analysis of eligible studies
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(11 to 24)
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Talc poudrage
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(11 to 24)
10 failures per 100
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(4 to 19)
–8 (–15 to 0)
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(17 to 52)
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i.e. 15 more failures per
100 participants


























































































































































Follow-up: up to 24
months
IPC –not daily drainage
(6 RCTs, 405 partici-
pants)







18 failures per 100 par-
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(11 to 24)
62 failures per 100
participants
(36 to 82)
44 (20 to 63)





(5 RCTs, 117 partici-
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18 failures per 100 par-
ticipants
(11 to 24)
35 failures per 100
participants
(13 to 65)
17 (–3 to 46)
i.e. 17 more failures per
100 participants
Lowa,d May be infe-
rior
Placebo
(4 RCTs, 159 partici-
pants)







18 failures per 100 par-
ticipants
(11 to 24)
77 failures per 100
participants
(42 to 95)
59 (26 to 77)




Network meta-analysis summary of findings definitions:
*Information is reported from studies included in the network meta-analysis for pleurodesis failure.
**Network meta-analysis estimates are reported as ORs.
***Calculated using data from primary outcome network of pleurodesis failure.
Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. Cr-Is around 'differences' allow for sampling uncertainty in this baseline parameter, as well as uncertainty in the OR.
^^Network estimate from sensitivity analysis of studies at low risk of bias. These data are included within the summary of findings to reflect the ORs and Cr-Is from the net-
work estimates in which we have the greatest level of certainty in the evidence.
Cr-I: credible interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial.

























































































































































High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate in limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level: evidence of indirectness. Of the studies evaluating talc slurry, 13/19 excluded trapped lung and 12/19 used a clinical definition of pleurodesis success. Of
the studies in the network evaluating bleomycin, 9/21 excluded trapped lung and 12/21 used a clinical definition of pleurodesis success and variability in the dose of bleomycin
noted.
There was no direct evidence in the network comparing doxycycline and talc slurry and almost all indirect comparisons forming network loops were based on a single study.
bDowngraded one level for study limitations: overall high risk of bias for trials forming direct and indirect evidence loops for this agent.
cDowngraded one level: evidence of inconsistency: I2 statistic between talc slurry and IPC (not daily drainage) comparison 61%.
dDowngraded one level: evidence of imprecision. Wide Cr-Is reduce the certainty in the estimate e)ect.
 
 
Summary of findings 2.   Adverse eects: procedure-related fever in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion
Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo  
Comparator (reference): talc slurry
Outcome: fever
Setting: inpatient and outpatients
Data: based on network meta-analysis of eligible studies                                                            

















(9 RCTs; 823 participants)
Reference com-
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(4 RCTs; 553 participants)
0.89
(0.11 to 6.67)
21 cases in every 100 partici-
pants
(11 to 33)
19 cases in every 100 par-
ticipants (3 to 67)
2 (–21 to 43)
i.e. 2 fewer cases per 100
participants
Lowa,b May be com-
parable
Bleomycin




21 cases in every 100 partici-
pants
(11 to 33)
39 cases in every 100 par-
ticipants
(10 to 79)
17 (–10 to 55)
i.e. 17 more cases per 100
participants
Lowa,b May be com-
parable
 
IPC – not daily drainage
(1 RCT; 101 participants)
0.41
(0.00 to 50.00)
21 cases in every 100 partici-
pants
(11 to 33)
10 cases in every 100 par-
ticipants
(0 to 93)
–10 (–28 to 70)
i.e. 10 fewer cases per
100 participants
Lowa,b May be com-
parable
Doxycycline
(4 RCTs; 308 participants)
0.85
(0.05 to 14.29)
21 cases in every 100 partici-
pants
(11 to 33)
19 cases in every 100 par-
ticipants
(1 to 80)
–2 (–23 to 56)
i.e. 2 fewer cases per 100
participants




(2 RCTs; 118 participants)
0.09
(0.00 to 5.00)
21 cases in every 100 partici-
pants
(11 to 33)
2 cases in every 100 par-
ticipants
(0 to 59)
–17 (–30 to 36)
i.e. 17 fewer cases per
100 participants
Lowa,b May be com-
parable
 
Network meta-analysis summary of findings definitions:
*Information is reported from studies included in the network meta-analysis for fever.
**Network meta-analysis estimates are reported as odds ratios.
***Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control. group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. Cr-Is around 'differences' allow for sampling uncertainty in this baseline parameter, as well as uncertainty in the OR.
Cr-I: credible interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial.
GRADE Working Group grades of evidence (or certainty in the evidence):
High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.

























































































































































Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. 
aDowngraded one level for imprecision due to wide credible intervals of all network estimates.
bDowngraded one level for indirectness: due to the nature of outcome (presence/absence of procedure-related fever) this was commonly reported as an adverse event and so




Summary of findings 3.   Adverse eects: procedure-related pain in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion
Interventions: talc poudrage, bleomycin IPC – not daily drainage, doxycycline, placebo
Comparator (reference): talc slurry
Outcome: procedure-related pain
Setting: inpatient and outpatient      
Data: based on network meta-analysis of eligible studies 




















8 out of every 100 participants
experiencing pain
(1 to 35)
Not estimable Not estimable Lowa,b Reference
comparator
Talc poudrage




8 out of every 100 participants
experiencing pain
(1 to 35)

















8 out of every 100 participants
experiencing pain
(1 to 35)



































































































































































IPC – not daily
drainage




8 out of every 100 participants
experiencing pain
(1 to 35)








Lowa,b May be com-
parable
Doxycycline




8 out of every 100 participants
experiencing pain
(1 to 35)








Lowa,b May be com-
parable
Placebo 3 studies reported data for procedure-related pain in participants receiving placebo but could not be includ-
ed in the network as no events occurred in each study arm, causing computational problems. 1 study com-
pared placebo with talc slurry and reported 0/17 participants receiving placebo and 0/14 receiving talc slurry
required analgesia post procedure (Sorensen 1984).
— —
Network meta-analysis summary of findings definitions:
*Information is reported from studies included in the network meta-analysis for pain.
**Network meta-analysis estimates are reported as odds ratios. Cr-I: credible interval.
***Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. Cr-Is around 'differences' allow for sampling uncertainty in this baseline parameter, as well as uncertainty in the OR.
Cr-I: credible interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial.
GRADE Working Group grades of evidence (or certainty in the evidence):
High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate in limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.


























































































































































bDowngraded one level for indirectness. Due to the nature of outcome (presence/absence of procedure-related pain), this was commonly reported as an adverse event and so
the time point at which measured, threshold for reporting and mode of assessment is oGen unstated and likely to di)er between studies.
cDowngraded one level for inconsistency in the talc poudrage to talc slurry comparison (I2 = 69%).
 
 
Summary of findings 4.   Patient-reported control of breathlessness in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion
Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo
Comparator (reference): talc slurry
Outcome: postintervention patient-reported control of breathlessness?
Setting: inpatient and outpatient
Data: based on direct meta-analysis of 100-mm VAS breathless score
Anticipated absolute effect****


















Not estimable Moderatea Reference
comparator
Talc poudrage











(1 RCT, 35 participants)
1 study assessed breathlessness by functional class score (numerical scale 1–4, where 1 = none and 4 =
breathless at rest) and found no difference between talc slurry and bleomycin (Zimmer 1997).
Very lowc,d,e Uncertain
IPC –not daily drainage
(2 RCTs, 160 participants)



































































































































































Doxycycline There was no direct evidence comparing talc slurry and doxycycline — —
Placebo There were no data reported on breathlessness improvement in people receiving placebo — —
Direct meta-analysis summary of findings definitions:
*Information is included from direct meta-analysis of studies using a 100-mm VAS breathlessness scale.
**The minimum clinically important difference for dyspnoea in malignant pleural effusion using the VAS breathlessness scale was 19 mm (95% CI 14 to 24) (Mishra 2015).
***Direct meta-analysis results are reported as standardised mean difference.
****Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. 
CI: confidence interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial; VAS: visual analogue scale.
GRADE Working Group grades of evidence (or certainty in the evidence):
High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate in limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for study limitations: lack of blinding of participants and clinicians (due to nature of trial interventions) leading to increased risk of bias in VAS score
reporting.
bDowngraded one level: evidence of indirectness: di)erent time points at which the VAS dyspnoea scores were measured (Davies 2012: 42 days, Thomas 2017: 180 days).
cDowngraded one level for study limitations due to lack of blinding of participants and clinicians.
dDowngraded one level for indirectness: participants were assessed before and 'aGer treatment' with no longer-term breathlessness outcomes. A functional scale was used to
assess breathlessness on a 1–4 scale, whereas other studies used a 100 mm VAS scale.
eDowngraded one level for imprecision due to low numbers of participants.
 
 
Summary of findings 5.   Overall mortality in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion


























































































































































Comparator (reference): talc slurry
Outcome: mortality
Setting: inpatient and outpatient      
Data: based on network meta-analysis of eligible studies                                                            
Anticipated absolute effect (95% Cr-I)***Total studies: 31*
Total participants: 2816















(13 RCTs, 1574 participants)
Follow-up: up to 12 months
Reference
comparator
31 deaths out of every 100
participants
(14 to 55)
Not estimable Not estimable Lowa,b Reference
comparator
Talc poudrage
(7 RCTs, 878 participants)
Follow-up: up to 10  months
0.87
(0.53 to 1.43)
31 deaths out of every 100
participants
(14 to 55)
28 deaths out of every
100 participants
(11 to 55)
–3 (–12 to 8)
i.e. 3 fewer deaths per 100
participants





(9 RCTs, 664 participants)
Follow-up: up to 9 months
1.03
(0.45 to 2.41)
31 deaths out of every 100
participants
(14 to 55)





i.e. 1 additional death per
100 participants
Lowa,b May be com-
parable
IPC – not daily drainage
6 RCTs, 587 participants
Follow-up: up to 12 months
0.80
(0.47 to 1.40)
31 deaths out of every 100
participants
(14 to 55)





i.e. 4 fewer deaths per 100
participants
Lowa,b May be com-
parable
Doxycycline




31 deaths out of every 100
participants
(14 to 55)


































































































































































i.e. 6 fewer deaths per 100
participants
 
Placebo No studies reported mortality data for participants receiving placebo — —
Network meta-analysis summary of findings definitions:
*Information is reported from studies included in the network meta-analysis for mortality.
**Network meta-analysis estimates are reported as ORs.
***Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. Cr-Is around 'differences' allow for sampling uncertainty in this baseline parameter, as well as uncertainty in the OR
Cr-I: credible interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial.
GRADE Working Group grades of evidence (or certainty in the evidence):
High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate in limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level for imprecision due to wide credible intervals of all network estimates.
bDowngraded one level for indirectness due to di)erent time points at which mortality was assessed (range 30 days to 12 months).
In the talc poudrage to talc slurry comparison 3/7 RCTs included only people with breast cancer.
cDowngraded one level for inconsistency in the talc poudrage to talc slurry comparison (I2 = 40%).
dDowngraded one level for study limitations in the doxycycline to talc slurry comparison, where direct evidence is formed from one study at high risk of bias in three domains.
 
 
Summary of findings 6.   Patient acceptability: need for repeat invasive pleural intervention in adults with malignant pleural eusion
Patient or population: adults with malignant pleural effusion
Interventions: talc poudrage, bleomycin, IPC – not daily drainage, doxycycline, placebo
Comparator (reference): talc slurry


























































































































































Setting: inpatient and outpatient      
Data: based on available direct evidence*























Not estimable Not estimable Moderatea,b Reference
comparator
Talc poudrage













–1 out of every 100 participants
(–7 to +8)




(1 RCT, 33 participants)









52 out of every 100
participants
(4 to 97)
+32 out of every 100 participants
(–16 to 77)
i.e. 32 more repeat procedures
required per 100 participants
Very lowd,e May be inferi-
or but the ev-
idence is un-
certain
IPC –not daily drainage









6 out of every 100
participants
(3 to 11)
–14 out of every 100 participants
 (–19 to –8)
i.e. 14 less per 100 participants
Moderatea,b Probably su-
perior
Doxycycline There were no direct data comparing doxycycline and talc slurry. — —
Placebo There were no direct data comparing placebo and talc slurry. — —
Direct meta-analysis summary of findings definitions:
*Based on direct meta-analysis.


























































































































































***Anticipated absolute effect: compares two risks by calculating the difference between the risk of the intervention group with the risk of the control group.
'Absolute effect' and 'difference' estimates are posterior medians from a Bayesian statistical analysis. These may not sum exactly, due to skew in the posterior distributions.
^Reference comparator absolute event rate estimates are based on a random-effects meta-analysis of arm-level data from all trials including a talc slurry arm and reporting
the relevant outcome. 
CI: confidence interval; IPC: indwelling pleural catheter; OR: odds ratio; RCT: randomised controlled trial.
GRADE Working Group grades of evidence (or certainty in the evidence):
High certainty: we are very confident that the true effect lies close to that of the estimate effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate in limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level: evidence of indirectness: people with trapped lung excluded by Thomas 2017, but not Boshuizen 2017 or Davies 2012.
bStudy limitations noted as blinding of participants and clinicians was not possible due to nature of the interventions. Evidence was not downgraded, as requirement for repeat
procedural intervention guided by symptoms and radiology. In one study, clinicians were required to discuss with a second, blinded clinician prior to repeat intervention in
participants with less than one-third opacification of the hemithorax (Bhatnagar 2020).
cDowngraded one level: evidence of indirectness: one study gave 5 g 'non-calibrated' talc via 28-Fr drains in both study arms (Terra 2009), whereas in Bhatnagar 2020 4 g graded
talc used and administered by 12- to 14-Fr drains in talc slurry arm (size 16- to 24-Fr drains placed in talc poudrage arm).
dDowngraded one level: study limitations: bleomycin data derived from one study, at high risk of bias in three domains and 'unclear' risk of bias for randomisation and sequence
generation.
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B A C K G R O U N D
Malignant pleural e)usion (MPE) is a common clinical problem,
with an estimated annual incidence of at least 150,000 in the
USA (American Thoracic Society 2000). FiGeen percent of people
diagnosed with cancer will develop pleural e)usion during the
course of their disease as a result of malignant infiltration of
the pleura. It oGen confers a poor prognosis (Rodrîguez-Panadero
1989). Breathlessness results from compression of the underlying
lung and impaired diaphragmatic and chest wall movement and is
oGen relieved by pleural fluid aspiration.
This is the first update of the review published in Issue 5, 2016 (Clive
2016), which replaced the original review published in 2004 (Shaw
2004).
Description of the condition
MPE is a condition whereby excess fluid accumulates in the pleural
cavity. It is thought to be  caused by a combination of direct
pleural tumour invasion, resulting in increased permeability of
the pleural microvessels and obstruction of local lymph drainage
channels causing reduced fluid re-absorption (Rodrîguez-Panadero
2008). The most common primary sites which metastasise to
the pleura are lung cancer in men and breast cancer in
women, but other primary sites include lymphoma, genitourinary
and gastrointestinal malignancy (DiBonito 1992; Sears 1987). In
addition, the pleura may be the primary site of the malignancy,
as is the case in mesothelioma. In the majority of cases, the
diagnosis of pleural malignancy is made by cytological analysis
of the pleural fluid or pleural biopsy. Depending on the clinical
situation, confirmation of malignancy elsewhere and an otherwise
unexplained (usually exudative) e)usion may also be attributed to
malignancy. Survival of these patients varies widely (Bielsa 2008;
Burrows 2000). Tools have been developed to aid estimation of an
individual's prognosis, which may in turn help with selection of
the most appropriate management strategy (Clive 2014; Psallidas
2018).
Description of the intervention
A number of di)erent approaches may be used to manage
MPE and the chosen method is likely to depend on clinical
factors, patient preferences and local availability of the various
techniques. Instillation of a sclerosant into the pleural cavity
through an intercostal chest drain, aGer complete fluid  drainage
has been the mainstay of treatment for many years (known as
'bedside' or 'slurry' pleurodesis). This technique aims to fuse the
pleural layers together by means of local inflammation induced
by the pleurodesis agent, thereby preventing pleural fluid re-
accumulation. The optimal management strategy to maximise
pleurodesis success in terms of the size of chest drain, patient
positioning, use of analgesia and type of sclerosant has historically
been the subject of debate (Roberts 2010).
Thoracoscopy is a method which can be used to drain an e)usion
and, during the same procedure, deliver a sclerosant into the
pleural cavity with a view to achieving pleurodesis (Rahman 2010).
Thoracoscopy can either be performed under moderate sedation
(medical thoracoscopy), or as a surgical procedure under general
anaesthetic (video-assisted thoracoscopic surgery (VATS)). In both
techniques, the pleural fluid is drained and the pleural cavity is
visualised using a fibreoptic camera. Loculations can be broken
down and biopsies may be taken to gain a histological diagnosis. At
the end of the procedure, a temporary chest tube is leG in place to
allow the lung to re-expand.
An alternative approach in the management of MPE is the use
of indwelling pleural catheters (IPCs). These are long-term chest
tubes  which are tunnelled under the skin and therefore allow
regular, intermittent fluid drainage to be performed in the
community, potentially minimising recurrent hospital attendances.
They have an established role in the management of pleural
e)usions in people with trapped lung, but are increasingly being
used for the primary management of malignant e)usions as an
alternative to chemical pleurodesis (Davies 2012; Demmy 2012;
Thomas 2017). Spontaneous pleurodesis may occur, allowing the
drain to be removed without recurrence of the e)usion (Tremblay
2006).
In certain clinical scenarios, none of the above options may
be suitable and simple pleural fluid aspiration or medical
management of a patient's breathlessness (e.g., using opiates) may
be deemed more appropriate. This may be the case for people in
the terminal phase of their illness where invasive techniques may
be considered to confer unnecessary discomfort.
How the intervention might work
Pleurodesis aims to induce inflammation between the pleural
layers causing them to become adhered. This e)ectively obliterates
the pleural space and by  so doing, prevents fluid recurrence.
For pleurodesis to be successful, the visceral and parietal pleural
surfaces must be opposed, hence if lung expansion is incomplete,
pleurodesis is more likely to fail.
Trapped lung (also known as 'entrapped' or 'non-expandable'
lung) can occur when full lung expansion is limited by either a
visceral pleural peel or endobronchial obstruction. In this situation,
even once the fluid is drained, visceral and parietal pleural
apposition does not readily occur, with attempts at inflating the
lung potentially distressing for patients. This results in pleurodesis
attempts being less e)ective and oGen limits the treatment options
to either an IPC or surgery.
IPCs allow regular, intermittent pleural fluid drainage, which
relieves the pressure on the diaphragm and chest wall, and
promotes lung re-expansion. By so doing, breathlessness is
improved and, in a small proportion of people, autopleurodesis
may occur (Dipper 2019).
Why it is important to do this review
Due to wider availability of pleural interventions, such as
thoracoscopy under sedation and IPCs, the management options
available to people with MPE are expanding. This review will
help to define the most e)ective pleurodesis approach, primarily
addressing the type of agent used.
Given the availability of many pair-wise comparisons for the
method of pleurodesis administration, type of pleurodesis agent
and approaches to IPC use, this is a multiple interventions review.
We performed network meta-analysis (NMA) to synthesise all the
available evidence and determine a treatment hierarchy.
In 2019, the National Institute for Health and Care Excellence
(NICE) in the UK commissioned the priority updating of this review
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)
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to inform the guideline Lung cancer: diagnosis and management
[NG122] (NICE 2019).
O B J E C T I V E S
To ascertain the optimal management strategy for adults with
malignant pleural e)usion in terms of pleurodesis success and
to quantify di)erences in patient-reported outcomes and adverse
e)ects between interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included reports of randomised controlled trials (RCTs) in this
review. This included randomised cross-over trials and cluster
randomised trials, although we did not identify any studies of
these types. We included both single- and multicentre studies. We
excluded studies that were stated to be randomised, but were at




• Adults over the age of 16 years.
• Symptomatic pleural e)usion resulting from an underlying
malignant process (of any type and stage).
Exclusion
• Studies recruiting both malignant and non-malignant
participants with no clear distinction between the two groups in
the results section.
• Studies evaluating the e)ect of a drug administered via any
method other than the intrapleural route.
• Studies including participants with e)usions within a variety
of body cavities (e.g. pleural, peritoneal, pericardial), where
the e)ect of the treatments in the subgroup of participants
with pleural e)usions could not be distinguished in the results
section.
Types of interventions
We identified studies comparing the following.
• Type of sclerosant.
• Mode of administration of sclerosant (thoracoscopic
pleurodesis and bedside pleurodesis).
• Bedside or thoracoscopic pleurodesis and IPC insertion.
• Techniques used to optimise pleurodesis success rate, namely:
* chest drain size;
* type of analgesia given;
* duration of drainage aGer instillation of sclerosant;
* patient positioning aGer pleurodesis (e.g. patient rotation);
* use of intrapleural fibrinolytics;
* methods to optimise IPC use including IPC drainage regimen
and combined talc administration via IPC.
We generated a network of interventions, including comparisons
between the types of sclerosant, mode of administration and
IPC use. We assumed that any participant meeting the inclusion
criteria could be, in principle, randomised to any of the eligible
interventions. This is referred to as the interventions being 'jointly
randomisable'. However, if we considered an intervention was not
jointly randomisable, for example the treatment was specific to a
certain tumour type, we reported the results separately from the
network (Salanti 2012).
Interventions of direct interest
We included RCTs that evaluated one or more of the
following intrapleural interventions: talc poudrage, talc slurry,
bleomycin, tetracycline, doxycycline, iodine, C parvum, IPC (both
daily drainage and without daily drainage), talc administered
via IPC, mitoxantrone, mustine, mepacrine, interferon,
triethylenethiophosphoramide and adriamycin  compared with
another intervention or placebo. If we identified other sclerosants
that we were not aware of, we considered them as eligible and
included them in the network aGer assessing their comparability
with the prespecified set of competing interventions. We reported
the findings for these interventions in the results and the
conclusions of the review.
Types of outcome measures
Primary outcomes
E)icacy of pleurodesis was our primary outcome measure.
Definitions of pleurodesis failure varied between studies and
although current practice would define this by a lack of recurrence
of symptoms or need for a repeat pleural intervention to manage
the e)usion, some older studies used less clinically relevant
definitions (e.g. re-accumulation of e)usion on imaging). We still
included these studies in the review, and documented the method
used to define pleurodesis for all studies in the assessment of the
risk of bias.
For the purposes of the primary outcome, we used the following
hierarchy of preferences to judge pleurodesis failure (if a study
reported more than one definition of pleurodesis failure, the
highest of these according to this hierarchy was used):
• need for a repeat pleural procedure to manage recurrence of the
e)usion, or continued drainage of pleural fluid from an IPC (if
applicable);
• evidence of significant pleural fluid re-accumulation on
radiological imaging (e.g. chest X-ray or ultrasound);
• pleurodesis failure in the opinion of the trial investigators.
For studies evaluating IPCs, we judged that an e)ective pleurodesis
was achieved when there was cessation of pleural fluid drainage or
device removal due to cessation of drainage, or both.
Similarly, we selected the time point used to define pleurodesis
e)icacy using the following hierarchy of preferences:
• 2 - 4 months;
• more than 4 - 7 months;
• more than 7 - 11 months;
• more than 11-12 months;
• less than 2 months;
• more than 12 months.
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)
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For participants who died before the time point at which
pleurodesis e)icacy was assessed, we classified these according to
their last known pleurodesis outcome prior to their death (i.e. their
last observation carried forward). If these data were not provided,
we used the available reported data.
Secondary outcomes
• Adverse e)ects  and complications due to interventions,
specifically the presence or absence of pain and fever aGer the
intervention.
• Patient-reported control of breathlessness, as measured by
a valid and reliable scale (e.g. visual analogue scale (VAS),
numerical rating scale or dyspnoea/breathlessness-specific
multidimensional scale).
• Participants' quality of life and symptom control (including
pain), measured by a valid and reliable scale.
• Relative costs of the comparative techniques as reported by the
individual trials. For ease of comparison, data reported in other
currencies were converted to USD.
• Overall mortality (we used the data for the reported outcomes
closest to three months).
• Median survival.
• Duration of inpatient stay in days (both total length of stay and
from time of intervention until discharge).
• Patient acceptability of the interventions as judged by a
valid scale (e.g. VAS or numerical rating scale). Within this,
we included the need for repeat invasive pleural intervention.
Search methods for identification of studies
Trials that compared at least two of the interventions (including
placebo) were eligible. We included all possible comparisons
formed by the interventions of interest.
Electronic searches
To identify studies for inclusion in this review, we searched the
following databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) (the
Cochrane Library) 2019, Issue 5;
• MEDLINE (Ovid) 1948 to 24 June 2019;
• Embase (Ovid) 1974 to week 25 2019;
• CINAHL (EBSCO) 1980 to June 2019;
• Web of Science Science Citation Index Expanded (SCI-
EXPANDED) and Social Sciences Citation Index (SSCI) searched
to 2015. (Due to a change in library provision we did not have
access beyond 2015.)
The search strategies can be viewed in Appendix 1. There were no
language restrictions. We included single and multicentre studies.
Searching other resources
We screened the reference lists from the included studies for
additional publications. We searched the reference lists from
relevant chapters in key resources, such as the British Thoracic
Society Pleural Disease Guidelines (Roberts 2010). We searched
clinicaltrials.gov (www.clinicaltrials.gov), and the World Health
Organization International Clinical Trials Registry Platform (ICTRP)
(apps.who.int/trialsearch/) for ongoing trials.
Data collection and analysis
Selection of studies
One author screened all titles and abstracts retrieved by the search
for relevance (AOC). For the 2020 update, this was performed by two
authors (AOC and AD) using the Covidence platform. We identified
potentially eligible studies and obtained the full papers. Two review
authors (AOC and NAM or AD) independently assessed each full text
for inclusion in the review and resolved any disagreement through
discussion or by a third review author (NP).
Data extraction and management
Two review authors (two of AOC, RB, NP and NAM up to 2016; two
of AOC, AD and RB; and NP and NAM from 2016 to 2020) extracted
data from each included study.
We resolved disagreements through discussion and referral to one
of the other review authors. If a review author was involved in one
of the included studies, they did not perform the data extraction for
that study. Data collected included the following.
• Publication details including:
* title, author(s), date, country and other citation details;
* study aim and design;
* study funding sources and author declarations of conflicts of
interest;
* primary and secondary outcomes;
* number of participants randomised.
• Details of the interventions and comparison group including
type of intervention, duration, dose, mode of administration
and number of doses.
• Primary and secondary outcomes (as detailed in Primary
outcomes; Secondary outcomes), and data on adverse
e)ects and complications.
• Assessment of the study's risk of bias.
• Data on potential e)ect modifiers including the following study
and participant characteristics:
* how pleurodesis was defined (radiology only or including
clinical need as well as radiology);
* whether people with trapped lung were included or not;
* size of the chest tube through which bedside pleurodesis
was administered (defined as small (less than 20-French (Fr)),
large (20-Fr or greater) or unknown);
* time point at which pleurodesis was defined;
* tumour types included in the study.
We requested additional data from the study authors as required.
One review author (AOC or AD) entered outcome data suitable for
pooling into Cochrane's statistical soGware (RevMan Web). Where
we performed a NMA, we transferred data to the WinBUGS soGware
(Lunn 2000).
Assessment of risk of bias in included studies
We limited inclusion to studies that were randomised as a
minimum. Two review authors (two of AOC, RB, NP and NAM
up to 2016; two of AOC, AD, RB, NP and NAM from 2016 to
2020) independently assessed risk of bias for each study, using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a), with any disagreements resolved
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by discussion. In our original protocol, we had planned to include
sample size in our risk of bias assessment. However, in view of
Cochrane guidance stating imprecision should not be considered a
risk of bias, we did not perform this assessment (Higgins 2011a). We
assessed the following for each study.
Random sequence generation (checking for possible selection
bias)
We assessed the method used to generate the allocation sequence
as: low risk of bias (any truly random process, e.g. random
number table; computer random-number generator); unclear risk
of bias (method used to generate sequence not clearly stated). We
excluded studies using a non-random process, that is, at high risk
of bias (e.g. odd or even date of birth; hospital or clinic record
number).
Allocation concealment (checking for possible selection bias)
The method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could have
been foreseen in advance of, or during, recruitment, or changed
aGer assignment. We assessed the methods as: low risk of bias
(e.g. telephone or central randomisation; consecutively numbered
sealed opaque envelopes); unclear risk of bias (method not clearly
stated). We excluded studies at high risk of bias that did not conceal
allocation (e.g. open list).
Blinding of participants and personnel (checking for possible
performance bias)
We assessed the methods used to blind study participants and
personnel from knowledge of which intervention a participant
received. We assessed the methods as: low risk of bias (study stated
there was blinding of participants and key study personnel and
unlikely blinding could be broken, or no blinding or incomplete
blinding but the outcome not likely to be influenced by lack of
blinding); unclear risk of bias (insu)icient information to permit
judgement of low or high risk of bias); high risk of bias (no blinding
or incomplete blinding, which is likely to influence the trial outcome
or blinding attempted but likely it could have been broken and the
outcome is likely to be influenced by lack of blinding).
Blinding of outcome assessment (checking for possible detection
bias)
We assessed the methods used to blind outcome assessors
from knowledge of which intervention a participant received. We
assessed the methods as: low risk of bias (study stated that it
was not blinded but the review authors judged that the outcome
measurement was not likely to be influenced by lack of blinding or
blinding of outcome assessment was ensured); unclear risk of bias
(study provided an inadequate description to permit judgement
of low risk or high risk); high risk of bias (no blinding of outcome
assessment and outcome likely to be influenced by lack of blinding,
or there was blinding of the outcome assessment but likely that the
blinding could have been broken).
Incomplete outcome data (checking for possible attrition bias
due to the amount, nature and handling of incomplete outcome
data)
We assessed the methods used to deal with loss to follow-up (LTFU)
for each of the given studies. Due to the challenges of inevitable
missing outcome data given the predictable attrition of patients
due to death in the palliative care population, we took into account
whether missing data had been justified, whether the rate was
similar in the di)erent treatment arms, whether the treatment
being evaluated was felt to have an impact on the degree of missing
outcome data and whether an intention-to-treat (ITT) analysis
had been attempted. We assessed the methods used to deal with
incomplete data as: low risk (rate of missing data were balanced
between the treatment arms, seemed reasonable and had been
justified; data had been analysed according to the participants'
randomised treatment allocation; a suitable imputation method
may have been used to account for missing data); unclear risk of
bias (insu)icient information given to allocate trial to high- or low-
risk group); high risk of bias (imbalanced missing outcome data
between the treatment arms or missing outcome data felt to be
related to the true outcome; reasons for LTFU poorly justified; no
attempt at ITT analysis; inappropriate imputation used).
Selective outcome reporting
We assessed the studies for selective outcome reporting using the
following criteria: low risk of bias (all outcomes predefined and
reported, e.g. in a published protocol, or all clinically relevant
and reasonably expected outcomes were reported); uncertain risk
of bias (unclear whether all predefined and clinically relevant
outcomes were reported); high risk of bias (one or more clinically
relevant and reasonably expected outcome was not reported and
data on these outcomes were likely to have been recorded).
Other sources of bias
This section was used to report other biases, which were detected
but did not fit into the above categories (e.g. industry bias,
academic bias or other methodological flaws that may have caused
bias). We assessed the methods used to deal with other sources of
bias as: low risk of bias (the trial appeared free from other potential
biases); unclear risk of bias; high risk of bias (other source of bias
was identified).
Measures of treatment eect
Relative treatment e%ects
For proportions (dichotomous outcomes), such as pleurodesis
e)icacy and mortality, we calculated the odds ratio (OR) with 95%
confidence intervals (CIs). For continuous data (such as length of
hospital stay and cost), we planned to use the mean di)erence (MD)
with 95% CIs and the number needed to treat for an additional
beneficial e)icacy outcome (NNTB), and the number needed to
treat for an additional harmful outcome (NNTH) for adverse e)ects.
We planned to treat ordinal outcome measures (e.g. breathlessness
scales and quality of life data) as continuous so long as the scale
was su)iciently long. If di)erent scales were used by the included
studies, we planned to use the standardised mean di)erence (SMD)
in meta-analyses.
We presented results from both pair-wise standard meta-analysis
(both random and fixed e)ect) and NMA (random e)ects only) as
summary relative e)ect sizes (OR, MD or SMD with 95% CIs) for each
possible pair of treatments (Deeks 2011).
Relative treatment ranking
Based on the results of the NMA, we estimated the rank of each
competing intervention's e)ectiveness. We presented estimated
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ranks (medians) with 95% credible intervals (Cr-Is) (representing
uncertainty about the true rank) produced from the Bayesian
analyses (Higgins 2011b).
Unit of analysis issues
If repeated observations on the same participants occurred during
the trial (e.g. pleurodesis success rate at di)erent time points),
we analysed these separately. We used only one measure per
participant for the primary endpoint (according to the hierarchy of
preferences detailed above Primary outcomes).
For the purpose of meta-analysis, if a study had multiple doses
for a certain substance, we combined and compared all relevant
experimental intervention groups with the combination of all
relevant control groups. We reported any evidence for e)ects of the
di)erent doses descriptively.
For cross-over trials, we planned to analyse data using pair-wise
meta-analysis, taking into account the cross-over design. If meta-
analysis had been performed containing cluster randomised trials
and the presented results had not accounted for clustering, then we
planned to make an appropriate adjustment, as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b).
We treated multi-arm studies as multiple independent two-arm
studies in the standard pair-wise meta-analysis. In the NMA, we
accounted for the correlation between the e)ect sizes from multi-
arm studies.
In meta-analysis of continuous outcomes, we pooled di)erences
in change from baseline, rather than di)erences in final values
(Higgins 2019).
Dealing with missing data
We attempted to contact the authors of included studies to clarify
any missing data.
We imputed missing standard deviations (SD) based on the mean
SDs from the other included studies if SDs for mean scores had
not been reported and it had not been possible to obtain the
information from the study authors. We only included data for
those participants whose results were known if an ITT analysis
was not reported by the study. However, we assessed the potential
impact of these missing data in the 'Risk of bias' table.
For continuous outcomes, where baseline and final values were
reported without a SD of change score or correlation coe)icient, we
imputed correlation coe)icients based on other studies in order to
estimate the SD of change.
Assessment of heterogeneity
Assessment of clinical and methodological heterogeneity within
treatment comparisons
We extracted data from study reports regarding clinical
heterogeneity such as details on the intervention and
control treatments, participant characteristics and the outcomes
evaluated.
We assessed the presence of clinical heterogeneity within
each pair-wise comparison by comparing the study population
characteristics across all eligible trials. We only performed meta-
analysis when considered reasonable based on the degree of
heterogeneity.
Assessment of transitivity across treatment comparisons
We assessed the assumption of transitivity by comparing the
distribution of the potential e)ect modifiers across the di)erent
pair-wise comparisons (Jansen 2013).
Assessment of reporting biases
We performed searches in multiple databases to ensure all
potentially eligible studies were identified (Electronic searches).
The review authors were alert to duplicated publication of results
when analysing the studies to ensure each participant was only
included once in the analysis.
If unpublished studies were identified, we tried to obtain su)icient
information in order for them to be included in the analysis. The
same applied for data published in abstract format.
In studies published in a language other than English, we made
every e)ort to obtain a translation of at least the abstract. If
su)icient information was available, we included the study in the
analysis.
Data synthesis
Methods for direct treatment comparisons
Since we expected some clinical heterogeneity between studies
(e.g. due to di)erent definitions of pleurodesis success, di)erent
time points and doses used), we believed that the assumption of a
single fixed intervention e)ect across included studies was unlikely
to be valid. Our primary analyses therefore employed random-
e)ects models. Since pooled e)ect estimates from random-
e)ects models give relatively more weight to smaller studies,
which is oGen considered undesirable, we performed sensitivity
analyses using fixed-e)ect meta-analysis models. We performed
standard pair-wise meta-analysis using a random-e)ects model in
Cochrane's statistical soGware, RevMan Web, for every treatment
comparison with two or more studies.
For binary outcome data, we meta-analysed ORs. For continuous
data, we planned to use the MD or SMD and perform a check to
identify if continuous outcome data were skewed. If this was the
case, we planned to analyse the data on a log scale. If we assessed
studies as unsuitable for meta-analysis, or insu)icient studies were
identified for meta-analysis to be performed, we planned to present
data by means of a narrative synthesis. If su)icient data were
available, we used similar analysis methods to analyse the adverse
e)ects data. Alternatively, we summarised this qualitatively.
Methods for indirect and mixed comparisons
Wherever possible, we performed a multiple-intervention, NMA of
primary and (separately) of each secondary outcome measure. We
used a Bayesian random-e)ects model, fitted using the WinBUGS
soGware (Dias 2018; Lunn 2000). We assumed binomial likelihoods
for count data, and modelled log ORs as random e)ects across
studies. We assigned vague prior distributions with mean 0 and
SD of 100 to all mean log ORs and to baseline event rates in each
study on the logit scale. We assumed a common between-studies
SD within a network, represented by the parameter Tau which was
assigned a Uniform (0.2) prior distribution.
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For each NMA, we used the Stata soGware to generate a network
plot (using the networkplot command) and inconsistency plot
(using the ifplot command) (Chaimani 2013).
Subgroup analysis and investigation of heterogeneity
Assessment of statistical heterogeneity
In pair-wise meta-analyses, we estimated the between-study SD
(Tau2) separately for each intervention comparison. We also
reported the I2 statistic for each pair-wise meta-analysis, which is
an estimate of the proportion of variability in e)ect estimates that
is due to heterogeneity (Higgins 2003).
The assessment of statistical heterogeneity in the NMA was based
on the magnitude of and Cr-Is for the between-studies SD (Tau),
which was assumed to be common across all comparisons within
a network.
As described below, reasons for heterogeneity were investigated
using subgroup or sensitivity analyses.
Assessment of statistical inconsistency
Inconsistency in the network refers to di)erences between the
direct and indirect e)ect estimates for the same comparison
(Donegan 2013). We used both a loop-specific approach and a
global approach to evaluate these e)ects.
To evaluate the presence of inconsistency locally we used the loop-
specific approach. This assesses the consistency assumption in
each closed loop of the network separately. We identified all the
triangular loops (comprising three direct treatment comparisons,
all compared with each other) and all the quadratic loops (involving
four comparisons) in the network. We compared the di)erences
between the direct and indirect estimates for these loops to
generate inconsistency factors, with 95% CIs, calculated and
displayed graphically using the 'ifplot' command in Stata (Chaimani
2013; Chaimani 2015). We assumed the estimated between-study
SD (Tau) from the Bayesian analysis of the full network for each
loop. We used the magnitude of the inconsistency factors to infer
the presence and degree of inconsistency in each loop.
In addition to this, we used a global approach, involving formally
comparing the fit of the NMA model (which assumes consistency)
with that of an 'inconsistency' model (in which all consistency
constraints are removed). The inconsistency model used is
equivalent to fitting a random-e)ects meta-analysis model for all
pair-wise comparisons, with a shared between-studies variance
parameter but no assumptions about direct and indirect evidence
forming coherent 'loops'. We calculated the mean residual deviance
and the deviance information criterion (DIC) for each model (mean
residual di)erence +pD). If the DIC for the inconsistency model
was more than five units higher than that of the consistency
model, this was viewed as evidence of inconsistency (Dias 2013).
We further examined di)erences in the estimated between-study
SD parameter (Tau) across the two models: a reduced estimate of
Tau in the inconsistency relative to the NMA model may also be
indicative of inconsistency (Dias 2018).
Further, for the main analyses, we plotted the mean residual
deviance contributions of each data point under the inconsistency
versus NMA models. This allows identification of specific data
points for which the inconsistency model has improved fit, that is,
data points that are potentially inconsistent with the network (Dias
2018).
Assessment of statistical imprecision
We evaluated precision of results, and subsequent rankings, based
on their 95% CIs (for pair-wise analysis) or Cr-Is (for Bayesian NMA).
Sensitivity analysis
Sensitivity analysis and investigation of heterogeneity and
inconsistency
We conducted subgroup or sensitivity network meta-analyses by
re-running the model on restricted numbers of studies according
to the following potential e)ect modifiers, which we felt could be
sources of inconsistency or heterogeneity, or both:
• analysis only including studies which used a clinico-radiological
definition of pleurodesis failure;
• analysis only including studies which analysed pleurodesis
e)icacy at one month aGer the intervention;
• analysis only including studies which analysed pleurodesis
e)icacy at three months aGer the intervention;
• analysis only including studies which analysed pleurodesis
e)icacy at more than six months aGer the intervention;
• analysis only including studies which excluded participants with
trapped lung;
• analysis only including studies which administered pleurodesis
through a large-bore chest tube (greater than 20-Fr)
• analysis only including studies which administered pleurodesis
through a chest tube (any size)
• analysis only including studies at a low risk of bias (maximum of
one domain assessed as high risk of bias).
In the protocol, we planned to investigate di)erent tumour types,
age of participants and baseline performance status, although
there were insu)icient data on this in the included studies to
perform these subgroup analyses.
We performed a post-hoc sensitivity NMA evaluating only
pleurodesis agents delivered via a chest tube (as opposed to being
given at thoracoscopy). We removed the trials evaluating talc
poudrage and IPC use from the main network and repeated the
analysis.
We performed sensitivity analyses of direct evidence on
pleurodesis failure using fixed-e)ect meta-analysis  models,
since  pooled e)ect estimates from random-e)ects  models give
relatively more weight to smaller studies, which is oGen considered
undesirable.
We performed an additional post-hoc pair-wise meta-analysis
comparing ipsilateral repeat invasive pleural intervention rates
(where data were available).
Summary of findings and assessment of the certainty of the
evidence
We created 'summary of findings' tables  for the most clinically
relevant outcomes:  pleurodesis failure and  breathlessness. We
summarised  adverse event data for procedure-related pain  and
fever. Data on mortality were also included.  We included the
need for an additional invasive pleural procedure, due to failure
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of the initial intervention for pleural fluid control, as this is an
important outcome of relevance to both patients and clinicians.
We used  talc slurry as our reference comparator. We graded
evidence relating to the most commonly compared interventions
with the most widespread availability. We calculated anticipated
absolute e)ect estimates using data from NMA for pleurodesis
failure, pain, mortality and fever. We used pair-wise analysis results
for breathlessness and repeat pleural intervention.
We followed the approach proposed by Yepes-Nunez and
colleagues and the methods and recommendations described
in Chapter 14 of the Cochrane Handbook of Systematic Reviews
of Interventions (Higgins 2019; Yepes-Nunez 2019). Two review
authors (AD and AOC) rated the quality of the direct and
indirect evidence using GRADE methodology. We considered study
limitations (overall risk of bias), assessments of inconsistency
(heterogeneity), indirectness and intransitivity, imprecision and
publication bias. We justified and documented judgements, which
have been incorporated into the reporting of results for each
outcome.
We reached an overall judgement on the certainty in the estimate
of the e)ect across these considerations, classified as 'high',
'moderate', 'low' or 'very low'. Our 'interpretation of findings'
reflects this certainty of evidence outcome and, where available,
this was combined with the overall ranking of each intervention in
our NMA.
R E S U L T S
Description of studies
Results of the search
We performed the literature search in June 2019, covering the
period from April 2015 when searches for the previous edition of
this review were conducted (Figure 1). We identified 1396 records
from database searches before exclusion of three duplicates.
We identified one additional record from references listed in a
systematic review (Putnam 1999, referenced in Sivakumar 2019).
From trials registry searches, we identified 21 records.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
We screened 1415 abstracts, of which 156  full-text articles were
retrieved and assessed for eligibility. A total of 18  studies met
eligibility criteria (see Characteristics of included studies table).
The 18  studies identified in our updated literature search were
combined with the 62 studies from the previous Cochrane Review
(Clive 2016). From the combined total of 3065 records screened
and 363  full-text reviews across the two searches, we included
80 studies (5507 participants randomised between 1977 and 2018)
in this review.
We excluded 15 studies (four identified from the 2019 literature
search), following an initial assessment that they were eligible for
inclusion (see Characteristics of excluded studies table). Thirteen
texts are awaiting classification (see Characteristics of studies
awaiting classification table). Eight studies are ongoing (see
Characteristics of ongoing studies table).
Included studies
Forty-six studies analysed the e)icacy of a variety of pleurodesis
agents. Twenty-seven trials evaluated talc, which was the
most studied agent. Bleomycin and tetracycline were other
commonly studied agents. Eight studies evaluated IPCs. Four
studies compared IPCs with talc slurry (Boshuizen 2017;  Davies
2012; Demmy 2012; Thomas 2017), and one with doxycycline
pleurodesis (Putnam 1999). Techniques to optimise outcomes
from IPCs were also considered; two examined IPC drainage
regimens (daily drainage versus symptom-guided or alternate
day regimens) (Muruganandan 2018; Wahidi 2017), and one
randomised participants to talc slurry administered via IPC or IPC
with saline placebo (Bhatnagar 2018).
Five studies evaluated the mode of administration of the
pleurodesis agent; four compared talc poudrage with talc slurry
(Bhatnagar 2020; Dresler 2005; Terra 2009; Yim 1996), and one
compared instillation of tetracycline thoracoscopically or through
an intercostal cannula (Evans 1993). Some studies evaluated
alternative techniques to improve pleurodesis success rates; one
study examined catheter size (Clementsen 1998); one examined a
combination of chest drain size and analgesia (non-steroidal anti-
inflammatory drugs (NSAIDs) versus opiates) (Rahman 2015); three
evaluated the duration of drainage aGer pleurodesis (Goodman
2006; Villanueva 1994; Yildirim 2005); one evaluated the duration
of drainage prior to instillation of the sclerosant (Ozkul 2014); one
assessed whether participant  rotation improved pleurodesis rate
(Mager 2002); and one evaluated the e)ect of talc particle size
(Maskell 2004). Three studies evaluated intrapleural fibrinolytics
(Mishra 2018; Okur 2011; Saydam 2015). One RCT evaluated
administration of three di)erent doses of silver nitrate through a
chest tube (Terra 2015), and one evaluated two di)erent doses of
iodine through a chest tube (Neto 2015).
Three studies compared surgical techniques to talc
pleurodesis;  one comparing talc pleurodesis with pleurectomy
(Rintoul 2014), and two comparing talc slurry with thoracoscopic
mechanical pleurodesis (TMP) (Crnjac 2004; Hojski 2015).
Additionally, we identified eight studies of agents specifically for
the treatment of e)usions due to lung cancer (Du 2013; Ishida 2006;
Kasahara 2006; Luh 1992; Masuno 1991; Wang 2018; Yoshida 2007;
Zhao 2009).
There were a number of methodological di)erences between the
included studies. FiGy-nine of 80 studies included all tumour
types. Two included all except mesothelioma; one included only
mesothelioma; one included all except lymphoma and small cell
lung cancer; two included only adenocarcinoma; eight included
only breast cancer;  and seven studies included only participants
with lung cancer.
The time point at which pleurodesis was evaluated varied widely
between studies, from one to 12 months. In addition, the methods
used to define pleurodesis failure varied. Nineteen of the 80 studies
used radiological criteria only to define a pleurodesis failure. The
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remaining 61 studies incorporated symptomatic recurrence or
need for a repeat pleural intervention into their definition. Six
studies evaluating IPCs defined pleurodesis success by cessation of
drainage from the catheter.
Pleurodesis techniques were not standardised. Studies used a
variety of chest drain sizes and durations of drainage aGer
sclerosant administration. Participants  with trapped lung were
excluded from 38/80 studies.
Excluded studies
We excluded 15 studies in total aGer initially being considered
eligible for inclusion, but with reasons for exclusion identified later
(Characteristics of excluded studies table). Three studies included
data for participants with ascites, which could not be separated
from participants with pleural e)usions (Kwasniewska-Rokicinska
1979; Lissoni 1995; Nio 1999).
Ten studies were not randomised (high risk of bias for sequence
generation) and therefore excluded as per protocol (Caglayan 2008;
Dryzer 1993; Elayouty 2012; Engel 1981; Gust 1990; Kleontas  2019;
Liu 2017;  Maiche 1993; Manes 2000; Tattersall 1982).  One study
combined data for adults and children (Ogunrombi 2014). One
study, initially included as an ongoing study, was published during
the process of this review.  On full-text review of the published
paper, it did not meet criteria for inclusion, as the primary outcome
was recruitment rate for a future multicenter phase 3 trial (Martin
2019).
Studies awaiting classification
Thirteen texts are awaiting classification (Characteristics of studies
awaiting classification table).
Ongoing studies
Eight studies are ongoing (Characteristics of ongoing studies table).
Risk of bias in included studies
A summary assessment of the risk of bias is presented in the
Characteristics of included studies table, Figure 2 and Figure 3.
Three studies were at low risk of bias in all domains (Bhatnagar
2018; Keeratichananont 2018; Mishra 2018).
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
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Figure 3.   (Continued)
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Allocation
All 80 studies were stated to have been randomised. Forty-
seven of these documented adequate sequence generation. The
most commonly used methods were computer or telephone
randomisation services, block randomisation, stratification,
opaque sealed envelopes or a random number generator. Since we
excluded studies with inadequate methods of sequence generation
as per the protocol, sequence generation was unclear in the
remaining 33 studies.
Allocation concealment was at low risk of bias in 42 studies. Since
we excluded studies with inadequate allocation concealment, as
per the protocol, allocation concealment was unclear for the
remaining 38 studies.
Blinding
Blinding of participants and personnel (performance bias)
Due to the nature of many of the interventions evaluated in
this review, blinding of the participants and clinicians was oGen
not possible. Thus, 49/80 studies were at high risk of bias
for this domain. Many of the pleurodesis agents have di)ering
visual appearances and those studies randomising participants to
di)erent modes of administration, an IPC or surgery could not
feasibly be blinded.
We assessed nine studies as low risk of performance bias and 22 as
unclear.
Blinding of outcome assessment (detection bias)
The assessment of pleurodesis success could oGen not be
blinded, as it was reliant on symptom reporting from unblinded
participants, in association with the radiological findings of
e)usion recurrence. Few studies reported whether the radiological
assessments were performed using a blinded method. Thirty-one
of 80 studies were at high risk of detection bias, and a further
33 of 80 studies had an unclear risk of bias for this domain. Sixteen
studies were low risk of detection bias.
Incomplete outcome data
Most studies were at low risk of bias because although there was
some inevitable attrition due to death, the rates were comparable
for the treatment arms. We classified 13 studies at high risk of
bias; nine due to very high attrition rates (Boshuizen 2017; Ke)ord
1980; Kessinger 1987; Masuno 1991; Ostrowski 1989; Patz 1998;
Ruckdeschel 1991; Sorensen 1984; Zaloznik 1983); one due to very
imbalanced LTFU between the treatment arms (Fentiman 1986);
in one the number randomised was not stated (Zimmer 1997);
for one the numbers provided did not add up (Hillerdal 1986);
and one excluded participants from the analysis who discontinued
treatment due to an allergic reaction (Gaafar 2014).
The risk of bias was unclear in six (Kuzdzal 2003: number
of randomised participants not stated, only stated number of
participants analysed; Alavi 2011: unable to access tables, and
numbers only given as percentages, rather than absolute values;
Demmy 2012: duration of trial follow-up unclear; Bagheri 2018
and Ozkul 2014: numbers of participants LTFU not stated; Saydam
2015: withdrawals not stated, and unclear how many participants
included in final outcome analysis).
Selective reporting
Most studies were at low risk of bias for selective outcome
reporting. We classified two studies as unclear; one as minimal
raw data were presented in the text and the tables could not
be accessed (Alavi 2011), and the other because pleurodesis
success data were not collected in an RCT of talc and tetracycline
pleurodesis (although the study was not designed to evaluate this)
(Maskell 2004).
Nine studies were at high risk; four provided minimal or no data
regarding adverse e)ects or survival, or both (Evans 1993; Kuzdzal
2003; Ozkul 2014; Salomaa 1995); one did not report data on
15/100 participants randomised (Ruckdeschel 1991); one did not
report pleurodesis outcomes for 11/40 participants and did not
give information on LTFU (Saydam 2015); one did not report how
long participants were followed up for or state the time at which
pleurodesis failure was assessed (Ibrahim 2015); and two did not
report on a stated outcome (Bagheri 2018: time to pleural e)usion
relapse; Tabatabaei  2015: breathlessness).
Other potential sources of bias
We classified 11/80 studies at high risk of bias in the 'other' domain.
The risk of bias was unclear in three studies. This was for a variety
of reasons (see Characteristics of included studies table). The
remaining studies had a low risk of bias for this domain.
Eects of interventions
See: Summary of findings for the main comparison Pleurodesis
failure rate in adults with malignant pleural e)usion; Summary of
findings 2 Adverse e)ects: procedure-related fever in adults with
malignant pleural e)usion; Summary of findings 3 Adverse e)ects:
procedure-related pain in adults with malignant pleural e)usion;
Summary of findings 4 Patient-reported control of breathlessness
in adults with malignant pleural e)usion; Summary of findings
5 Overall mortality in adults with malignant pleural e)usion;
Summary of findings 6 Patient acceptability: need for repeat
invasive pleural intervention in adults with malignant pleural
e)usion
Primary outcome: pleurodesis failure rate
Pair-wise (direct) meta-analysis
Results of the direct, pair-wise random-e)ects meta-analysis of
the main pleurodesis techniques for the primary outcome of
pleurodesis failure are presented in Table 1.  Few studies made
the same direct comparisons; meta-analysis was therefore only
possible for 12 direct comparisons. Results are also displayed for an
additional 30 direct comparisons that were each made in only one
study (Table 1).
In most cases, there was no evidence against the null hypothesis
of no true di)erence between interventions (Table 1). However, in
14/42 direct comparisons made, the OR and 95% CI lay away from
the null value of 1, giving evidence against the null hypothesis of no
di)erence.
A number of interventions had a higher pleurodesis failure rate
than talc poudrage. This included tetracycline (pleurodesis failure
of tetracycline versus talc poudrage: OR 12.10, 95% CI 1.32 to
111.30; studies = 1; participants = 33; Analysis 4.1; bleomycin: OR
9.70, 95% CI 2.10 to 44.78; studies = 2, participants = 57; Analysis
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1.1; doxycycline: OR 42.69, 95% CI 2.13 to 856.61; studies = 1,
participants = 31; Analysis 8.1; mustine: OR 8.00, 95% CI 1.40 to
45.76; studies = 1, participants = 37; Analysis 16.1).
The evidence suggests that participants treated with an IPC had
more pleurodesis failures than those receiving talc slurry. Two
studies compared talc slurry to IPCs without daily drainage (OR
0.18, 95% CI 0.07 to 0.45; studies = 2, participants = 249; Analysis
2.1; Davies 2012; Thomas 2017). One study compared talc slurry
to daily IPC drainage (Demmy 2012: OR 0.30, 95% CI 0.08 to 1.14;
participants = 55; Analysis 2.1). Two studies comparing IPCs without
daily drainage to IPCs with daily drainage suggested a higher
pleurodesis failure rate in those without daily drainage (OR 3.23,
95% CI 1.79 to 5.85; participants = 236; Analysis 6.1; Muruganandan
2018;  Wahidi 2017). Results from one study suggest that talc
administration via IPC may result in fewer pleurodesis failures than
drainage alone (OR 0.36, 95% CI 0.18 to 0.73; participants = 139;
Analysis 25.1; Bhatnagar 2018).
There was evidence that tetracycline, mitoxantrone and interferon
were less e)ective (i.e. associated with a higher likelihood of
pleurodesis failure) than bleomycin (tetracycline: OR 2.00, 95%
CI 1.07 to 3.75; studies = 5, participants = 220; Analysis 4.1;
mitoxantrone: OR 3.18, 95% CI 1.17 to 8.65; studies = 1, participants
= 85; Analysis 17.1; interferon: OR 3.25, 95% CI 1.54 to 6.89;
studies = 1, participants = 160; Analysis 12.1). Bleomycin and
triethylenephosphoramide were less e)ective than mepacrine
(bleomycin: OR 6.40, 95% CI 1.12 to 36.44; studies = 1, participants
= 36; Analysis 1.1; triethylenephosphoramide: OR 4.95, 95% CI 1.02
to 24.10; studies = 1, participants = 29; Analysis 13.1).
There was generally little evidence of statistical heterogeneity
between studies making direct comparisons. However, the
comparison between C parvum and bleomycin estimated a very
high level of heterogeneity (Tau2 = 10.59, I2 = 94%) because the
two included studies had conflicting results (C parvum versus
bleomycin: OR 0.05, 95% CI 0.01 to 0.29 in Hillerdal 1986; OR 5.69,
95% CI 1.38 to 23.48 in Ostrowski 1989; Analysis 5.1). The number
of participants in the comparison was small (98 participants
randomised across the two studies; 78 of whom had su)icient
data to be included in the primary outcome analysis) and Hillerdal
1986 was at high risk of bias for two domains and unclear risk of
bias for a further two. Hillerdal 1986 only included people with
adenocarcinoma or bronchogenic carcinoma, whereas Ostrowski
1989 included all cell types. The evidence suggests that there may
be some heterogeneity in the direct comparison of IPC without daily
drainage and talc slurry (I2 = 61%, Chi2 = 2.58, P = 0.11; studies = 2;
participants = 249; Analysis 6.1).
Appendix 2 demonstrates no obvious di)erence in the distribution
of potential e)ect modifiers between direct comparisons.
Sensitivity analysis of the direct comparisons using the fixed-e)ect
meta-analysis model did not reveal any clinically or statistically
meaningful di)erences (see Appendix 3).
Network meta-analysis
Selection of trials for inclusion in the network meta-analysis
We evaluated and assessed all the interventions from the included
studies for inclusion in the network. We considered a number
of interventions were not jointly randomisable and hence we
did not include them. These interventions included specific
surgical techniques (Rintoul 2014), di)erent talc particle sizes
(Maskell 2004), interventions to improve the e)icacy of pleurodesis
(Clementsen 1998; Evans 1993; Goodman 2006; Mager 2002;
Mishra 2018; Okur 2011; Ozkul 2014; Rahman 2015; Saydam
2015; Villanueva 1994; Yildirim 2005), tumour-specific intrapleural
therapy (Du 2013; Ishida 2006; Kasahara 2006; Luh 1992; Masuno
1991; Wang 2018; Yoshida 2007; Zhao 2009), di)erent doses of silver
nitrate (Terra 2015), and di)erent doses of iodine (Neto 2015).
For computational reasons, we could not include one intervention
(combined tetracycline and bleomycin) in the NMA: this
combination was evaluated in only one trial, with no pleurodesis
failures occurring in the relevant study arm. Inclusion of this trial
led to convergence problems (Emad 1996). We did not include
an additional study in the analysis as there were no pleurodesis
failures in either study arm (Yim 1996). Such studies cannot
statistically contribute to the estimate of relative intervention
e)ects (Higgins 2011b).
We included 55 studies in the primary NMA. Most studies included
all cell types. Twenty-six of 55 excluded participants with trapped
lung. Pleurodesis was defined using symptom recurrence and
radiology in 37/55 studies and usually defined within four months
of the intervention.
It was di)icult for us to assess whether the distribution of potential
e)ect modifiers was comparable for all the direct treatment
comparisons because there were few studies per direct comparison
(at most five studies per comparison, seen in the bleomycin versus
talc slurry and bleomycin versus tetracycline comparisons) (see
Appendix 2).
The final network can be seen in Figure 4.
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Figure 4.   Network plot of the pleurodesis eicacy network. The nodes are weighted according to the number of
participants randomised to the intervention. The edges (line thicknesses) are weighted according to the number
of studies included in each comparison. IFN: interferon; IPC: indwelling pleural catheter without daily drainage;
thioTEPA: triethylenephosphoramide; TMP: thoracoscopic mechanical pleurodesis.
 
Results from network meta-analysis
Estimated ORs for the pleurodesis failure outcome generated by the
NMA, which comprised 55 studies of 21 agents and included 3758
participants, are shown in Table 2. The estimated ranks for each of
the interventions in terms of pleurodesis success (i.e. lowest chance
of failure) are shown in Figure 5. The summary of findings from the
NMA of pleurodesis failure rate are shown in Summary of findings
for the main comparison.
 
Figure 5.   Estimated (95% credible interval (Cr-I)) ranks for each of the pleurodesis methods from the main network.
IFN: interferon; IPC: indwelling pleural catheter without daily drainage; thioTEPA: triethylenephosphoramide; TMP:
thoracoscopic mechanical pleurodesis.
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Based on the NMA, there was evidence that talc poudrage results
in fewer pleurodesis failures than bleomycin, tetracycline, mustine,
interferon, IPC not daily drainage, mitoxantrone and placebo (Table
2). The estimated (posterior median) rank of talc poudrage was
third of 21 interventions, but with a much tighter Cr-I than those
interventions with median rank of 1 or 2 (estimated rank 3, 95% Cr-
I 1 to 6).
We had a moderate level of certainty in the network estimate of the
pleurodesis failure rate of talc poudrage compared to talc slurry. We
downgraded evidence by one level for serious study limitations due
to an overall high risk of bias for trials forming direct and indirect
evidence loops in the talc poudrage to talc slurry comparison. There
was little evidence of a di)erence between these two interventions
in the primary NMA (talc poudrage versus talc slurry: OR 0.50, 95%
Cr-I 0.21 to 1.02). Restricting analysis only to studies at low risk
of bias provided greater certainty that these interventions have a
comparable pleurodesis failure rate (OR 0.78, 95% Cr-I 0.16 to 2.08).
The OR and 95% Cr-I for IPC (without daily drainage) compared
to talc slurry demonstrates that IPCs are likely to have a higher
pleurodesis failure rate than talc slurry (OR 7.60, 95% Cr-I 2.96
to 20.47). Our level of certainty in this result is moderate.
We downgraded one level for inconsistency, due to a high I2 value (I2
= 61%) in the IPC without daily drainage to talc slurry comparison.
Talc slurry was associated with fewer pleurodesis failures than
mitoxantrone and placebo (talc slurry versus mitoxantrone: OR
0.10, 95% Cr-I 0.02 to 0.41; talc slurry versus placebo: OR 0.06,
95% Cr-I 0.01 to 0.27). We had a low level of certainty that talc
slurry may result in fewer pleurodesis failures than bleomycin and
doxycycline (bleomycin versus talc slurry: OR 2.24, 95% Cr-I 1.10
to 4.68; doxycycline versus talc slurry: OR 2.51, 95% Cr-I 0.81 to
8.40). We downgraded by one level in the bleomycin to talc slurry
comparison for serious study limitations due to an overall high
risk of bias for trials forming direct and indirect evidence loops,
and by one level for evidence of indirectness (due to variation in
the dose of bleomycin used and di)erent approaches between
studies to inclusion of patients with trapped lung and definition of
pleurodesis failure). We downgraded evidence in the doxycycline
to talc slurry comparison for imprecision (due to the wide Cr-I
around the e)ect estimate) and indirectness (as there was no direct
evidence comparing doxycycline and talc slurry, and evidence
forming indirect evidence loops were based on few studies).
The NMA provides some evidence that mistletoe (viscum) may
be associated with fewer pleurodesis failures than placebo,
mitoxantrone and IPC without daily drainage, with ORs and 95% Cr-
Is lying away from the null value of 1. However, these comparisons
are based only on indirect data with small sample sizes. The only
direct evidence on mistletoe (viscum) was from a comparison with
bleomycin made in a single study (OR 0.19, 95% Cr-I 0.02 to 1.62;
participants = 17). Mistletoe (viscum) was estimated to have a
high rank (rank 2/21) but with a very wide Cr-I (1 to 16) reflecting
uncertainty within the network as to its true rank.
The NMA also provides some evidence that TMP may be more
e)ective (i.e. result in fewer pleurodesis failures) than interferon,
IPC – not daily drainage, mitoxantrone and placebo. TMP similarly
ranked highly on average, but with a wide Cr-I reflecting
considerable uncertainty (ranked joint second with mistletoe
(viscum), 95% Cr-I 1 to 11). The evidence for TMP is based on
two studies, recruiting a combined total of 123 participants. We
considered both studies at high risk of bias and therefore we did not
include them in the sensitivity analysis of studies at low risk of bias.
The NMA results are consistent with the pair-wise meta-analysis
results in providing some evidence that a daily IPC drainage
regimen (ranked joint 11th of 21 interventions, 95% Cr-I 4 to
18) has increased chance of pleurodesis success compared with
IPCs without daily drainage (ranked 18th, 95% Cr-I 13 to 21). Talc
administration combined with IPC ranked joint 12th but the very
wide Cr-I demonstrates uncertainty of its true rank (95% Cr-I 3 to
20).
Placebo administration was associated with the highest likelihood
of pleurodesis failure, with an estimated rank lowest of 21
interventions (95% Cr-I 15 to 21). We had a moderate level of
certainty that placebo is associated with more pleurodesis failures
than talc slurry (OR 15.90, 95% Cr-I 3.76 to 79.90) with evidence
downgraded one level for imprecision due to the wide Cr-I of this
estimate. The ORs and 95% Cr-Is comparing placebo with TMP, talc
poudrage, mepacrine, talc slurry, C parvum and iodine were all far
away from 1, providing evidence that placebo is less e)ective at
achieving a pleurodesis.
Other potentially e)icacious agents were mepacrine, iodine and C
parvum, with estimated ranks of 5th (95% Cr-I 1 to 13) for mepacrine
and joint 7th (95% Cr-I 2 to 14) for iodine and C parvum.
Heterogeneity within the network meta-analysis
We estimated the between-study SD in treatment e)ect estimates
(log ORs) across the whole network to be Tau = 0.70 (95% Cr-I 0.30 to
1.17), suggesting a high degree of heterogeneity, although the wide
Cr-I indicates a substantial degree of uncertainty around this.
We performed several sensitivity analyses to explore potential
reasons for this heterogeneity, based on predefined potential
clinical e)ect modifiers (see Appendix 4). Due to the smaller
number of studies in these analyses, many of them contained fewer
interventions  than the main network. The estimated rank orders
were generally similar to those in the main network (Appendix 5;
Appendix 6).
The estimated between-trial heterogeneity across the network
remained high for most sensitivity analyses, but was reduced in
the NMA restricted to trials at low risk of bias (Tau 0.37, 95% Cr-I
0.02 to 1.47) and the NMA restricted to trials excluding people with
trapped lung (Tau 0.31, 95% Cr-I 0.01 to 1.19). We note however that
the Cr-Is around these estimates of Tau are very wide, indicating
considerable uncertainty about the extent of heterogeneity. More
generally, estimates of Tau in all sensitivity analyses were very
imprecise. The upper limit of the 95% Cr-Is for these values was
oGen close to 2. Since we assumed a uniform (0.2) prior distribution
for Tau in each analysis, it is likely that the upper limits would
increase further still if we assumed  a wider prior distribution
(Appendix 4; Appendix 5; Appendix 7).
Results were fairly robust to exclusion of the higher risk of bias
studies, although doxycycline and C parvum both ranked higher
than in the main NMA, probably due to the removal of two particular
studies (Kuzdzal 2003; Ostrowski 1989) (Appendix 5; Appendix
7). Talc poudrage and talc slurry were associated with the least
pleurodesis failures and their Cr-Is were the same (talc poudrage:
rank 2, 95% Cr-I 1 to 9; talc slurry: rank 4, 95% Cr-I 1 to 9) with
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the OR and Cr-I of talc poudrage versus talc slurry suggesting little
di)erence between the two agents (OR 0.78, 95% Cr-I 0.16 to 2.08). ).
We observed a diverse range of doses used for many of the
pleurodesis agents evaluated, which is a potential cause for the
unexplained heterogeneity. Unfortunately, it was not feasible to
examine the e)ect of dose on comparative estimates (ORs).
Inconsistency within the network meta-analysis
There was no statistical evidence for global inconsistency in the
main network or in any of the subgroup or sensitivity NMAs
(see Figure 6). For the primary outcome analysis of pleurodesis
failure, the residual deviance was four points lower (indicating
slightly better fit) for the 'inconsistency model' relative to the
NMA. However, aGer penalising for the increased complexity of the
inconsistency model (101 'e)ective parameters' required versus 91
for the NMA), the DIC indicated a preference for the NMA model (DIC
of 209.3 relative to 214.9 for the inconsistency model).
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Figure 6.   Inconsistency plot for the main network. Treatment codes: 01: adriamycin; 02:autologous blood;
03:bleomycin; 04:C parvum; 05:doxycycline; 06:interferon; 07:indwelling pleural catheter (IPC) –daily drainage;
08:IPC –not daily drainage; 09:iodine; 10:mepacrine; 11:mistletoe (viscum); 12:mitoxantrone; 13:mustine; 14:placebo;
15:silver nitrate; 16:thoracoscopic mechanical pleurodesis (TMP); 17:talc poudrage; 18:talc slurry; 19:talc via IPC;
20:tetracycline; 21:triethylenethiophosphoramide. Abbreviations: ROR:ratio of odds ratios; 95% CI:95% confidence
interval. Heterogeneity variance was set at 0.4929 (reflecting the estimation of Tau from the network).
 
Similarly, there was no statistical evidence for loop-specific
inconsistency within any of the networks. Inconsistency factors
(ratio of odds ratios (RORs)) with 95% CIs for the main network can
be found in Figure 6. Although none of these CIs exclude the null
value of 1, we note that some of the RORs are large, with extremely
wide CIs, due to the small volume of evidence per loop. The
possibility of true inconsistencies cannot therefore be excluded.
The largest ROR (30.4, truncated 95% CI 1 to 1632.0) related to
the loop doxycycline – IPC not daily drainage – talc slurry – talc
poudrage. We note that the only direct evidence on doxycycline
versus talc poudrage was from a small trial of 31 participants, with
zero pleurodesis failures in the talc poudrage arm (Kuzdzal 2003),
which appears to be the driver of this large ROR. The residual
deviance contribution plot (Figure 7) indicates that the data points
that were fitted 'better' by the inconsistency model relative to the
NMA tended to similarly be those with zero cells: in particular, the
Kuzdzal 2003 trial is highlighted again as potentially inconsistent
from other evidence using this approach. As the residual deviance
is known to be numerically unstable in the presence of zero cells,
this does not cause concern (Dias 2018).
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Figure 7.   Residual deviance contribution plot for the main network meta-analysis. * indicates 0 events.
 
Additional post-hoc sensitivity analysis
The post-hoc sensitivity analysis that only evaluated agents given
through an intercostal chest tube included 37 studies of 16 agents
(Appendix 7; Appendix 8). There was very little evidence of
di)erence between the agents: Cr-Is were wide and the estimated
rankings for the individual agents were also very imprecise. The
estimated degree of heterogeneity was even higher than the main
network (Tau 0.87, 95% Cr-I 0.37 to 1.52).
Primary outcomes for the methods not included in the network
meta-analysis
Pleurodesis techniques
The results of the pair-wise comparisons of the interventions not
included in the NMA are shown in Table 3.
We did not include one study in the NMA as it was a three-arm
trial evaluating di)erent doses of silver nitrate administered via a
chest tube (Terra 2015). Only two of 60 participants had a failed
pleurodesis, both in the group receiving the highest dose of silver
nitrate.
We could not include eight studies in the NMA as they evaluated
tumour-specific therapies for people with MPE due to non-small
cell lung cancer (NSCLC) (Du 2013; Ishida 2006; Kasahara 2006; Luh
1992; Masuno 1991; Wang 2018; Yoshida 2007; Zhao 2009). The
results could not be generalised to people with other tumour types
and hence we did not consider these interventions to be jointly
randomisable. All of these studies randomised only small numbers
of participants. However, in five of the direct comparisons, the OR
and 95% CI lay far away from the null value of 1, giving evidence
against the null hypothesis of no di)erence (Table 3).
Du 2013 randomised people with NSCLC to receive three cycles
of either cisplatin plus intrapleural bevacizumab (a humanised
monoclonal antibody to vascular endothelial growth factor (VEGF))
or cisplatin alone. More participants in the cisplatin-alone group
had pleurodesis failure than in the combination group (6/36 with
cisplatin plus bevacizumab versus 17/34 with cisplatin alone; OR
5.00, 95% CI 1.66 to 15.09; studies = 1; participants = 70; Analysis
22.1).
Masuno 1991 randomised people with NSCLC with MPE to
receive up to two doses of either intrapleural LC9018 (lyophilised
Lactobacillus casei) plus adriamycin or adriamycin alone. There
were more pleurodesis failures in the control group compared to
those who received LC9018 (23/38 with adriamycin alone versus
10/38 with LC9018 plus adriamycin; OR 4.29, 95% CI 1.62 to 11.35;
studies = 1, participants = 76; Analysis 14.1).
Ishida 2006  conducted a three-arm trial, comparing intrapleural
OK-432, an inactivated product of Streptococcus pyogenes A3
with antitumour immune-modulatory e)ects in lung cancer, with
cisplatin and combined therapy (both OK-432 and cisplatin). People
treated with OK-432 alone had a higher pleurodesis failure rate than
those receiving combination treatment (OR 12.44, 95% CI 1.32 to
117.03; studies = 1, participants = 32), but a lower failure rate than
those receiving cisplatin alone (OR 0.48, 95% CI 0.12 to 1.92; studies
= 1, participants = 34; Analysis 10.1).
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Wang 2018 administered intrathoracic cisplatin in combination
with intravenous pemetrexed as the control intervention for people
with lung adenocarcinoma and compared this with the addition of
intrathoracic Endostar. Participants in the intervention arm had a
lower pleurodesis failure rate aGer three cycles of treatment (OR
0.43, 95% Cr-I 0.20 to 0.93; participants = 128; Analysis 29.1).
Other methods to optimise pleurodesis
We evaluated several other methods to optimise pleurodesis, but
did not include them in the NMA because we did not consider them
to be  jointly randomisable (see Table 4). Most studies included
small numbers of participants and none provided evidence of
a di)erence in pleurodesis failure rates between the treatments
being compared (see Table 4).
Three studies investigated the use of intrapleural fibrinolytics.
Mishra 2018 recruited people with non-draining MPE to receive
either intrapleural urokinase or placebo with coprimary outcome
measures of dyspnoea change and time to pleurodesis failure.
Seventy-one participants were randomised. The authors reported
no significant di)erence between groups in time to pleurodesis
failure over the 12-month study period (13/35 failures in
participants receiving urokinase compared with 11/34 receiving
placebo; OR 1.24, 95% CI 0.46 to 3.34; Analysis 27.1), and  no
di)erence between groups in the number of participants achieving
a clinically significant decrease in VAS dyspnoea scores.
Saydam 2015 randomised 40 participants to receive either
streptokinase or saline placebo in people with multiloculated MPE.
Pleurodesis outcome data were not presented for 11 participants,
but failure occurred in 2/18 participants receiving streptokinase
and 5/11 receiving placebo control (P = 0.07). In Okur 2011, the total
volume of pleural fluid drained was   higher in the streptokinase
group than control; however, there was no di)erence observed
between groups in pleurodesis failure rates (streptokinase versus
control: OR 0.46, 95% CI 0.11 to 1.90; Analysis 28.1).
Two studies compared small- and large-bore chest drains.
Clementsen 1998 randomised 21 participants to receive
tetracycline via 10-Fr and 24-Fr drains (administered at the end of
medical thoracoscopy). They observed no di)erence in pleurodesis
failures between groups (small-bore versus large-bore pleurodesis
failure: OR 0.57, 95% CI 0.07 to 4.64; Analysis 18.1).
The TIME-1 2×2 factorial study (Rahman 2015), compared the
e)ect of small- and large-bore drains and analgesia (NSAIDs versus
opiates) on pain and pleurodesis outcomes in 320 people with
MPE. Small chest tubes (12 Fr) failed to meet non-inferiority for
pleurodesis e)icacy at three months when compared with large (24
Fr) drains, with 15/50 pleurodesis failures in the 12-Fr group and
12/50 failures in the 24-Fr group (small versus large bore: OR 1.36,
95% CI 0.56 to 3.30; Analysis 18.1).
We did not identify any RCTs examining the role of pleuroperitoneal
shunts.
Secondary outcomes
Due to the diversity of reporting techniques and outcome
measures, it was not possible to perform a formal statistical
analysis of many of the predefined secondary outcomes.
Adverse e%ects and complications
Most studies reported data on adverse e)ects of the interventions,
however four studies did not (Evans 1993; Kuzdzal 2003; Saydam
2015;  Villanueva 1994). Ke)ord 1980 reported adverse events
but we could not di)erentiate the participants with pleural
e)usions  from those with ascites or pericardial e)usions. Two
study authors provided data on adverse events by personal
communications (Goodman 2006; Mager 2002). The methods used
to describe the adverse e)ects observed varied widely between
studies.
One study demonstrated that mixed particle talc is associated
with more lung and systemic inflammation, hypoxaemia and acute
respiratory distress syndrome (ARDS) than graded talc (with its
smallest particles removed) and tetracycline (Maskell 2004).
Other notable complications included  a possible increased risk
of cellulitis and pleural infection associated with IPCs. One study
comparing IPCs without daily drainage to talc slurry pleurodesis
reported more cases of infection in the IPC arm (five cases of pleural
infection requiring admission for intravenous antibiotics, plus 2/52
participants who were managed as outpatients with oral antibiotics
in the IPC arm, compared to 1/54 participants requiring hospital
admission for pleural infection in the talc slurry arm). However, no
IPCs were removed as a consequence of infection (Davies 2012).
In another study, 2/74 participants developed a pleural infection
and 3/74 developed cellulitis in the IPC arm compared with 1/72
participants with pleural infection in the talc slurry arm (Thomas
2017). Boshuizen 2017, however, reported no di)erence in the
rate of infection between participants receiving an IPC without
daily drainage and those receiving a chest drain and talc slurry
pleurodesis, with two infections occurring in each group. One study
comparing daily IPC drainage to talc slurry pleurodesis reported
only one wound infection in the IPC group (Demmy 2012).
One study comparing IPCs without daily drainage to doxycycline
pleurodesis reported 6/99 participants receiving an IPC had a
local cellulitis infection, which responded to oral antibiotics. No
participants with an infection required IPC removal (Putnam 1999).
Neither study comparing daily IPC drainage to IPCs without daily
drainage observed a di)erence in the rate of pleural infection
between study arms (Muruganandan 2018; Wahidi 2017).
We used NMA to compare rates of the most commonly reported
adverse e)ects: fever and pain.
Presence of procedure-related fever 
Pair-wise (direct) meta-analysis
The direct evidence regarding fever is shown in Appendix 9.
Twenty-six direct comparisons were each informed by between one
and five studies.
There was   evidence that talc slurry may be associated with
more fever than autologous blood (OR 3.92, 95% CI 1.31 to 11.72;
studies = 1; participants = 110; Analysis 2.2) and that placebo,
tetracycline and triethylenethiophosphoramide were associated
with less fever than mepacrine (placebo: OR 0.31, 95% CI 0.12
to 0.79; Analysis 15.2; tetracycline: OR 0.13, 95% CI 0.02 to 0.89;
Analysis 4.2; triethylenethiophosphoramide: OR 0.04, 95% CI 0.01
to 0.30; Analysis 13.2).
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Network meta-analysis
We performed NMA of fever data from 30 trials of 14 di)erent
treatments, including 2004 participants. ORs from the NMA are
shown in Table 5 and estimated rankings of the interventions
in Figure 8. The summary of findings from the NMA on risk of
developing a fever can be seen in Summary of findings 2.
 
Figure 8.   Estimated rank (95% credible interval (Cr-I)) for causing fever (a low rank suggests increased risk
of fever).
 
Most estimates had very wide Cr-Is, indicating a large degree of
imprecision. Silver nitrate and placebo appeared to be associated
with the least fever (estimated rank joint 2nd of 14 interventions
(silver nitrate: 95% Cr-I 1 to 7; placebo: 95% Cr-I 1 to 11)) (talc slurry
versus silver nitrate: OR 17.33, 95% CI 1.07 to 336.40; talc slurry
versus placebo: OR 10.65, 95% CI 0.2 to 931). The interventions
associated with the most fever appeared to be C parvum and
mepacrine, with estimated ranks of joint 13th (C parvum: 95% Cr-I
10 to 14; mepacrine: 95% Cr-I 8 to 14) (talc slurry versus C parvum:
OR 0.07, 95% CI 0.01 to 0.88; talc slurry versus mepacrine: OR 0.09,
95% CI 0.01 to 1.69).
There was no statistical evidence for a di)erence in the risk of
fever, relative to talc slurry, of talc poudrage (OR 0.89, 95% Cr-I 0.11
to 6.67)), bleomycin (OR 2.33, 95% Cr-I 0.45 to 12.50)), IPC – not
daily drainage (OR 0.41, 95% Cr-I 0.00 to 50.00) and doxycycline
(OR 0.85, 95% Cr-I 0.05 to 14.29). We tentatively suggest that these
interventions may be comparable to talc slurry, but we have a
low level of certainty in this conclusion: we downgraded evidence
for imprecision due to the wide Cr-Is of all network estimates. We
also downgraded evidence for indirectness, due to di)erences in
adverse event reporting of procedure-related fever, using di)erent
temperature thresholds and time frames for which a fever may be
considered attributable to the intervention.
The between-study SD (Tau) for the fever NMA was 1.67 (95%
Cr-I 1.08 to 1.98), indicating a very high degree of statistical
heterogeneity. We note that the upper limit of the prior distribution
was set to 2.
Comparison of DIC values for the NMA model versus the
inconsistency model suggested comparable model fit aGer
penalising for complexity (DIC 121.5 for the NMA model versus 121.2
for the inconsistency model). However, we noted a reduction in
the SD when moving from the NMA to inconsistency model, which
does indicate the possibility of inconsistency within the network.
Comparison of residual deviance contributions of individual data
points highlighted three studies as potentially inconsistent from
the rest of the evidence, two of which included zero counts in the
2×2 outcome data (i.e. either all or no participants in one trial
arm experienced fever, which leads to computational instability in
residual deviance calculations) (Figure 9). The inconsistency factor
method provided no evidence of loop inconsistency (Appendix 4).
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Figure 9.   Residual deviance contribution plot for the fever network meta-analysis. * indicates 0 events. 
 
Other findings
For those studies that were not included in the NMA but provided
data on fever, the majority revealed no di)erence between the
interventions (Emad 1996; Kasahara 2006; Masuno 1991; Terra
2015). Two studies evaluating OK-432 revealed more fever in this
group compared to the control groups (Ishida 2006; Luh 1992;
Yoshida 2007) (Analysis 10.2). The mixed talc group had more
fever than the graded talc group (OR 15.92, 95% CI 1.81 to 140.16;
participants = 46; studies = 1; Analysis 20.2; Maskell 2004). The
group who received cisplatin alone had less fever than those who
also received rAd-p53 (OR 0.09, 95% CI 0.02 to 0.51; studies = 1,
participants = 35; Analysis 22.2; Zhao 2009).
Presence of procedure-related pain 
We only included studies reporting dichotomous outcomes
(presence or absence of pain post procedure) in the pair-wise and
NMA.
Pair-wise (direct) meta-analysis
The direct evidence regarding pain is shown in Appendix 10.
There was evidence that tetracycline pleurodesis may cause pain
more frequently than autologous blood (OR 69.00, 95% CI 7.61 to
625; studies = 1), mustine (OR 33.87, 95% CI 1.80 to 636; studies
= 1) and silver nitrate (OR 55.08, 95% CI 3.02 to 1003; studies = 1)
(Analysis 4.3).  One study provided evidence that talc slurry may
cause pain more frequently than autologous blood (OR 3.57, 95%
CI 1.19 to 10.74; participants = 110; Analysis 2.3).
Network meta-analysis
We included 31  studies and 14 treatments (including 2753
participants) in the NMA regarding pain (Appendix 11; Appendix
12). The summary of findings from the NMA of risk of developing
procedure-related pain can be seen in Summary of findings 3.
There was evidence to suggest that five agents, including
bleomycin (OR 19.46, 95% Cr-I 3.47 to 138.70), doxycycline (OR
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22.87, 95% Cr-I 2.99 to 223.60), talc poudrage (OR 8.64, 95% Cr-I 1.45
to 96.71) and talc slurry (OR 6.77, 95% Cr-I 1.40 to 39.01) may be
associated with a higher number of participants having pain post
procedure than autologous blood (estimated rank 1, 95% Cr-I 1 to
4).
There was no statistical evidence for a di)erence in risk of
procedure-related pain, relative to talc slurry, of bleomycin (OR
2.85, 95% Cr-I 0.78 to 11.53), IPC – not daily drainage (OR 1.30,
95% Cr-I 0.29 to 5.87), doxycycline (OR 3.35, 95% Cr-I 0.64 to 19.72)
or talc poudrage (OR 1.26, 95% Cr-I 0.45 to 6.04). We tentatively
suggest that these interventions may have a comparable frequency
of procedure-related pain to talc slurry, but we have a low level of
certainty in this conclusion. Estimates had very wide CIs; therefore,
we downgraded by one level in all comparisons for imprecision. We
also downgraded evidence for indirectness for all comparisons. The
time point at which pain was reported, threshold for reporting and
mode of assessment was oGen unstated by studies (as occurrence
of pain was reported as an adverse event) and therefore we felt this
was likely to di)er between studies. In addition, we downgraded
evidence one level for inconsistency in the talc poudrage to talc
slurry comparison (I2 = 69%).
The between-study SD (Tau) for the network was 0.69 (95% Cr-
I 0.11 to 1.51), indicating considerable heterogeneity. The DIC
indicated comparable fit between the NMA and inconsistency
models, with a di)erence in DIC of 4.8 points (marginally in
favour of the inconsistency model, but not reaching the predefined
cut-o) of 5 points' di)erence for global inconsistency). There
was a slight reduction in estimated Tau when moving to the
inconsistency model, which is however suggestive of possible
global inconsistency (Appendix 4). Inspection of the contributions
of individual data points to the mean residual deviance showed
that the slightly better fit of the inconsistency model was driven
by trials in which either all or no participants in one trial arm
experienced pain post procedure (i.e. presence of a zero count in
the 2×2 outcome data) (Figure 10).
 
Figure 10.   Residual deviance contribution plot for the pain network meta-analysis. * indicates 0 events. 
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Other findings
Seven studies reported results from pain scales rather than
dichotomous outcome data and , therefore, we could not include
these in the pair-wise analysis or NMA (Agarwal 2011; Alavi 2011;
Bjermer 1995; Davies 2012; Hojski 2015; Paschoalini 2005; Zimmer
1997). Bjermer 1995 reported that "pain scores were significantly
higher  in the mepacrine group (p = < 0.001)" compared to the
mitoxantrone group as measured by the WHO analgesic ladder (no
raw figures provided) (WHO 2016). In Hojski 2015, VAS pain scores
demonstrated that participants in the mechanical pleurodesis
group had less pain than the talc slurry group at 12 hours'
postpleurodesis; however, there was no di)erence between groups
at 48 hours. The other six studies did not provide evidence of a
di)erence in pain between the interventions studied.
Eight studies  that we did not include in the network (as we did
not consider interventions to be jointly randomisable) revealed
no di)erence between interventions (Kasahara 2006; Luh 1992;
Masuno 1991; Neto 2015; Okur 2011; Terra 2015; Yoshida 2007; Zhao
2009).
Two studies that evaluated interventions to optimise pleurodesis
reported pain outcomes according to drain size. Clementsen 1998
reported fewer participants experienced pain at the time of drain
insertion in those with small-bore drains (10 Fr) compared with
large-bore drains (24 Fr) (OR 0.08, 95% CI 0.01 to 0.75; Analysis 18.2)
and that smaller (10-Fr) drains were better tolerated. Placement
of large-bore (24-Fr) chest tubes was associated with more pain
in the TIME-1 study, but the study authors reported this was not
clinically significant (Rahman 2015). There was no di)erence in
pain scores between participants receiving NSAIDs and opiates,
although participants in the NSAID group did require more rescue
analgesia (Rahman 2015).
One study reported that more participants experienced pain in the
OK-432 group than control (Analysis 10.3; Ishida 2006).
Patient-reported control of breathlessness
Twenty studies reported breathlessness outcomes, using a
variety of scoring systems: Medical Research Council (MRC)
Dyspnoea Scale (Mohsen 2011); VAS score (Bhatnagar 2018;
Bhatnagar 2020; Bjermer 1995; Davies 2012; Diacon 2000;
Mishra 2018; Muruganandan 2018; Terra 2015; Thomas 2017);
'dyspnoea index' (Demmy 2012); BORG score and Guyatt Chronic
Respiratory Questionnaire (CRQ) (Putnam 1999); Modified Borg
Score (Boshuizen 2017); EORTC Core Quality of Life Questionnaire
(QLQ-C30)/Lung Cancer Module (EORTC QLQ-LC13) questionnaires
(Hojski 2015; Rintoul 2014), functional class (Masuno 1991; Rafiei
2014; Zimmer 1997), scale 0 to 10 (Alavi 2011); and patient
satisfaction questionnaire with breathlessness rating (Wahidi
2017).
Pair-wise (direct) meta-analysis
Results from meta-analysis of patient-reported control of
breathlessness are presented in Summary of findings 4.
We performed direct meta-analysis of data from two studies
which used a 100-mm VAS breathlessness scale in participants
undergoing talc slurry pleurodesis and IPC insertion without daily
drainage. Davies 2012 used a scale with no breathlessness at 0 mm
and maximum possible breathlessness at 100 mm. We inverted the
results reported by Thomas 2017, since they used a scale where 0
mm represented "worst imaginable breathlessness" and 100 mm
no breathlessness. The minimum clinically important di)erence
using a 100-mm VAS breathlessness scale in MPE was 19 mm (95%
CI 14 to 24) (Mishra 2015). We had low certainty in the evidence from
our results that IPC without daily drainage may o)er comparable
breathlessness improvement when compared to talc slurry (MD –
6.12 mm, 95% CI –16.32 to 4.08) from a fixed-e)ect meta-analysis.
We downgraded evidence for serious study limitations due to lack
of blinding (which was not possible due to the nature of the
interventions). We also downgraded for indirectness due to the
di)erent time points at which VAS data with total numbers of
participants was reported by studies (Davies 2012: 42 days; Thomas
2017: 180 days).
One study used a 100-mm VAS breathlessness scale (0 mm
representing absence of breathlessness and 100 mm most severe
symptoms) to compare talc poudrage with talc slurry pleurodesis
(Bhatnagar 2020). The authors reported no significant di)erence
in VAS dyspnoea scores between intervention arms at all time
points (absolute di)erence in mean VAS score from baseline of
talc poudrage versus talc slurry: 0.8, 95% CI –4.6 to 6.2; P = 0.78).
Data from this study demonstrated an MD of 4 mm (95% CI –
6.26 to 14.26) between talc poudrage and talc slurry. We had a
moderate level of certainty in the evidence and downgraded for
serious study limitations only, due to lack of blinding of participants
and clinicians (which was not possible due to the nature of the
interventions).
Network meta-analysis
There were insu)icient comparable data to perform an NMA.
Other findings
Two studies compared dyspnoea scores for participants with
daily IPC drainage and IPCs without daily drainage. In the
AMPLE-2 study, authors reported that  there was no significant
di)erence between VAS breathlessness scores over the first 60
days postintervention (ratio of geometric means 1.32, 95% CI
0.88 to 1.97; P = 0.18; Muruganandan 2018). In the ASAP study,
the proportion of participants with relief of breathlessness at
two weeks was 0.65 in the aggressive (daily) drainage arm and
0.40 in the standard (alternate day drainage), with between-group
di)erences maintained at 12 weeks' postintervention (Wahidi
2017).
Putnam 1999 compared IPC without daily drainage and doxycycline
pleurodesis, demonstrating an improvement in breathlessness
in all groups and time points compared to baseline. The only
between-group di)erence identified was change in Borg score on
exertion at 30 days, which appeared to favour IPC (mean 2.2 (SD 2.4)
in IPC group versus mean 1.0 (SD 2.4) in doxycycline group; P = 0.05).
One study comparing talc slurry pleurodesis with IPC – not daily
drainage found that participants from both groups reported less
breathlessness at six weeks and the improvement was similar in
both treatment arms (mean Modified Borg Score improvement: 2.2
in talc slurry group versus 1.6 in IPC group; P = 0.44), although there
was substantial data attrition due to 35/94 participants dying within
six weeks (Boshuizen 2017).
Demmy 2012 demonstrated that participants with an IPC drained
on a daily basis had significantly better dyspnoea scores at 30 days
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than those in the talc slurry group (8.5 with IPC drained daily versus
6.1 with talc slurry; P = 0.047).
Participants receiving talc through their IPC had less breathlessness
at day 56 than those with an IPC alone in the IPC Plus study (mean
VAS score di)erence –7.9 points, 95% CI –15.5 to –0.3 in IPC plus
talc group; P = 0.04). However, mean VAS dyspnoea scores over the
70-day trial period did not di)er between the treatment arms (–3.6
points, 95% CI –8.5 to 1.3; P = 0.15) (Bhatnagar 2018).
Urokinase for multi-loculated malignant e)usions had no
significant impact on breathlessness when compared to placebo
(adjusted MD from baseline between groups 23.8 mm, 95% CI 212
to 4.4; P = 0.36; Mishra 2018).
Rafiei 2014 found more participants receiving doxycycline had
severe dyspnoea at two months compared to those receiving
bleomycin (5/20 (24%) with doxycycline versus 1/21 (5%) with
bleomycin; P = 0.01). Bjermer 1995 noted that participants receiving
mitoxantrone had a larger reduction in breathlessness than the
mepacrine-treated participants (absolute values not reported; P
≤ 0.001). Masuno 1991  did not provide the absolute figures but
reported "statistically significant" improvements in dyspnoea one
week aGer treatment at "the final judgement" in the LC9018
group. Alavi 2011 observed lower dyspnoea scores for participants
receiving bleomycin than those receiving iodine at one-month
postintervention, although no figures were included in the paper.
Hojski 2015 observed improved QLQ-C30 dyspnoea scores in the
TMP group compared to talc slurry.
In the remaining studies reporting dyspnoea, there were no
di)erences between the study arms in terms of the degree of
improvement of dyspnoea (Diacon 2000; Mohsen 2011; Rintoul
2014; Terra 2015; Zimmer 1997).
Participants' quality of life and symptom control
Twenty-four of 80 studies reported quality of life or assessed a
symptom score other than dyspnoea. We did not perform pair-wise
(direct) meta-analysis or NMA of quality of life scores as there was
insu)icient comparable data. 
The methods used were Karnofsky Performance Score (KPS)
(Demmy 2012; Du 2013; Groth 1991; Masuno 1991; Wahidi 2017;
Zhao 2009), QLQ-C30 questionnaire (Bagheri 2018; Davies 2012;
Dresler 2005; Hojski 2015; Rintoul 2014; Wang 2018), SF36 scale
(Bhatnagar 2020; Terra 2009; Wahidi 2017), WHOQOL-BREF scale
(Neto 2015; Terra 2015), EQ-5D (Bagheri 2018; Bhatnagar 2020;
Muruganandan 2018; Rintoul 2014; Thomas 2017), VAS Score
(Diacon 2000; Thomas 2017), Guyatt CRQ (Putnam 1999), a
symptom questionnaire (Bjermer 1995), and numerical pain scale
(Alavi 2011; Paschoalini 2005; Zimmer 1997).
Five studies evaluating IPCs reported quality of life data. One study
found no di)erence in the number of participants experiencing
'general malaise' between those randomised to IPC without daily
drainage and talc slurry pleurodesis (Boshuizen 2017). Neither
study comparing IPC (without daily drainage) to talc slurry
observed a di)erence in quality of life between treatment arms
(Davies 2012; Thomas 2017). KPS (MD 8.5, 95% CI –6.2 to 23.3;
P = 0.24) and 36-item Short Form (SF-36) (MD –12.6, 95% CI –
29.3 to 4.1) scores were similar in participants with daily IPC
drainage versus IPC without daily drainage at 12 weeks in the
ASAP trial (Wahidi 2017). Participants were asked to complete a
'social functioning score' as a component of the SF-36 survey in
Wahidi 2017. There were similar improvements across quality of
life measures in participants with both daily and alternate day
IPC drainage regimens.   Participants in the daily IPC drainage
group had a bigger improvement in EQ-5D-5L scores over the
six-month AMPLE-2  study period, compared with those in the
symptom-guided drainage group, representing a better quality of
life (estimated di)erence in means 0.112, 95% CI 0.0198 to 0.204;
P = 0.0174; Muruganandan 2018). However, the authors reported
no between-group di)erences in the VAS quality of life scores
(ratio of geometric means 1.220, 95% CI 0.871 to 1.709; P = 0.25;
Muruganandan 2018). There was no di)erence in Guyatt CRQ scores
between participants randomised to IPC (without daily drainage)
and doxycycline pleurodesis (Putnam 1999).
Bhatnagar 2018 reported that participants who received talc via
IPC had higher quality of life scores (with higher scores indicating
a better quality of life) than those who received placebo at all time
points. Di)erences in QLQ-C30 scores reached significance at day
28 (di)erence 9.2 points, 95% CI 1.1 to 17.4; P = 0.03) and EQ-5D-5L
at day 42 (di)erence 0.12 points, 95% CI 0.01 to 0.22; P = 0.03)
(Bhatnagar 2018).
Most studies reported no di)erence in quality of life measures
between the treatment groups (Alavi 2011; Bhatnagar 2020; Davies
2012; Diacon 2000; Groth 1991; Paschoalini 2005; Terra 2009; Terra
2015; Zimmer 1997). Bjermer 1995 reported a "larger reduction" in
tiredness in the mitoxantrone group compared to the mepacrine
group (absolute figures not provided; P ≤ 0.001). Dresler 2005 noted
less fatigue in the talc poudrage group than the talc slurry group
(absolute figures not provided; P = 0.016). Those participants who
received LC9018 "demonstrated a significant improvement of PS
(performance status) at 1 week" than those who did not (absolute
figures not provided; P ≤ 0.05) (Masuno 1991). Zhao 2009  found
that more participants who received combination treatment with
cisplatin plus Ad-p53 had a performance score "improvement rate
that was significantly higher" at six weeks than those receiving
cisplatin alone (11/17 (65%) with cisplatin plus Ad-p53 versus
6/18 (33%) with cisplatin alone; P = < 0.05). The participants who
underwent a video-assisted thoracoscopic partial pleurectomy had
"significantly better" EQ-5D scores at six months than the talc
group in the MesoVATS study (MD 0.08, 95% CI 0.003 to 0.16);
P = 0.042), but no di)erence in their QLQ-C30 scores (Rintoul
2014). Demmy 2012 did not provide data by treatment group. Du
2013 reported 30 participants (83%) receiving bevacizumab and
cisplatin had an "improved quality of life" (measured by KPS) as
opposed to 15 (50%) in the cisplatin group. Hojski 2015 observed
an "improvement of quality of life" in both the TMP and talc
slurry groups, but with pre- and post-treatment QLQ-C30 scores
demonstrating higher global health scores and less fatigue  in the
TMP group compared to talc slurry.
No studies reported on the potential patient burden of community
IPC drainages and impact this may have on quality of life.
Relative costs of the comparative techniques
Seven of 80 trials reported the relative costs of the interventions.
Rapid pleurodesis was cheaper than standard care in Yildirim 2005
(USD 245 (SD 71.5) with rapid pleurodesis versus USD 860 (SD 496)
with standard care). Talc slurry was cheaper than bleomycin in
three studies: Ong 2000 evaluated the cost per dose (USD 1 per
dose with talc slurry versus USD 309 per dose with bleomycin);
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Haddad 2004 calculated the complete cost for the entire procedure
(USD 488 (SD 212.5) with talc slurry versus USD 796 (SD 207.3) with
bleomycin) and Zimmer 1997 calculated the cost of each treatment
(USD 12.36 with talc slurry versus USD 955.83 with bleomycin).
Talc poudrage was also cheaper than bleomycin in Diacon 2000
(CHF 3893 (Swiss Francs) (USD 4206) with talc poudrage versus
CHF 4169 (USD 4504) with bleomycin). The total cost of VATS
pleurectomy was more than talc pleurodesis (GBP 14,252 (USD
21,682) with VATS pleurectomy versus GBP 10,436 (USD 15,876)
with talc pleurectomy) (Rintoul 2014). Dresler 2005 reported no
di)erence between the cost of talc slurry and poudrage (no figures
quoted).
A costing study performed alongside the TIME-2 study found IPCs
to be a cost-e)ective choice when compared to talc slurry and
most economical in participants with limited survival. "Substantial
uncertainty" about the longer-term cost-e)ectiveness of IPCs was
acknowledged due to limitations including sample size of the study
population (which was not powered to detect cost-e)ectiveness
di)erences) and variables such as nursing time required for IPC
drainage and life-expectancy (Olfert 2017).
At 12 weeks' postintervention, nine (69%) participants undergoing
daily IPC drainage and seven (58%) participants with alternate-day
IPC drainage in the ASAP trial considered that catheter supplies
posed no financial burden. Ten (77%) participants in the 'aggressive
drainage' arm and six (50%) participants in the standard care arm
had costs completely covered by insurance (Wahidi 2017).
Overall mortality
Forty-five studies provided participant mortality data (number of
study participants who had died).
Pair-wise (direct) meta-analysis
The direct evidence regarding mortality is shown in Appendix
13. Only one direct comparison found evidence of a di)erence
between treatment arms; in the comparison between interferon
and bleomycin  those receiving interferon had a higher rate of
mortality (OR 2.16, 95% CI 1.15 to 4.07; participants = 160; Analysis
12.4).
Network meta-analysis
We incorporated 31 trials of 15 treatments, including 2816
participants, into an NMA analysing mortality (Appendix 14;
Appendix 15). Results from the NMA are summarised in Summary
of findings 5.
Rankings within the network were imprecise, with wide CIs; for this
reason, we downgraded certainty in the evidence by one level in
all comparisons. We also downgraded for indirectness, due to the
di)erent time points at which studies reported mortality data.
Tetracycline may be associated with higher mortality rates than six
agents including bleomycin (OR 2.58, 95% Cr-I 1.09 to 6.76), talc
poudrage (OR 3.06, 95% Cr-I 1.05 to 9.76) and talc via IPC (OR 7.74,
95% Cr-I 1.33 to 50.51). We tentatively suggest that bleomycin (OR
1.03, 95% Cr-I 0.43 to 2.50) and IPC – not daily drainage (OR 0.80,
95% Cr-I 0.42 to 1.61) may be comparable to talc slurry but have a
low level of certainty in this conclusion.
We are uncertain whether talc poudrage may be comparable to
talc slurry (OR 0.87, 95% Cr-I 0.51 to 1.49; very-low certainty). In
addition to downgrading for imprecision and indirectness, we also
downgraded the evidence for this comparison for inconsistency (I2
= 40%). We are uncertain whether doxycycline may be comparable
to talc slurry (OR 0.71, 95% Cr-I 0.15 to 3.23); very-low certainty)
and downgraded evidence for serious study limitations in addition
to imprecision and indirectness.
The degree of heterogeneity was low (Tau 0.22, 95% Cr-I 0.01 to
0.73).
There was no evidence of global inconsistency in this network:
the DIC was 5 points lower (indicating better fit aGer penalising
for complexity) for the NMA model than for the inconsistency
model, and the estimate of between-study heterogeneity (Tau)
was very similar under both models. The residual deviance under
each of the two models was almost identical (53.8 NMA versus
54.1 inconsistency model): therefore, we did not present plots
of residual deviance contributions for this outcome, as these
are uninformative. Similarly, there was no evidence of loop
inconsistency (Appendix 4).
Other findings
Most studies that were not included in the network showed no
di)erences in mortality (Clementsen 1998; Crnjac 2004; Goodman
2006; Ishida 2006; Mager 2002; Maskell 2004; Rahman 2015; Rintoul
2014; Terra 2015; Villanueva 1994; Yildirim 2005; Yoshida 2007; Zhao
2009).
Median survival
Thirty studies reported median survival (days) for the treatment
groups.   Two studies found a survival di)erence between the
treatment arms. Masuno 1991 found a median survival of 232 days
with LC9018 versus 125 days with control (participants = 95; P =
0.008). Mishra 2018 observed an increase in time to death in the
urokinase group (median survival: 69 days with urokinase versus 48
days with placebo; P = 0.026).
Kasahara 2006 reported a longer median survival in participants
receiving high-dose OK-432 than low-dose OK-432, but did not
report the spread or whether this di)erence was significant (33.6
days with high dose versus 22.6 days with low dose; participants
= 38). Evans 1993 found survival was longer aGer thoracoscopic
tetracycline pleurodesis than bedside administration (total
participants = 34; P = 0.03; raw data only available as a survival
curve).
Duration of inpatient stay
Twenty-eight of 80 studies reported data for duration of inpatient
stay.
Total length of stay
Many studies reported no di)erence between interventions (Bayly
1978; Bhatnagar 2018; Bhatnagar 2020; Haddad 2004; Ibrahim
2015; Lynch 1996; Muruganandan 2018; Ong 2000; Paschoalini
2005; Rahman 2015; Schmidt 1997; Terra 2009; Yim 1996; Zimmer
1997).
Yildirim 2005 and Goodman 2006 reported a shorter length of
stay when chest drains were removed earlier following sclerosant
administration compared to standard care (Yildirim 2005: mean:
2.33 days (SD 0.62) with shorter versus 8.33 days (SD 4.85) with
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standard; P ≤ 0.001; participants = 27; Goodman 2006: median:
4 days (interquartile range (IQR) 4 to 8) with shorter versus 8
(IQR 6 to 9) with standard; P ≤ 0.01; participants = 41). Ozkul
2014, which evaluated a rapid drainage strategy prior to sclerosant
administration, also showed this group had a shorter length of stay
than the standard care group (mean: 2.2 days with rapid versus 9.0
days with standard; P ≤ 0.001; participants = 79). The talc group
had a shorter length of stay than the VATS partial pleurectomy
group in the MesoVATS study (median: 3 days (IQR 2 to 5) with talc
versus 7 days (IQR 5 to 11) with VATS; P ≤ 0.001; participants = 196)
(Rintoul 2014). Participants undergoing TMP had a shorter hospital
stay than those receiving talc slurry in Crnjac 2004 (mean: 5.5 days
(SD 2.5) with TMP versus 7.5 (SD 3.3) with talc slurry; P  = 0.001;
participants = 87). Although the mean duration of thoracic drainage
was shorter for participants undergoing TMP in Hojski 2015, there
was no di)erence in the total length of hospital stay.
Thomas 2017 reported that participants receiving an IPC (without
daily drainage) spent fewer days in hospital from procedure to
death or 12 months compared to those receiving talc slurry (10 days
(IQR 3 to 17) with IPC (without daily drainage) versus 12 days (IQR
7 to 21) with talc slurry; P = 0.03; participants = 146). Over the 12-
month TIME-2 study, participants receiving an IPC (without daily
drainage) spent a median of 1 day (IQR 0 to 3 days) in hospital for
drainage or drainage-related complications compared to a median
of 4.5 days (IQR 2.5 to 7.5) in the talc slurry pleurodesis group (P
≤ 0.001) (Davies 2012). Talc administration via IPC and daily IPC
drainage did not result in a di)erence in the number of days spent in
hospital when compared to IPC without daily drainage (Bhatnagar
2018; Muruganandan 2018).
Time from intervention to discharge
Putnam 1999 reported that participants randomised to receive an
IPC had a  reduced hospital admission time from randomisation
to discharge compared to those receiving doxycycline pleurodesis
(median: 1 day with IPC versus 6.5 with doxycycline; P ≤ 0.001;
participants = 144). This was mirrored by Boshuizen 2017  who
reported a median hospitalisation period of 4 days versus 0 days (P
≤ 0.0001) favouring participants in the IPC without daily drainage
arm compared to those receiving talc slurry pleurodesis. Thomas
2017 reported a reduced length of initial hospital admission for
IPC insertion (median stay: 1 day (IQR 1-2 days) with IPC insertion
versus 3 days (IQR 3-4 days) with talc pleurodesis; P ≤ 0.001). In the
TIME-2 study, time from randomisation to discharge was a median
of 0 days (IQR 0 to 1) in the IPC (without daily drainage) group and 4
days (IQR 2 to 6) in the talc pleurodesis group (di)erence: 3.5 days
fewer, 95% CI –4.8 to –1.5; P ≤ 0.01) (Davies 2012).
Participants receiving urokinase for non-draining MPE had a shorter
length of hospital stay from randomisation to discharge compared
to those receiving placebo (mean 6.2 days (SD 2.7) with urokinase
versus 8.7 days (SD 6.5) with placebo; P = 0.049) (Mishra 2018).
Participants randomised to autologous blood pleurodesis had
a shorter duration of postpleurodesis hospital stay than those
receiving talc slurry (mean: 2.8 days (SD 0.9) with autologous
blood pleurodesis versus 3.6 days (SD 1.8) with talc slurry; P
= 0.04) (Keeratichananont 2018), and tetracycline (2.6 (SD 1.2)
with autologous blood pleurodesis versus 4.3 days (SD 2.4) with
tetracycline; P = 0.03) (Keeratichananont 2015).
Mohsen 2011 found participants receiving iodine had a shorter
postprocedural length of stay than those undergoing talc poudrage
(mean: 4.5 days (SD 1.1) with iodine versus 5.7 (SD 2) with talc
poudrage; P = 0.02; participants = 42).
Patient acceptability
Three trials reported patient acceptability of the interventions
(Demmy 2012; Dresler 2005; Wahidi 2017).
Participants recruited to the ASAP trial showed an overall high
level of satisfaction with IPCs when asked to complete a patient
satisfaction questionnaire. At 12 weeks' postintervention, 12
participants (92%) in the 'aggressive' daily drainage study arm and
11 participants (92%) in the standard (not daily drainage) arm felt
they would choose an IPC again as a treatment for pleural e)usion-
related breathlessness. When asked at 12 weeks' postintervention,
nine (69%) participants in the daily drainage group and five (42%)
participants in the standard care group reported it was 'extremely
easy' to drain the catheter at home (Wahidi 2017).
No studies reported on the potential patient burden of community
IPC drainages and the impact this may have on quality of life.
Demmy 2012 did not provide raw data by treatment group. Dresler
2005 reported no di)erence between talc slurry and talc poudrage
in terms of participants' perception of convenience (no raw data
provided).
The only trial evaluating mistletoe (viscum) reported that 2/13
participants in the mistletoe arm withdrew their consent for
ongoing study participation aGer experiencing allergic reactions
to the first dose. The outcomes for these participants were not
available and hence the trial deemed them non-evaluable (Gaafar
2014).
Need for repeat invasive pleural intervention
We considered that the risk of requiring a repeat invasive
pleural procedure for symptomatic re-accumulation of pleural
fluid is an important factor when selecting an initial management
strategy for MPE. Pleural fluid re-accumulation, due to failure of
the initial pleurodesis, is frequently associated with increasing
breathlessness. Undergoing an additional procedure commonly
incurs more time in hospital and re-exposure to the risk of
procedure-related complications.
Direct (pair-wise) meta-analysis
We performed pair-wise meta-analyses comparing talc poudrage,
bleomycin and IPCs without daily drainage to talc slurry, in
terms of need for repeat invasive pleural intervention. Results are
summarised in Summary of findings 6.
We had a moderate level of certainty that participants receiving
talc poudrage probably have a comparable risk of requiring repeat
invasive pleural intervention than those receiving talc slurry (OR
0.96, 95% Cr-I 0.59 to 1.56; studies = 2; participants = 380; Bhatnagar
2020; Terra 2009). We downgraded certainty in the evidence by one
level for indirectness, due to di)erences between study protocols
(Bhatnagar 2020 administered 4 g of graded talc by 12-Fr to 14-
Fr drains in the talc slurry arm and by 16-Fr to 24-Fr drains in the
talc poudrage arm, whereas Terra 2009 administered 5 g of 'non-
calibrated' talc via 28-Fr drains).
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Participants receiving an IPC (without daily drainage) are probably
less likely to require repeat invasive pleural intervention than
participants receiving talc slurry pleurodesis (OR 0.25, 95% Cr-I
0.13 to 0.48; studies = 3; participants = 343; moderate certainty;
Boshuizen 2017; Davies 2012; Thomas 2017). We downgraded
evidence by one level for indirectness, as participants with trapped
lung were excluded by one study (Thomas 2017), but included by
Boshuizen 2017 and Davies 2012.
We made note of study limitations due to lack of blinding (which
was not possible due to the nature of the study interventions) in
the talc poudrage to talc slurry and IPC without daily drainage
to talc slurry comparisons, but did not downgrade evidence as
requirement for repeat intervention was guided by symptoms and
radiology, with involvement of a second blinded clinician in one
study (Bhatnagar 2020) prior to repeat intervention in participants
with less than one-third opacification of the hemithorax.
Data were also available from one study comparing bleomycin
to talc slurry, but the result was very imprecise (OR for repeat
procedure 4.33, 95% Cr-I 0.16 to 114.58; participants = 33; very-
low certainty; Zimmer 1997). We downgraded evidence by one level
for serious study limitations, as data comparing bleomycin to talc
slurry were available from only one study, at high risk of bias in
three domains. We downgraded evidence by two levels due to gross
concerns of imprecision due to the small number of participants
(33) and very wide CIs.
There was no direct evidence comparing doxycycline or placebo to
talc slurry.
From these results, we estimated that 20/100 participants (95% CI
16 to 24) will require a repeat invasive procedure with talc slurry,
19/100 (95% CI 11 to 30) with talc poudrage, 6/100 (95% CI 3 to 11)
with IPC without daily drainage and 52/100 (95% CI 4 to 97) with
bleomycin.
Network meta-analysis
We performed a post-hoc NMA for requirement for ipsilateral repeat
invasive pleural intervention. However, there were no meaningful
results. There was only one evidence loop in the entire network
and the indirect evidence was computationally unstable due to the
presence of a zero cell count.
D I S C U S S I O N
This is the first update of the review published in Issue 5, 2016 (Clive
2016), which replaced the original review published in 2004 (Shaw
2004).
Summary of main results
The management of MPE has long been subject to debate and
research. This systematic review of the current literature attempts
to combine all the available randomised evidence regarding the
wide variety of interventions for the condition.
Since the last iteration of this review in 2016, a number of robust,
large randomised trials have been published evaluating some key,
clinically important questions in this area.  These have provided
us with a wealth of new data, including more important patient-
reported outcomes and better insights into the role for IPCs in MPE
management.
Our primary NMA evaluating pleurodesis failure indicated that talc
poudrage may have fewer pleurodesis failures than talc slurry (OR
0.50, 95% Cr-I 0.21 to 1.02; moderate-certainty evidence). However,
direct evidence from four statistically homogeneous trials (I2 = 0%)
estimated an OR closer to the null value of 1 (OR 0.81, 95% CI 0.61 to
1.08; Analysis 3.1), indicating that the two interventions may have
comparable e)icacy. A sensitivity NMA restricted to studies at low
risk of bias provided a similar e)ect estimate, with a wide Cr-I (OR
0.78, 95% Cr-I 0.16 to 2.08).  Estimated ranks of talc poudrage and
talc slurry were third (95% Cr-I 1 to 6) and sixth (95% Cr-I 3 to 10) of
21 interventions from the primary NMA and second (95% Cr-I 1 to 9)
and fourth (95% Cr-I 1 to 9) of 18 interventions from the sensitivity
analysis restricted to trials at low risk of bias.
A large number of trials estimated pleurodesis failure rates with
talc slurry (907 participants randomised to this intervention across
19 studies): talc slurry was therefore used as the comparator
intervention in the 'Summary of findings' tables (Summary of
findings for the main comparison;Summary of findings 2; Summary
of findings 3;  Summary of findings 4;  Summary of findings
5;  Summary of findings 6). Although other interventions, such
as mistletoe (viscum) and TMP, appeared to rank highly within
the primary NMA, these interventions were only evaluated by
very small studies (63 participants randomised to TMP and 10
to mistletoe (viscum) in total), all with an overall  high risk of
bias. Hence, estimates of the relative e)icacy or rank of these
interventions are very imprecise (wide Cr-Is) and we excluded
both of these agents from the low risk of bias sensitivity analysis.
Given the very small number of participants randomised to these
interventions, it is not possible to draw conclusions about their use
in routine clinical practice.
Our results indicate that IPCs without daily drainage (rank 18th,
95% Cr-I 13 to 21) of 21 interventions in the main network and
rank 15th (95% Cr-I 9 to 18) of 18 interventions in the sensitivity
analysis excluding studies at high risk of bias) are less likely to e)ect
a definitive pleurodesis allowing IPC removal than several other
interventions, including talc poudrage and talc slurry (moderate
certainty). However, pleurodesis e)icacy may be increased with
daily IPC drainage or by administration of talc slurry via the IPC.
Importantly, direct meta-analysis demonstrated that participants
with an IPC (without daily drainage) were less likely to require
repeat invasive pleural intervention than participants treated with
talc slurry pleurodesis (OR 0.25, 95% CI 0.13 to 0.48; studies
= 3, participants = 343; moderate-certainty evidence). This is a
potentially important finding for patients, since requirement of
a repeat invasive pleural intervention may be a more relevant
and meaningful outcome than obtaining a definitive pleurodesis.
We considered this  an important  factor with regard to  patient
acceptability of the available interventions.
The networks evaluating  fever and pain  found only uncertain
evidence of minimal di)erences between agents, with no evidence
for di)erences between the most commonly used interventions
reported in the 'Summary of findings' tables.
Five studies provided data on infection rates in participants
receiving IPCs compared to chemical pleurodesis (Boshuizen 2017;
Davies 2012; Demmy 2012; Putnam 1999; Thomas 2017). Data from
three studies suggest participants receiving an IPC may have a
higher risk of developing cellulitis or pleural infection. Notably, no
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IPCs were removed as a consequence of infection (Davies 2012;
Putnam 1999; Thomas 2017).
There were insu)icient comparable data to perform an NMA
of breathlessness outcomes. However, the evidence suggests
no di)erence in postintervention VAS breathlessness scores of
participants receiving an IPC (without daily drainage) compared
to talc slurry pleurodesis, based on a direct meta-analysis of data
from two studies (MD  in change in 0-mm to 100-mm VAS score –
6.12 mm, 95% CI –16.32 to 4.08; low-certainty evidence) (minimum
clinically important di)erence for dyspnoea in MPE using the
VAS breathlessness scale 19 mm, 95% CI 14 to 24; Mishra 2015).
Direct comparison from one study demonstrated likely comparable
outcomes for breathlessness control between talc poudrage and
talc slurry (MD 4.00 mm, 95% CI –6.26 to 14.26; moderate-certainty
evidence; Bhatnagar 2020).
There was also insu)icient comparable data to perform an
NMA of quality of life outcomes. Most studies reported no
di)erence between interventions on quality of life outcomes.
Only seven studies reported the relative costs of interventions.
Three studies found talc slurry to be cheaper than bleomycin. A
costing study performed alongside the TIME-2 trial found IPCs to
be a cost-e)ective choice when compared to talc slurry and most
economical in participants with limited survival, but noted further
research is needed about the longer-term cost-e)ectiveness of IPCs
(Olfert 2017).
The NMA evaluating mortality found  only uncertain evidence
of  minimal di)erences between agents, with no evidence for
di)erences between the most commonly used interventions
reported in the 'Summary of findings' tables.
Twenty-eight of 30 studies reporting median survival (days) found
no di)erence between interventions.
Participants receiving an IPC spent fewer days in hospital over
the course of their remaining life, or until 12 months, in two
studies (Davies 2012; Thomas 2017). Data also demonstrates that
participants undergoing an IPC insertion had a faster time to
hospital discharge than those admitted for a chemical pleurodesis
(Boshuizen 2017; Davies 2012; Putnam 1999; Thomas 2017).
Overall completeness and applicability of evidence
This is the largest systematic review of the evidence surrounding
interventions in MPE in the published literature. We used robust
search strategies to identify all the available randomised evidence
and diligently contacted the study authors regarding missing data
where possible.
However, despite attempting to contact the study authors, we
were unable to obtain additional information regarding 40 records
during the full-text screening process  (36/207 records identified
from searches in 2016, included within the 135 listed as 'not
eligible'  and a further 4/156 records identified in 2019 updated
searches, included within the 124 'not relevant' records) in order to
confirm whether eligibility criteria for inclusion in the review were
met.  We only included RCTs within this review. As per the protocol,
we excluded studies which were not randomised (at high risk of
bias for sequence generation, allocation concealment, or both). It
is possible that publication bias may therefore a)ect the validity of
the results.
The small number of studies for each pair-wise comparison
(maximum of five), meant funnel plots would not be informative
(Sterne 2011). As the interventions could not be logically ordered,
we also decided a comparison-adjusted funnel plot for the network
was not valid (Salanti 2014).
Several studies included in this review had very small numbers
of participants, which raises the possibility of small-study e)ects,
which may have resulted in an overestimation of treatment e)icacy.
Only 13/80 included studies had outcome data for more than 100
participants (Bhatnagar 2018; Bhatnagar 2020; Davies 2012; Dresler
2005; Keeratichananont 2018; Putnam 1999; Rahman 2015; Rintoul
2014; Sartori 2004; Thomas 2017; Wahidi 2017; Wang 2018; Yoshida
2007). However, a comparison between pair-wise meta-analysis
results from random-e)ects versus fixed-e)ect models (which gives
relatively more weight to larger studies, hence reducing the impact
of small studies) found no meaningful di)erences.
When evaluating di)erent pleurodesis agents, we elected to
combine di)erent doses of each agent from the available studies for
the purposes of comparison. This was necessary due to variation in
the doses between studies, which would have made the network
more sparse and unconnected. This is a limitation of our review,
since di)erential treatment e)ects according to doses could have
been missed. This is one possible explanation for the high levels
of heterogeneity observed in our meta-analyses, which we were
unable to investigate further due to the complexity of the data.
One included study was designed to compare di)erent doses of
silver nitrate and this revealed no di)erence in terms of pleurodesis
e)icacy or adverse e)ects (Terra 2015).
Many of the included studies did not assess patient quality of life,
symptom control, acceptability of the intervention to the patient,
duration of  inpatient  stay and costs. Of those that did, we were
limited by the diversity of outcome measurement systems used and
inconsistent reporting of data and it was therefore not possible to
perform an NMA for these outcomes. Although pair-wise and NMA
of the risk of having procedure-related pain was possible using data
from studies that reported the presence or absence of pain,  we
were unable to incorporate data from studies which used a scoring
system to grade severity of  pain (continuous outcome data), due
to the range of di)erent scales used.  Although such  outcomes
were secondary objectives of our review, they are important factors
when selecting a management strategy and hence the paucity
of data on these important patient-reported outcome measures
limits the applicability of the evidence from this review to everyday
clinical practice.
It is also important to consider the global availability of some
of these agents when considering the clinical applicability of our
findings. Agents such as tetracycline and C parvum are not widely
available, precluding their routine use. Other sclerosants included
in this review are unlicensed for use as a pleurodesis agent.
Our data regarding the adverse e)ects of these treatments are
limited. As we have selected only RCTs for inclusion in this
review, there is the potential that rare but important adverse
e)ects were missed using our methodology. There are reports of
adverse e)ects of pleurodesis agents resulting from absorption
of the agent into the systemic circulation. For example, systemic
absorption of mixed particle size talc is thought to be linked to
rare but occasionally life-threatening acute respiratory distress
syndrome, a risk that is minimised by the use of graded (large-
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particle) talc (Maskell 2004), now standard practice in Europe
and increasingly available worldwide. Mepacrine gained popularity
in Scandinavia as a pleurodesis agent, although rare psychotic
episodes and seizures, thought to be related to systemic absorption
if administered at high doses, limited its use (Bjorkman 1989).
We only managed to synthesise the data on the main adverse
e)ects and so we cannot reliably infer the full adverse e)ect profiles
of these treatments from this review. An appreciation of the adverse
e)ect profile of these interventions is vital when weighing up the
risks and benefits of the procedures, particularly as many of the
patients in this population have a limited life-expectancy and hence
minimising discomfort during their remaining time is imperative.
The definition of pleurodesis e)icacy varied between studies,
with many relying on radiology alone, which is increasingly
considered inadequate without considering symptom recurrence.
Achieving a pleurodesis  may not represent  the best strategy
for all. Patients may have a personal preference regarding the
best treatment strategy for themselves. Therefore, factors such
as breathlessness control and risk of repeat invasive pleural
intervention are also important to discuss when selecting the best
treatment strategy.  Many patients would rather avoid hospital
admission and elect for an outpatient pathway, which may make
the use of an IPC more appealing than a chemical pleurodesis.
Quality of the evidence
The overall certainty of the evidence ranged from moderate to
very low (Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3;   Summary of findings 4;
Summary of findings 5; Summary of findings 6).
The risk of bias in several included studies is substantial and
we downgraded evidence for study limitations in the pleurodesis
failure rate network, patient-reported breathlessness control meta-
analysis, mortality NMA and meta-analysis of  risk of requiring
a repeat invasive pleural intervention. The vast majority of
studies were unblinded, which in part reflects the nature of the
interventions but also the symptom-based nature of the endpoints
measured, precluding blinding of the outcome reporting as well.
Documentation of the methods used for sequence generation and
allocation concealment were frequently omitted and it was oGen
not possible to obtain this information retrospectively. However,
in a sensitivity analysis including only studies at low risk of bias
(defined as a maximum of one high-risk domain in the risk of bias
assessment), the relative rankings of interventions were similar.
The heterogeneity estimate (Tau) was substantially reduced in this
sensitivity analysis (from 0.70 to 0.37), indicating that bias may have
been a contributor to the high level of heterogeneity in the primary
analysis.
Given the inevitable death of patients in this palliative population,
true ITT analysis was oGen not performed, resulting in the potential
for attrition bias. These missing data were handled di)erently by
the various included studies. Some studies included participants
on the basis of their 'last observation carried forward' (i.e. their
last outcome prior to death) and others excluded these participants
from the analysis completely. No studies used other imputation
methods to account for these missing data.
We downgraded evidence for indirectness  due to variation in
definitions of  pleurodesis failure, inconsistencies in the doses of
sclerosant used and the di)erent approaches towards inclusion
or exclusion of participants with trapped lung. There was also
variation in how participant attrition was handled and the time
point at which pleurodesis failure was assessed. We did state how
this would be handled a priori, using hierarchies of preferences;
however, these factors may have impacted on the results of the final
NMA.
Additionally, we downgraded evidence due to imprecision; many
ranks and e)ect estimates had wide Cr-Is. This was particularly
evident in the NMAs of risk of procedure-related fever and pain, and
risk of mortality, where all relative e)ect estimates had wide Cr-Is.
We had very high concerns of imprecision in the bleomycin to talc
slurry comparison in the risk of repeat pleural intervention meta-
analysis and evidence was downgraded by two levels.
We downgraded evidence by one level for inconsistency for the IPC
without daily drainage to  talc slurry comparison for pleurodesis
failure rate (I2 = 61%) and for the  talc poudrage to talc slurry
comparison within the pain (I2 = 69%) and mortality (I2 = 40%)
outcomes.
There was a substantial degree of both statistical and clinical
heterogeneity in each network of comparisons. Aside from the
analyses restricted to studies at lower risk of bias and trials
excluding trapped lung (which did appear to reduce the degree
of heterogeneity) the other sensitivity analyses, selected on the
basis of factors hypothesised to be clinical e)ect modifiers, did
not appear to explain the high level of heterogeneity. This signifies
the complexity of this condition and the treatments, which results
in substantial clinical heterogeneity. Possible explanations include
di)erent e)ects of varying tumour subtypes, early lung entrapment
which is not clinically detectable, varying drug doses and subtle
technique-related procedural factors, such as adequacy of pleural
fluid drainage prior to instillation of the sclerosant.
Potential biases in the review process
This review is based on the available published evidence and not
on individual patient data, which would give a more accurate
estimation of treatment e)ect and a clearer understanding of the
heterogeneity (Deeks 2011). However, as we have included studies
published as long ago as 1977, individual patient information
was therefore not available and patient-level meta-analysis would
not be possible without excluding the majority of the available
evidence.
In order to allow inclusion of as many eligible studies as
possible, we combined data obtained using di)erent definitions of
pleurodesis failure and timings in the same analysis. We predefined
the methodology for this in the protocol using hierarchies of
preferences. We performed sensitivity analyses to ensure the
results were robust.
A potential source of bias in our primary outcome measure,
pleurodesis failure, is the inevitable participant attrition due
to mortality reported in many studies. If there had been real
di)erences in mortality (and therefore dropout) across the
interventions, this could bias the estimates of relative pleurodesis
failure rates. However, analysis of the data on mortality and
median survival times showed only a possible association between
tetracycline and increased mortality rates and no di)erences in the
vast majority of comparisons.
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It should also be noted that the initial screening of titles and
abstracts up to 2016 was performed by just one review author. From
2016 to 2020, this was done by two review authors.
Agreements and disagreements with other studies or
reviews
Several other systematic reviews have been published in this area
(Iyer 2019; Mummadi 2015; Shaw 2004; Sivakumar 2019; Tan 2006;
Xia 2014). All have presented only direct comparisons, rather than
also incorporating indirect comparisons of alternative agents using
NMA methods. We consider that NMA is much more informative, as
the diversity of the control groups used when comparing one agent
with 'all others' means that important relative treatment e)ects
may be either over- or underestimated.
We used robust inclusion and exclusion criteria to identify
eligible studies, which resulted in some studies included in other
systematic reviews in this field being excluded from this one.
These studies have been recorded in the Excluded studies section
of this review, with justifications given for their exclusion. The
main reasons were failure to use a truly random process to assign
treatment groups and the inclusion of ascites or pericardial fluid
accumulation, which could not be di)erentiated in the results
section.
Previously published meta-analyses have suggested that talc is
the most e)ective agent (associated with the fewest pleurodesis
failures)  and is best delivered thoracoscopically, however,
Mummadi 2015 found both talc poudrage and talc slurry o)ered
similar rates of pleurodesis e)icacy, in keeping with our results.
In a systematic review of quality of life following intervention
for MPE, Sivakumar 2019 also acknowledged limitations due to
heterogeneity in study design and varied measurement tools. While
thoracoscopic talc poudrage, talc slurry and IPCs improved short-
term health-related quality of life, no consensus was formed on the
overall best treatment approach, with particular respect to long-
term outcomes.
Our review has demonstrated that IPCs are associated with reduced
rates of invasive ipsilateral re-intervention and reduced procedure-
related length of hospital stay, mirrored by Iyer 2019.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For clinicians and for people with malignant pleural eusions
This systematic review suggests that of the commonly available
pleurodesis techniques, talc poudrage and talc slurry both rank
highly and are more e)ective at achieving a pleurodesis than
sclerosants such as bleomycin (rank 11th, 95% credible interval (Cr-
I) 7 to 15) and doxycycline (rank 12th, 95% Cr-I 5 to 18).
Although indwelling pleural catheters (IPCs) are probably
associated with higher pleurodesis failure rates than many of the
other interventions described, this is likely to be improved by daily
catheter drainage or instillation of talc slurry via the IPC. Moreover,
pair-wise meta-analysis suggests that the use of IPCs results in
less need for further invasive pleural interventions than talc slurry,
which may be an important advantage for some patients. Talc
poudrage was associated with a similar risk of requiring further
invasive pleural procedures when compared to talc slurry (odds
ratio (OR) 0.96, 95% Cr-I 0.59 to 1.56).
Where breathlessness outcomes were reported, symptom relief for
participants with IPCs may be comparable to talc slurry. For those
undergoing talc poudrage  pleurodesis, breathlessness relief  was
probably comparable to talc slurry pleurodesis. In four studies, IPCs
were associated with a reduced length of hospital stay (Boshuizen
2017; Davies 2012; Putnam 1999; Thomas 2017), a clinically relevant
outcome for a patient group where anticipated survival is oGen
short. Where pleurodesis success is not the primary outcome of
interest, such as for those with trapped lung or previous pleurodesis
failure, or for patients who wish to minimise repeated invasive
procedures or avoid a hospital admission, IPCs may be a favourable
choice.
We have noted comparable improvements in postintervention
quality of life outcomes in participants with IPCs (with or
without daily drainage), talc slurry, talc poudrage and doxycycline
pleurodesis (Bhatnagar 2020; Davies 2012; Muruganandan 2018;
Putnam 1999; Thomas 2017; Wahidi 2017). The OPTIMUM study,
which is currently recruiting in the UK, with health-related quality
of life as its primary outcome in participants undergoing IPC with
talc via IPC and talc slurry pleurodesis, will further inform practice.
This review was not designed to evaluate rarer but potentially
clinically important adverse e)ects. However, graded (large particle
talc) has less systemic absorption than mixed particle size talc and
should therefore be used to reduce the rare but important risk
of acute respiratory distress syndrome (Maskell 2004). Concerns
regarding the dose-dependent systemic absorption of intrapleural
mepacrine, and the subsequent risk of transient psychotic
episodes and seizures, have not been identified in the randomised
trials of these agents, but are likely to limit its routine use
(Bjorkman 1989). Non-steroidal anti-inflammatory drug (NSAID)
use has not been shown to adversely a)ect pleurodesis outcomes
(Rahman 2015).  Data from three studies suggest participants
receiving an IPC may have a higher risk of cellulitis and pleural
infection  (Davies 2012; Putnam 1999; Thomas 2017). Therefore,
appropriate information  regarding IPC care and symptoms of
infection should be given.
Worldwide, talc is reported to be the most commonly used
pleurodesis agent (Lee 2003; Roberts 2010; Zarogoulidis 2013), and
consequently it is likely to have the best appreciated adverse e)ect
profile. Therefore, if graded talc is available, this would appear to
be an e)ective choice for bedside pleurodesis,  supported by the
largest body of evidence.
For policy makers
We have identified that many of the available treatment options
have their own advantages and disadvantages, in terms of their
e)ectiveness at inducing a pleurodesis, their adverse event profile
and the chance a patient will need a subsequent invasive pleural
intervention. Therefore, it is important that a range of treatment
strategies are accessible and available to patients depending on
their clinical situation and their personal preference. For example,
there should be adequate provision of both IPC and an inpatient
pleurodesis to allow patients and clinicians to decide on an optimal
treatment pathway for that individual.
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For funders of the intervention
There are insu)icient data regarding the relative costs of many
of the interventions described in this review to provide robust
conclusions regarding this. In the short term, IPCs have been found
to be a cost-e)ective choice but the longer-term cost implications
have not been formally established.
Implications for research
General implications
There is a paucity of data regarding patient preference. Although
people with an IPC are likely to spend less time in hospital, we found
no data relating to considerations such as lifestyle restrictions
imposed by drainage regimens, limitation on social and functional
activities, and consequent impact on wellbeing. An improved
understanding of the key outcomes which are important to people
with malignant pleural e)usion (MPE) would be beneficial. Carer
burden is another significant consideration, particularly in regions
where community healthcare services do not provide IPC drainage.
The health economic implications of the available interventions
are additional important factors that warrant further research.
Limited data suggest that IPCs are a cost-e)ective choice in people
with limited survival (Olfert 2017), but substantial uncertainty
around this estimate remains, particularly in respect to long-term
outcomes. The cost of community nursing and environmental
implications associated with single-use drainage equipment may
make IPCs a less favourable choice in some settings.
There is a lack of robust randomised evidence for surgical
interventions in the MPE population. Our review has highlighted
that pleurodesis success from thoracoscopic mechanical
pleurodesis may yield results similar to talc poudrage, but further
high-quality evidence is required to delineate the role of this.
The  AMPLE 3 study, comparing talc slurry via IPC with video-
assisted thoracoscopic surgery (VATS) mechanical abrasion or talc
poudrage may provide further clarity.
There is limited evidence regarding the most e)ective management
of people with trapped lung. Case series suggest trapped lung
a)ects 10% to 20% of people with MPE and the rapid recurrence
of fluid aGer pleural interventions and the loss of elasticity of
the visceral pleura oGen results in severe symptoms of recurrent
breathlessness and pain during fluid aspirations (Brims 2012; Lan
1997; Warren 2008). OGen these patients are excluded from MPE
trials given the lack of e)icacy of pleurodesis in this subgroup
and hence there is a dearth of evidence on how best to manage
them. Future randomised controlled trials (RCTs) to delineate
the optimal management strategy specific to this population
would be beneficial.  Further understanding of how the disease
course of mesothelioma may di)er from metastatic pleural disease
may influence future treatment choices when considering the
management of MPE. The MesoTRAP pilot study, which is currently
recruiting in the UK, may lead to a phase III study comparing
the e)icacy of IPC versus VATS partial pleurectomy/decortication
for participants with malignant pleural mesothelioma with pleural
e)usion and trapped lung.
As our understanding of the pathology of MPE develops and
our knowledge of the available management options expands, a
universal approach to all patients with malignant e)usions is likely
to underestimate the complexity of this condition and a hunt for
the 'best' pleurodesis technique to over-simplify its challenges.
Di)erent strategies are already known to have unique advantages
and disadvantages and may therefore be suited to di)erent cohorts
of patients. We have demonstrated the heterogeneity of this
patient population. It is only by gaining an understanding of the
priorities of patients themselves and the real-life implications
of the various treatment options that we will be able to select
the most appropriate management strategy for an individual.
Further patient-centred qualitative research, as well as study of the
methods to optimise current strategies (SIMPLE trial) and combine
techniques to amalgamate the benefits of the varying modalities,
are exciting potential areas of ongoing and future research.
Design
Understanding the factors contributing to the high risk of bias
in a large number of the previous studies in this field is crucial
when designing future clinical trials in MPE. Attempting to minimise
these risks by careful trial design has the potential to improve our
evidence base and ensure robust, valid conclusions are drawn from
the available evidence.
Measurement (endpoints)
An important limitation of this review is the heterogeneous
reporting of patient-centred outcome measures across trials, which
precluded network meta-analyses of these clinically important
outcomes. This has important implications for future research.
Selection of appropriate, clinically relevant, standardised outcome
measures is essential to aid robust, unbiased analysis of trial data
and facilitate future systematic reviews (Williamson 2012). Specific
to this review, an international agreement on the definition of
pleurodesis success, the timing at which it should be assessed and
development of MPE-specific, validated patient-reported outcome
measurement tools would be hugely beneficial when combining
data from future RCTs, along with a consensus about how to handle
the inevitable patient attrition due to death.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Single-centre RCT comparing the efficacy of cosmetic talc with iodopovidone for pleurodesis (India).
Participants Inclusion criteria: recurrent symptomatic pleural effusion with improvement of breathlessness with
thoracentesis; or primary or secondary pneumothorax.
Exclusion criteria: allergy to iodine; thyroid disorder; trapped lung; air leak; advanced malignancy with
expected survival < 30 days.
36 participants randomised.
Interventions 28-Fr intercostal drain to completely drain effusion or treat pneumothorax. Pleurodesis agent given
when < 150 mL/day drainage and complete lung re-expansion on CXR. All participants received in-
trapleural lignocaine 2 mg/kg and IV tramadol prior to pleurodesis.
Iodopovidone: 20 mL 10% iodopovidone in 80 mL saline.
Cosmetic talc: 5 g sterilised 'baby powder.'
After agent administered, chest tube clamped for 4 hours. Repeat administration of agent if > 250 mL/
day drainage. Drain removed when < 100 mL/day output.
Follow-up at 1 week, 1 month, 3 months and 6 months, and then every 3 months thereafter.
Agarwal 2011 
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Outcomes Pleurodesis success according to need for thoracentesis (CR: relief of symptoms related to the effusion
and no re-accumulation on CXR at 30 days; PR: reduced dyspnoea related to effusion with only partial
re-accumulation of fluid on CXR and no requirement for therapeutic thoracentesis; failure: lack of suc-
cess as defined above)
Chest pain (measured by VAS)
Complications
Time to pleurodesis
Notes People with trapped lung excluded.
Unpublished data obtained from authors relating to subgroup of participants in the study with MPE –
only these data were included for the purposes of this review.
Included in network meta-analysis for pleurodesis failure and fever.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence.
Allocation concealment
(selection bias)





High risk Quote: "Blinding of the allocation to treatments was not possible."
Comment: agents had different appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence, VAS scores and complications would all be biased by





Low risk No LTFU. ITT analysis performed.
Selective reporting (re-
porting bias)
Low risk All reported.
Other bias Low risk Cosmetic talc used rather than medicinal talc, but sterilised and comparable




Methods Single-centre RCT of povidone-iodine and bleomycin pleurodesis for MPE (Iran).
Participants Inclusion criteria: biopsy or cytologically confirmed MPE (all tumour types); recurrent and symptomatic
effusion; CXR confirming lung expansion of 90% after thoracentesis; KPS > 70.
Alavi 2011 
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Exclusion criteria: comorbidities that precluded GA; bleeding disorders; massive thoracic skin infiltra-
tion; active infectious disease.
39 participants randomised.
Interventions All participants underwent a 28-Fr intercostal drain under local anaesthetic (± IV opiates if required).
Study agent administered intrapleurally the next day with 5 mL 2% lidocaine.
Bleomycin group: bleomycin 1 mg/kg in 60 mL saline. 1 dose.
Povidone-iodine group: 5% (volume unclear). 1 dose.
After administration of study agent, drain was clamped for 1 hour and removed when < 200 mL fluid
output/day. If fluid output remained high after 10 days, they were discharged home with a Heimlich
valve in place.
Outcomes Effusion recurrence on CXR at 30 days
Pain (measured by numerical scale) at discharge and day 30
Dyspnoea (measured by numerical scale) at discharge and day 30
Notes Minimal raw data in results section – tables quoted in text but not available online. Attempted to con-
tact study authors by emails – no response.
People with trapped lung excluded from trial entry.
Pleurodesis success measured only using CXR criteria.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation.
Allocation concealment
(selection bias)





High risk Differing appearances of bleomycin and iodine make blinding not possible (al-
though not stated explicitly in paper).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Pain and dyspnoea may be biased by lack of blinding. Not stated whether CXRs





Unclear risk Unable to obtain the tables. Response rates only given as % (no actual num-
bers), so unclear whether there was LTFU.
Selective reporting (re-
porting bias)
Unclear risk Raw data not provided for many of the outcomes. Tables missing.
Alavi 2011  (Continued)
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Methods Single-centre RCT comparing efficacy and safety of iodopovidone and bleomycin for pleurodesis in
MPE (Iran).
Participants Inclusion criteria: MPE with positive cytology who were candidates for pleurodesis.
Exclusion criteria: none stated.
60 participants randomised. 
Interventions All participants underwent chest tube insertion and entered the study once drain output < 100 mL and
CXR confirmed complete lung expansion.
Bleomycin group: 15 mg in 100 mL normal saline via chest tube, clamped for 6 hours.
Iodopovidone group: 20 mL 10% iodopovidone in 80 mL normal saline via chest tube, clamped for 6
hours.
CXRs obtained 24 hours postprocedure and at 2 weeks, 1 month and 6 months after discharge.





Notes Attempted to contact study authors by email for further information – no response.
Trapped lung excluded.
Included in network meta-analysis for pleurodesis failure, pain and fever.
Study funding source: no financial support received for the research, authorship, publication, or a com-
bination of these.
Study author conflicts of interest statements: none.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation and random numbers table. 
Allocation concealment
(selection bias)
Unclear risk No information given on who determined treatment allocation or how this was





Low risk Investigators and participants were unaware of the treatment allocation; how-
ever, no description of practical aspects and methods to maintain blinding
were given. 
Bagheri 2018 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No comment made on outcome assessment. Authors contacted by email for




Unclear risk No comment on whether there was a target for recruitment. No information-
 regarding data completeness or withdrawals. Mortality rate not stated, al-
though results given for all participants randomised. Authors contacted by
email to clarify – no reply.
Selective reporting (re-
porting bias)
High risk Limited outcome data given. No data presented on time to relapse.




Methods 2-centre RCT of intrapleural quinacrine (mepacrine) vs tetracycline via tube thoracostomy for MPE
(USA).
Participants Inclusion criteria: documented cancer with pleural effusion; pleural fluid cytology or pleural biopsy
confirming malignancy or exudate effusion presumed to be malignant; symptomatic from the effusion




Interventions Both groups had a closed tube thoracostomy, drained overnight prior to installation.
Quinacrine group: intrapleural quinacrine 100 mg in 30 mL normal saline once daily for 4 days.
Tetracycline group: 1 dose of intrapleural tetracycline 500 mg in 30 mL normal saline.
Drains clamped for 6 hours postinstallation with patient rotation. Drain removed when < 60 mL/24-
hour drainage.
Outcomes Pleurodesis success (defined on CXR criteria only at 30 days as CR: complete lack of re-accumulation of
pleural fluid; PR: re-accumulation of pleural fluid < 50% of the volume present before the sclerosis; fail-
ure: re-accumulation of fluid to > 50% of the volume present before the attempted sclerosis)
Adverse effects of treatment (pain, fever)
Notes People with trapped lung not excluded.
CR and PR counted as a pleurodesis success for purposes of analysis.
1 participant allocated to quinacrine arm having had treatment failure with tetracycline not included in
analysis.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bayly 1978 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified and unable to contact study authors.
Allocation concealment
(selection bias)





Unclear risk No comment on whether study was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated whether CXR evaluation was blinded. Pain and fever outcomes may
have been affected if participants were unblinded to treatment allocation;




Low risk 2/14 randomised to tetracycline excluded from analysis (1 died and 1 LTFU).
No LTFU in mepacrine arm (overall LTFU 13%).
Selective reporting (re-
porting bias)
Low risk All specified endpoints reported.





Methods Multicentre RCT comparing talc slurry pleurodesis via IPC with saline placebo (UK) – IPC Plus.
Participants Inclusion criteria: symptomatic MPE, IPC chosen for treatment, expected survival > 2 months, ECOG
performance status ≤ 2 after fluid removal.
Exclusion criteria: aged < 18 years, extensive lung entrapment or fluid loculation, ipsilateral attempt at
pleurodesis within the previous 8 weeks, any contraindication to trial procedures.
154 participants randomised.
Interventions Insertion of IPC under local anaesthetic with maximal fluid drainage at time of catheter placement. Dis-
charged home same day, with minimum of 3 further IPC drainages. Review at day 10 and randomisa-
tion if > 75% pleural apposition on CXR or < 1/3 opacification due to fluid on USS.
Talc group: 4 g sterile, graded talc slurry with 50 mL 0.9% saline.
Placebo group: 50 mL intrapleural 0.9% saline.
Participants discharged after 2-hour observation period with next IPC drainage 12–36 hours after ad-
ministration of talc or placebo. Subsequent drainage frequency determined by local team, but mini-
mum twice per week for duration of trial. Follow-up until 70 days postrandomisation or death, with tri-
al consultations every 14 days.
Outcomes Primary: pleurodesis success at day 35 (< 50 mL fluid drained on 3 consecutive occasions through the
IPC and CXR taken after these drainages showing < 25% opacification).
Secondary: QoL, breathlessness, chest pain, total volume drained from IPC, number of inpatient hospi-
tal days, all-cause mortality, degree of fluid complexity (septation or loculation), successful pleurodesis
Bhatnagar 2018 
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at day 70, successful pleurodesis at both day 35 and day 70, number of therapeutic pleural procedures,
adverse events and deaths. 
Notes People with some lung entrapment on CXR at day 10 were eligible for randomisation, but this was in-
cluded as a variable in the minimisation criteria. Severe lung entrapment was an exclusion criteria.
Included in network meta-analysis for pleurodesis failure, pain and mortality.
Study funding source: unrestricted grant from Becton Dickinson.
Study author conflicts of interest statements: Dr Bishop received educational fees and donated med-
ical equipment from Rocket Medical UK and educational fees and equipment from Becton Dickinson;
Dr Ahmed received grant support from Becton Dickinson and GE Medical; Dr Psallidas employed by As-
traZeneca in addition to his affiliation with the University of Oxford; Dr Lee received grant support and
medical supplies from Rocket Medical UK and fees for serving on an advisory board from Becton Dick-
inson; Dr Rahman received consulting fees from Rocket Medical UK; Dr Miller received lecture fees and
travel support from Gilead Sciences and lecture fees from Janssen, Merck and ViiV Health-care; and
Dr Maskell received grant support and consulting fees from Becton Dickinson and grant support from
Rocket Medical UK. No other potential conflict of interest relevant to this article was reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralised computer-based randomisation with minimisation variables.
Allocation concealment
(selection bias)





Low risk Participants blinded. Talc and placebo administered with opaque syringes.
Community nurses who recorded the drainage volumes were also blinded. Tri-
al group assignments were known only to the local clinical team.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk ITT analysis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.





Methods Multicentre (17 sites) RCT comparing talc poudrage with talc slurry pleurodesis (UK) – TAPPS.
Participants Inclusion criteria: MPE (histocytologically confirmed or unexplained effusion and cancer or pleural
changes on cross-sectional imaging consistent with malignancy), able to tolerate local anaesthetic tho-
racoscopy under moderate sedation and estimated survival > 3 months.
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Exclusion criteria: aged < 18 years, requiring diagnostic thoracoscopy, pregnant or lactating, con-
traindication to pleurodesis (e.g. trapped lung or loculation), insufficient pleural fluid to perform local
anaesthetic thoracoscopy without an induced pneumothorax, contraindication to any study interven-
tion.
330 participants randomised.
Interventions Local anaesthetic thoracoscopy arm: 4 g sterile graded talc insufflated following complete drainage
and inspection of pleural cavity. Placement of a 16- to 24-Fr drain.
Talc slurry group: 12- to 14-Fr seldinger drain placed under USS guidance. 4 g sterile talc slurry 18–24
hours later if no evidence of non-expanded lung or significant residual pleural opacification on CXR.
Unless clinically indicated, chest tubes were not removed within 24 hours of talc administration or if
fluid output remained > 250 mL/24 hours.
Outcomes Primary outcome: pleurodesis failure at 90 days. Defined as requirement for therapeutic thoracentesis
of > 100 mL, chest tube insertion for fluid management, insertion of an IPC or thoracoscopy of any type
on the same side during the trial follow-up period. 
Secondary outcomes: pleurodesis failure at day 30 and day 180, time to pleurodesis failure, number of
nights in hospital, thoracic pain (VAS score), breathlessness (VAS score), QoL (EQ-5D-5L), mortality, %
radiographic opacification at time of drain removal.
Notes Included in network meta-analysis for pleurodesis failure, pain and mortality.
Study funding source: University of Bristol, to which Dr Bhatnagar, Dr Walker, Dr Clive, Ms Zahan-Evans
and Dr Maskell were affiliated, and to the University of Oxford, to which Ms Laskawiec-Szkonter, Ms Pi-
otrowska, Dr Little, Ms Mei, Dr Luengo-Fernandez, Mr Quaddy and Dr Rahman were affiliated. The study
was funded by the UK National Institute for Health Research and sponsored by North Bristol National
Health Service (NHS) Trust.
Study author conflicts of interest statements: Dr Maskell reported receiving grants and personal fees
from Beckton Dickinson (BD), grants from Rocket Medical and personal fees from Cook Medical outside
the submitted work. Dr Ahmed received grants from BD and Rostrees Charity Trust outside the submit-
ted work. Dr Blyth received grants from Rocket Medical UK Ltd outside the submitted work. Dr Miller re-
ceived personal fees from Gilead outside the submitted work. Dr Psallidas served as a medical science
director for Astra Zeneca in a field unrelated to pleural diseases. No other disclosures reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralised web-based computer system.
Allocation concealment
(selection bias)





High risk Participants and clinicians aware of treatment allocation – blinding not possi-
ble due to practical differences between interventions. 
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Although data collectors unblinded to treatment allocation, if fluid recurrence
postintervention was limited to within 1/3 of the hemithorax, a second blinded
clinician advised on need for repeat pleural intervention. Adverse events cate-
gorised by a blinded independent pulmonologist. Authors confirmed that sta-
tisticians were blinded to treatment allocation.
Bhatnagar 2020  (Continued)
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Low risk ITT analysis. LTFU well matched between study arms.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods RCT of mitoxantrone vs mepacrine via an intercostal drain (Sweden – number of centres not specified).
Participants Cytologically confirmed, symptomatic MPE with an expected survival > 3 months (KPS > 60). Excluded if
cytotoxic chemotherapy in the preceding month.
All cell types included.
30 participants randomised.
Interventions Both groups had a 12- to 14-Fr chest tube inserted and effusion drained. Pleurodesis agent was given
through the chest tube and participant's position changed for 2 hours after administration.
Group 1: 1 dose of intrapleural mitoxantrone 30 mg in 50 mL normal saline; drain closed for 48 hours
and removed after the 'pleural cavity was emptied.'
Group 2: 2 doses of intrapleural mepacrine chloride 200 mg in 20 mL normal saline given on consecu-
tive days and drain removed when < 150 mL fluid production/day.
Outcomes Pleural fluid re-accumulation at 4 weeks and 12 weeks (defined as CR; PR: if recurrence of pleural fluid
but thoracentesis not considered to be indicated; or progressive disease.
Adverse effects/toxicity (VAS pain and fever scores)
Symptom questionnaires (participant grades symptom on a numerical scale for 4 key symptoms – pain,
shortness of breath, nausea and tiredness)
Pharmacokinetics of mitoxantrone
Notes People with trapped lung not excluded from study.
CR and PR counted as pleurodesis success for analysis.
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: grants from Swedish Society Against Cancer and the Lions Foundation.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified and unable to find contact details for study authors.
Allocation concealment
(selection bias)
Unclear risk Not specified and unable to find contact details for study authors.
Bjermer 1995 
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Low risk Study personnel not blinded as drugs were different colours. However, partici-
pants were blinded to treatment allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Participants blind to treatment allocation, therefore, fever, pain and symptom
scores unbiased.




Low risk 1 participant in each study arm did not receive treatment due to "unexpect-
ed medical emergencies," therefore deemed non-evaluable. Follow-up data
clearly documented for the remaining participants.
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes reported.
Other bias Low risk Drain suction use was imbalanced between the treatment arms (10/14 re-




Methods RCT comparing talc slurry pleurodesis with IPC and symptom-guided drainage.
Participants Inclusion criteria: histocytologically confirmed MPE or progressive malignancy with pleural effusion af-
ter exclusion of an alternative cause.
Exclusion criteria: previous ipsilateral talc pleurodesis, previous ipsilateral IPC, impaired immunity,
platelets < 50 × 109/L.
94 participants randomised.
Interventions Talc slurry group: 3–5 g talc, as per Dutch guidelines via 15- to 20-Fr drain.
IPC group: IPC insertion with symptom-guided drainage.
Outcomes Primary outcome: improvement in MBS score at rest and on exercise 6 weeks' postrandomisation. 
Secondary outcomes: daily MBS score at rest and on exercise for 2 weeks' postrandomisation, number
of hospital visits, pleural re-intervention, hospital stay, time to pleurodesis failure, adverse events. 
Notes Treatment failure defined as fluid re-accumulation leading to ipsilateral repeat intervention, when no
talc was instilled despite drain placement and when participants survived < 6 weeks. No data present-
ed for number of participants with an IPC in whom the device could be removed due to pleurodesis
success. 
Contacted authors for additional information. 
Included in network meta-analysis for mortality and pain. 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised randomisation with stratification.
Boshuizen 2017 
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Allocation concealment
(selection bias)





High risk Interventions unblinded to participants and clinicians.
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Low risk All outcomes reported. 




Methods Single-centre RCT of tetracycline pleurodesis using a small percutaneous catheter (CH10), compared to
a large-bore chest tube (CH24) inserted after thoracoscopy (Denmark).
Participants Symptomatic, recurrent MPE, confirmed on pleural fluid cytology. Expected survival of > 3 months (all
tumour types included).
21 participants randomised.
Interventions Group 1: small percutaneous catheter (CH10 65 cm) inserted under local anaesthesia.
Group 2: medical thoracoscopy, followed by insertion of a large-bore chest tube (CH24).
Both groups received pleurodesis with tetracycline 500 mg and bupivacaine 100 mg intrapleurally. The
drain was clamped for 6 hours after instillation after which suction was applied. Drain removed when
fluid output < 200 mL in 24 hours.
Outcomes Treatment response at 3 weeks, 6 weeks and 9 weeks defined by roentgenographic response (CR: no
recurrence of pleural fluid; PR: slight re-accumulation with blunted costophrenic angle; no response:
complete recurrence of pleural fluid) and clinical response (by the need for new thoracentesis).
Questionnaire evaluating discomfort in connection with the tube and the pleurodesis.
Notes Trapped lung not accounted for in inclusion/exclusion criteria, but 1 participant excluded as they had
hydropneumothorax at time of instillation.
CR and PR included as pleurodesis successes for analysis.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Clementsen 1998 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Allocation by lot."
Allocation concealment
(selection bias)





High risk Not possible to blind, as different drain sizes used (although not stated explic-
itly in paper).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote: "All data were evaluated by the same physician, who was without
knowledge of the result of the randomisation."
Comment: however, symptom-based adverse events and symptomatic need




Low risk All data reported and justified. Missing outcome data balanced between the 2
treatment arms (2 excluded from group 1 (1 died of cancer soon after drain in-
sertion and 1 developed hydropneumothorax necessitating large-bore drain),




Low risk All outcomes reported.




Methods Single-centre RCT comparing TMP with talc slurry (Slovenia).
Participants Inclusion criteria: breast carcinoma and a resulting morphologically confirmed MPE.
Exclusion criteria: unfit for GA.
87 participants randomised.
Interventions TMP: thoracoscopy (under GA) with adhesiolysis, pleural biopsy and scarification of the visceral and
parietal pleura to induce bleeding. Chest tube inserted at the end of procedure.
Talc slurry: chest tube inserted under local anaesthetic. 5 g talc in 100 mL saline insufflated through
chest tube.
Participants in both arms had the drain removed when < 100 mL/24-hour drainage.
Outcomes Recurrence of effusion on CXR at 1 day, 1 week, 1 month, 3 months and 6 months
Duration of chest tube drainage
Duration of hospitalisation
Complications
Mortality (30 days and 6 months)
Crnjac 2004 
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Notes People with trapped lung not excluded.
Pleurodesis success defined using CXR criteria alone.
Included in network meta-analysis for pleurodesis failure. 
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Not feasible to blind the study as comparing talc slurry with TMP.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Not stated whether radiological assessments were done using a blinded
method. Complication reporting, time of tube drainage may be affected by





Low risk ITT analysis performed. Minimal missing data. 6/45 participants died within 6
months in TMP group vs 8/42 in talc slurry arm.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Other bias Low risk No documentation of participant experience (e.g. QoL or degree of discom-
fort), relative costs or need for repeat pleural intervention.
Pleurodesis success defined using radiology only. Participants who did not




Methods Unblinded, multicentre RCT comparing IPC with talc slurry pleurodesis (UK) – TIME-2 trial.
Participants Inclusion criteria: clinically confident diagnosis of MPE requiring pleurodesis.
Exclusion criteria: aged < 18 years, expected survival < 3 months, chylothorax, previous ipsilateral
lobectomy or pneumonectomy, previous attempted pleurodesis, pleural infection, WCC < 1000/μL, hy-
percapnic ventilatory failure, pregnancy, lactating mothers, irreversible bleeding diathesis, irreversible
visual impairment.
106 participants randomised.
Interventions Group 1: IPC inserted with drainage 3 times a week (or as required to relieve dyspnoea).
Davies 2012 
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Group 2: 12-F Seldinger chest tube and 4 g talc slurry as an inpatient.
All participants had standard oncological management for the primary tumour.
Outcomes Primary outcome: mean daily dyspnoea VAS over the first 42 days
Secondary outcomes: proportion achieving clinically significant decrease in mean VAS dyspnoea; mean
VAS dyspnoea at 6 weeks, 3 months and 6 months; mean daily chest pain VAS over the first 42 days;
mean VAS chest pain at 6 weeks, 3 months and 6 months; nights spent in hospital; self-reported QoL;
frequency of adverse events
Notes Participants with trapped lung in group 2 did not receive talc pleurodesis, but remained in trial fol-
low-up.
Pleurodesis in the IPC group defined as removal of IPC following spontaneous cessation of drainage
with no significant fluid recurrence on CXR or USS and no further ipsilateral pleural intervention. In the
talc group, pleurodesis failure defined as the need for further ipsilateral pleural intervention.
If participants died during follow-up, included as a pleurodesis success if no intervention prior to
death.
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: unrestricted education grant from the British Lung Foundation and the Robert
Lu) Foundation, London, UK. Sponsored by University of Oxford. The IPCs and drainage bottles were
provided by Rocket Medical, Washington, UK.
Study author conflicts of interest statements: all authors completed and submitted the ICMJE Form for
Disclosure and Potential Conflicts of Interest. Dr Wrightson received honoraria, grant support to attend
a conference from Boehringer Ingelheim. Dr Guhan received support from Medico for expert testimo-
ny; having served on the speakers' bureau for Astra Zeneca, Glaxo Smith Kline, and Chiesi; and received
support for conference attendance from Chiesi and Glaxo Smith Kline. Dr C Davies served on the speak-
ers' bureau for AstraZeneca. Dr Lee received honoraria from Care Fusion and Sequana Medical as an
advisory board member. Dr Miller received support for lectures on HIV infection from Merck and Gilead.
Dr Rahman acted as a consultant to Rocket Medical for device development. No other conflicts of inter-
est reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Central telephone randomisation.
Allocation concealment
(selection bias)





High risk Not possible to blind participants or personnel due to nature of interventions
(IPC vs talc slurry).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk VAS scores, QoL and symptom recurrence (which informs assessment of pleu-




Low risk LTFU clearly documented with reasons given.
Davies 2012  (Continued)
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Selective reporting (re-
porting bias)
Low risk All predefined endpoints reported.




Methods Multicentre RCT comparing bedside talc pleurodesis and daily tunnelled catheter drainage for manage-
ment of MPE (USA).
Participants Inclusion criteria: symptomatic people with histo/cytologically confirmed malignancy and a previously
untreated, unilateral pleural effusion requiring management; ECOG Performance Score 0–2.
Exclusion criteria: active pleural infection; talc allergy; contraindications to talc use; trapped lung; sur-
vival < 60 days; severe comorbid medical conditions.
68 participants randomised.
Interventions Talc pleurodesis group: 4–5 g sterile talc slurry in 100 mL saline infused into pleural space via > 24-Fr
chest drain. Tube clamped for 2 hours. Drain removed when < 150 mL drainage/24 hours.
IPC group: PleurX catheter inserted and drained daily (output volumes recorded). Removed when < 30
mL output on 3 consecutive days.
Outcomes Primary: compare the proportion of maintained successful treatments 30 days after the interven-
tion (success defined as being alive, no effusion recurrence, > 90% lung re-expansion after complete
drainage and completion of the intervention by 2 weeks, i.e. drain removed or IPC functioning normal-
ly)
Secondary: QoL; dyspnoea; patient satisfaction and acceptability; lung expansion; pleurodesis success;
fluid drainage volume; days device in place; removal of device before death; survival
Notes Pleurodesis success measured at 30 days according to CXR and need for repeat pleural intervention.
People with known trapped lung excluded from trial entry.
Included in network meta-analysis for pleurodesis failure, mortality and pain.
Study funding source: supported, in part, by grants from the NCI (CA31946) to CALGB and to the CALGB
Statistical Centre (CA33601).
Study author conflicts of interest statements: individual authors disclosed they had no financial rela-
tionships.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Permuted block randomisation via a web-based randomisation service.
Allocation concealment
(selection bias)




High risk Due to nature of interventions, not possible to blind participants or personnel
(IPC vs talc slurry).
Demmy 2012 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote (personal communication): "Pleurodesis success was classified by an
unblinded local investigator."
Comment: QoL, symptom recurrence and patient satisfaction questionnaires




Unclear risk 5 excluded from analysis in each arm, but justifications given. Some aspects
unclear, e.g. trial follow-up period 60 days but range of days drainage device in
place for IPC group was up to 286 days suggesting longer follow-up.
Selective reporting (re-
porting bias)
Low risk All reported.




Methods Prospective, single-centre RCT of thoracoscopic talc poudrage vs bedside bleomycin pleurodesis via a
small-bore chest tube (Switzerland).
Participants Inclusion criteria: documented MPE (all cell types); complete lung expansion on postdrainage CXR; im-
provement in symptoms after drainage; expected survival > 1 month; capable of undergoing medical
thoracoscopy.
Exclusion criteria: loculated effusion; previous drainage or previous pleurodesis; adverse reaction to
the study medication; severe coagulation disorder.
36 participants randomised.
Interventions Group 1: bedside pleurodesis via small-bore chest tube (outside diameter 2.7 mm) of bleomycin 60 IU.
Tube unclamped after 2 hours and leG on suction until removal ≥ 48 hours later.
Group 2: thoracoscopy with induced pneumothorax under sedation. 5 g talc sprayed into pleural cavity
under direct vision after drainage of effusion and disruption of adhesions. Drain kept under suction for
≥ 48 hours.
Outcomes Recurrence of effusion (defined as a newly detected effusion needing drainage or occupying > 33% of
the pleural space on CXR as compared with the first CXR after drain removal, or death from any cause)
at 30 days, 90 days and 180 days
Medication use
Volume of fluid drained
Duration of hospital stay
Cost
Symptom VAS scores (pain, shortness of breath, cough and general well-being)
Notes People with trapped lung excluded from study enrolment.
Included in network meta-analysis for pleurodesis failure, mortality, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Diacon 2000 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence.
Allocation concealment
(selection bias)





High risk Not possible to blind participants or personnel due to nature of interventions
(talc poudrage vs bleomycin via chest tube).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Not stated if radiology was interpreted by a blinded physician. However,
length of stay, VAS scores and symptom recurrence may be biased by lack of





Low risk 5 withdrawals in total, but a similar number in each group.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Multicentre RCT comparing talc poudrage with talc slurry pleurodesis in MPE. Both groups received 4–5
g sterile talc intrapleurally (USA).
Participants Inclusion criteria: history of malignancy (all tumour types), pleural effusion requiring sclerosis, ECOG
performance status 0–2, life-expectancy > 2 months, ability to undergo GA.
Exclusion criteria: pregnancy, previous intrapleural therapy or radiotherapy encompassing the entire
hemithorax, changes in systemic therapy within 2 weeks, chylous or bilateral effusions requiring thera-
py.
501 participants randomised.
Interventions Talc slurry group: talc administered as a slurry in 100 mL saline through a chest tube at bedside.
Talc insufflation group: talc insufflated during thoracoscopy in operating theatre.
Outcomes Primary outcome: percentage of participants whose lung initially re-expanded > 90% and who had a
successful pleurodesis at 30 days after treatment (defined according to CXR criteria)
Secondary outcomes: time to recurrence of effusion; frequency of complications and toxicities; ability
to re-expand the lung as assessed by CXR; pain; patient satisfaction; QoL
Notes People with trapped lung excluded from analysis.
Included in network meta-analysis for pleurodesis failure, mortality, pain and fever.
Dresler 2005 
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Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation lists.
Allocation concealment
(selection bias)





High risk Not possible to blind the study due to the nature of the interventions (talc
poudrage vs talc slurry).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Not stated if radiological assessment was blinded. QoL and complications may




Low risk Missing data accounted for and balanced between the treatment arms (10 in
slurry group vs 9 in thoracoscopy group excluded as ineligible or participant
withdrew consent; 33/163 slurry participants vs 25/177 thoracoscopy partici-
pants died within 30 days of randomisation).
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.
Other bias Low risk Trapped lung defined by different means in the 2 treatment arms, which may
have affected their primary endpoint. However, this does not have an impact




Methods Single-centre RCT of intrapleural cisplatin ± bevacizumab in MPE due to NSCLC (China).
Participants Inclusion criteria: advanced NSCLC; large uni- or bilateral pleural effusion; positive pleural fluid cy-
tology; no intrapleural therapy in previous month; KPS > 60; aged > 18 years; predicted survival > 3
months; no major organ dysfunction; no previous chemotherapy in previous 6 weeks.
Exclusion criteria: squamous cell carcinoma; allergy to biological agents; no detectable lesions; uncon-
trolled central nervous system metastasis; pregnancy or breastfeeding; infected wound; refractory psy-
chiatric illness.
72 participants randomised.
Interventions Participants underwent pleural fluid drainage by thoracentesis. Treatment given intrapleurally. Rest for
2 hours. Then rotate every 15 minutes. Given every 2 weeks for 3 cycles.
Cisplatin: cisplatin 30 mg intrapleurally.
Cisplatin + bevacizumab: cisplatin 30 mg + bevacizumab 300 mg intrapleurally.
Outcomes Treatment response (CR: accumulated fluid disappeared and stable for at least 4 weeks; PR: ≥ 50% of
the accumulated fluid had disappeared, symptoms had improved and the remaining fluid had not in-
Du 2013 
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creased for ≥ 4 weeks; remission not obvious: ≤ 50% of the accumulated fluid had disappeared; pro-





Pleural fluid VEGF levels
Notes People with trapped lung eligible for trial involvement.
Pleurodesis defined clinically and using radiology.
Not included in network meta-analysis.
Study funding source: supported by grants from the National Health Research Foundation (no.
W2010BX055), the National Natural Science Foundation of China (no. 81000994), the Chinese Wu Jie-
ping Medical Foundation (no. 320.6750.1083), the Beijing Municipal Science and Technology Commis-
sion (no. Z121107001012080) and the National Natural Science Outstanding Youth Foundation of China
(no. 39825111).
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Methods not stated and no response from study authors to clarify.
Allocation concealment
(selection bias)





Unclear risk Not stated if blinded and no response from study authors to clarify.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated if anyone was blinded. If not blinded, QoL, performance status, ad-




Low risk Missing data accounted for. ITT analysis.
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.
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Methods 3-arm, single-centre RCT comparing intrapleural bleomycin, tetracycline and combination treatment
for pleurodesis of MPE (Iran).
Participants Inclusion criteria: histologically or cytologically confirmed, symptomatic MPE (all cell types).
Exclusion criteria: none.
60 participants randomised.
Interventions All participants had 28-Fr intercostal drain inserted into 6th intercostal space. Complete drainage of the
effusion was confirmed on CXR. All participants given 10–15 mL 1% lignocaine intrapleurally.
Tetracycline arm: tetracycline 20 mg/kg (maximum 2 g) in 50 mL saline given intrapleurally. 1 dose.
Bleomycin arm: bleomycin 1 U/kg (maximum 60 units) in 50 mL saline given intrapleurally. 1 dose.
Combination arm: tetracycline 20 mg/kg in 40 mL saline + bleomycin 1 U/kg in 50 mL saline, given in-
trapleurally, 1 after the other (tube clamped for 5 minutes between instillations).
Drain clamped for 2 hours postinstillation with participant rotation. Suction connected after 24 hours.
Drain removed when < 50 mL/8 hours drainage and complete lung expansion on CXR.
Outcomes Pleurodesis success (defined as CR: no accumulation of effusion on CXR; PR: effusion recurred but did
not require aspiration; or failure: participant required repeat thoracentesis for re-accumulation of the
effusion) at 30 days (also at 60 days, 90 days and 6 months)
Adverse effects
Notes All participants in the study were receiving chemotherapy or tamoxifen, or both.
People with trapped lung not excluded from participation in study.
Participants who died prior to the analysed time point were excluded from analysis.
Combination of clinical need for repeat intervention and radiological re-accumulation of effusion used
to define pleurodesis failure.
Included in network meta-analysis for pleurodesis failure, mortality and fever.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "…simple randomised manner."
Comment: no further details given.
Allocation concealment
(selection bias)





High risk Not stated explicitly and unable to contact authors. However, different vol-
umes and regimens were used for the 3 groups.
Blinding of outcome as-
sessment (detection bias) 
High risk Not stated if radiology reported blindly. Complication-reporting may have
been affected by lack of participant blinding.
Emad 1996 
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Low risk Minimal data on baseline participant characteristics, but all outcome data re-
ported and withdrawals justified. 6 participants died within 6 months of ran-




Low risk All stated outcomes reported.




Methods Single-centre RCT of medical vs surgical pleurodesis with tetracycline (UK).
Participants Inclusion criteria: cytology-confirmed MPE and histological or cytological evidence of metastatic breast
cancer.
Exclusion criteria: unsuitable for GA; aged > 75 years; severe non-metastatic lung disease; evidence of
life-threatening metastatic disease at other sites.
34 participants randomised.
Interventions Medical group: intercostal cannula inserted into mid-axillary line 7th/8th intercostal space and fluid as-
pirated. When drainage complete, tetracycline 500 mg in 100 mL normal saline inserted intrapleurally.
Drain removed after 24 hours.
Surgical group: under GA, bronchoscopy then thoracoscopy performed. 500 mL tetracycline in 100 mL
saline inserted after fluid removed. Drain removed at 24 hours.
Outcomes Fluid re-accumulation on CXR
Need for repeat pleural aspirations
Mortality
Notes Pleurodesis failure defined as need for repeat aspiration. Trapped lung not accounted for.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given regarding randomisation.
Allocation concealment
(selection bias)




High risk Unable to blind due to nature of the interventions (surgery vs chest tube).
Evans 1993 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Need for repeat aspirations and other treatments given for cancer after pleu-
rodesis may have been biased by lack of blinding of personnel and partici-




Low risk Reasons given for withdrawals (5/34 excluded (15%) – 3 never received the
treatment, 1 was randomised in error, 1 participant's records were lost).
Selective reporting (re-
porting bias)
High risk No data on safety or adverse effects.




Methods Single-centre RCT of talc poudrage and mustine (via chest tube) in people with breast cancer. All partic-
ipants underwent VATS procedure under GA (UK).
Participants Inclusion criteria: histologically confirmed breast cancer and radiologically verified pleural effusion.
Exclusion criteria: no previous local treatment; non-malignant cause for the effusion.
46 participants randomised.
Interventions Talc group: talc poudrage performed during VATS (dose of talc not stated), 2 chest drains in place for 5
days (with or without suction).
Mustine group: after VATS and once lung fully re-expanded on CXR, mustine 15 mg solution instilled via
intercostal drain. Clamped for 2 hours. Drain removed when drainage stopped.
Outcomes Success of pleurodesis (defined by lack of re-accumulation of effusion on CXR) at 1 month
Complications
Notes If died prior to 1-month follow-up, excluded from analysis of pleurodesis success.
Participants with trapped lung eligible for enrolment.
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Unclear risk Not stated.
Fentiman 1983 
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High risk Not possible to blind participants or personnel due to nature of procedures.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated whether radiographic interpretation of CXRs were performed by a
blinded person. Reporting of complications could be biased by lack of partici-




Low risk 3/23 non-evaluable in talc group; 6/23 non-evaluable in mustine group. All
non-evaluable participants died prior to 1-month follow-up.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Other bias High risk Different number of intercostal drains in the 2 groups. Different duration of




Methods Single-centre RCT of intrapleural talc and tetracycline in MPE secondary to breast cancer (UK).
Participants Inclusion criteria: histologically confirmed breast cancer and a symptomatic pleural effusion on radiol-
ogy.
Exclusion criteria: previous treatment for effusion, other than simple needle aspiration; non-malignant
cause for effusion; unsuitable for GA; history of sensitivity to tetracycline.
41 participants randomised.
Interventions Talc group: thoracoscopy, talc insufflated (dose not stated). Intercostal drain remained in situ for 5
days.
Tetracycline group: thoracoscopy. Tetracycline 500 mg in 40 mL normal saline inserted 16–24 hours lat-
er via chest tube. Intercostal drain leG in place for 3–5 days.
Outcomes Pleurodesis success (defined by lack of re-accumulation on CXR)
Complications
Mortality
Notes Pleurodesis success defined according to CXR only.
Participants with trapped lung eligible for trial entry.
Included in network meta-analysis of pleurodesis failure and mortality.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Fentiman 1986 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised with stratification for metastatic disease."
Allocation concealment
(selection bias)





High risk Not possible to blind participants or personnel due to the nature of the proce-
dures.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated whether radiographic interpretation of CXRs were performed by a
blinded person. Reporting of complications could be biased by lack of partici-




High risk Participants were excluded from the primary analysis if they died within first
month. Higher proportion of deaths in the talc group (6/18 = 33%) compared
to the tetracycline group (2/23 = 9%).
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre, prospective RCT comparing intrapleural administration of mistletoe preparation (viscum
fraxini-2) with bleomycin in people with MPE (Egypt).
Participants Inclusion criteria: histologically confirmed, recurrent, symptomatic MPE (all cell types); aged > 18 years;
ECOG Performance Score ≤ 2; adequate bone marrow, liver and kidney function; written consent; abili-
ty to comply with the follow-up.
Exclusion criteria: chronic air leak; known hypersensitivity to mistletoe (viscum); uncorrectable bleed-
ing tendency; encysted pleural effusion; pregnancy/breastfeeding; currently active second malignancy;
co-enrolment in another clinical trial; previous unsuccessful pleurodesis; pleural infection.
23 participants randomised.
Interventions Participants underwent effusion drainage using a chest tube or needle drainage (depending on effusion
size). Agent injected through the needle or chest tube.
Mistletoe (viscum) group: 5 ampoules in 10 mL 5% glucose instilled intrapleurally.
Bleomycin group: 60 units delivered intrapleurally.
Outcomes Pleurodesis efficacy (assessed at 6 weeks)
Toxicity (measured using NCI common terminology for adverse events)
Notes People with trapped lung not excluded from participation.
Pleurodesis defined using radiology and symptomatic effusion recurrence.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated
Gaafar 2014 
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Study author conflicts of interest statements: no conflicts of interest to declare.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "randomised."
Comment: no other details given and no response from study authors.
Allocation concealment
(selection bias)
Unclear risk Quote: "randomised."





High risk Not stated explicitly but drugs were of different formulations.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 2 participants in mistletoe (viscum) arm excluded from analysis as treatment
was discontinued due to an allergic reaction.
Selective reporting (re-
porting bias)
Low risk Data available although minimal data on adverse effects.




Methods Single-centre RCT evaluating duration of chest tube drainage after talc slurry pleurodesis (UK).
Participants Inclusion criteria: confirmed MPE requiring palliation of breathlessness due to the effusion (all cell
types).
Exclusion criteria: expected survival < 3 months; KPS < 40; previous unsuccessful pleurodesis; ipsilater-
al endobronchial obstruction; evidence of trapped lung.
41 participants randomised.
Interventions All participants had 8- to 14-Fr intercostal drain inserted under USS guidance. 4 g talc slurry when effu-
sion fully drained and trapped lung excluded on CXR.
Group 1: drain removed after 24 hours.
Group 2: drain removed at 72 hours.
Drains removed regardless of fluid drainage.
Outcomes Pleurodesis failure at 1 month (defined according to fluid recurrence requiring repeat aspiration)
Length of hospital stay
Mortality
Goodman 2006 
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Notes People with trapped lung excluded from the study. Study did not complete recruitment numbers re-
quired by the power calculation.
Participants who died in first month after randomisation excluded from the analysis.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: no conflicts of interest for either author relating to this
study.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes in random blocks of 10.
Allocation concealment
(selection bias)





High risk Not possible to blind due to nature of interventions (drain removal after 24 or
48 hours).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Need for repeat pleural interventions, length of stay may be biased by lack of




Low risk Deaths within the first month well matched between the 2 arms (3 participants
in each arm). No other LTFU.
Selective reporting (re-
porting bias)
Low risk All predefined outcomes reported. Unpublished data on complications provid-
ed by the authors.




Methods RCT comparing intrapleural mitoxantrone with normal saline after thoracoscopy in people with MPE
(Germany).
Participants Inclusion criteria: complete resolution of the effusion after thoracoscopy; malignancy on pleural biop-
sy.
Exclusion criteria: no chemotherapy within 4 weeks of pleurodesis.
103 participants randomised.
Interventions All participants underwent thoracoscopy. After 24 hours, participants were randomised.
Mitoxantrone arm: mitoxantrone 30 mg given intrapleurally.
Control arm: isotonic saline instilled intrapleurally.
Groth 1991 
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Drain clamped for 48 hours and if > 300 mL effusion after 48 hours, a second dose was given; if not, the
drain was removed. If a second dose was given, the drain was removed 48 hours later.
Outcomes Pleural fluid re-accumulation at 2 months (defined as a CR: complete disappearance of all pleural effu-
sion; PR: half of the effusion or doubling of the time for thoracentesis; no change: the same volume of




Notes Treatment response definitions unclear.
People with trapped lung eligible for trial involvement.
Included in network meta-analysis for pleurodesis failure and fever.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not specified.
Allocation concealment
(selection bias)





Unclear risk No mention of blinding or whether drugs were of similar appearances or vol-
umes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated whether CXR interpretation was blinded to treatment allocation.
Adverse effects and performance status reporting could be biased if partici-




Low risk 8/103 participants excluded from the analysis (7 died within 4 weeks of ran-
domisation due to tumour progression; 1 LTFU).
Selective reporting (re-
porting bias)
Low risk All reported.




Methods Single-centre RCT comparing talc slurry and bleomycin pleurodesis (Brazil).
Participants Inclusion criteria: documented recurrent symptomatic MPE (with positive cytology or confirmed
metastatic disease elsewhere with no other cause found for the effusion); symptomatic relief by thera-
peutic aspiration; complete lung re-expansion after therapeutic aspiration.
Haddad 2004 
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Exclusion criteria: previous unsuccessful pleurodesis; pleural infection; chronic air leak; KPS < 30%.
71 participants randomised.
Interventions 28- to 36-Fr chest tube inserted under local anaesthetic. Lung re-expansion confirmed prior to ran-
domisation.
Talc group: 4 g talc in 100 mL saline intrapleurally.
Bleomycin group: bleomycin 60 units in 100 mL saline intrapleurally.
After instillation, drain clamped for 4 hours, then put on suction for 24 hours. Drain removed when <
200 mL/24 hours drained.
Outcomes Pleurodesis success (defined as no recurrence of effusion on clinical and radiological follow-up or pa-
tient symptom-free with small residual effusion not requiring thoracentesis) at 1 month, 3 months and
6 months
Length of hospital stay
Cost analysis
Complications
Notes People with trapped lung excluded from trial entry.
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence.
Allocation concealment
(selection bias)





High risk Quote (personal communication with authors): "study not blinded."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote (personal communication with authors): "study not blinded."
Comment: not stated if radiology reported blindly but pleurodesis efficacy also





Low risk All reported.
Selective reporting (re-
porting bias)
Low risk All outcomes reported and further clarification received from authors regard-
ing complications and mortality.
Haddad 2004  (Continued)
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Other bias High risk High levels of steroid use in participants, which may have affected pleurodesis
success rates. Steroid use not well balanced between the treatment arms (4/37




Methods Prospective, single-centre RCT of bleomycin and talc in MPE secondary to breast cancer (UK).
Participants Inclusion criteria: breast carcinoma with radiographically confirmed pleural effusion.
Exclusion criteria: previous local treatment (apart from simple aspiration); evidence of a non-malignant
cause for the effusion.
29 participants randomised.
Interventions All participants had effusion drained to dryness under GA.
Talc group: talc pleurodesis (dose and mode of administration not specified, but assumed to be
poudrage from text).
Bleomycin group: chest tube inserted. Bleomycin 1 mg/kg in 50 mL normal saline instilled after a CXR
confirming lung re-expansion.
Outcomes Success of pleurodesis (defined as continued absence of re-accumulation of pleural fluid on all fol-
low-up radiographs)
Notes Different modes of administration of talc and bleomycin.
Contacted study authors for more information, but no reply.
People with trapped lung eligible for study entry.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Not possible to blind due to the nature of the interventions (talc poudrage vs
bleomycin).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated whether radiology reporting was blinded.
Hamed 1989 
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Low risk A number of participants not included in the primary analysis, but bal-




Low risk All reported.




Methods Multicentre RCT of pleurodesis using Corynebacterium parvum vs bleomycin (Sweden).
Participants Inclusion criteria: pleural effusion due to metastases from cytologically or histologically confirmed
bronchogenic carcinoma or adenocarcinoma; ≥ 2 previous aspirations of effusion.
40 participants randomised.
Interventions C parvum group: C parvum 7 mg in 10–20 mL saline intrapleurally.
Bleomycin group: bleomycin 60 mg in 100 mL saline intrapleurally.
A second dose of the allocated agent was given if the first was ineffective.
No details given about method of drainage prior to instillation of pleurodesis agent or how long the
drain remained in place.
Outcomes Pleurodesis success (success: no recurrence of fluid within 6 weeks; partial success: 2 instillations re-
quired within 6 weeks, with no recurring effusion within 6 weeks of the second instillation)
Notes People with trapped lung eligible for trial entry.
For the purposes of this review, if participants required > 1 treatment due to effusion recurrence within
6 weeks, they were counted as a failure.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk No specific mention of blinding but drugs reconstituted in different volumes.
Hillerdal 1986 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Definition of pleurodesis efficacy quite vague and not stated if blinded. Ad-





High risk No data on mortality. Numbers did not add up for adverse effects data.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre RCT analysing release of growth factors in pleural fluid and blood following talc slur-
ry and mechanical pleurodesis (Slovenia).
Participants Inclusion criteria: breast carcinoma and cytologically confirmed MPE, lung re-expanded after thoracic
drainage, eligible for surgery, ECOG Performance Score 0–2.
Exclusion criteria: unfit for surgery under GA, trapped lung.
36 participants randomised.
Interventions Chemical pleurodesis group: 40 mL 1% lidocaine 20–30 minutes prior to 5 g talc and 100 mL 0.9% saline
slurry via chest drain. Drain clamped for 2 hours then placed on suction. 
Mechanical pleurodesis group: 2-port VATS with mechanical abrasion of parietal pleura.
All participants received suction at –15 cmH2O applied for 24 hours. Drains removed once < 200 mL/24
hour output and CXR favourable.
Pleural fluid and blood samples were taken at baseline, 3 hours, 12 hours, 24 hours, 36 hours and 48
hours. Participants followed up for 12 months.
Outcomes Primary outcome: analysis of growth factor release for 48 hours postpleurodesis
Secondary outcomes: pleurodesis effectiveness, symptoms (VAS pain score at 0 hours, 12 hours, 24
hours and 48 hours), QoL (EORTC QLQ-C30) at 1 week pre-, 1 week and 1 month postpleurodesis
Notes Trapped lung excluded. Pleurodesis success determined by CXR and pleural USS and by requirement
for additional thoracentesis. Raw data only provided for number of participants requiring additional
thoracentesis, which was used for network meta-analysis of pleurodesis success.
Contacted authors by email for further information but no reply received. 
Included in network meta-analysis for pleurodesis failure.
Study funding source: University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia for full
amount.
Study author conflicts of interest statements: no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Hojski 2015 
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Random sequence genera-
tion (selection bias)









High risk Unblinded due to nature of interventions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No comment on withdrawals or LTFU over trial period. 5 participants survived




Low risk All outcome measures reported.
Other bias High risk Pleurodesis success and participant-reported outcomes measured as sec-
ondary endpoints, with small numbers of participants randomised to each
arm. Radiological criteria for pleural effusion re-accumulation not given. Time




Methods Single-centre RCT comparing talc slurry pleurodesis and iodine for treatment of recurrent MPE (Egypt).
Participants Inclusion criteria: clinical and histopathologically diagnosed recurrent MPE.
Exclusion criteria: allergy to iodine, incompletely inflated lung on radiograph.
39 participants randomised.
Interventions Therapeutic thoracentesis performed for all participants. After randomisation, all participants received
a wide-bore chest drain 28- to 36-Fr, under local anaesthetic with free drainage of pleural fluid over 6–
12 hours.
Group 1: 5 g sterile talc in 50 mL 0.9% saline.
Group 2: 20 mL 10% povidone-iodine mixed with 10 mL 1% lidocaine and 30 mL 0.9% saline.
Drain clamped for 6 hours in both groups. Chest drains removed once < 100 mL fluid drained in 24
hours, with no air leak, and a CXR showed satisfactory lung expansion.
Outpatient follow-up at 2 weeks, 2 months and 6 months.
Outcomes Primary outcome: pleurodesis success, defined on CXR as CR: absence of pleural fluid re-accumula-
tion; PR: residual pleural fluid or re-accumulation which did not require further drainage or remained
asymptomatic; and failed: additional pleural procedures necessary
Secondary outcomes: pain (assessed with a comparative pain scale into minor, moderate and severe),
complications (fever, allergy and empyema)
Ibrahim 2015 
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Notes Trapped lung excluded.
Attempt to contact authors by email for further information – no reply received.
Included in network meta-analysis for pleurodesis failure, chest pain, fever and mortality. For chest
pain analyses, participants who experienced minor and moderate pain were included in the total (no
participants from either arm experienced severe pain).
Study funding source: not stated.
Study author conflicts of interest statements: declared they have no competing interests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "simple randomisation with allocation concealment."
Comment: no clear description of method used for randomisation.
Allocation concealment
(selection bias)
Unclear risk Quote: "simple randomisation with allocation concealment."





High risk Unblinded trial.
Blinding of outcome as-
sessment (detection bias) 
All outcomes









High risk Participants were followed up at 2 weeks, 2 months and 6 months, but the
time point at which data for pleurodesis success were measured was unclear.
Unclear if all participants were followed to 6 months. 
Other bias Low risk Participants receiving talc pleurodesis did not receive lidocaine, which may af-
fect chest pain scores. The time point at which participants were asked to rate




Methods Single-centre RCT of intrapleural cisplatin vs OK-432 vs combination (Japan).
Participants Inclusion criteria: symptomatic, histocytologically confirmed pleural malignancy secondary to NSCLC,
ECOG Performance Score 0–3, adequate renal, haematological and cardiac function.
Exclusion criteria: previous intrapleural therapy, trapped lung or atelectasis after chest tube inserted.
49 participants randomised.
Ishida 2006 
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Interventions All participants underwent pleural fluid drainage via a 20-Fr chest tube. After administration of the allo-
cated treatment, chest drain was clamped for 6 hours and then connected to 20 cmH2O suction. Drain
removed when < 100 mL/day.
Cisplatin group: cisplatin 50 mg via chest tube on day 1 and 4.
OK-432 group: 1 dose of OK-432 5 KE via chest tube.
Combination group: 50 mg cisplatin on day 1 and 4, followed by OK-432 5 KE on day 7.
Outcomes Effusion recurrence (as defined by a newly detected effusion needing drainage or occupying > 33% of
pleural space on CXR); mortality; adverse events
Notes People with trapped lung excluded from study.
Study authors contacted for further information, but no response.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk No mention of blinding but participants received different dosing regimens de-
pending on study arm.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Adverse event reporting could be affected by knowledge of treatment alloca-
tion. Not stated whether CXR interpretation was performed using a blinded




Low risk Number of deaths clearly stated. If participants died, still included in analysis
for pleurodesis success prior to death.
Selective reporting (re-
porting bias)
Low risk All predefined outcomes reported.
Other bias High risk Drain leG in for different durations in the 3 groups. Steroids were given to par-




Methods Multicentre phase II trial of OK-432, evaluating 2 different doses of intrapleural OK-432 (Japan).
Kasahara 2006 
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Participants Inclusion criteria: histological or cytological proof of MPE with NSCLC; no previous therapy for MPE;
aged > 20 years; ECOG Performance Score 0–3; life-expectancy > 12 weeks; adequate organ and bone
marrow function; daily chest tube drainage < 200 mL.
Exclusion criteria: previous tuberculosis pleuritis; unstable heart disease or diabetes; active double
cancer; pregnancy; lactation; allergy to OK-432 or benzylpenicillin.
38 participants randomised.
Interventions All participants underwent chest tube drainage. 2 doses of OK-432 given (on days 1 and 3).
Group A: intrapleural OK-432 at dose of 10 KE in 100 mL saline.
Group B: intrapleural OK-432 at dose of 1 KE in 100 mL saline.
Outcomes MPE control on day 28 (defined as a CR: effusion disappeared completely and no further treatment re-
quired; PR: effusion persisted but local treatment not needed; or no change: further local treatment







Notes People with trapped lung included in study.
For purposes of this review, CR and PR were counted as pleurodesis successes.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk Not stated whether blinded. Drugs diluted in same volume in both study
groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Need for repeat intervention and adverse effects could be biased if partici-
pants and personnel unblinded, but not stated if this was the case.
Incomplete outcome data
(attrition bias) 
Low risk No LTFU.
Kasahara 2006  (Continued)
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Low risk All stated outcomes reported.
Other bias High risk In group B, if low dose ineffective, participants given a high dose of OK-432
anyway (prior to measurement of primary outcome).





Methods Single-centre RCT to determine efficacy and safety of autologous blood pleurodesis compared with
tetracycline for MPE (Thailand).
Participants Inclusion criteria: aged > 18 years, symptomatic MPE (histocytologically confirmed), life-expectancy > 3
months, agreement to receive chemical pleurodesis.
Exclusion criteria: active pleural or systemic infection, haemodynamic instability, haemothorax, serum
haematocrit < 25%, chylothorax, combined causes of pleural effusion, history of tetracycline or lido-
caine allergy, CXR showing trapped lung after chest tube drainage, pregnancy.
48 participants randomised.
Interventions Participants received either 8- to 10-Fr small-bore drain or 20- to 32-Fr large-bore drain. Pleural fluid
drained until < 100 mL/24 hour and CXR showed full lung expansion. The autologous blood group re-
ceived 100 mL autologous venous blood instilled via the chest drain without intrapleural lidocaine, fol-
lowed by 50 mL 0.9% saline. The tetracycline group received 20 mL 1% lidocaine, made up to 50 mL
with 0.9% saline, instilled via the chest drain, followed by tetracycline 1 g diluted in 100 mL 0.9% saline.
The chest drain was clamped for 2 hours, then placed on –20 cmH2O pressure suction. Chest drains re-
moved once draining < 150 mL/24 hours with full lung re-expansion on. CXR. Non-response to autolo-
gous blood pleurodesis were treated with tetracycline pleurodesis. Non-response to tetracycline was
treated with other sclerosants such as iodine or talc.
Outcomes Primary outcome: pleurodesis efficacy at 30 days assessed as CR: no pleural effusion; PR: minimal
pleural fluid without need for repeat thoracentesis or drainage; no response: massive effusion or need
for repeat thoracentesis or pleurodesis). CR and PR defined as success
Secondary outcomes: length of stay, complications, pleurodesis-related pain (numerical rating scale 0–
10)
Notes Trapped lung excluded. 
Of 4 participants who had 'no response' to autologous blood pleurodesis, 2 underwent repeat pleu-
rodesis with tetracycline, with success in 1 participant.
Included in network meta-analysis for pleurodesis failure, fever and chest pain (those who required ad-
ditional IV analgesia). Unable to include in network for mortality as 0 events in both study arms which
caused computational problems. 
Authors contacted by email for further information, no reply received. 
Study funding source: Thoracic Society of Thailand for Clinical Fellowship Research Award 2013.
Study author conflicts of interest statements: no conflicts of interest to declare.
Risk of bias
Keeratichananont 2015 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation. 
Allocation concealment
(selection bias)
Unclear risk No information given. The authors were contacted by email to seek further in-





Unclear risk No information regarding blinding of participants or clinicians was given. Con-
tacted authors for further information but no reply received. 
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Low risk All stated outcomes reported.
Other bias Low risk Treatment groups were broadly similar; however, 17 of the tetracycline group





Methods Single-centre RCT comparing the efficacy of autologous blood and talc for pleurodesis (Thailand).
Participants Inclusion criteria: aged > 18 years, recurrent symptomatic MPE (cytologically or histologically con-
firmed), predicted life-expectancy > 1 month (ECOG Performance Score 0–2 and without severe comor-
bidity), who agreed to receive chemical pleurodesis.
Exclusion criteria: active pleural or systemic infection, serum haematocrit < 25% or haemodynamic in-
stability, haemothorax, chylothorax or pleural effusion or multiple aetiology, history of previous chem-
ical pleurodesis, allergy to talc or lidocaine, CXR after chest tube drainage showing a trapped lung on
the affected side, pregnancy.  
123 participants randomised. 
Interventions A small-bore 8- to 10-Fr or wide-bore 20- to 32-Fr drain was inserted. Drainage until < 150 mL/day and
CXR. 
Autologous blood pleurodesis group: 100 mL autologous peripheral venous blood instilled via drain,
without intrapleural lidocaine, followed by 50 mL 0.9% saline. Drain clamped for 2 hours.
Talc slurry group: 20 mL 1% lidocaine made up to 50 mL with 0.9% saline, followed by 4 g sterile graded
talc in 100 mL 0.9% saline instilled over 5̵–10 minutes. Drain clamped for 2 hours. 
All participants then had –20 cmH2O suction applied. When drainage < 150 mL within 8 hours of tho-
racic suction CXR was repeated and drain removed after full lung re-expansion. 
Keeratichananont 2018 
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In cases of non-response to autologous blood pleurodesis, repeat pleurodesis with talc was adminis-
tered. For non-response to talc pleurodesis, another sclerosing agent (except autologous blood) was
offered. 
Outcomes Primary outcome: pleurodesis effectiveness at 30 days, defined as CR: no re-accumulation on CXR; PR:
recurrence of small volume effusion, not requiring repeat drainage; and no response: recurrence of ef-
fusion requiring repeat drainage). CR and PR were considered successful.
Secondary outcomes: length of stay, postpleurodesis hospital stay, pleurodesis-related complications,
cardiopulmonary adverse events, fever, pleurodesis-related pain (measured on a 0–10 scale). 
Notes Trapped lung excluded.
Included in network meta-analysis for pleurodesis failure, mortality, fever and pain. Participants in-
cluded in the chest pain analysis were those requiring additional IV opioid analgesia. 
Study funding source: no specific grants or funding received.
Study author conflicts of interest statements: no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Web-based central randomisation system.
Allocation concealment
(selection bias)





Low risk Participants and clinicians unblinded to treatment allocation. However, pleu-
rodesis success assessed against objective criteria by blinded chest physicians,
therefore lack of blinding not likely to influence primary outcome.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 3 LTFU from each study arm – reasons stated for all (all due to chemothera-
py-related adverse events). 3 deaths from the blood pleurodesis arm and 4




Low risk All outcomes reported.




Methods Single-centre RCT of intrapleural adriamycin, nitrogen mustard and rolitetracycline (Australia).
Participants Histocytologically confirmed malignant effusions (pleural or pericardial or peritoneal); no previous in-
tracavitary chemotherapy; no concurrent radiotherapy or systemic treatment.
Keord 1980 
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38 participants reported as being randomised in total (26 of whom had MPE). However, the discussion
referred to 90 participants being randomised originally.
Interventions All participants had a needle thoracentesis to dryness. The drug was diluted in 20 mL saline and inject-
ed through needle as a bolus.
Adriamycin group: adriamycin 30 mg intrapleurally.
Nitrogen mustard group: nitrogen mustard 20 mg intrapleurally.
Rolitetracycline group: rolitetracycline 500 mg intrapleurally.
Outcomes Pleurodesis success at 8 weeks (defined as CR: absence of significant effusion on CXR; PR: reduction in
frequency of aspiration with improvement in exercise tolerance and CXR; or no response)
Complications
Notes People with trapped lung eligible for the trial.
For the purposes of this review, only data on participants with pleural effusions included in our analysis
and only CR counted as a pleurodesis success.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk No mention of whether anyone was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Quote: "More than half of the original 90 patients randomised were ineligible
for assessment because of subsequent systemic therapy … or … early death."
Comment: although in the results, it stated 38 participants were randomised.
Selective reporting (re-
porting bias)
Low risk Only a brief report and adverse effects data for the pleural and peritoneal effu-
sions combined. However, generally all predefined outcomes reported.
Other bias Unclear risk 6 participants received > 1 of the treatments, but not clear whether reran-
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Methods Single-centre RCT comparing intrapleural bleomycin and tetracycline in MPE (USA).
Participants Inclusion criteria: histologically confirmed malignancy; symptomatic pleural effusion with either > 3 g/
dL protein or malignant cells on cytology.
Exclusion criteria: allergy to either study drug.
42 procedures randomised in 34 participants.
Interventions All participants underwent chest tube drainage.
Tetracycline group: tetracycline 500 mg in 50 mL saline intrapleurally. 1 dose.
Bleomycin group: bleomycin 89 units in 50 mL saline intrapleurally. 1 dose.
For both arms, drain clamped for 8 hours after instillation and participant moved positions. Thereafter,
tube opened and suction applied. Drain removed when < 40 mL/24 hours drained (or on day 7 if ongo-
ing high output).
Outcomes Treatment response at 1 month (CR: no re-accumulation of the effusion; PR: asymptomatic re-accumu-
lation of the effusion developed that was < 50% of its original volume; and no response)
Adverse effects
Length of time chest tube in place following pleurodesis
Notes Bilateral disease included. Some participants randomised to the trial more than once.
People with trapped lung eligible for trial entry.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "toss of coin."
Allocation concealment
(selection bias)





Unclear risk No mention of blinding. Both drugs administered in 50 mL saline.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





High risk 11/34 (32%) participants non-evaluable for pleurodesis outcome (3 in
bleomycin group and 8 in tetracycline group).
Kessinger 1987 
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Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Other bias High risk Unclear whether participants who were given both agents because the first




Methods Single-centre, prospective RCT of mepacrine vs bleomycin as pleurodesis agent in MPE (Norway).
Participants Inclusion criteria: MPE; previous treatment with a therapeutic tap; life-expectancy > 1 month.
Exclusion criteria: previous pleurodesis; renal failure; participant requiring continuous oxygen.
40 participants randomised.
Interventions 28-Fr or 32-Fr chest tube inserted under local anaesthetic. Suction applied until fluid production about
100 mL/day and no effusion on CXR. Tube clamped and sclerosing agent injected. Participant rotation
for 2 hours after instillation. Drain removed when < 100 mL/day output.
Mepacrine group: mepacrine 800 mg in 20 mL saline.
Bleomycin group: bleomycin 60 mg in 100 mL saline.
Outcomes Pleurodesis success (classified as no re-accumulation, small amounts of fluid re-accumulation with no
or mild symptoms, re-accumulation of fluid with severe dyspnoea needing thoracentesis)
Median survival
Adverse effects
Notes People with trapped lung not excluded from trial entry.
For purposes of this review, participants with no re-accumulation or small amount of re-accumulation
with no or mild symptoms were counted as pleurodesis successes.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised using sealed envelopes.
Allocation concealment
(selection bias)





High risk Not stated specifically but drugs reconstituted in different volumes.
Koldsland 1993 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Participant reporting of symptoms may be affected by lack of blinding. Not




Low risk High mortality in first 3 months, therefore data only analysed at month 1.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre, prospective RCT of talc vs doxycycline in the control of MPE (Poland).
Participants Inclusion criteria: pleural effusion with clinical suspicion of malignant origin.
Exclusion criteria: failure to confirm malignancy by pleural biopsy; mesothelioma; failure to achieve full
re-expansion of the lungs.
33 participants randomised.
Interventions All participants all VATS under GA and pleural biopsy. First dose of sclerosant given at end of procedure.
Tube removed when full re-expansion, no air leak and < 150 mL/day drainage. Rotation after proce-
dure.
Talc: single 10 g dose intrapleurally by insufflation.
Doxycycline: 500 mg in 25 mL solution given intrapleurally. Up to 3 doses (if daily drainage > 150 mL/
day).
Outcomes 'Long-term' and 'short-term' pleurodesis outcome (defined by need for repeat thoracentesis as excel-
lent: no fluid re-accumulation; good: limited residual fluid, not increasing, no indications for thoracen-
tesis; or poor: fluid re-accumulation requiring thoracentesis
Complications
Notes For purposes of this review, 'Excellent' and 'Good' pleurodesis outcomes included as pleurodesis suc-
cesses for analysis.
Study authors emailed for further information, but no response.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Kuzdzal 2003 
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Allocation concealment
(selection bias)





High risk Unable to blind due to the nature of the interventions, although not stated ex-
plicitly.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Pleurodesis efficacy defined by symptom recurrence and hence could be bi-
ased by lack of blinding. Not stated whether assessment of fluid re-accumula-




Unclear risk Number of participants randomised not clear from paper.
Selective reporting (re-
porting bias)
High risk Treatment complications and survival not reported.




Methods RCT (2 recruiting centres) of intrapleural Corynebacterium parvum and tetracycline for pleurodesis of
MPE (UK).
Participants Inclusion criteria: histologically or cytologically confirmed MPE.
Exclusion criteria: participants on chemotherapy; participants receiving treatment with steroids.
36 participants randomised.
Interventions Effusion aspirated to dryness prior to administering study agent. After agent instilled, the participants
moved from side to side for 6 hours. If the participant had symptomatic recurrence of the effusion with-
in 1 month, the allocated treatment was repeated.
Tetracycline group: tetracycline 500 mg in 20 mL saline given intrapleurally via an intercostal tube at 1
centre and with needle drainage at the other centre.
C parvum group: C parvum 7 mg in 20 mL saline intrapleurally through a needle, after the effusion was
drained to dryness.
Outcomes Symptomatic recurrence of pleural effusion 1 month after the last dose
Adverse effects (pain, fever, nausea and vomiting, and rash)
Notes People with trapped lung eligible for trial entry.
Adverse effects were reported per procedure rather than per participant.
For this review, if participants had a successful pleurodesis after the second dose of study agent, these
were included in the analysis as a success. For the tetracycline group, the results from the 2 administra-
tion methods were combined for the purposes of analysis.
Included in network meta-analysis for pleurodesis failure, fever, pain and mortality.
Study funding source: not stated.
Leahy 1985 
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Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation.
Allocation concealment
(selection bias)





Unclear risk Blinding not mentioned in the paper. Both drugs reconstituted in 20 mL saline.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk If study was unblinded, reporting of adverse effects, symptomatic pleural fluid




Low risk Participants excluded from analysis if died prior to 1 month, but the numbers
were small and fairly well balanced between the groups (1/17 in C parvum
group vs 3/19 in tetracycline group, i.e. 11% LTFU in total).
Selective reporting (re-
porting bias)
Low risk Thorough reporting of toxicity.




Methods Single-centre RCT of tetracycline and mechlorethamine (mustine) for pleurodesis of MPEs (Greece).
Participants Inclusion criteria: documented MPE (all tumour types); respiratory distress was the main problem of
participants.
Exclusion criteria: other therapy given simultaneously (chemotherapy or radiotherapy).
40 participants randomised.
Interventions All participants had a 32-Fr intercostal drain inserted with local anaesthetic and effusion drained
overnight. Complete drainage confirmed on CXR.
After pleurodesis, drain flushed with 20 mL saline. Participants rotated and drain unclamped after 2
hours and put onto –20 cmH2O suction. Drain removed when < 50 mL/day drainage.
Tetracycline group: tetracycline 500 mg in 20 mL 2% lignocaine intrapleurally. 1 dose.
Mechlorethamine group: mechlorethamine 0.2 mg/kg in 20 mL saline intrapleurally. 1 dose.
Outcomes Response to therapy at 60 days (CR: complete lack of re-accumulation of pleural fluid for ≥ 60 days; PR:
small pleural effusion, asymptomatic, not requiring further treatment; failure: all other cases)
Adverse effects
Notes Minimal data provided on baseline participant characteristics of the 2 groups.
Loutsidis 1994 
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Pleurodesis defined according to symptomatic effusion recurrence.
For the purposes of this review, CR and PR included as a successful pleurodesis.
People with trapped lung included in the study.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk No mention of blinding in the paper. Drugs given in the same volume but not
stated whether their appearances were similar.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk All participants followed up until the primary endpoint at 60 days.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre RCT of OK-432 and mitomycin C pleurodesis in people with lung cancer with MPE (Tai-
wan).
Participants Inclusion criteria: histology/cytology confirmed MPE due to lung cancer; effusion requiring repeated
thoracentesis; ECOG performance score 0–3.
Exclusion criteria: previous anticancer chemotherapy within 4 weeks; previous radiotherapy to the ipsi-
lateral chest within 4 weeks; concomitant systemic chemo or radiotherapy; history or evidence of peni-
cillin allergy.
55 participants randomised.
Interventions All participants hospitalised and a chest drain or pigtail catheter inserted into effusion. Drainage until <
200 mL/day. Tube clamped for 1 hour after drug administration. Drug administration repeated weekly
for 4 weeks or until effusion resolved.
Luh 1992 
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OK-432 group: OK-432 1 KE intrapleurally.
Mitomycin C: mitomycin C 8 mg in 30 mL water intrapleurally.
Outcomes Pleurodesis success at 4 weeks (defined as CR: no fluid accumulation and participants free of symp-
toms; PR: recurrence of effusion < 50% of original effusion volume, not symptomatic and no need for
thoracentesis for symptom relief; or failure: recurrence of effusion > 50% of the original volume, symp-
tomatic and need for thoracentesis to relieve symptoms)
Survival
Effusion-free period
Notes People with trapped lung included in the study.
For this review, PR and CR counted as pleurodesis successes.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sealed envelopes.
Allocation concealment
(selection bias)





Unclear risk No mention of whether the study was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 2 participants excluded due to early death, both in OK-432 group.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods RCT of bleomycin, tetracycline and talc for pleurodesis of MPE.
Participants Inclusion criteria: MPE (either cytology positive or an exudative effusion attributed to a histologically
confirmed malignancy elsewhere) (all cell types); life-expectancy > 2 months.
Lynch 1996 
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Exclusion criteria: contraindication to placement of a chest tube; allergy to bleomycin, talc or tetracy-
cline.
50 participants randomised.
Interventions Chest tube placed using blunt dissection and allowed to drain for ≥ 24 hours until < 150 mL/day output.
Sclerosing agent instilled intrapleurally. Participants repositioned every 7 minutes after agent instilled.
Then, tube unclamped and suction applied, until < 150 mL/24 hours drainage when the drain was re-
moved. If the drainage remained high, a second instillation was attempted.
Bleomycin group: bleomycin 60 units in 50 mL 5% dextrose.
Tetracycline group: tetracycline 750 mg in 100 mL saline, with lidocaine 100 mg.
Talc group: 5 g talc in 250 mL saline, with lidocaine 100 mg.
Outcomes Success of sclerosis at 30 days (defined as a lack of significant re-accumulation on CXR with control of
symptoms due to the effusion)
Survival
Median length of hospitalisation from date of sclerosis to discharge
Adverse effects
Notes Participants who died within 30 days of the sclerosis were included as treatment failures in the study.
Small difference in median age and cell types between the treatment arms.
Trapped lung not accounted for.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: partially supported by grants CA-06516 and CA-19589 awarded by the NCI, NIH
and DHHS.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number generator.
Allocation concealment
(selection bias)





High risk Not stated explicitly if the study was blinded, but the different drugs were giv-
en as different volumes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom and adverse effect reporting would be affected by lack of blinding.




Low risk 4/50 (8%) LTFU for primary outcome but balanced between the treatment
arms.
Lynch 1996  (Continued)
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Selective reporting (re-
porting bias)
Low risk All reported.




Methods Single-centre RCT evaluating the distribution of talc during a talc slurry pleurodesis – comparing rota-
tion with non-rotation of participants after instillation of talc slurry (the Netherlands).
Participants Inclusion criteria: symptomatic MPE confirmed by cytology or histology (all cell types).
Exclusion criteria: haemorrhagic disease; trapped lung; previous pleurodesis on ipsilateral side; oth-
er disease which would interfere with the study; participants on systemic treatment or expected to be
within 4 weeks of pleurodesis; expected survival < 1 month.
20 participants randomised.
Interventions Chest drain inserted and pleurodesis performed when drainage < 150 mL/24 hours and lung fully re-ex-
panded. Talc suspension was radiolabelled. Dynamic scintigraphy performed during, immediately after
and 1 hour after instillation.
Rotation arm: sequence of 4 positions changing every 10 minutes after instillation of talc for 1 hour.
Non-rotation arm: strict bed rest in supine position after instillation.
Tube removed when < 100 mL/24 hour fluid drained.
Outcomes Distribution of talc in the thoracic cavity, measured on scintigram immediately after instillation of talc
and after 1 hour
Success rate of pleurodesis (defined on CXR) at 4 weeks
Notes People with trapped lung excluded.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk Unable to blind due to the nature of the interventions.
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Not stated if CXR reporting was performed by a blinded individual.
Mager 2002 
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Low risk No serious adverse effects. Some discomfort in rotation group (not quanti-
fied). All study participants alive at 1 months' follow-up (personal communica-
tion).




Methods Single-centre RCT of tetracycline vs bleomycin pleurodesis in MPE (Spain).
Participants Inclusion criteria: MPE (all cell types) causing respiratory symptoms, confirmed by cytological examina-
tion or pleural biopsy and an expected survival ≥ 1 month, with a KPS ≥ 50.
Exclusion criteria: prior intrapleural instillation therapy; CXR during the preceding 2 weeks; previously
received systemic bleomycin; trapped lung; allergy to study drugs.
70 participants randomised.
Interventions All participants underwent tube thoracostomy with suction drainage until < 100 mL/day output.
Tetracycline group: tetracycline 1.5 g in 100 mL saline intrapleurally, with 9 mL 5% lignocaine.
Bleomycin group: bleomycin 60 mg in 100 mL saline intrapleurally.
Tube clamped for 4 hours after instillation, then suction drainage. Drain removed when < 100–150 mL/
day output.
Outcomes Response to pleurodesis (defined as CR: no clinical or radiological recurrence of effusion; PR: small
amount of fluid re-accumulation on CXR but no symptoms; failure: re-accumulation of fluid causing
symptoms or needing thoracentesis)
Adverse effects of procedure
Notes People with trapped lung excluded from trial entry.
For this review, CR and PR included as pleurodesis successes.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation.
Allocation concealment
(selection bias)
Low risk Computer randomisation.
Martinez-Moragon 1997 
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Unclear risk No mention of blinding in the paper. Agents given in the same volume but no
comment on whether appearances were similar.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated if CXR interpretation was blinded. Other symptom and adverse ef-
fect outcomes could be biased if participants and personnel not blind to treat-




Low risk 8/70 (11%) participants excluded from analysis due to death (5) or LTFU (3).
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre RCT comparing pleurodesis using mixed particle Talc (> 50% of particles are < 20 μm) vs
graded talc (< 50% of particles are < 20 μm) (UK).
Participants Inclusion criteria: symptomatic pleural effusion, confirmed to be malignant by cytology or pleural biop-
sy (all cell types).
Exclusion criteria: expected survival < 6 weeks; bleeding diathesis contraindicating intercostal drain
insertion; extensive trapped lung; previous ipsilateral pleurodesis; aged < 18 years; inability to give in-
formed consent.
48 participants randomised.
Interventions 12-Fr intercostal drain inserted. Drainage until < 150 mL/day output. Agent instilled and leG in for 2
hours, before suction being applied. Drain removed after 48 hours.
Mixed particle talc group: > 50% of talc particles are < 20 μm. Single 4 g intrapleural dose.
Graded talc group: < 50% of talc particles are < 20 μm. Single 4 g intrapleural dose.
Outcomes Change in alveolar–arterial gradient 48 hours postpleurodesis breathing air
Change in partial pressure of oxygen at 48 hours postpleurodesis
Clinical efficacy of pleurodesis at 3 months
Presence/absence of fever at 48 hours
Change in C-reactive protein
Change in interleukin-8
Notes People with trapped lung excluded.
Pleurodesis success defined as no re-accumulation of pleural fluid sufficient to require drainage.
Paper presented 2 trials and only trial 2 was relevant to this review (trial 1 was RCT of mixed talc vs
tetracycline, but pleurodesis success data were not collected).
Not included in network meta-analysis.
Maskell 2004 
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Study funding source: supported partly by a Medical Research Council grant (G9721289) covering NAMs
salary and partly through internal funds.
Study author conflicts of interest statements: no authors have a financial relationship with a commer-
cial entity that has an interest in the subject of this manuscript.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Presealed numbered, opaque, sealed envelopes with stratification.
Allocation concealment
(selection bias)





Low risk Quote (personal communication with authors): "investigators and patients
blind to treatment allocation."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote (personal communication with authors): "investigators and patients








Unclear risk Study comprised 2 sections and pleurodesis success only reported for the par-
ticle size section. The RCT of talc/tetracycline did not report pleurodesis suc-
cess, but this was not 1 of the predefined outcome measures.




Methods Multicentre RCT of LC9018 + doxorubicin vs doxorubicin alone in MPE secondary to lung cancer
(Japan).
LC9018 is a biological response modifier prepared from heat-killed, freeze-dried Lactobacillus casei YIT
9018.
Participants Inclusion criteria: positive histology for primary lung cancer; unilateral pleural effusion; expected sur-
vival > 8 weeks; no treatment within 4 weeks; performance score 0–3; no concurrent cancer; no severe
hepatic/renal/bone marrow failure; aged ≤ 75 years.
Exclusion criteria: previous intrapleural treatment with a biological response modifier; pregnant
women and women of child-bearing potential; history of allergy.
95 participants randomised.
Interventions Effusion completely drained. Both treatment arms received ≤ 2 intrapleural doses, 1 week apart.
Control group: doxorubicin 40 mg in 20–50 mL saline.
LC9018 group: as control group, then LC9018 0.2 mg in 20–50 mL saline.
Masuno 1991 
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Outcomes Efficacy of effusion control at 4 weeks (defined as CR: negative cytological findings with no re-accumu-
lation of fluid; PR: negative cytological findings with asymptomatic minimal fluid accumulation, not re-
quiring additional aspiration; or failure: detectable intrapleural fluid even after tube drainage with no
improvement or exacerbation on radiology compared with before treatment, or failure to confirm con-
version to negative cytology)
Adverse effects
Change in performance status
Notes People with trapped lung excluded postrandomisation.
For this review, CR and PR counted as pleurodesis success.
Not included in network meta-analysis.
Note: doxorubicin is the generic name for adriamycin.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Central telephone randomisation system.
Allocation concealment
(selection bias)





Unclear risk Not clear.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 19/95 participants excluded from final analysis, for a variety of reasons, includ-
ing 5 participants with protocol violations.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Other bias Unclear risk Primary outcome measure included CXR resolution and conversion to cytol-
ogy negative effusion. Not clear from methodology whether some participants
who were asymptomatic had effusion drained to evaluate cytology status and




Methods Single-centre RCT of mepacrine hydrochloride, triethylenethiophosphoramide and pleurocentesis
alone in the treatment of MPE (Denmark).
Mejer 1977 
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Participants Inclusion criteria: unilateral MPE (positive cytology > 200 IU/L lactate dehydrogenase and > 30 g/L pro-
tein) (all cell types); 1 previous pleurocentesis of > 500 mL.
Exclusion criteria: participant receiving chemotherapy or radiotherapy.
41 participants randomised.
Interventions Pleurocentesis with intrapleural instillation of the study agent, 3 times a week for 1 week.
Mepacrine group: mepacrine 100 mg for first dose, 200 mg for second dose, 200 mg for third dose (i.e.
500 mg in total).
Triethylenethiophosphoromide group: triethylenethiophosphoromide 20 mg at each instillation (i.e. 60
mg total).
Pleurocentesis group: 10 mL saline at each instillation.
All participants were followed up at 3 weeks, 6 weeks, 2 months and 3 months, when a pleurocentesis
was performed.
Outcomes Treatment effect (a beneficial effect was defined as < 500 mL fluid aspirated at each pleurocentesis per-
formed up to 3 months)
Adverse effects
Notes People with trapped lung not excluded from trial entry.
Minimal data presented on whether the treatment groups were well balanced at baseline.
Included in network meta-analysis for pleurodesis failure, pain and fever.
Study funding source: mepacrine hydrochloride (Atabrine) supplied by Winthrop Medicinal Company A/
S, Copenhagen.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given.
Allocation concealment
(selection bias)





Unclear risk No mention of blinding in the paper.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Minimal early deaths (3/25) and numbers well matched between the groups.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Mejer 1977  (Continued)
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Other bias High risk Unsure if groups well balanced at baseline. Pleurodesis success defined by as-





Methods RCT of intrapleural Corynebacterium parvum vs mustine in recurrent MPE (UK).
Participants Recurrent effusion associated with histologically confirmed malignant disease (all cell types); ≥ 2 previ-
ous pleural aspirations; symptoms of dyspnoea, cough or local pain.
21 participants randomised.
Interventions Effusion completely aspirated using an Abrams pleural biopsy needle.
Group A: intrapleural mustine 20 mg (maximum 2 doses).
Group B: intrapleural C parvum 7 mg (maximum 2 doses).
Outcomes Response to pleurodesis (defined by fluid re-accumulation on CXR and need for repeat aspiration – suc-
cess/partial success/failure) at 4 weeks
Symptoms (nausea, vomiting, pain)
Notes Trapped lung not accounted for.
Only 'success' counted as a pleurodesis success for analysis (not partial successes as these participants
required a further aspiration of effusion).
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: C parvum supplied by Dr Priestman of the Wellcome Research Laboratories.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk No mention of blinding in the paper.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No mention of blinding in the paper. If unblinded, symptom and adverse effect




Low risk 3 participants excluded from analysis as died before primary outcome mea-
sure.
Millar 1980 
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Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Multicentre RCT comparing the effect of intrapleural urokinase on dyspnoea and pleurodesis success in
people with non-draining MPE – TIME 3 (UK).
Participants Inclusion criteria: adults with MPE (histocytological diagnosis or a recurrent large pleural effusion in the
context of histologically confirmed cancer outside the pleural space), with a patent and correctly sited
chest tube inserted for dyspnoea relief and significant residual pleural fluid (> 25% opacification of the
hemithorax on CXR). A trial modification was made from March 2011 in response to increasing use of
USS in the UK to include people with > 15% opacification on CXR or > 2 cm of loculated pleural fluid on
USS.
Exclusion criteria: aged < 18 years, expected survival < 28 days, trapped lung of sufficient severity that
pleurodesis would be futile, previous lobectomy or pneumonectomy on the side of the effusion, pleur-
al infection, previous intrapleural fibrinolytic use, urokinase allergy, coincidental stroke, major haem-
orrhage or major trauma, major surgery in the previous 5 days, chylothorax, pregnancy, lactation, irre-
versible bleeding diathesis, platelet count < 100 × 109/L, irreversible visual impairment, inability to con-
sent or comply with protocol.
71 participants randomised.
Interventions Urokinase group: 3 doses of urokinase 100,000 units in 20 mL 0.9% saline intrapleurally at 12-hour in-
tervals via chest tube.
Placebo: 3 doses of exactly matched placebo vials in 20 mL 0.9% saline intrapleurally at 12-hour inter-
vals via chest tube.
CXR obtained in all participants 24 hours after last dose and talc slurry pleurodesis performed with 4
g sterile graded talc. Pleurodesis was performed regardless of ongoing fluid drainage volume and CXR
appearance. Chest drain removed once draining < 150 mL/24 hours.
Outcomes Primary outcomes: mean daily dyspnoea score over first 28 days after enrolment by VAS and time to
pleurodesis failure (defined as symptomatic ipsilateral pleural fluid recurrence).
Secondary outcomes: radiographic change on day 2 postrandomisation, total volume pleural fluid
drained, all-cause mortality to 12 months, length of stay postrandomisation, frequency of serious and
non-serious adverse events, blood parameters including biomedical and full blood count.
Notes Trapped lung excluded.
Initially participants with highly chemosensitive tumours such as small cell lung cancer were excluded
unless the participant had already undergone chemotherapy, but this exclusion was removed in March
2011.
Not included in network meta-analysis.
Study funding source: urokinase and placebo supplied by Syner-Med Ltd, who had no role in design
and conduct of the study, data or manuscript.
Study author conflicts of interest statements: Dr Mishra reported grants from National Cancer Research
Institute, during the conduct of the study; Dr Rahman reported grants from Synermed UK, during the
conduct of the study; and received consultancy fees from Rocket Medical UK; Dr Rehal reported grants
from Oxford Respiratory Trials Unit,  during the conduct of the study; Dr Corcoran reported grants from
National Cancer Research Institute, non-financial support from Syner-Med Ltd,  during the conduct of
Mishra 2018 
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the study; Dr Lee reported grants and non-financial support from Rocket Medical Ltd, outside the sub-
mitted work; and he was an advisor to Lung Therapeutic Ltd which is conducting a phase I study of a
fibrinolytic drug for intrapleural use in pleural infection. The other authors had no disclosures.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Telephone randomisation with minimisation criteria.
Allocation concealment
(selection bias)





Low risk Treating physicians and participants were blinded to treatment allocation
throughout.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk ITT analysis. Significant mortality rate (31/36 in urokinase group vs 35/35 in
placebo group) over 12-month trial period; however, deaths occurring after




Low risk All outcomes reported.




Methods Single-centre RCT of thoracoscopic talc poudrage vs povidone-iodine pleurodesis through an inter-
costal drain (Egypt).
Participants Inclusion criteria: MPE as a complication of breast carcinoma.
Exclusion criteria: performance status > 3; allergy to iodine; trapped lung; no change in MRC Dyspnoea
Scale after thoracentesis; pleural fluid pH < 7.2; pleural fluid glucose < 60 mg/dL; extrathoracic metas-
tasis.
42 participants randomised.
Interventions All participants underwent a VATS drainage and adhesiolysis.
Talc poudrage group: 4 g talc insufflation under thoracoscopic guidance at the end of the VATS proce-
dure.
Iodine group: recovered from VATS. Then later that day, 20 mL 10% povidone-iodine in 30 mL saline in-
jected through the chest drain at the bedside. Drain clamped for 4 hours after instillation.
Outcomes Efficacy of pleurodesis at 2 months (response defined as CR: absence of fluid re-accumulation; PR:
residual pleural fluid or re-accumulation, which did not require further thoracentesis or remained
asymptomatic; or failure: additional pleural procedures were necessary
Mohsen 2011 
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Complications
Length of hospital stay (in days)
Survival
Change in MRC Dyspnoea Score
Notes People with trapped lung excluded from trial entry.
CR and PR counted as pleurodesis success for analysis.
Included in network meta-analysis for pleurodesis failure, mortality and fever.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation software used.
Allocation concealment
(selection bias)





High risk Not able to blind given the nature of the interventions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom and adverse effect reporting would be affected by lack of blinding.
Not stated if radiology was interpreted blindly. Mortality would not be biased








Low risk All stated outcomes reported.




Methods Multicentre RCT comparing daily vs symptom-guided IPC drainage and breathlessness scores in people
with symptomatic MPE (11 centres in Australia, New Zealand, Hong Kong and Malaysia).
Participants Inclusion criteria: adults requiring IPC for management of MPE, malignant cells in pleural fluid or
pleural biopsy or large exudative effusion without other cause in people with known disseminated ex-
trapleural malignancy.
Exclusion criteria: aged < 18 years, expected survival < 3 months, pleural infection, chylothorax, preg-
nancy, lactation, uncorrectable bleeding diathesis, previous ipsilateral lobectomy or pneumonecto-
Muruganandan 2018 
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my, significant loculation likely to preclude effective drainage, significant visual impairment, inability
to consent or comply with study protocol.
87 participants randomised.
Interventions All participants received an IPC and were randomised within 72 hours of insertion and after maximum
pleural fluid drainage. 
'Aggressive' daily drainage group: participants (or their carers or community nurses) were asked to
drain the IPC daily for the first 60 days unless clinically contraindicated or spontaneous pleurodesis had
occurred.
Symptom-guided group: IPC drainage when they had effusion-related symptoms, with minimum
drainage once every 2 weeks.
Outcomes Primary outcome:  mean daily breathlessness score in first 60 days postrandomisation (VAS score).
Secondary outcomes: rate of spontaneous pleurodesis, QoL (EQ-5D-5L and VAS at randomisation, 2
weeks, 4 weeks and then monthly to 6 months), number of episodes and duration of hospital stay for
any cause (excluding elective admissions for chemotherapy), adverse and serious adverse events.
Notes Pleurodesis defined as < 50 mL of fluid removed on 3 consecutive drainages in the aggressive group
and at 2 attempts 2 weeks apart in the symptom-guided group, in the absence of substantial residual
pleural fluid collection on imaging.
Included in network meta-analysis for pleurodesis failure, mortality and pain (defined as those who re-
quired narcotics). 
Contacted authors for further information by email but no reply received. 
Study funding source: Cancer Council of Western Australia and the Sir Charles Gairdner Research Advi-
sory Group.
Study author conflicts of interest statements: YCGL, DF-K and NAM served on the advisory board of
CareFusion/BD Ltd. NAM received an unrestricted educational grant from Rocket Medical plc (UK) and
CareFusion/BD. YCGL received an unrestricted educational grant from Rocket Medical plc (UK). All oth-
er authors declared no competing interests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Automated telephone-based randomisation service with minimisation for can-
cer type, performance status, trapped lung and prior pleurodesis.
Allocation concealment
(selection bias)






High risk Blinding not possible due to nature of interventions. Primary outcome was VAS
breathlessness score, which may be influenced by knowledge of the treatment
arm. 
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk ITT analysis.
Muruganandan 2018  (Continued)
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Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods RCT comparing pleurodesis with 1% and 2% iodopovidone for MPE (Brazil).
Participants Inclusion criteria: recurrent symptomatic MPE, > 70% lung re-expansion on CX.R after drainage, Karnof-
sky Performance Status > 40.
Exclusion criteria: < 70% lung re-expansion after drainage, haemorrhagic diathesis (prothrombin time <
50%, platelets < 80 × 109/L), active pleural or systemic infection, neoplastic infiltration of the skin at the
site of pleural catheter insertion, aged < 18 years, previous ipsilateral pleural intervention (exception of
thoracentesis and pleural needle biopsies), inability to understand QoL questionnaires, contralateral
pleurodesis < 30 days prior to enrolment, iodine allergy, thyroid disease.
60 participants randomised.
Interventions All participants had a 28-Fr drain inserted with a CXR 24 hours after insertion to evaluate lung re-expan-
sion. Pleurodesis performed 48 hours after chest drain insertion with either 100 mL 1% iodopovidone
or 100 mL 2% iodopovidone. 2 mg/kg lidocaine was added to each solution. 
Outcomes Primary objective: identification of adverse events and evaluation of the influence of iodopovidone
dose on incidence of adverse events. 
Secondary: pleurodesis efficacy, QoL (WHOQOL-BREF questionnaire at baseline and 4 weeks postpleu-
rodesis), chest pain (VAS score at baseline, day 2, day 4, day 10 and day 30), dyspnoea (MRC Dyspnoea
Score at day 2, day 4, day 10, day 30), observations (oxygen saturation, blood pressure, heart rate, tem-
perature), visual acuity, electrocardiogram, blood tests.
Notes Trapped lung excluded.
Pleurodesis efficacy based on need for further pleural procedures or recurrence of pleural fluid associ-
ated with worsening symptoms within 30 days of pleurodesis. 
Not included in network meta-analysis.
Contacted authors via email for further information but no reply received. 
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Block randomisation.
Allocation concealment
(selection bias)




Low risk Quote: "Investigators and patients were blinded to group allocation."
Neto 2015 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Slightly higher number of deaths in group receiving 2% iodine (5 with 2% vs 2
with 1%) suggested by consort diagram, but due to discrepancy in total num-




Low risk No data given regarding MRC Dyspnoea Scores. All other outcomes reported.




Methods Single-centre RCT of talc vs bleomycin in MPE (Belgium).
Participants Inclusion criteria: hist/cytologically confirmed, symptomatic MPE; KPS ≥ 50; expected survival ≤ 1 year.
Exclusion criteria: previous pleurodesis attempt.
26 participants randomised.
Interventions 14-Fr chest drain with suction drainage until completely drained. Intrapleural lignocaine and subcuta-
neous morphine given prior to instillation of study drug. After instillation of drug, drain clamped for 30
minutes and then leG on suction drainage until output < 150 mL/24 hours.
Bleomycin group: bleomycin 1 mg/kg in 50 mL saline intrapleurally. 1 dose.
Talc group: 5 g talc in 50 mL saline intrapleurally. 1 dose.




Notes People with trapped lung were included in the study.
Included in network meta-analysis for pleurodesis failure and fever.
Study funding source: not stated.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated numerical table.
Allocation concealment
(selection bias)
Low risk Computer-generated numerical table.
Noppen 1997 
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High risk Not stated explicitly but drugs had different appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence and adverse effects could be biased by lack of blinding.




Low risk No LTFU. Outcome data provided on all participants.
Selective reporting (re-
porting bias)
Low risk Time point used to define pleurodesis not specified.




Methods Single-centre RCT of intrapleural streptokinase in MPE undergoing chest drainage (Turkey).
Participants Inclusion criteria: definitive diagnosis of MPE with dyspnoea.
Exclusion criteria: mesothelioma; endobronchial tumour causing obstruction; anticoagulant medica-
tion.
48 participants randomised between January 2007 and December 2008.
Interventions All participants had 10-Fr pleural catheter inserted under local anaesthetic. Pleurodesis (5 g talc in 50
mL saline) given only in those participants with complete lung re-expansion and < 250 mL drain output
per day. Drain removed when output < 150 mL/day or after 3 days.
Those randomised to streptokinase received 3 doses of 250,000 IU in 100 mL normal saline at 12-hourly
intervals intrapleurally prior to pleurodesis.
Outcomes Primary: lung expansion on CXR
Secondary: success of pleurodesis at 1 month; volume of 24-hour pleural drainage before and after fib-
rinolytic
Notes Pleurodesis defined as "no accumulation of moderate to massive pleural fluid or any accumulation
which causes dyspnoea."
Did not pleurodese people with trapped lung.
Degree of loculation or septation on imaging at baseline not recorded.
Not included in network meta-analysis.
Study funding source: no specific grant from any funding agency received.
Study author conflict of interest statements: no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Okur 2011 
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Random sequence genera-
tion (selection bias)
Low risk Web-based random-number generator.
Allocation concealment
(selection bias)





High risk Nature of interventions precluded blinding (1 group received 3 doses of drug
and other group received nothing).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No mention of blinding and adverse effects and symptom reporting could be




Low risk LTFU for pleurodesis success (1/17 in control group; 4/23 in streptokinase
group – 1 died; 1 in intensive care; 3 LTFU). Only those with full lung re-expan-
sion were given pleurodesis and this could have been affected by giving strep-
tokinase, which might affect pleurodesis success rate, although this was not
the study's primary outcome measure.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre RCT of talc vs bleomycin in MPE (Singapore).
Participants Inclusion criteria: symptomatic, unilateral MPE confirmed by cytology or pleural biopsy (all cell types).
Exclusion criteria: trapped lung or loculated effusion; incomplete drainage (e.g. > 100 mL/day for 10
days); previously treated effusions; life-expectancy < 1 month.
50 participants randomised.
Interventions 20- to 24-Fr tube thoracostomy until complete lung re-expansion on CXR and < 100 mL/day for 2 days.
Both drugs diluted in 50 mL saline and 10 mL 1% lignocaine. After study drug inserted, drain clamped
for 6 hours with patient rotation. Then suction applied. Drain removed when < 200 mL/day drainage.
Talc group: 5 g talc intrapleurally. 1 dose.
Bleomycin group: bleomycin 1 unit/kg intrapleurally. 1 dose.
Outcomes Treatment response at 1 month (according to recurrence of effusion on CXR. Scoring system 0–3 used
for size of effusion)
Hospital stay (days)
Adverse effects within 48 hours of pleurodesis
Notes People with trapped lung excluded from trial entry.
Pleurodesis success based only on radiology.
Included in network meta-analysis for pleurodesis failure, pain, fever and mortality.
Ong 2000 
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Study funding source: not stated. 
Study author conflict of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Not stated explicitly, however, drugs had differing appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "A single investigator who was blinded to treatment allocation scored








Low risk All stated outcomes reported.




Methods Multicentre RCT bleomycin vs C parvum in MPE (UK).
Participants Inclusion criteria: histocytologically confirmed malignancy with effusion (all cell types); life-expectancy
> 30 days.
Exclusion criteria: previous intrapleural drug administration; change in cancer treatment in previous 30
days.
58 participants randomised.
Interventions Aspiration of effusion with a cannula. Study drug instilled through cannula. After cannula removed,
participant repositioned every 5 minutes.
Bleomycin group: bleomycin 60 mg in 100 mL saline. Single dose intrapleurally.
C parvum group: 7 mg in 20 mL saline. Single dose intrapleurally.
Outcomes Efficacy of pleurodesis agent at 30 days (defined as: CR: no re-accumulation of fluid confirmed by CXR;
PR: minimal fluid re-accumulation not sufficient to produce symptoms or need for a further aspiration
(or both); or failure)
Duration of treatment response
Toxicity
Ostrowski 1989 
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Efficacy of pleurodesis at 2 months, 3 months, 6 months, 9 months and 12 months
Notes People with trapped lung included in study.
For this review, CR and PR counted as pleurodesis success.
Included in network meta-analysis for pleurodesis failure, mortality, fever and pain.
Study funding source: not stated.
Study author conflict of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Sequentially labelled sealed envelopes.
Allocation concealment
(selection bias)





High risk Not stated explicitly, but agents given as different volumes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence and adverse effect reporting would be influenced by lack
of blinding. Not stated if CXR assessment was blinded. Mortality data would




High risk 14/58 (24%) participants excluded from primary analysis due to death or not
receiving drug. But, balanced numbers between groups.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre, prospective RCT comparing rapid and standard drainage prior to talc slurry pleurodesis
(Turkey).
Participants Inclusion criteria: potentially recurrent histologically or cytologically confirmed MPE, or both (all cell
types).
Exclusion criteria: participants whose lung did not expand; endobronchial lesion; suitable for curative
therapy.
79 participants randomised.
Interventions All participants underwent insertion of 12-Fr chest drain in the posterior axillary lune with local anaes-
thetic (bupivacaine) and intramuscular ketorolac.
Rapid group: 1 L drained every 8 hours until complete drainage. Then talc slurry administered once CXR
showed complete fluid evacuation and no trapped lung.
Ozkul 2014 
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Standard group: drainage of a maximum of 1.5 L/day. Talc slurry administered once CXR showed com-
plete fluid evaluation and no trapped lung and pleural fluid drainage < 300 mL/day.
Outcomes Primary outcome: efficacy of pleurodesis assessed at 1 month, 2 months, 3 months and 6 months
Secondary outcome: hospital length of stay
Notes People with trapped lung excluded from study entry.
Pleurodesis efficacy defined using a combination of radiology and symptomatic effusion re-accumula-
tion.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflict of interest statements: authors declared no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Internet-based random-number generator.
Allocation concealment
(selection bias)





High risk Not possible to blind given nature of 2 treatment groups with such different
drainage regimens.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk Unclear if any LTFU – not stated in paper and no response from study authors.
Selective reporting (re-
porting bias)
High risk Minimal data provided on adverse effect and mortality data. Not all time
points reported as stated in methods.




Methods 2-centre, prospective RCT of silver nitrate vs talc slurry in MPE (Brazil).
Participants Inclusion criteria: documented MPE (positive pleural biopsy or cytology – all cell types); KPS > 60; life-
expectancy > 1 month.
Exclusion criteria: loculated or trapped lungs after drainage.
60 participants randomised.
Paschoalini 2005 
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Interventions 26/28-Fr chest tube. After study drug instilled, clamped for 1 hour with patient rotation. Then suction
applied. Drain removed when < 100 mL drained.
Talc group: 5 g talc in 50 mL saline. 1 dose intrapleurally.
Silver nitrate group: 20 mL of 0.5 mL silver nitrate. 1 dose intrapleurally.
Outcomes Radiological resolution of effusion on CXR (monthly for 4 months)
Pain before and after treatment (measured on a 0–10 linear scale)
Notes People with trapped lung excluded from study entry.
Included in network meta-analysis for pleurodesis failure and fever.
Study funding source: not stated.
Study author conflict of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Picking paper from a box.
Allocation concealment
(selection bias)





High risk Not stated if blinded but agents had different appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk High rate of LTFU (11/60 (18%)) but reasons explored in the discussion.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Prospective RCT of bleomycin vs doxycycline in MPE (USA).
Participants Inclusion criteria: symptomatic effusion; confirmed or strongly suspected that malignancy is the cause
for the effusion.
Exclusion criteria: previous pleurodesis; allergy to bleomycin or doxycycline; chemotherapy in the pre-
vious 30 days.
Patz 1998 
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106 participants randomised.
Interventions All participants underwent 14-Fr chest drain insertion. When drainage < 200 mL/day and lung fully re-
expanded on CXR, participant randomised.
Bleomycin group: bleomycin 60 units in 50 mL saline intrapleurally.
Doxycycline group: doxycycline 500 mg in 50 mL saline + 10 mL lignocaine.
After 18–24 hours, if drainage < 200 mL, drain removed. If > 200 mL, second dose of the same agent giv-
en and drain then removed.
Outcomes Radiographic response at 30 days (classified as: CR, PR, progressive disease, expired with no re-accu-
mulation, expired with re-accumulation, LTFU)
Mortality
Adverse effects
Notes Trapped lung not accounted for.
If participants died prior to day 30, included in analysis according to their outcome at the time of their
death.
For this review, CR, PR and expired with no re-accumulation counted as pleurodesis success.
Included in network meta-analysis for pleurodesis failure, mortality, fever and pain.
Study funding source: not stated.
Study author conflict of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation.
Allocation concealment
(selection bias)





High risk Quote (personal communication with study authors): "Study investigators and
participants not blinded to treatment allocation."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Quote (personal communication with study authors): "Study investigators and




High risk Significant LTFU rate (26/106 (25%)).
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.
Other bias Low risk Radiological outcome on CXR used to define pleurodesis success.
Patz 1998  (Continued)
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Methods RCT comparing IPCs and doxycycline pleurodesis for MPE.
Participants Inclusion criteria: malignancy with moderate pleural effusion and breathlessness relived after thora-
centesis.
Exclusion criteria: chylothorax, previous ipsilateral lobectomy or pneumonectomy, previous attempt-
ed pleurodesis, autoimmune deficiency syndrome, KPS < 50, bilateral moderate/large effusion, multi-
ple loculations, mediastinal shiG towards side of effusion, pleural infection, abnormal coagulation.
144 participants randomised.
Interventions IPC group: IPC insertion and drainage up to 1.5 L. A further 1 L was drained every 8 hours until drainage
complete. Participants were instructed to drain the IPC on alternate days. If no pleural fluid drained on
3 consecutive drainages and pleurodesis had occurred, the IPC was removed.
Doxycycline group: chest drain insertion (any size) and effusion drainage. If lung failed to re-expand by
72 hours, the participant was assumed to have trapped lung and pleurodesis not attempted. If lung ex-
panded and drainage < 150 mL/24 hours doxycycline 500 mg administered via chest tube. Doxycycline
was re-administered if the 24-hourh drainage volume failed to fall below 100 mL/24 hours by day 4. 
Outcomes Length of hospital stay




Notes Included in network meta-analysis for pleurodesis failure, pain and fever. 
Study funding source: supported by Denver Biomaterials, CO.
Study author conflict of interest statements: Dr Light, Dr Rodriguez and Dr Putnam owned shares of
stock in Surgimedics, which is a parent company of Denver Biomaterials. 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table.
Allocation concealment
(selection bias)





High risk Not possible due to different types of intervention.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated.
Incomplete outcome data
(attrition bias) 
Low risk Participants with protocol violations excluded from analysis; however, with-
drawals well matched between interventions.
Putnam 1999 
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Low risk All outcomes reported.




Methods Single-centre RCT comparing the pleurodesis success of doxycycline and bleomycin in MPE (Iran).
Participants Inclusion criteria: symptomatic, cytologically confirmed MPE.
Exclusion criteria: allergy to doxycycline or bleomycin; history of sclerotherapy; systemic chemothera-
py immediately prior to or in the next 2 months after sclerotherapy.
42 participants randomised.
Interventions All participants underwent 'fluid evacuation'. Agent then instilled through the tube, which was
clamped for 1 hour. Then suction applied and drain removed when < 100 mL/24-hour drainage.
Bleomycin group: bleomycin 45 mg intrapleurally.
Doxycycline group: doxycycline 600 mg in 50 mL saline and 10 mL 1% lignocaine intrapleurally.
Outcomes CXR appearances of the effusion size at 2 months (mild, moderate or severe)
Need for repeat pleural fluid drainage
Dyspnoea (mild, moderate or severe)
Complications
Notes People with trapped lung not excluded.
Pleurodesis success primarily defined radiologically, but data presented at 3 months for need for re-
peat pleural intervention.
For this review, need for repeat pleural drainage was used as measure of pleurodesis success.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: financial support from Islamic Azad University Najafabad.
Study author conflict of interest statements: authors declared no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated and no response from study authors to clarify.
Allocation concealment
(selection bias)




Unclear risk Not stated if anyone was blinded. No response from study authors.
Rafiei 2014 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No LTFU.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods 2×2 factorial design multicentre RCT assessing the effect of chest tube size and analgesia on pain and
clinical efficacy related to pleurodesis in people with MPE – TIME 1 (UK, USA, Canada).
Participants Inclusion criteria: aged > 18 years, symptomatic MPE clinically determined to require pleurodesis (his-
tocytologically confirmed pleural malignancy or typical features of pleural malignancy visualised dur-
ing thoracoscopy or pleural effusion in the context of histologically confirmed cancer elsewhere).
Exclusion criteria: primary lymphoma or small cell lung cancer, pregnant or lactating, history of gas-
trointestinal bleed or peptic ulceration, sensitivity to NSAIDs or opiates, hypercapnic respiratory fail-
ure, current IV drug misuse, severe renal or liver disease, known bleeding diathesis, current warfarin
therapy, expected survival < 1 month. 
320 participants randomised.
Interventions Participants undergoing thoracoscopy received a 24Fr drain and were randomised to either NSAID or
opioid analgesic treatment and were not included in primary analysis of chest tube size outcome. 
Participants not undergoing thoracoscopy were randomised to one of four groups (24Fr drain and opi-
oid analgesia; 24Fr drain and NSAID analgesia; 12Fr drain and opioid analgesia; 12Fr drain and NSIAD
analgesia).  
All received regular background analgesia (paracetamol 1 g 4 times a day). Participants allocated to
NSAID treatment received Ibuprofen 800 mg 3 times a day and those to opiate received oral morphine
10 mg 4 times a day, escalating to 20 mg 4 times a day if needed for the duration that the drain was in
situ. Breakthrough analgesia with IV morphine was permitted in both groups.
Pleurodesis performed using 4 g sterile graded talc according to written standard operating proce-
dures.
Outcomes Primary outcomes: superiority comparison of pain scores (mean VAS measured 4 times a day and prior
to any rescue analgesia over duration of chest drain treatment) and a non-inferiority comparison of the
occurrence of pleurodesis failure at 3 months. 
Secondary outcomes: change in pain over time, time to pleurodesis failure 6 months postrandomisa-
tion, pain scores at 4 weeks and 12 weeks postrandomisation, volume of pleural fluid drained, num-
ber of times rescue medication taken, all-cause mortality up to 12 months, complications during chest
drain insertion, safety outcomes, serious and non-serious adverse events. 
Notes Pleurodesis failure judged as requirement for further ipsilateral pleural intervention as per trial proto-
col (breathlessness and > 50% opacification of the hemithorax on CXR. If < 50% opacification, the case
was referred to a second blinded clinician).
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Trapped lung not excluded. Participants who died but did not require further drainage were classified
as pleurodesis success.
Not included in network meta-analysis.
Study funding source: Grant G0600475 from UK Medical Research Council. Dr Rahman funded by UK
Medical Research Council and UK National Institute for Health Research Oxford Biomedical Research
Center Programme. 
Study author conflicts of interest statements: Dr Miles reported receipt of fees for educational meetings
sponsored by GlaxoSmithKline, AstraZeneca, Meda, Pfizer and Chiesi. Dr Lee reported advisory board
membership for CareFusion and Sequana Medical and receipt of equipment from Rocket Ltd for a clini-
cal trial. No other disclosures were reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Central telephone randomisation service. Minimisation (histological tissue
type, procedure and centre of recruitment) with a random component.
Allocation concealment
(selection bias)





High risk Participants aware of treatment allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk ITT analysis. Mortality and withdrawals similar across intervention groups. 
Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods Open-label, multicentre, parallel group RCT of VATS pleurectomy and talc pleurodesis (either slurry or
poudrage) in mesothelioma (UK).
Participants Inclusion criteria: aged > 18 years; confirmed or suspected MPM with pleural effusion; fit enough for
VATS pleurectomy.
Exclusion criteria: previous pleurodesis; previous primary treatment for MPM; history of previous malig-
nancy and suspected MPM.
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Interventions VATS pleurectomy group: thoracoscopic debulking pleurectomy-decortication under GA, according to
agreed protocol.
Pleurodesis group: 4 g talc pleurodesis (either slurry or poudrage).
Outcomes Primary outcome: survival at 1 year postrandomisation
Secondary outcomes: presence or absence of effusion on CXR, QoL (EQ-5D and QLQ-LC13, QLQ-C30),
lung function and exercise tolerance, complications, healthcare utilisation costs
Notes People with trapped lung included. No data available on whether participants in the pleurodesis arm
who had poudrage may have had trapped lung released at the same time.
Pleurodesis success defined according to CXR (as assessed by reporting radiologist, unblinded to treat-
ment allocation).
Not included in network meta-analysis.
Study funding source: BUPA Foundation.
Study author conflicts of interest statements:  RCR was a member of an advisory board for Lilly UK. JGE
received honoraria from Lilly UK. All other authors declared no competing interests. 
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised random-number generator in blocks of 10. 1:1. stratified by
EORTC score (low or high).
Allocation concealment
(selection bias)





High risk Not possible to blind due to nature of interventions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Participants and investigators not blinded, leading to potential bias in report-
ing of QoL, exercise tolerance and complications. CXRs not interpreted blindly




Low risk Participants excluded after randomisation if MPM not confirmed, but this was
stated a priori. Missing data well balanced between the treatment arms.
Selective reporting (re-
porting bias)
Low risk Very thorough reporting of all stated outcomes.




Methods Multicentre RCT of intrapleural bleomycin and tetracycline in MPE (USA).
Participants Inclusion criteria: exudative MPE (confirmed by cytology or pleural biopsy); ECOG Performance Score
0–2.
Ruckdeschel 1991 
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Exclusion criteria: previous intrapleural therapy; prior systemic therapy with bleomycin; severe conges-
tive heart failure; radiotherapy to the chest in the previous 2 weeks.
115 participants randomised.
Interventions All participants had a chest tube placed and evidence of lung re-expansion on CXR. After the study drug
was inserted the tube was clamped and the participant's position rotated. After several hours the chest
tube was removed.
Group 1: tetracycline 1 g intrapleurally in 100 mL saline.
Group 2: bleomycin 120 units intrapleurally in 100 mL saline (due to slow accrual, this group was
dropped after accruing 15 participants).
Group 3: bleomycin 60 units intrapleurally in 100 mL saline.
Outcomes Recurrence of effusion at 30 days and 90 days (defined according to CXR).
Time to effusion recurrence within 90 days.
Time to maximum change in ECOG Performance Score.
Change from initial Performance Score to the best Performance Score (worsened/no change/im-
proved).
Adverse events.
Notes People with trapped lung excluded.
Group 2 dropped due to slow accrual and data on the 15 participants assigned to this group not provid-
ed.
Included in network meta-analysis for pleurodesis failure, mortality, pain and fever.
Study funding source: supported by Bristol Myers US Pharmaceutical Group.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation, with stratification.
Allocation concealment
(selection bias)





Unclear risk Not stated if anyone was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 41/115 "non-evaluable" participants excluded from analysis. Reasons given.
Ruckdeschel 1991  (Continued)
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Selective reporting (re-
porting bias)
High risk Data on 15 participants randomised to high-dose bleomycin group not report-
ed.




Methods Single-centre RCT of pleurodesis with doxycycline and C parvum in MPE (Finland).
Participants Inclusion criteria: pleural effusion refractory to repeat aspirations; pleural malignancy – all cell types
(histocytologically confirmed or confirmed malignancy elsewhere).
Exclusion criteria: none.
41 participants randomised.
Interventions 16-Fr Argyll drain inserted under local anaesthetic and drained with suction until output < 100 mL/day.
CXR to confirm lung re-expansion prior to pleurodesis.
D100 group: doxycycline 100 mg intrapleurally. 1 dose.
D600 group: doxycycline 600 mg intrapleurally. 1 dose.
C1 group: C parvum 1 mg intrapleurally. 1 dose.
C7 group: C parvum 7 mg intrapleurally. 1 dose.
All drugs diluted in 20 mL saline with 50-mL flush administered after dose. Chest tube removed imme-
diately after sclerosant given.




Daily C-reactive protein for 7 days
Notes For the purposes of our analysis, we decided to combine the 2 doses of each agent to allow comparison
between the agents themselves.
People with trapped lung excluded from study.
Included in network meta-analysis for pleurodesis failure, fever and pain.
Study funding source: Finnish Antituberculous Association and the Vaino and Laina Kivi Foundation.
Study author conflicts of interest statements: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Salomaa 1995 
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Allocation concealment
(selection bias)





Unclear risk Not stated if anyone was blinded. Unable to contact study authors.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 6/41 (15%) participants LTFU.
Selective reporting (re-
porting bias)
High risk Minimal data provided on survival or biochemical markers. Minimal data on
baseline participant characteristics and whether treatment groups were well
matched.




Methods Single-centre RCT evaluating intrapleural bleomycin vs interferon alfa-2b in the palliative treatment of
malignant effusion (Italy).
Participants Inclusion criteria: cytologically confirmed MPE requiring ≥ 2 thoracenteses in preceding 4 weeks; ≥ 3 L
drained in the preceding 4 weeks; adequate pulmonary re-expansion on CXR after thoracentesis; last




Interventions All participants underwent a 9-Fr intercostal drain insertion under USS guidance. Fluid drained via a 3-
way-tap until USS revealed no residual effusion. Study drug administered intrapleurally via the chest
tube. Tube was then clamped for 2 hours and participants changed position every 15 minutes. Tube re-
moved 24–48 hours after last dose.
Bleomycin group: bleomycin 0.75 mg/kg in 50 mL saline. A repeated dose was given if > 100 mL/day
output 3 days after the first dose.
Interferon alpha-2b group: interferon alpha-2b 1 million units/10 kg in 200 mL saline. 6 doses given
every 4 days.
Outcomes Treatment response at 30 days (CR: no fluid re-accumulation; PR: asymptomatic fluid recurrence < 50%
of the original effusion, not requiring thoracentesis; no response: fluid recurrence > 50% of the original
effusion, requiring thoracentesis)
Time to progression
Number of thoracenteses until death
Notes Deaths included in the analysis as failures (as presented in the paper as ITT analysis).
People with trapped lung excluded from trial entry.
Sartori 2004 
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Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: the authors indicated no potential conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation.
Allocation concealment
(selection bias)





High risk Not stated explicitly but 2 drugs were given as different volumes.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence and adverse event reporting may be biased by lack of





Low risk ITT analysis performed.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods RCT comparing the effect of streptokinase on pleurodesis therapy in multiloculated MPE (Turkey).
Participants Inclusion criteria: multiloculated MPE.
Exclusion criteria: lung carcinoma with endobronchial obstruction, bleeding diathesis, anticoagulation.
40 participants randomised.
Interventions CT performed on all participants prior to drain insertion. 20-Fr drain inserted into largest locule and
maintained on continuous suction at –20 cmH2O. 
Fibrinolytic group: streptokinase 250,000 units in 50 mL saline delivered via chest drain 24 hours, 36
hours, 48 hours and 60 hours after drain insertion. After each instillation, the drain was clamped for 2
hours and on unclamping attached to suction.
Control group: 50 mL saline placebo used at same time intervals with the same trial procedures.
Pleurodesis with 4 g sterile talc performed 4 days following chest drain insertion and drains removed
on day 5 unless participants were oxygen dependent.
Outcomes Drainage volume at 48 hours and 72 hours postdrain insertion
Saydam 2015 
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CT images pre- and post-therapy (repeated on day 3)
Dyspnoea after treatment (oxygen-dependence)
Pleural effusion recurrence
Notes Excluded from network meta-analysis. 
Contacted authors for further information but no reply received.
No comment regarding inclusion/exclusion of people with trapped lung. 
Study funding source: not stated.
Study author conflicts of interest statement: authors declared no conflict of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated permuted blocks.
Allocation concealment
(selection bias)





Unclear risk Blinding of participants and physicians not stated.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk Withdrawals/LTFU and mortality unreported. Unclear how many participants
were followed to 30 days.
Selective reporting (re-
porting bias)
High risk Limited results presented – pleurodesis outcomes given for 29/40 participants,
outcomes for remaining 11 participants unclear with no explanation regard-
ing LTFU or withdrawals. Number of participants followed to 30 days unstat-
ed. Data presented on number of participants with 'dyspnoea' but unclear at
which time point and how this was measured as definition uncertain (the text
suggests this is the number of participants dependent on oxygen rather than
symptom based). Limited information about baseline characteristics of the 2
groups was given. 
Other bias High risk Primary outcome of study was unclear. The method used and time point for di-




Methods Multicentre RCT comparing pleurodesis using bleomycin with mitoxantrone (Germany). Paper in Ger-
man.
Participants Inclusion criteria: symptomatic, cytologically confirmed MPE; life-expectancy > 3 months; WHO Perfor-
mance Score 0–2
Schmidt 1997 
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Exclusion criteria: prior chemotherapy or pleurodesis in previous 4 weeks; contraindication to
bleomycin or mitoxantrone; persistent pneumothorax; leukopenia; thrombocytopenia; incomplete
pleural fluid drainage.
102 participants randomised.
Interventions All participants had 24-Fr chest drain inserted and leG in situ for 48 hours.
Bleomycin group: bleomycin 60 mg in 100 mL saline intrapleurally. 1 dose.
Mitoxantrone group: mitoxantrone 30 mg in 100 mL saline intrapleurally. 1 dose.
Drains clamped for 6 hours after instillation and leG in place for 24–48 hours with or without suction.
Outcomes Pleurodesis success rate at 4 weeks (defined by recurrence of effusion requiring repeat pleural proce-
dure)
Toxicity/adverse events
Length of hospital stay
Time to repeat pleural intervention
Notes Translated from German.
People with trapped lung excluded from participation.
Included in network meta-analysis for pleurodesis failure, mortality, fever and pain.
Study funding source: not stated.
Study author conflicts of interest statement: not declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk Not stated if anyone was blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated if anyone was blinded. If unblinded, symptom recurrence, adverse




Low risk 6 participants excluded from analysis, but reasons given and balanced num-
bers in the 2 treatment arms.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.
Other bias Low risk No other biases identified.
Schmidt 1997  (Continued)
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Methods Single-centre RCT comparing talc instillation with pleural drainage only in the treatment of MPE (Den-
mark).
Participants Inclusion criteria: histologically confirmed MPE (all cell types) causing respiratory distress, which is pro-
gressive and resistant to conventional therapy.
Exclusion criteria: failure of the underlying lung to totally re-expand within 72 hours of the thora-
coscopy.
31 participants randomised.
Interventions All participants underwent thoracoscopy, during which multiple biopsies were taken and a drain insert-
ed. Suction applied until complete lung re-expansion.
Drainage alone group: constant suction for 72 hours after complete lung re-expansion. Then, drain re-
moved.
Talc and drainage group: 10 g sterile talc in 250 mL saline instilled through chest tube and clamped for
2 hours. Then suction applied for 72 hours and the drain was removed.
Outcomes Fluid re-accumulation on CXR every month for 3 months
Notes People with trapped lung excluded from trial entry.
No data provided on whether treatment arms well matched at baseline.
Power calculation performed.
Unclear if adverse events reported for all participants or only those who completed the follow-up.
Pleurodesis defined using radiology only.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statement: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Unable to blind due to nature of the interventions (pleural drainage alone, or
with talc administration).
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 10/31 (32%) participants excluded from primary analysis (but well balanced
between the 2 treatment arms).
Sorensen 1984 
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Low risk No comment on mortality or survival, but an old study and not stated as an
outcome measure in the paper.




Methods RCT investigating the effectiveness of silver nitrate vs tetracycline for pleurodesis in MPE (Iran).
Participants Inclusion criteria: cytologically or histologically confirmed MPE, anticipated survival > 1 month, dysp-
noea secondary to the effusion.
Exclusion criteria: 'inappropriate expansion of lungs during drainage of the effusion', 'pulmonary in-
volvement with tumoral mass', air leak, previous pleurodesis, history of ipsilateral intrapleural therapy
or radiotherapy.
50 participants randomised.
Interventions All participants received a 26-Fr or 28-Fr drain under local anaesthetic and drainage of effusion. 
Silver nitrate group: 20 mL 0.5% silver nitrate in 30 mL 0.9% saline and 0.1% lidocaine via chest drain.
Tetracycline group: tetracycline 2.5 g in 30 mL 0.9% saline and 0.1% lidocaine via chest drain.
Drains were clamped for 1 hour after pleurodesis and participants were asked to rotate from right to
leG decubitus, prone and supine positions for 10–15 minutes. Drains removed once volume drained <
100 mL.
Outcomes Pleurodesis success (radiological criteria) at 24 hours and 30 days
Chest pain (scale of mild/moderate/severe)
Fever (> 38 °C)
Dyspnoea score
Notes Trapped lung excluded.
Contacted authors via email for further information but no reply received.
Included in the network meta-analysis for pleurodesis failure. Unable to include mortality network as
zero events per arm and unable to include in pain network as 100% event rate in 1 arm and only trial in-
cluded in that network for silver nitrate.
Study funding source: none.
Study author conflicts of interest statement: none declared.  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method used for randomisation not stated.
Allocation concealment
(selection bias)
Unclear risk Methods used not stated.
Tabatabaei  2015 
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Unclear risk Blinding not stated.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No missing data, all participants included in analyses.
Selective reporting (re-
porting bias)
High risk Limited reporting of results. Dyspnoea scores unreported. Time point for eval-
uation of fever, chest pain and dyspnoea unclear.




Methods Single-centre RCT evaluating VATS talc poudrage and talc slurry in MPE (Brazil).
Participants Inclusion criteria: biopsy or cytology confirmed MPE (all cell types); recurrent and symptomatic effu-
sion; CXR confirming lung expansion of > 90% after thoracentesis; KPS ≥ 70.
Exclusion criteria: comorbidities that precluded GA; bleeding disorders; massive thoracic skin infiltra-
tion; active infection; refusal to sign informed consent.
60 participants randomised.
Interventions 1 dose of 5 g non-calibrated talc given intrapleurally to both trial groups. Postprocedure care and anal-
gesia the same for the 2 groups. No suction used in either group. Drain removed when < 200 mL/24-
hour drainage, or after 10 days if drain volume too high, participants were discharged with the drain in
situ and a Heimlich valve.
VATS group: VATS performed under GA, followed by talc poudrage. 28-Fr chest drain inserted at end of
procedure.
Talc slurry group: 28-Fr chest drain inserted under local anaesthetic. Following day, talc suspended in
60 mL saline with 5 mL 2% lignocaine and instilled through chest drain. Clamped for 1 hour postproce-
dure.
Outcomes Lung expansion on CT measured on a 3-point scale at baseline, 1 month, 3 months and 6 months






Length of hospital stay
Perioperative complications
Terra 2009 
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Notes Raw data for survival, pleurodesis rates at certain time points, intervention rates at certain time points
and QoL data not presented.
People with trapped lung excluded from trial entry.
Pleurodesis success rate defined using symptoms and radiology.
Contacted study authors for further information, but no reply.
Included in network meta-analysis for pleurodesis failure and fever.
Study funding source: not stated.
Study author conflicts of interest statement: no significant conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Unable to blind due to nature of the interventions (talc poudrage vs talc slur-
ry).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence, QoL, inpatient stay and adverse event reporting could
be biased by lack of blinding. Interpretation of CTs was done by 2 blinded ob-





Low risk No LTFU.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods Single-centre RCT evaluating 3 different doses of silver nitrate for pleurodesis in MPE (Brazil).
Participants Inclusion criteria: recurrent and symptomatic MPE (with pleural histological or cytological confirma-
tion); previous CXR showing full lung expansion (> 90%) after chest drainage; KPS > 40; written consent.
Exclusion criteria: trapped lung after pleural catheter insertion; haemorrhagic diathesis (prothrombin
< 50% or platelets < 80 × 109/L); active pleural or systemic infection; neoplastic infiltration of the skin
at the site of pleural catheter insertion; inability to understand QoL questionnaires; contralateral pleu-
rodesis < 30 days before study entry.
60 participants randomised.
Terra 2015 
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Interventions All participants were admitted for 5 days and had baseline assessment. All had a 14-Fr chest drain in-
serted under USS guidance prior to randomisation. The randomised interventions were given via the
chest tube, which was then clamped for 1 hour. Drain removed on day 5.
The silver nitrate was dissolved in 100 mL distilled water, which was passed through a 0.22 μm filter to
ensure sterility within 6 hours of instillation.
Group 1: 30 mL of 0.3% silver nitrate 90 mg intrapleurally. 1 dose.
Group 2: 30 mL of 0.5% silver nitrate 150 mg intrapleurally. 1 dose.
Group 3: 60 mL of 0.3% silver nitrate 180 mg intrapleurally. 1 dose.
Outcomes Primary outcome: occurrence of serious or severe adverse event during follow-up
Secondary outcomes: systemic inflammation (measured using C-reactive protein); chest pain (mea-
sured using VAS score); effusion recurrence (defined as need for additional pleural procedures during
trial follow-up); residual pleural cavity volume (calculated using difference between day 5 and day 30
on CT)
Notes People with trapped lung excluded from study entry.
Pleurodesis failure defined as need for additional pleural procedure during follow-up.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statement: Renato T Bellato received an institutional (Heart Institute,
University of Sao Paulo Medical School) fellowship grant for participating in this work.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomisation.
Allocation concealment
(selection bias)





Low risk Pharmacy employees and clinicians who instilled the sclerosant were aware
of treatment allocation, but these clinicians were not involved in patient fol-
low-up. Participants, investigators that followed participants up and rated
their complications were blinded to group allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Pharmacy employees and clinicians who instilled the sclerosant were aware
of treatment allocation, but these clinicians were not involved in patient fol-
low-up. Participants, investigators that followed participants up and rated




Low risk LTFU well balanced and justified.
Selective reporting (re-
porting bias)
Low risk No data provided for MRC dyspnoea score. Otherwise all predefined outcome
measures reported.
Other bias Low risk No other biases identified.
Terra 2015  (Continued)
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Methods Multicentre RCT comparing IPCs with talc slurry pleurodesis for MPE (Australia, New Zealand, Singa-
pore, Hong Kong).
Participants Inclusion criteria: histocytologically confirmed pleural malignancy or recurrent exudative pleural effu-
sion with no alternative cause in the setting of histocytologically confirmed extrapleural cancer.
Exclusion criteria: aged < 18 years, effusion < 2 cm maximum depth on imaging, expected survival < 3
months, chylothorax, previous lobectomy or pneumonectomy on side of effusion, previous attempted
pleurodesis, pleural infection, hypercapnic ventilatory failure, blood leukocyte count < 1 x 109/L, preg-
nancy, lactating, irreversible bleeding diathesis, visual impairment.
146 participants randomised.
Interventions Participants randomised to the IPC group had fluid removed at the time of catheter insertion, followed
by ambulatory drainage as guided by symptoms. IPCs were removed when clinically indicated.
Participants randomised to receive talc pleurodesis underwent 12- to 18-Fr intercostal drain insertion,
followed by instillation of talc slurry as per routine practice of the recruiting hospital. 
All participants received usual standard care including chemotherapy, radiotherapy and palliative care.
Outcomes Primary outcome: total number of days spent in hospital from trial intervention to death or follow-up
at 12 months. Any hospital (or hospice) admission for ≥ 1 days was included. 
Secondary outcomes: total number of days and episodes of hospitalisation from pleural effusion-relat-
ed causes, need for further pleural drainage procedures, breathlessness (VAS score), QoL (EQ-5D ques-
tionnaire and VAS scale), survival, adverse and serious adverse events.
Notes Trapped lung included, which was balanced for in minimisation criteria.
Included in network meta-analysis for pleurodesis failure, mortality and pain (participants with proce-
dure-related pain). 
Study funding source: trial received funding support from the Sir Charles Gairdner Research Adviso-
ry Committee, Cancer Council of Western Australia, and the Dust Disease Board of New South Wales,
Australia. Investigators had research fellowship funding support from the National Health and Medical
Research Council (Drs YCG Lee, Thomas, and Fysh) and the WA Cancer and Palliative Care Network (Dr
Thomas). Dr Smith received grants from Health Research Council New Zealand, the New Zealand Can-
cer Society and the New Zealand Lotteries Commission.
Study author conflicts of interest statements: Dr YCG Lee reported receiving grants, non-financial sup-
port, personal fees, other funding (or a combination of these) from the Cancer Council of Western Aus-
tralia, Dust Diseases Board of New South Wales, Sir Charles Gairdner Research Advisory Committee, Na-
tional Health & Medical Research Council Australia, Rocket Ltd (unrestricted educational grant), Care-
Fusion/BD (advisory board) and Sequana Medical (advisory board). Dr Kosky reported serving on the
advisory board of Teva Pharmaceutical Australia and receiving travel grants and speakers' fees from
UCBUK. Drs Thomas, Kwan, Yap, Lam, Garske, Shrestha, and YCG Lee are investigators of the AMPLE-2
trial for which Rocket Ltd provided the drainage supplies without charge. No other disclosures were re-
ported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-based randomisation.
Thomas 2017 
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Allocation concealment
(selection bias)





High risk Participants and trial personnel unblinded to trial intervention – due to nature
of the interventions blinding was not possible.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk All admissions were reviewed by an independent physician to ensure need for





Low risk ITT analysis.
Selective reporting (re-
porting bias)
Low risk Full healthcare economic analysis not calculated, which may bias in favour of
IPCs; however, all stated outcomes reported.




Methods Single-centre RCT comparing intrapleural talc and mepacrine given via a chest tube after thoracoscopy
(Sweden).
Participants Inclusion criteria: recurrent, symptomatic pleural effusions, known or suspected to be due to malig-
nancy; eligible for thoracoscopy and pleurodesis.
Exclusion criteria: incomplete lung re-expansion after thoracoscopy.
89 participants with confirmed MPEs were randomised (110 participants randomised in total, but some
had benign causes).
Interventions All participants underwent a local anaesthetic thoracoscopy, with biopsies and a 20-Fr drain was insert-
ed at end of procedure. CXR performed to ensure lung re-expansion before randomisation.
Mepacrine group: mepacrine 500 mg in 200 mL saline intrapleurally.
Talc group: 5 g talc in 200 mL saline intrapleurally.
In both groups, second dose given if > 50 mL/day drainage on day 3. Drains removed when < 50 mL/24-
hour drainage.
Outcomes Primary: pleurodesis success (using clinical and radiological definition). Reported at day 6, 2 weeks, 2
months, 4 months and 6 months
Secondary: analgesia use; adverse effects; mortality
Notes People with trapped lung excluded. Note that 2 doses may have been given.
Included in network meta-analysis for pleurodesis failure and mortality.
Study funding source: grants from King Oscar II Jubilee Foundation and the Stockholm City Council. 
Study author conflicts of interest statements: not stated.
Risk of bias
Ukale 2004 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation.
Allocation concealment
(selection bias)





High risk Unable to blind as drugs had different appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Radiologists reporting CXRs were blind to treatment allocation. Symptom re-




Low risk Reasons for LTFU and exclusions reported and well matched between groups.
Selective reporting (re-
porting bias)
Low risk Data for those with confirmed MPE obtained from authors.




Methods Single-centre RCT of short-term vs long-term drainage before tetracycline pleurodesis of MPE (USA).
Participants Inclusion criteria: moderate-to-large MPE, confirmed by cytology or pleural biopsy, causing respiratory
symptoms; expected survival > 1 month; KPS > 40%.
Exclusion criteria: previous chemical pleurodesis on the ipsilateral side; ipsilateral atelectasis due to
complete airway obstruction by tumour.
25 participants randomised.
Interventions 28-Fr chest drain inserted. Tetracycline 1.5 g in 100–150 mL pleurodesis.
Standard care (long-term drainage): tube suction drainage until lung re-expansion and < 150 mL/day
drainage, then tetracycline pleurodesis and drain removed the following day.
Short-term drainage: tube suction drainage until lung re-expansion, then tetracycline pleurodesis and
drain removed the following day.
Outcomes Pleurodesis success at 1 month (defined using CXR and need for repeat procedure)
Duration of tube drainage
Patient outcome (dead/alive – time point unclear)
Notes Lung re-expansion confirmed on CXR prior to instillation of tetracycline.
Not included in network meta-analysis.
Study funding source: not stated.
Villanueva 1994 
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Study author conflicts of interest statements: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation.
Allocation concealment
(selection bias)





High risk Unable to blind as different timings of interventions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence could be biased by lack of blinding. Not stated if radiolo-




Low risk 1/25 participants LTFU.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported; minimal information on safety/complications.




Methods Multicentre RCT comparing daily IPC drainage with alternate day drainage in achieving autopleurodesis
for people with MPE (USA).
Participants Inclusion criteria: aged > 18 years, recurrent symptomatic pleural effusion in the setting of known ma-
lignancy with positive fluid cytology or pleural biopsy or recurrent effusion with no other identifiable
cause, symptomatic improvement after therapeutic thoracentesis, recurrent symptoms with recur-
rence of pleural effusion.
Exclusion criteria: life-expectancy < 30 days, trapped lung on CXR, loculated pleural effusion, ipsilateral
previous surgery or attempted pleurodesis, chylothorax, pleural infection, inability to adequately per-
form pleural drainage at home, uncorrectable bleeding disorder, skin infection at site of intended IPC
insertion, pregnancy.
149 participants randomised.
Interventions IPC drainage performed at home by a visiting nurse or family member.
Standard care: maximum 1 L drained alternate days.
'Aggressive' arm: maximum 1 L drained daily.
In either group, drainage was stopped if cessation of pleural fluid flow occurred or participant devel-
oped persistent cough, breathlessness, chest tightness or pain.
Outcomes Primary endpoint: incidence of autopleurodesis following placement of an IPC.
Wahidi 2017 
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Secondary endpoints:  time to autopleurodesis, KPS, QoL (SF-36 questionnaire), satisfaction of partici-
pants and carers (questionnaire) and adverse event rate.
Notes Trapped lung excluded.
Autopleurodesis defined as CR (≤ 50 mL drained on 3 consecutive drainages, radiographic score 0–1
and lack of symptoms) or PR (as per CR but radiographic scores of 2–5).
Included in network meta-analysis for pleurodesis failure, mortality and pain (agreed between data ex-
tractors as those experiencing pain with IPC drainages).
Study funding source: supported by an unrestricted grant from CareFusion, Inc.
Study author conflicts of interest statements: Dr Feller-Kopman reported personal fees from CareFu-
sion, Inc,  during the conduct of the study; Dr Lamb reported other from Boston Scientific,  outside
the submitted work; Dr Light reported non-financial support from Care Fusion, outside the submitted
work; in addition, Dr Light has a patent transforming growth factor-beta pleurodesis issued; Dr Reddy
reported personal fees and non-financial support from Carefusion, Inc., outside the submitted work; Dr
Wahidi reported consulting fees from Carefusion, outside the submitted work. The remaining authors
had nothing to disclose.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-based block design.
Allocation concealment
(selection bias)





High risk Participant and treating physicians not blinded to treatment allocation.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk CXR interpretation and management decisions were made by the treating
physician (unblinded); however, assessment of primary outcome based on ob-





Low risk ITT analysis. Significant withdrawal rate from standard arm before 12 weeks
(22/76 participants) compared with daily drainage arm (9/73 participants). Au-
thors commented that "the rate of death and inability to complete the study
were anticipated because of the known medical complexity and short sur-
vival" of participants with MPE. Their data were included in the analysis up to
the point they leG the study.
Selective reporting (re-
porting bias)
Low risk All outcomes reported.




Methods RCT evaluating the effects of intrathoracic perfusion of Endostar with chemotherapy in the manage-
ment of MPE (China).
Wang 2018 
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Participants Inclusion criteria: pathological or cytologically confirmed diagnosis of lung adenocarcinoma, KPS 1–2,
estimated survival > 3 months, measurable primary and metastatic disease allowing for an objective
judgement of any therapeutic effect, medium-to-large MPE confirmed by USS or CT and who had not
received intrathoracic chemotherapy within the last month, no chemotherapy contraindications, nor-
mal liver/kidney/heart function, normal routine blood tests.
128 participants randomised. 
Interventions All participants received an USS-guided central venous catheter inserted into the thoracic cavity with
intrathoracic chemotherapy once the effusion was drained. The drain was clamped for 24 hours and re-
moved when the volume of drained was < 50 mL. Prior to treatment all participants received dexam-
ethasone, folic acid and vitamin B12.
Endostar group: IV pemetrexed 500 mg/m2 on day 1; intrathoracic cisplatin 75 mg/m2 day 2, day 5 and
day 8; intrathoracic Endostar 45 mg day 1, day 4 and day 7 in a 21-day cycle.
Control group:  IV pemetrexed 500 mg/m2 on day 1; intrathoracic cisplatin 75 mg/m2 day 2, day 5 and
day 8.
Evaluation of therapeutic effect assessed aGer 3 cycles.
Outcomes Outcomes: effective treatment rate defined as CR or PR (CR: pleural effusion disappeared for > 4 weeks;
PR: pleural effusion reduced by > 50% for > 4 weeks; stable disease: pleural effusion reduced < 50% or
increased < 25%; progressive disease: pleural effusion increased by > 25% with other signs of progres-
sive disease).
Pleural effusion control rate was the proportion of participants who did not require repeat thoracente-
sis.
QoL (EORTC QLQ C30 questionnaire at baseline and after 3 cycles of treatment).
Toxicity and adverse effects.
Notes Not included in network meta-analysis.
Included people with lung adenocarcinoma only. 
No comment on exclusion criteria. Attempted to contact authors by email for further information. 
Study funding source: not stated.
Study author conflicts of interest statements: authors declared no conflicts of interests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table.
Allocation concealment
(selection bias)





Unclear risk Not stated.
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Not stated. 
Wang 2018  (Continued)
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Low risk Duration of follow-up unclear ("all patients followed up for 6 months to 1
year"); however, not thought to influence outcome.
Selective reporting (re-
porting bias)
Low risk Definition of pleurodesis success was unclear, as 2 different definitions were
stated by the paper (quote: "the proportion of patients who did not need tho-
racentesis again" and "CR+PR+SD [stable disease]"). Limited reporting of QoL
outcome data.




Methods Single-centre RCT of rapid vs standard pleurodesis with oxytetracycline (Turkey).
Participants Symptomatic MPE, confirmed on cytology or pleural biopsy.
27 participants randomised.
Interventions 12-Fr drain inserted. Pleurodesis agent: oxytetracycline 35 mg/kg.
Standard protocol: drainage until lung re-expansion and fluid drainage < 150 mL/day. Then pleurodesis
as a single dose. Drain clamped for 6 hours and removed when < 150 mL/day drainage.
Rapid protocol: pleurodesis given as 4 divided doses, every 6 hours after aspiration through the drain.
Outcomes Response to pleurodesis (CR/PR/failure) as defined by radiological recurrence and need for thoracente-
sis
Notes People with trapped lung not excluded.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number table.
Allocation concealment
(selection bias)





High risk Unable to blind as different durations of drainage and aspiration schedules.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence and duration of hospital stay may be biased by lack of
blinding. Mortality not biased by lack of blinding.
Yildirim 2005 
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Low risk Missing data well balanced between the groups. At 1 month, 2/27 participants
had died and were therefore non-evaluable.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods Single-centre RCT of talc insufflation vs talc slurry for symptomatic MPE (Hong Kong).
Participants Inclusion criteria: established, symptomatic MPE (all cell types); dyspnoea improved after tube thora-
costomy or large volume thoracentesis.
Exclusion criteria: KPS < 30%; FEV1 < 0.5 L; trapped lung; chemotherapy or radiotherapy within 6
months.
57 participants randomised.
Interventions Talc insufflation group: all participants underwent a GA with 1 lung ventilation in the lateral decubi-
tus position. 10 mm port inserted. Adhesions and loculations broken down. 5 g talc insufflated into the
chest. 28-Fr tube at end of procedure, connected to suction. Drain removed when < 50 mL/24 hours
drainage.
Talc slurry group: chest tube. 5 g talc in 50 mL saline and 10 mL 2% lidocaine instilled through the drain.
Drain clamped for 2 hours and participant turned Drain reconnected to suction and removed when out-
put < 50 mL/24hours.
Outcomes Radiological recurrence of effusion
Complications of the procedure
Postprocedure chest drain duration
Length of hospital stay
Parenteral meperidine use
Notes People with trapped lung excluded from trial entry.
Included in network meta-analysis for mortality. Excluded from main network meta-analysis as no
pleurodesis failures in either study arm.
Study funding source: this study was supported by University Funds (A/C 1635-23).
Study author conflicts of interest statements: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)
Unclear risk Not stated.
Yim 1996 
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High risk Unable to blind due to nature of interventions.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Adverse event reporting and length of stay may be biased by lack of blinding.




Low risk All data reported. Survival data not entirely clear.
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.
Other bias Low risk Unclear how many participants in the poudrage arm had a drain in situ at the




Methods Multicentre RCT of bleomycin, OK-432 and cisplatin plus etoposide pleurodesis in MPE (Japan).
Participants Inclusion criteria: cytology or histology confirmed MPE associated with newly diagnosed NSCLC; aged
≤ 75 years; ECOG Performance Score 0–2; full lung re-expansion after chest drainage; adequate bone
marrow reserve, liver and renal functions.
Exclusion criteria: prior chemotherapy, thoracic radiotherapy or thoracic surgery; bilateral pleural ef-
fusion or pericardial effusion; symptomatic brain metastases; active synchronous cancer; interstitial
pneumonitis; pulmonary fibrosis; uncontrolled angina/myocardial infarction in preceding 3 months;
uncontrolled diabetes or hypertension; pregnancy or breastfeeding; penicillin allergy.
102 participants randomised.
Interventions Large- or small-bore chest tube inserted. After instillation of the study agent, participant rotated posi-
tion for 3 hours.
Bleomycin group: bleomycin 1 mg/kg (maximum 60 mg) intrapleurally in 100 mL saline. 1 dose.
OK-432 group: OK-432 0.2 KE units/kg (maximum 10 KE) intrapleurally in 100 mL saline. 1 dose.
Cisplatin + etoposide group: cisplatin 80 mg/m2 1 dose + etoposide 80 mg/m2 intrapleurally in 100 mL
saline.




Notes People with trapped lung not eligible for inclusion.
Study authors emailed for more information, but no response.
Not included in network meta-analysis.
Study funding source: supported in part by Grants-in-Aid for cancer research from the Ministry of
Health and Welfare of Japan.
Yoshida 2007 
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Study author conflicts of interest statement: authors had none to declare.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Unclear risk Not stated if anyone was blinded. Same volume of instillate in both arms.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not stated if anyone was blinded. If unblinded, reporting of symptom recur-
rence and toxicity could have been biased. Not stated if radiology was report-





Low risk No LTFU.
Selective reporting (re-
porting bias)
Low risk All stated outcomes reported.




Methods RCT of tetracycline pleurodesis vs placebo of the same pH as tetracycline (USA).
Participants Inclusion criteria: biopsy confirmed malignancy; recurrent pleural effusion; expected survival > 1
month; KPS ≥ 40%.
30 participants randomised.
Interventions Chest tube inserted and in place for ≥ 24 hours. After pleurodesis agent instilled, tube clamped for 2
hours and participant's position changed. Then leG in place for 12–24 hours until minimal drainage.
Tetracycline group: tetracycline 500 mg in 50 mL saline intrapleurally. 1 dose.
Control group: 0.6 mL multivitamins, 5 mL of 0.1 normal hydrochloric acid and 50 mL saline intrapleu-
rally. 1 dose.
Outcomes Re-accumulation of effusion on CXR at 1 month and 3 months (CR/PR/stabilisation/progression)
Adverse effects
Notes CR, PR and stable disease counted as pleurodesis success for purposes of analysis.
Some participants with bilateral effusions entered into the study, but not clear whether both sides were
randomised. Therefore, for purposes of analysis, only the first side has been included.
Included in network meta-analysis for pleurodesis failure.
Zaloznik 1983 
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Study funding source: not stated.
Study author conflicts of interest statement: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





Low risk Quote: "double-blind" (no further details given).
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Time point at which primary outcome measured not clear. Minimal data on
baseline participant characteristics. Participants who died within 1 month ex-
cluded from analysis (11/30 not evaluable).
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.




Methods Single-centre RCT of intrapleural Ad-p53 and cisplatin, compared with cisplatin alone in MPE due to
lung cancer (China).
Participants Inclusion criteria: MPE due to lung cancer confirmed by CT, thoracic ultrasound and cytohistological ex-
amination; expected survival > 3 months; KPS > 60.
Exclusion criteria: abnormal ECG, liver function, kidney function and routine blood examination; previ-
ous chemotherapy, radiotherapy or biological therapy.
35 participants randomised.
Interventions All participants had chest drain inserted and effusion drained completely. All received systemic vinorel-
bine. All received dexamethasone 10 mg intrapleurally after instillation of trial drugs. Drug administra-
tion was repeated weekly for 4 weeks or until pleural effusion resolved.
Combination group: Ad-p53 (1 × 1012 viral particles) in 100 mL saline intrapleurally. Then cisplatin 40
mg/m2 in 100 mL saline intrapleurally.
Single agent group: cisplatin 40 mg/m2 in 100 mL saline intrapleurally.
Outcomes Therapeutic efficacy (CR/PR/stable disease/progressive disease) – as defined by extent of effusion and
radiology and symptoms, at 4 weeks
Change in KPS from baseline to 4 weeks
Zhao 2009 
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Adverse events
Notes People with trapped lung not excluded from the study.
CR and PR counted as a successful pleurodesis for the purposes of analysis.
Study authors emailed for further information, but no response.
Not included in network meta-analysis.
Study funding source: not stated.
Study author conflicts of interest statements: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Not stated explicitly but combination group received 2 intrapleural treat-
ments, while other arm only received 1.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptoms, QoL and adverse events could be biased by lack of blinding. Not




Low risk No LTFU.
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.




Methods Prospective RCT of talc vs bleomycin pleurodesis for symptomatic MPE (USA).
Participants Inclusion criteria: MPE (all cell types); life-expectancy > 1 month.
Exclusion criteria: significant loculated effusions; trapped lung.
40 procedures randomised in 35 participants.
Interventions All participants underwent tube thoracostomy (either at the end of a limited thoracotomy (2 partici-
pants) or inserted at bedside (33 participants)). Tube remained on suction. After sclerosant injected in-
trapleurally, tube clamped for 2 hours and participant rotated.
Talc group: 5 g talc in 50 mL saline, with 20 mL 1% lignocaine. 1 dose.
Zimmer 1997 
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Bleomycin group: bleomycin 60 U in 50 mL saline, with 20 mL 1% lignocaine. 1 dose.
Outcomes Effusion control on CXR (at a minimum of 2 weeks)
Dyspnoea (according to functional class 1–4)
Pain (according to scale 0–10)
Cost
Length of hospital stay
Notes People with trapped lung excluded.
Participants only included in primary analysis if out of hospital and able to attend follow-up at 2 weeks.
Study authors emailed for more information, but no response.
Included in network meta-analysis for pleurodesis failure.
Study funding source: not stated.
Study author conflicts of interest statement: not stated.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated.
Allocation concealment
(selection bias)





High risk Not explicitly stated but drugs had different appearances.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Symptom recurrence, pain, breathlessness, duration of stay and adverse





High risk No clear time point when follow-up performed. Only those available for fol-
low-up included in the analysis. Unclear how many randomised to each arm
(only data on numbers analysed by treatment arm).
Selective reporting (re-
porting bias)
Low risk All outcomes reported on.
Other bias Low risk No other biases identified.
Zimmer 1997  (Continued)
CALGB: Cancer and Leukemia Group B; CR: complete response; CT: computer tomography; CXR: chest x-ray; DHHS: Department of Health
and Human Services; ECOG: Eastern Cooperative Oncology Group; EQ-5D-5L: 5-level EQ-5D; FEV1: forced expiratory volume in one second;
Fr: French; GA: general anaesthetic; IPC: indwelling pleural catheter; ITT: intention to treat; IV: intravenous; KE: klinische Einheit (clinical
unit); KPS: Karnofsky Performance Score; LTFU: loss to follow-up; MBS: Modified Borg Scale; MPE: malignant pleural e)usion; MPM:
malignant pleural mesothelioma; NCI: National Cancer Institute; NSAID: non-steroidal anti-inflammatory drug; NSCLC: non-small cell
lung cancer; PR: partial response; QoL: quality of life; RCT: randomised controlled trial; SF-36: 36-item Short Form; TMP: thoracoscopic
mechanical pleurodesis; USS: ultrasound scan; VAS: visual analogue scale; VATS: video-assisted thoracoscopic surgery; VEGF: vascular
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endothelial growth factor; WCC: white cell count; WHO: World Health Organization; WHOQOL-BREF: World Health Organization Quality of
Life: Brief Version.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Caglayan 2008 Study not truly randomised (high risk of bias for sequence generation). Participants allocated to
treatment groups using alternation.
Dryzer 1993 Unable to differentiate between participants with benign and malignant disease in the results sec-
tion. Also, not truly randomised (high risk of bias from randomisation method as allocated to treat-
ment groups based on the last digit of their hospital number).
Elayouty 2012 Unclear from text if truly randomised – participants given number on entering study – allocated to
bleomycin if number was odd and allocated to povidone group if number was even. Study authors
emailed for clarification but no response.
Engel 1981 Study not truly randomised. Participants allocated to treatment groups based on the day of the
calendar month. High risk of bias for sequence generation. 
Gust 1990 Pilot data (not randomised) and randomised data presented grouped together. Unable to differen-
tiate out the non-randomised data. No contact details available for study authors.
Kleontas  2019 Not truly randomised (high risk of bias for sequence generation and allocation concealment. Addi-
tional information obtained from author who explained participants allocated to each arm consec-
utively).
Kwasniewska-Rokicinska 1979 Participants with pleural effusions and ascites included, but unable to differentiate between them
in the results section.
Lissoni 1995 Unable to differentiate between pleural, pericardial and peritoneal effusions in the results. No re-
sponse from study authors.
Liu 2017 High risk of bias for sequence generation and allocation concealment (not randomised). We were
unable to contact the authors for further clarification.
Maiche 1993 Study not randomised (high risk of bias for sequence generation). Participants allocated to
bleomycin group if met a list of criteria, otherwise given mitoxantrone.
Manes 2000 Study not truly randomised (high risk of bias for sequence generation). Participants allocated to
treatment groups based on the month of their diagnosis with MPE.
Martin 2019 Feasibility study to determine whether sufficient numbers could be recruited for a future multi-
centre RCT to test the impact of pleural elastance directed indwelling pleural catheter or talc slur-
ry pleurodesis management. Excluded from review as does not meet inclusion criteria (study does
not give outcome data from comparison of different methods of managing malignant pleural effu-
sion). 
Nio 1999 Participants with pleural and peritoneal effusions included in the study and unable to differentiate
them in the results.
Ogunrombi 2014 Excluded due to inclusion of a child in study. An attempt was made to contact the authors by email
to obtain data for adults only but no reply was received. 
Tattersall 1982 Not randomised (high risk of bias for sequence generation and allocation concealment), therefore
excluded.
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MPE: malignant pleural e)usion.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT comparing the time to pleurodesis in people with MPE receiving doxycycline + IPC vs IPC alone
(OPUS).
Participants MPE
Interventions IPC + doxycycline: doxycycline 500 mg in 50 mL saline via IPC.
Placebo: 50 mL normal saline via IPC.
Outcomes Primary outcome: time to pleurodesis
Secondary outcomes: pleurodesis rate at 90 days postinsertion of IPC, adverse events, effects on
pulmonary function
Notes Study identified from clinical trials registry during literature search and listed as currently recruit-
ing. Authors contacted for further information but no reply received. Recruitment started 2009.
Amjadi – OPUS Trial 
 
 
Methods Randomised study comparing highly agglutinative staphylococcin plus cisplatin with cisplatin
alone.
Participants 74 participants with MPE and ascites.
Interventions Unclear from abstract how agents were delivered.
Outcomes Reduction in effusion/ascites volume
KPS
Notes Full text only available in Chinese and unable to translate. Need to confirm if pleural and ascites da-




Methods Randomised study comparing the therapeutic effect and safety of bevacizumab combined with cis-
platin on MPE of people with NSCLC.
Participants 54 people with NSCLC and MPE.
Interventions Control group:  intrathoracic injection of cisplatin 75 mg/m2 twice, each cycle 21 days.
Combined treatment group: intrathoracic bevacizumab 5 mg/kg twice, plus cisplatin as per control
group regimen.
Outcomes Pleural effusion control rate, adverse reactions, level of pleural fluid vascular endothelial growth
factor before each cycle.
Notes Full text only available in Chinese alphabet and unable to translate.
Chen 2015 
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Methods RCT of pleural perfusion of nedaplatin and cisplatin in MPE due to NSCLC.
Participants 68 participants with lung cancer associated with MPE.
Interventions Participants randomised into 2 groups.
Group 1: nedaplatin 40 mg/m2 and dexamethasone 10 mg given intrapleurally.
Group 2: cisplatin 40 mg/m2 and dexamethasone 10 mg in 40 mL saline given intrapleurally.
Agents given weekly for 2–4 weeks.
Outcomes Treatment response, adverse effects, KPS, survival.




Methods RCT of intrapleural adriamycin and Nocardia rubra cell wall skeleton compared with adriamycin
alone.
Participants 55 participants with MPE due to lung cancer.
Interventions Agents given via tube thoracostomy. No other details available.
Outcomes Treatment response.




Methods Trial comparing bleomycin, OK-432 and cisplatin + etoposide in MPE due to NSCLC.
Participants MPE due to previously untreated NSCLC.
Interventions Intrapleural bleomycin, OK-432 and cisplatin + etoposide.
Outcomes Progression-free survival.
Notes In Japanese. Unable to translate. No details in abstract as to whether it is randomised or the num-




Methods Randomised study evaluating the efficacy and safety of tranexamic and bleomycin for pleurodesis
in MPE.
Participants 63 people with MPE.
Mohamed 2013 
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Interventions Randomised to receive tranexamic acid, bleomycin or tranexamic acid + bleomycin via chest drain.
Outcomes Pleurodesis success, complications.





Methods RCT comparing intrapleural Pseudomonas aeruginosa, with cisplatin and interleukin-2.
Participants 90 participants with MPE.
Interventions Agents administered through intrathoracic infusion. No other information available.
Outcomes Clinical efficacy and adverse reactions.




Methods RCT of intrapleural Ya-Dan-Zhi's grease (YDZ) and cisplatin in MPE.
Participants 72 participants with MPE.
Interventions Randomly divided between 3 groups:
Group 1: YDZ 80 mL and cisplatin 60 mg intrapleurally once per week;
Group 2: YDZ 80 mL intrapleurally once per week;
Group 3: cisplatin 60 mg intrapleurally once per week.
Outcomes Treatment effect, adverse effects.
Notes In Chinese and unable to obtain a translation. Unclear from abstract if study would be eligible for




Methods RCT comparing intrapleural doxycycline and bleomycin.
Participants 34 participants with MPE requiring repeated thoracentesis.
Interventions Participants received either intrapleural doxycycline or bleomycin.
Outcomes Fluid volume, adverse effects, response to treatment (on CXR and clinical examination), survival.
Notes In Korean. Only abstract available in English. Unable to obtain a translation.
Won 1997 
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Methods RCT evaluating the effect of intrapleural highly agglutinative staphylococcin combined with
nedaplatin, compared to nedaplatin alone.
Participants 58 participants with MPE.
Interventions Participants randomised to 2 groups.
Group 1: intrapleural highly agglutinative staphylococcin with nedaplatin.
Group 2: nedaplatin alone.
Outcomes Treatment response, adverse effects, quality of life.
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Un-




Methods RCT comparing cisplatin and lentinan in MPE.
Participants 64 participants with MPE.
Interventions Randomised into 2 groups:
Group 1: intrathoracic cisplatin and lentinan;
Group 2: intrathoracic cisplatin only.
Outcomes Response rates.
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Un-




Methods RCT comparing matrine injection (yanshu) combined with intrapleural cisplatin for treatment of
haematological malignancies complicated by pleural effusion.
Participants 46 participants with haematological malignancy complicated by pleural effusion.
Interventions Participants randomly divided into 2 groups.
Group 1: intrapleural cisplatin 20 mg/m2 and yanshu 10 mL/m2 and dexamethasone 5 mg/m2.
Group 2: intrapleural cisplatin 20 mg/m2 and dexamethasone 5 mg/m2.
Outcomes Efficacy, adverse effects.
Notes In Chinese. Only abstract available in English and unclear from it whether the study is eligible. Un-
able to obtain translation of the full text.
Zhuang 2012 
CXR: chest x-ray; IPC: indwelling pleural catheter; KPS: Karnofsky Performance Score; MPE: malignant pleural e)usion; NSCLC: non-small
cell lung cancer; RCT: randomised controlled trial.
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Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title The Australasian Malignant Pleural Effusion (AMPLE) Trial 3: a randomised study of the relative
benefits of combined indwelling pleural catheter (IPC) and talc pleurodesis therapy or video-assist-
ed thoracoscopic surgery (VATS) in the management of participants with malignant pleural effu-
sion.
Methods Multicentre, international RCT comparing IPC and talc pleurodesis to VATS for the management of
MPE.
Participants Inclusion criteria: people with symptomatic MPE, predicted survival > 6 months, ECOG score 0–1.
Exclusion criteria: aged < 18 years, unable to undergo surgical procedure, pleural infection, chy-
lothorax, pregnancy or lactation, uncorrectable bleeding diathesis, previous ipsilateral lobecto-
my/pneumonectomy, unable to consent or comply with protocol.
Interventions IPC arm: after complete evacuation of the pleural space and if lung fully expanded with no con-
traindication 4–5 g talc administered by IPC with daily drainage for 14 days.
VATS arm: VATS pleurodesis by talc poudrage or thoracoscopic mechanical pleural abrasion.
Outcomes Primary outcome: proportion of participants requiring a repeat ipsilateral pleural procedure for
symptomatic effusion re-accumulation.
Secondary outcomes: time to effusion recurrence, all-cause hospital days, breathlessness (VAS),
pain (VAS), QoL (EQ-5D-5L), physical activity patterns (measured by actigraphy), adverse event re-







Trial name or title MesoTRAP
Methods Feasibility study that includes a pilot multicentre, RCT comparing VAT partial pleurectomy/decorti-
cation with IPC in people with trapped lung and pleural effusion due to MPM. 
Participants Inclusion criteria: trapped lung requiring intervention in people with MPM with pleural effusion,
aged > 18 years, expected survival > 4 months, suitable and willing to undergo VAT partial pleurec-
tomy/decortication or IPC insertion.
Exclusion criteria: full lung re-expansion following pleural drainage and evidence of active pleural
infection.
Interventions VAT-PD: VAT partial pleurectomy/decortication under general anaesthetic.
IPC: IPC insertion under local anaesthetic.
Outcomes Primary outcome: VAS Dyspnoea Score.
MesoTRAP 
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Secondary outcomes: VAS chest pain score, EQ-5D-5L and EORTC QLQ-C30 scores, 30-day and 12-







Trial name or title A study to compare the efficacy and safety of intrapleural doxycycline vs iodopovidone for per-
forming pleurodesis in malignant pleural effusion.
Methods RCT comparing doxycycline and iodine pleurodesis.
Participants Inclusion criteria: recurrent, symptomatic MPE with dyspnoea improvement follow thoracentesis.
Interventions Participants randomised to receive doxycycline 500 mg slurry via chest drain or 20 mL 10% beta-
dine via chest drain.









Trial name or title OPTIMUM
Methods Multicentre RCT comparing whether outpatient management of MPE with an IPC and pleurodesis
improves QoL compared with inpatient care with a chest drain and talc pleurodesis.
Participants Inclusion criteria: MPE, WHO Performance Score 0–2, expected survival > 3 months.
Exclusion criteria: aged < 18 years, pregnant or lactating, allergy to talc or lignocaine, lack of symp-
tomatic relief from effusion drainage, district nurse/carer/hospital unable to carry out at least twice
weekly IPC drainage, lymphoma or small cell carcinoma except if failure of chemotherapy or for
palliative management, non-malignant effusion, loculated effusion that would prevent successful
drain insertion or symptomatic benefit, unable to provide written consent.
Interventions IPC group: talc pleurodesis via IPC day 4 postprocedure if output < 150 mL/day and satisfactory
lung expansion.
Usual care: ultrasound-guided chest drain and talc pleurodesis.
Outcomes Primary outcome: health-related QoL at 30 days measured using the EORTC QLQ-C30.
OPTIMUM 
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Trial name or title Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIM-
PLE).
Methods Multicentre RCT designed to evaluate whether use of thoracic ultrasound in hospitalised people
with MPE before and during the first 24–72 hours post-talc administration, accurately identifies
pleural adherence early in treatment, permitting shorter hospital stay without adversely affecting
pleurodesis success.
Participants Inclusion criteria: confirmed MPE requiring pleurodesis.
Exclusion criteria: aged < 18 years, poor prognosis (patient in whom pleurodesis would not be of-
fered in normal practice), irreversible contraindication to chest drain insertion.
Interventions Control: chest drain removed postpleurodesis once pleural fluid output < 250 mL/24 hours, there is
satisfactory evacuation of the fluid on CXR and the lung remains fully expanded.
Thoracic ultrasound group: talc pleurodesis once there is ultrasound evidence of effusion resolu-
tion. Drain removed postpleurodesis on the basis of ultrasound appearances.
Outcomes Primary outcome: number of days in hospital during the initial hospitalisation.
Secondary outcomes: pleurodesis success at 1 month' and 3 months' postrandomisation, number
of days postrandomisation with chest drain in situ, breathlessness (VAS) and thoracic pain (VAS),







Trial name or title A randomised comparative phase 3 trial of pleurodesis in malignant pleural effusions: sterile grad-
ed talc vs. OK-432 (WJOG8415L).
Methods RCT to compare efficacy and safety of graded talc and OK-432 in pleurodesis for MPE.
Participants Inclusion criteria: histocytologically confirmed symptomatic MPE, previous chest tube drainage,
life-expectancy > 30 days, aged > 20 years.
Exclusion criteria: hypersensitivity to talc or OK-432, hypersensitivity to penicillin, severe infection,
severe pulmonary fibrosis or emphysema, myocardial infarction within 30 days, severe coagulopa-
thy, indication for bilateral pleurodesis, major surgical intervention of the affected hemithorax,
Sterile-graded talc versus OK-432 
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previous ipsilateral pleurodesis, concurrent massive ascites, glucocorticoid treatment, pregnancy
or lactation, unable to co-operate with study.
Interventions Instillation of OK-432 distilled in 50 mL of saline into thoracic cavity. 
Talc group: 4 g graded talc distilled in 50 mL of saline.
Outcomes Primary outcome: pleural effusion recurrence-free rate at 30 days after primary pleurodesis.
Secondary outcomes: pleural effusion recurrence free survival time, pleural effusion recurrence




Sterile-graded talc versus OK-432  (Continued)
 
 
Trial name or title Pivotal multi center, randomized, controlled, single-blinded study comparing the silver nitrate
coated indwelling pleural catheter to the uncoated PleurX catheter for the management of sympto-
matic, recurrent, malignant pleural effusions.
Methods RCT to determine whether a silver nitrate-coated IPC is safe and effective in treating MPEs com-
pared to approved catheters.
Participants Inclusion criteria: symptomatic MPE requiring intervention, aged > 18 years, ≥ 1 ipsilateral pleural
effusion causing dyspnoea that responded to thoracentesis where the lung expanded and the dys-
pnoea was improved, sufficient pleural fluid to allow safe insertion of an IPC, negative pregnancy
test if appropriate, participant or carer is able to perform home drainage of the pleural effusion (UK
participants will have drainage managed by home-care nurses).
Exclusion criteria: significant trapped lung, or a proximal bronchial obstruction which is likely to
lead to trapped lung, KPS < 50 or ECOG > 3, pregnant or lactating, empyema, chylothorax, uncor-
rectable coagulopathy, hypersensitivity to new or existing pleural catheter, systemic or pleural
infection, ipsilateral lobectomy or pneumonectomy, previous attempt at ipsilateral pleurodesis
which has failed, immunodeficiency, bilateral pleural effusions, fluid loculation such that attempts
at pleurodesis are likely to be futile, mediastinal shiG of ≥ 2 cm toward the side of the effusion, re-
ceiving concurrent intrapleural chemotherapy or radiotherapy to the ipsilateral chest, no access to
a telephone.
Interventions Silver nitrate-coated IPC vs standard IPC.
Outcomes Primary outcome: proportion of participants achieving pleurodesis without recurrence.
Secondary outcomes: time to pleurodesis; time to recurrence; proportion of surviving participants
without a trapped lung diagnosis following IPC placement who have confirmed pleurodesis with-
out recurrence at 14 days, 30 days, 60 days and 90 days; proportion of participants with confirmed
pleurodesis and without recurrence 30 days after IPC placement by cancer type (lung, breast and
others); incidence of IPC occlusion; incidence of empyema and cellulitis; pain (VAS).
Starting date April 2018
Contact information Joseph B Shrager, Stanford University
Notes  
SWIFT 
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Trial name or title A Trial of Intra-pleuraL bacterial immuno-Therapy in mesothelioma (TILT): a feasibility study using
the 'trial within a cohort' methodology.
Methods RCT investigating intrapleural bacterial immunotherapy in MPM using the 'Trial within a Co-
hort' (TwiC) methodology. Participants are recruited from an existing observational cohort (the
ASSESS-meso study).
Participants 24 eligible participants are identified from the cohort, of whom 16 participants are randomly se-
lected to be offered either OK432 or BCG.
Inclusion criteria: histocytological diagnosis of MPM, enrolled in ASSESS-meso cohort study and
given consent to undergo randomisation for future trials, IPC in situ that has drained > 50 mL of flu-
id on previous 3 drainages or willing to have an IPC and has a pleural effusion suitable for IPC in-
sertion, no chemotherapy in preceding 4 weeks and none planned in subsequent 4 weeks, Perfor-
mance Status ≤ 2, Performance Status 3 and felt clinically suitable for trial, predicted survival ≥ 12
weeks, to consent.
Exclusion criteria: no IPC in situ and has contraindication to IPC insertion; clinico-radiological diag-
nosis of mesothelioma; trapped lung with < 50% pleural apposition on x-ray; moderately heavy or
heavily loculated pleural effusion; known immunodeficiency or immunosuppressive medication;
intercurrent infection (pleural or elsewhere) or clinical signs of sepsis; known sensitivity or aller-
gy to OK432 or penicillin; previous treatment with immunotherapy; currently enrolled in any oth-
er interventional clinical trial; brain metastases or central nervous system involvement of mesothe-
lioma; pregnancy or lactation; aged < 18 years; any other factor that, in the opinion of the chief in-
vestigator, would mean participation in the study would be contraindicated.
Interventions Either OK432 or BCG delivered intrapleurally as a single dose via IPC. Participants are followed up
at 4 trial visits over 12 weeks. On completion of the trial, they return to standard follow-up in the
ASSESS-meso cohort study. Outcome data compared with 8 control participants from ASSESS-
meso. Qualitative interviews are undertaken at the end of trial to assess acceptability of the
methodology to participants.
Outcomes Feasibility assessed by: recruitment rates to time and target > 66%, attrition rate < 20%, data com-
pleteness rates > 90%.
Secondary outcomes: acceptability of the TwiC methodology; acceptability of the intervention;
safety of intrapleural OK432 or BCG; tumour response rates measured on CT chest at baseline and
week 12 using modified RECIST criteria; progression-free survival rates at week 12; patient-report-
ed chest pain and breathlessness (VAS); patient-reported QoL (EQ-5D-5L); pleurodesis rates; bio-
marker response, assessed using serum mesothelin blood tests at baseline, week 3, week 6 and
week 12; immunological response (BCG arm only) assessed using Mantoux skin testing at baseline
and week 6.
Starting date 2018
Contact information Dr A Bibby
Notes  
TILT 
BCG: Bacillus Calmette-Guérin; CT: computer tomography; CXR: chest x-ray; ECOG: Eastern Cooperative Oncology Group; EORTC QLQ-
C30: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D-5L: 5-level EQ-5D; FACT-L:
Functional Assessment of Cancer Therapy – Lung; IPC: indwelling pleural catheter; KPS: Karnofsky Performance Score; MPE: malignant
pleural e)usion; MPM: malignant pleural mesothelioma; QoL: quality of life; RCT: randomised controlled trial; RECIST: Response Evaluation
Criteria in Solid Tumors; VAS: visual analogue scale; VAT-PD: video-assisted thoracoscopic partial pleurectomy/decortication; VATS: video-
assisted thoracoscopic surgery; WHO: World Health Organization.
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Comparison 1.   Bleomycin





Statistical method Effect size
1 Pleurodesis failure rate 22   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Bleomycin vs iodine 2 99 Odds Ratio (M-H, Random,
95% CI)
1.54 [0.51, 4.64]
1.2 Bleomycin vs talc slurry 5 199 Odds Ratio (M-H, Random,
95% CI)
1.22 [0.55, 2.70]
1.3 Bleomycin vs tetracycline 5 220 Odds Ratio (M-H, Random,
95% CI)
0.50 [0.27, 0.93]
1.4 Bleomycin vs talc poudrage 2 57 Odds Ratio (M-H, Random,
95% CI)
9.70 [2.10, 44.78]
1.5 Bleomycin vs C parvum 2 78 Odds Ratio (M-H, Random,
95% CI)
1.81 [0.02, 189.25]
1.6 Bleomycin vs doxycycline 2 122 Odds Ratio (M-H, Random,
95% CI)
1.50 [0.54, 4.20]
1.7 Bleomycin vs interferon (IFN) 1 160 Odds Ratio (M-H, Random,
95% CI)
0.31 [0.15, 0.65]
1.8 Bleomycin vs mitoxantrone 1 85 Odds Ratio (M-H, Random,
95% CI)
0.31 [0.12, 0.86]
1.9 Bleomycin vs mepacrine 1 36 Odds Ratio (M-H, Random,
95% CI)
6.40 [1.12, 36.44]
1.10 Bleomycin vs combined tetracycline
and bleomycin
1 38 Odds Ratio (M-H, Random,
95% CI)
5.57 [0.25, 124.19]
1.11 Bleomycin vs cisplatin and etoposide 1 69 Odds Ratio (M-H, Random,
95% CI)
1.1 [0.39, 3.07]
1.12 Bleomycin vs OK-432 1 68 Odds Ratio (M-H, Random,
95% CI)
1.43 [0.49, 4.17]
1.13 Bleomycin vs viscum 1 17 Odds Ratio (M-H, Random,
95% CI)
5.33 [0.62, 45.99]
2 Fever 17   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Bleomycin vs talc slurry 3 99 Odds Ratio (M-H, Random,
95% CI)
0.90 [0.31, 2.56]
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Statistical method Effect size
2.2 Bleomycin vs talc poudrage 1 32 Odds Ratio (M-H, Random,
95% CI)
0.87 [0.11, 7.05]
2.3 Bleomycin vs tetracycline 5 250 Odds Ratio (M-H, Random,
95% CI)
2.05 [0.67, 6.34]
2.4 Tetracycline vs C parvum 2 80 Odds Ratio (M-H, Random,
95% CI)
0.43 [0.17, 1.12]
2.5 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random,
95% CI)
151.35 [9.08, 2522.62]
2.6 Bleomycin vs mitoxantrone 1 96 Odds Ratio (M-H, Random,
95% CI)
1.11 [0.37, 3.36]
2.7 Bleomycin vs mepacrine 1 40 Odds Ratio (M-H, Random,
95% CI)
0.52 [0.14, 1.92]
2.8 Bleomycin vs doxycycline 2 148 Odds Ratio (M-H, Random,
95% CI)
2.69 [0.08, 89.51]
2.9 Bleomycin vs combined tetracycline and
bleomycin
1 40 Odds Ratio (M-H, Random,
95% CI)
0.47 [0.04, 5.69]
2.10 Bleomycin vs OK432 1 67 Odds Ratio (M-H, Random,
95% CI)
0.7 [0.23, 2.13]
2.11 Bleomycin vs cisplatin and etoposide 1 69 Odds Ratio (M-H, Random,
95% CI)
2.22 [0.82, 6.01]
2.12 Bleomycin vs iodine 1 60 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.60]
3 Pain 15   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Bleomycin vs talc slurry 2 73 Odds Ratio (M-H, Random,
95% CI)
1.66 [0.41, 6.80]
3.2 Bleomycin vs tetracycline 4 220 Odds Ratio (M-H, Random,
95% CI)
0.61 [0.29, 1.27]
3.3 Bleomycin vs talc poudrage 1 32 Odds Ratio (M-H, Random,
95% CI)
0.28 [0.01, 7.31]
3.4 Bleomycin vs C parvum 2 71 Odds Ratio (M-H, Random,
95% CI)
0.70 [0.27, 1.85]
3.5 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random,
95% CI)
32.34 [1.89, 552.23]
3.6 Bleomycin vs mitoxantrone 1 96 Odds Ratio (M-H, Random,
95% CI)
0.48 [0.15, 1.56]
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Statistical method Effect size
3.7 Bleomycin vs mepacrine 1 40 Odds Ratio (M-H, Random,
95% CI)
0.46 [0.11, 1.94]
3.8 Bleomycin vs doxycycline 2 148 Odds Ratio (M-H, Random,
95% CI)
0.84 [0.26, 2.70]
3.9 Bleomycin vs OK-432 1 67 Odds Ratio (M-H, Random,
95% CI)
0.40 [0.14, 1.12]
3.10 Bleomycin vs cisplatin and etoposide 1 69 Odds Ratio (M-H, Random,
95% CI)
0.83 [0.32, 2.16]
3.11 Bleomycin vs iodine 1 60 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.60]
4 Mortality 11   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 Bleomycin vs combined tetracycline and
bleomycin
1 40 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.06, 17.18]
4.2 Bleomycin vs talc slurry 2 116 Odds Ratio (M-H, Random,
95% CI)
0.89 [0.29, 2.75]
4.3 Bleomycin vs tetracycline 2 125 Odds Ratio (M-H, Random,
95% CI)
0.63 [0.27, 1.44]
4.4 Bleomycin vs talc poudrage 1 32 Odds Ratio (M-H, Random,
95% CI)
0.82 [0.20, 3.43]
4.5 Bleomycin vs C parvum 1 55 Odds Ratio (M-H, Random,
95% CI)
0.60 [0.19, 1.94]
4.6 Bleomycin vs IFN 1 160 Odds Ratio (M-H, Random,
95% CI)
0.46 [0.25, 0.87]
4.7 Bleomycin vs mitoxantrone 1 96 Odds Ratio (M-H, Random,
95% CI)
2.15 [0.95, 4.86]
4.8 Bleomycin vs OK-432 1 68 Odds Ratio (M-H, Random,
95% CI)
2.66 [0.98, 7.23]
4.9 Bleomycin vs doxycycline 2 122 Odds Ratio (M-H, Random,
95% CI)
1.44 [0.53, 3.90]
4.10 Bleomycin vs cisplatin and etoposide 1 69 Odds Ratio (M-H, Random,
95% CI)
2.22 [0.82, 6.01]
5 Repeat pleural intervention 1 33 Odds Ratio (M-H, Fixed, 95%
CI)
4.33 [0.16, 114.58]
5.1 Bleomycin vs talc slurry 1 33 Odds Ratio (M-H, Fixed, 95%
CI)
4.33 [0.16, 114.58]
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Analysis 1.1.   Comparison 1 Bleomycin, Outcome 1 Pleurodesis failure rate.
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Bleomycin vs iodine  
Alavi 2011 4/19 5/20 42.55% 0.8[0.18,3.57]
Bagheri 2018 10/30 5/30 57.45% 2.5[0.74,8.5]
Subtotal (95% CI) 49 50 100% 1.54[0.51,4.64]
Total events: 14 (Bleomycin), 10 (Other)  
Heterogeneity: Tau2=0.16; Chi2=1.33, df=1(P=0.25); I2=25.03%  
Test for overall effect: Z=0.77(P=0.44)  
   
1.1.2 Bleomycin vs talc slurry  
Haddad 2004 7/34 6/37 34.62% 1.34[0.4,4.48]
Lynch 1996 4/14 9/17 24.15% 0.36[0.08,1.59]
Noppen 1997 3/12 3/14 17.1% 1.22[0.2,7.59]
Ong 2000 6/20 2/18 18.4% 3.43[0.59,19.8]
Zimmer 1997 1/14 0/19 5.73% 4.33[0.16,114.58]
Subtotal (95% CI) 94 105 100% 1.22[0.55,2.7]
Total events: 21 (Bleomycin), 20 (Other)  
Heterogeneity: Tau2=0.1; Chi2=4.53, df=4(P=0.34); I2=11.61%  
Test for overall effect: Z=0.48(P=0.63)  
   
1.1.3 Bleomycin vs tetracycline  
Emad 1996 2/19 3/19 10.7% 0.63[0.09,4.26]
Kessinger 1987 5/13 7/18 18.27% 0.98[0.23,4.25]
Lynch 1996 4/14 7/15 16.53% 0.46[0.1,2.13]
Martinez-Moragon 1997 2/25 4/24 12.11% 0.43[0.07,2.63]
Ruckdeschel 1991 11/37 19/36 42.4% 0.38[0.14,0.99]
Subtotal (95% CI) 108 112 100% 0.5[0.27,0.93]
Total events: 24 (Bleomycin), 40 (Other)  
Heterogeneity: Tau2=0; Chi2=1.23, df=4(P=0.87); I2=0%  
Test for overall effect: Z=2.18(P=0.03)  
   
1.1.4 Bleomycin vs talc poudrage  
Diacon 2000 10/17 2/15 74.32% 9.29[1.57,54.77]
Hamed 1989 5/15 0/10 25.68% 11[0.54,225.13]
Subtotal (95% CI) 32 25 100% 9.7[2.1,44.78]
Total events: 15 (Bleomycin), 2 (Other)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=2.91(P=0)  
   
1.1.5 Bleomycin vs C parvum  
Hillerdal 1986 17/19 6/20 49.39% 19.83[3.45,114.09]
Ostrowski 1989 8/22 13/17 50.61% 0.18[0.04,0.73]
Subtotal (95% CI) 41 37 100% 1.81[0.02,189.25]
Total events: 25 (Bleomycin), 19 (Other)  
Heterogeneity: Tau2=10.59; Chi2=17.04, df=1(P<0.0001); I2=94.13%  
Test for overall effect: Z=0.25(P=0.8)  
   
1.1.6 Bleomycin vs doxycycline  
Patz 1998 10/42 7/38 90.02% 1.38[0.47,4.1]
Favours bleomycin 1000.01 100.1 1 Favours other
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Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rafiei 2014 1/21 0/21 9.98% 3.15[0.12,81.74]
Subtotal (95% CI) 63 59 100% 1.5[0.54,4.2]
Total events: 11 (Bleomycin), 7 (Other)  
Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
1.1.7 Bleomycin vs interferon (IFN)  
Sartori 2004 13/83 29/77 100% 0.31[0.15,0.65]
Subtotal (95% CI) 83 77 100% 0.31[0.15,0.65]
Total events: 13 (Bleomycin), 29 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.08(P=0)  
   
1.1.8 Bleomycin vs mitoxantrone  
Schmidt 1997 8/47 15/38 100% 0.31[0.12,0.86]
Subtotal (95% CI) 47 38 100% 0.31[0.12,0.86]
Total events: 8 (Bleomycin), 15 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.27(P=0.02)  
   
1.1.9 Bleomycin vs mepacrine  
Koldsland 1993 8/18 2/18 100% 6.4[1.12,36.44]
Subtotal (95% CI) 18 18 100% 6.4[1.12,36.44]
Total events: 8 (Bleomycin), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.09(P=0.04)  
   
1.1.10 Bleomycin vs combined tetracycline and bleomycin  
Emad 1996 2/19 0/19 100% 5.57[0.25,124.19]
Subtotal (95% CI) 19 19 100% 5.57[0.25,124.19]
Total events: 2 (Bleomycin), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
1.1.11 Bleomycin vs cisplatin and etoposide  
Yoshida 2007 11/35 10/34 100% 1.1[0.39,3.07]
Subtotal (95% CI) 35 34 100% 1.1[0.39,3.07]
Total events: 11 (Bleomycin), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.18(P=0.86)  
   
1.1.12 Bleomycin vs OK-432  
Yoshida 2007 11/35 8/33 100% 1.43[0.49,4.17]
Subtotal (95% CI) 35 33 100% 1.43[0.49,4.17]
Total events: 11 (Bleomycin), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
1.1.13 Bleomycin vs viscum  
Gaafar 2014 4/7 2/10 100% 5.33[0.62,45.99]
Subtotal (95% CI) 7 10 100% 5.33[0.62,45.99]
Total events: 4 (Bleomycin), 2 (Other)  
Favours bleomycin 1000.01 100.1 1 Favours other
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
Test for subgroup differences: Chi2=36.99, df=1 (P=0), I2=67.56%  
Favours bleomycin 1000.01 100.1 1 Favours other
 
 
Analysis 1.2.   Comparison 1 Bleomycin, Outcome 2 Fever.
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Bleomycin vs talc slurry  
Lynch 1996 5/16 8/19 47.08% 0.63[0.15,2.52]
Noppen 1997 3/12 5/14 33.44% 0.6[0.11,3.3]
Ong 2000 4/20 1/18 19.48% 4.25[0.43,42.19]
Subtotal (95% CI) 48 51 100% 0.9[0.31,2.56]
Total events: 12 (Bleomycin), 14 (Other)  
Heterogeneity: Tau2=0.1; Chi2=2.26, df=2(P=0.32); I2=11.4%  
Test for overall effect: Z=0.21(P=0.84)  
   
1.2.2 Bleomycin vs talc poudrage  
Diacon 2000 2/17 2/15 100% 0.87[0.11,7.05]
Subtotal (95% CI) 17 15 100% 0.87[0.11,7.05]
Total events: 2 (Bleomycin), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.89)  
   
1.2.3 Bleomycin vs tetracycline  
Emad 1996 1/20 1/20 12.08% 1[0.06,17.18]
Kessinger 1987 8/16 2/16 22.74% 7[1.18,41.36]
Lynch 1996 5/16 6/15 27.52% 0.68[0.16,2.99]
Martinez-Moragon 1997 6/31 0/31 11.57% 16.06[0.86,298.78]
Ruckdeschel 1991 4/44 3/41 26.09% 1.27[0.27,6.04]
Subtotal (95% CI) 127 123 100% 2.05[0.67,6.34]
Total events: 24 (Bleomycin), 12 (Other)  
Heterogeneity: Tau2=0.63; Chi2=6.6, df=4(P=0.16); I2=39.43%  
Test for overall effect: Z=1.25(P=0.21)  
   
1.2.4 Tetracycline vs C parvum  
Hillerdal 1986 10/16 14/20 46.02% 0.71[0.18,2.87]
Ostrowski 1989 6/25 10/19 53.98% 0.28[0.08,1.03]
Subtotal (95% CI) 41 39 100% 0.43[0.17,1.12]
Total events: 16 (Bleomycin), 24 (Other)  
Heterogeneity: Tau2=0; Chi2=0.91, df=1(P=0.34); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
   
1.2.5 Bleomycin vs IFN  
Sartori 2004 41/83 0/77 100% 151.35[9.08,2522.62]
Subtotal (95% CI) 83 77 100% 151.35[9.08,2522.62]
Total events: 41 (Bleomycin), 0 (Other)  
Heterogeneity: Not applicable  
Favours bleomycin 1000.01 100.1 1 Favours other
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Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=3.5(P=0)  
   
1.2.6 Bleomycin vs mitoxantrone  
Schmidt 1997 8/49 7/47 100% 1.11[0.37,3.36]
Subtotal (95% CI) 49 47 100% 1.11[0.37,3.36]
Total events: 8 (Bleomycin), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
   
1.2.7 Bleomycin vs mepacrine  
Koldsland 1993 11/20 14/20 100% 0.52[0.14,1.92]
Subtotal (95% CI) 20 20 100% 0.52[0.14,1.92]
Total events: 11 (Bleomycin), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
1.2.8 Bleomycin vs doxycycline  
Patz 1998 7/52 0/54 43.48% 17.97[1,323.17]
Rafiei 2014 5/21 7/21 56.52% 0.63[0.16,2.42]
Subtotal (95% CI) 73 75 100% 2.69[0.08,89.51]
Total events: 12 (Bleomycin), 7 (Other)  
Heterogeneity: Tau2=5.18; Chi2=4.91, df=1(P=0.03); I2=79.62%  
Test for overall effect: Z=0.55(P=0.58)  
   
1.2.9 Bleomycin vs combined tetracycline and bleomycin  
Emad 1996 1/20 2/20 100% 0.47[0.04,5.69]
Subtotal (95% CI) 20 20 100% 0.47[0.04,5.69]
Total events: 1 (Bleomycin), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
1.2.10 Bleomycin vs OK432  
Yoshida 2007 25/35 25/32 100% 0.7[0.23,2.13]
Subtotal (95% CI) 35 32 100% 0.7[0.23,2.13]
Total events: 25 (Bleomycin), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
   
1.2.11 Bleomycin vs cisplatin and etoposide  
Yoshida 2007 25/35 18/34 100% 2.22[0.82,6.01]
Subtotal (95% CI) 35 34 100% 2.22[0.82,6.01]
Total events: 25 (Bleomycin), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
   
1.2.12 Bleomycin vs iodine  
Bagheri 2018 2/30 2/30 100% 1[0.13,7.6]
Subtotal (95% CI) 30 30 100% 1[0.13,7.6]
Total events: 2 (Bleomycin), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=21.3, df=1 (P=0.03), I2=48.35%  
Favours bleomycin 1000.01 100.1 1 Favours other
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Analysis 1.3.   Comparison 1 Bleomycin, Outcome 3 Pain.
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Bleomycin vs talc slurry  
Lynch 1996 4/16 4/19 79.42% 1.25[0.26,6.07]
Ong 2000 2/20 0/18 20.58% 5[0.22,111.43]
Subtotal (95% CI) 36 37 100% 1.66[0.41,6.8]
Total events: 6 (Bleomycin), 4 (Other)  
Heterogeneity: Tau2=0; Chi2=0.62, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.71(P=0.48)  
   
1.3.2 Bleomycin vs tetracycline  
Kessinger 1987 6/16 16/26 22.77% 0.38[0.1,1.35]
Lynch 1996 4/16 7/15 17.81% 0.38[0.08,1.74]
Martinez-Moragon 1997 10/31 16/31 30.23% 0.45[0.16,1.25]
Ruckdeschel 1991 11/44 7/41 29.18% 1.62[0.56,4.68]
Subtotal (95% CI) 107 113 100% 0.61[0.29,1.27]
Total events: 31 (Bleomycin), 46 (Other)  
Heterogeneity: Tau2=0.19; Chi2=4.51, df=3(P=0.21); I2=33.53%  
Test for overall effect: Z=1.33(P=0.18)  
   
1.3.3 Bleomycin vs talc poudrage  
Diacon 2000 0/17 1/15 100% 0.28[0.01,7.31]
Subtotal (95% CI) 17 15 100% 0.28[0.01,7.31]
Total events: 0 (Bleomycin), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
   
1.3.4 Bleomycin vs C parvum  
Hillerdal 1986 3/11 8/16 34.4% 0.38[0.07,1.95]
Ostrowski 1989 13/25 10/19 65.6% 0.98[0.3,3.22]
Subtotal (95% CI) 36 35 100% 0.7[0.27,1.85]
Total events: 16 (Bleomycin), 18 (Other)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
   
1.3.5 Bleomycin vs IFN  
Sartori 2004 14/83 0/77 100% 32.34[1.89,552.23]
Subtotal (95% CI) 83 77 100% 32.34[1.89,552.23]
Total events: 14 (Bleomycin), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.4(P=0.02)  
   
1.3.6 Bleomycin vs mitoxantrone  
Schmidt 1997 5/49 9/47 100% 0.48[0.15,1.56]
Subtotal (95% CI) 49 47 100% 0.48[0.15,1.56]
Total events: 5 (Bleomycin), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.22(P=0.22)  
   
1.3.7 Bleomycin vs mepacrine  
Favours bleomycin 1000.01 100.1 1 Favours other
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Koldsland 1993 13/20 16/20 100% 0.46[0.11,1.94]
Subtotal (95% CI) 20 20 100% 0.46[0.11,1.94]
Total events: 13 (Bleomycin), 16 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.05(P=0.29)  
   
1.3.8 Bleomycin vs doxycycline  
Patz 1998 6/52 11/54 58.26% 0.51[0.17,1.5]
Rafiei 2014 17/21 15/21 41.74% 1.7[0.4,7.2]
Subtotal (95% CI) 73 75 100% 0.84[0.26,2.7]
Total events: 23 (Bleomycin), 26 (Other)  
Heterogeneity: Tau2=0.3; Chi2=1.72, df=1(P=0.19); I2=41.75%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.3.9 Bleomycin vs OK-432  
Yoshida 2007 19/35 24/32 100% 0.4[0.14,1.12]
Subtotal (95% CI) 35 32 100% 0.4[0.14,1.12]
Total events: 19 (Bleomycin), 24 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
1.3.10 Bleomycin vs cisplatin and etoposide  
Yoshida 2007 19/35 20/34 100% 0.83[0.32,2.16]
Subtotal (95% CI) 35 34 100% 0.83[0.32,2.16]
Total events: 19 (Bleomycin), 20 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
   
1.3.11 Bleomycin vs iodine  
Bagheri 2018 2/30 2/30 100% 1[0.13,7.6]
Subtotal (95% CI) 30 30 100% 1[0.13,7.6]
Total events: 2 (Bleomycin), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=11.12, df=1 (P=0.35), I2=10.06%  
Favours bleomycin 1000.01 100.1 1 Favours other
 
 
Analysis 1.4.   Comparison 1 Bleomycin, Outcome 4 Mortality.
Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Bleomycin vs combined tetracycline and bleomycin  
Emad 1996 1/20 1/20 100% 1[0.06,17.18]
Subtotal (95% CI) 20 20 100% 1[0.06,17.18]
Total events: 1 (Bleomycin), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.4.2 Bleomycin vs talc slurry  
Favours bleomycin 1000.01 100.1 1 Favours other
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Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Haddad 2004 30/33 34/37 45.36% 0.88[0.17,4.71]
Ong 2000 4/24 4/22 54.64% 0.9[0.2,4.14]
Subtotal (95% CI) 57 59 100% 0.89[0.29,2.75]
Total events: 34 (Bleomycin), 38 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
   
1.4.3 Bleomycin vs tetracycline  
Emad 1996 1/20 1/20 8.65% 1[0.06,17.18]
Ruckdeschel 1991 15/44 19/41 91.35% 0.6[0.25,1.44]
Subtotal (95% CI) 64 61 100% 0.63[0.27,1.44]
Total events: 16 (Bleomycin), 20 (Other)  
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=1.1(P=0.27)  
   
1.4.4 Bleomycin vs talc poudrage  
Diacon 2000 6/17 6/15 100% 0.82[0.2,3.43]
Subtotal (95% CI) 17 15 100% 0.82[0.2,3.43]
Total events: 6 (Bleomycin), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.78)  
   
1.4.5 Bleomycin vs C parvum  
Ostrowski 1989 7/29 9/26 100% 0.6[0.19,1.94]
Subtotal (95% CI) 29 26 100% 0.6[0.19,1.94]
Total events: 7 (Bleomycin), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
   
1.4.6 Bleomycin vs IFN  
Sartori 2004 36/83 48/77 100% 0.46[0.25,0.87]
Subtotal (95% CI) 83 77 100% 0.46[0.25,0.87]
Total events: 36 (Bleomycin), 48 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.39(P=0.02)  
   
1.4.7 Bleomycin vs mitoxantrone  
Schmidt 1997 28/49 18/47 100% 2.15[0.95,4.86]
Subtotal (95% CI) 49 47 100% 2.15[0.95,4.86]
Total events: 28 (Bleomycin), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.84(P=0.07)  
   
1.4.8 Bleomycin vs OK-432  
Yoshida 2007 25/35 16/33 100% 2.66[0.98,7.23]
Subtotal (95% CI) 35 33 100% 2.66[0.98,7.23]
Total events: 25 (Bleomycin), 16 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
   
1.4.9 Bleomycin vs doxycycline  
Patz 1998 13/42 9/38 100% 1.44[0.53,3.9]
Favours bleomycin 1000.01 100.1 1 Favours other
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Study or subgroup Bleomycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Rafiei 2014 0/21 0/21   Not estimable
Subtotal (95% CI) 63 59 100% 1.44[0.53,3.9]
Total events: 13 (Bleomycin), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
   
1.4.10 Bleomycin vs cisplatin and etoposide  
Yoshida 2007 25/35 18/34 100% 2.22[0.82,6.01]
Subtotal (95% CI) 35 34 100% 2.22[0.82,6.01]
Total events: 25 (Bleomycin), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
Test for subgroup differences: Chi2=17.74, df=1 (P=0.04), I2=49.28%  
Favours bleomycin 1000.01 100.1 1 Favours other
 
 
Analysis 1.5.   Comparison 1 Bleomycin, Outcome 5 Repeat pleural intervention.
Study or subgroup Bleomycin Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.5.1 Bleomycin vs talc slurry  
Zimmer 1997 1/14 0/19 100% 4.33[0.16,114.58]
Subtotal (95% CI) 14 19 100% 4.33[0.16,114.58]
Total events: 1 (Bleomycin), 0 (Talc slurry)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
Total (95% CI) 14 19 100% 4.33[0.16,114.58]
Total events: 1 (Bleomycin), 0 (Talc slurry)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Favours bleomycin 1000.01 100.1 1 Favours talc slurry
 
 
Comparison 2.   Talc slurry





Statistical method Effect size
1 Pleurodesis failure rate 20   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Talc slurry vs talc poudrage 4 919 Odds Ratio (M-H, Random,
95% CI)
1.24 [0.92, 1.65]
1.2 Talc slurry vs bleomycin 5 199 Odds Ratio (M-H, Random,
95% CI)
0.82 [0.37, 1.82]
1.3 Talc slurry vs indwelling pleural catheter
(IPC) – not daily drainage
2 249 Odds Ratio (M-H, Random,
95% CI)
0.18 [0.07, 0.45]
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Statistical method Effect size
1.4 Talc slurry vs mepacrine 1 89 Odds Ratio (M-H, Random,
95% CI)
0.48 [0.14, 1.60]
1.5 Talc slurry vs placebo 1 21 Odds Ratio (M-H, Random,
95% CI)
0.07 [0.00, 1.51]
1.6 Talc slurry vs iodine 2 75 Odds Ratio (M-H, Random,
95% CI)
0.85 [0.24, 3.08]
1.7 Talc slurry vs tetracycline 1 32 Odds Ratio (M-H, Random,
95% CI)
1.29 [0.32, 5.17]
1.8 Talc slurry vs silver nitrate 1 25 Odds Ratio (M-H, Random,
95% CI)
5.82 [0.21, 158.82]
1.9 Talc slurry vs thoracoscopic mechanical
pleurodesis (TMP)
2 123 Odds Ratio (M-H, Random,
95% CI)
2.28 [0.83, 6.23]
1.10 Talc slurry vs autologous blood 1 110 Odds Ratio (M-H, Random,
95% CI)
0.69 [0.24, 1.95]
1.11 Talc slurry vs IPC – daily drainage 1 55 Odds Ratio (M-H, Random,
95% CI)
0.30 [0.08, 1.14]
2 Fever 9   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Talc slurry vs talc poudrage 2 479 Odds Ratio (M-H, Random,
95% CI)
1.65 [0.42, 6.48]
2.2 Talc slurry vs bleomycin 3 98 Odds Ratio (M-H, Random,
95% CI)
0.95 [0.36, 2.51]
2.3 Talc slurry vs tetracycline 1 34 Odds Ratio (M-H, Random,
95% CI)
1.09 [0.28, 4.32]
2.4 Talc slurry vs iodine 2 75 Odds Ratio (M-H, Random,
95% CI)
1.07 [0.32, 3.59]
2.5 Talc slurry vs silver nitrate 1 60 Odds Ratio (M-H, Random,
95% CI)
0.7 [0.15, 3.24]
2.6 Talc slurry vs autologous blood 1 110 Odds Ratio (M-H, Random,
95% CI)
3.92 [1.31, 11.72]
3 Pain 12   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Talc slurry vs bleomycin 3 99 Odds Ratio (M-H, Random,
95% CI)
0.60 [0.15, 2.46]
3.2 Talc slurry vs talc poudrage 2 812 Odds Ratio (M-H, Random,
95% CI)
1.27 [0.41, 3.96]
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews





Statistical method Effect size
3.3 Talc slurry vs tetracycline 1 34 Odds Ratio (M-H, Random,
95% CI)
0.30 [0.07, 1.36]
3.4 Talc slurry vs iodine 2 75 Odds Ratio (M-H, Random,
95% CI)
2.0 [0.55, 7.30]
3.5 Talc slurry vs IPC – not daily drainage 2 232 Odds Ratio (M-H, Random,
95% CI)
0.62 [0.19, 1.95]
3.6 Talc slurry vs placebo 1 31 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
3.7 Talc slurry vs autologous blood 1 110 Odds Ratio (M-H, Random,
95% CI)
3.57 [1.19, 10.74]
3.8 Talc slurry vs IPC – daily drainage 1 57 Odds Ratio (M-H, Random,
95% CI)
0.31 [0.01, 7.95]
4 Breathlessness 3 344 Mean Difference (IV, Fixed,
95% CI)
1.09 [-6.14, 8.32]
4.1 Talc slurry vs IPC (not daily drainage) 2 160 Mean Difference (IV, Fixed,
95% CI)
6.12 [-4.08, 16.32]
4.2 Talc slurry vs talc poudrage 1 184 Mean Difference (IV, Fixed,
95% CI)
-4.0 [-14.26, 6.26]
5 Mortality 14   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 Talc slurry vs talc poudrage 3 725 Odds Ratio (M-H, Random,
95% CI)
1.10 [0.69, 1.75]
5.2 Talc slurry vs bleomycin 2 116 Odds Ratio (M-H, Random,
95% CI)
1.12 [0.36, 3.46]
5.3 Talc slurry vs iodine 2 75 Odds Ratio (M-H, Random,
95% CI)
2.71 [0.10, 70.65]
5.4 Talc slurry vs IPC – not daily drainage 3 344 Odds Ratio (M-H, Random,
95% CI)
1.43 [0.91, 2.23]
5.5 Talc slurry vs mepacrine 1 89 Odds Ratio (M-H, Random,
95% CI)
1.88 [0.70, 5.02]
5.6 Talc slurry vs TMP 1 87 Odds Ratio (M-H, Random,
95% CI)
10.64 [0.55, 203.85]
5.7 Talc slurry vs autologous blood 1 117 Odds Ratio (M-H, Random,
95% CI)
1.38 [0.30, 6.47]
5.8 Talc slurry vs IPC – daily drainage 1 57 Odds Ratio (M-H, Random,
95% CI)
0.59 [0.19, 1.79]
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Statistical method Effect size
6 Repeat pleural intervention 6 756 Odds Ratio (M-H, Random,
95% CI)
1.95 [0.90, 4.20]
6.1 Talc slurry vs IPC – not daily drainage 3 343 Odds Ratio (M-H, Random,
95% CI)
3.91 [1.98, 7.72]
6.2 Talc slurry vs talc poudrage 2 380 Odds Ratio (M-H, Random,
95% CI)
1.05 [0.64, 1.71]





Analysis 2.1.   Comparison 2 Talc slurry, Outcome 1 Pleurodesis failure rate.
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 Talc slurry vs talc poudrage  
Bhatnagar 2020 38/159 36/161 31.17% 1.09[0.65,1.83]
Dresler 2005 114/240 97/242 64.67% 1.35[0.94,1.94]
Terra 2009 4/30 5/30 4.15% 0.77[0.19,3.2]
Yim 1996 0/29 0/28   Not estimable
Subtotal (95% CI) 458 461 100% 1.24[0.92,1.65]
Total events: 156 (Talc slurry), 138 (Other)  
Heterogeneity: Tau2=0; Chi2=0.89, df=2(P=0.64); I2=0%  
Test for overall effect: Z=1.43(P=0.15)  
   
2.1.2 Talc slurry vs bleomycin  
Haddad 2004 6/37 7/34 34.62% 0.75[0.22,2.49]
Lynch 1996 9/17 4/14 24.15% 2.81[0.63,12.61]
Noppen 1997 3/14 3/12 17.1% 0.82[0.13,5.08]
Ong 2000 2/18 6/20 18.4% 0.29[0.05,1.68]
Zimmer 1997 0/19 1/14 5.73% 0.23[0.01,6.1]
Subtotal (95% CI) 105 94 100% 0.82[0.37,1.82]
Total events: 20 (Talc slurry), 21 (Other)  
Heterogeneity: Tau2=0.1; Chi2=4.53, df=4(P=0.34); I2=11.61%  
Test for overall effect: Z=0.48(P=0.63)  
   
2.1.3 Talc slurry vs indwelling pleural catheter (IPC) – not daily
drainage
 
Davies 2012 12/54 25/51 47.79% 0.3[0.13,0.69]
Thomas 2017 16/71 52/73 52.21% 0.12[0.06,0.25]
Subtotal (95% CI) 125 124 100% 0.18[0.07,0.45]
Total events: 28 (Talc slurry), 77 (Other)  
Heterogeneity: Tau2=0.26; Chi2=2.58, df=1(P=0.11); I2=61.31%  
Test for overall effect: Z=3.66(P=0)  
   
2.1.4 Talc slurry vs mepacrine  
Ukale 2004 5/48 8/41 100% 0.48[0.14,1.6]
Favours talc slurry 1000.01 100.1 1 Favours other
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Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 48 41 100% 0.48[0.14,1.6]
Total events: 5 (Talc slurry), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.19(P=0.23)  
   
2.1.5 Talc slurry vs placebo  
Sorensen 1984 0/9 5/12 100% 0.07[0,1.51]
Subtotal (95% CI) 9 12 100% 0.07[0,1.51]
Total events: 0 (Talc slurry), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
   
2.1.6 Talc slurry vs iodine  
Agarwal 2011 2/18 1/18 26.54% 2.13[0.18,25.78]
Ibrahim 2015 4/21 5/18 73.46% 0.61[0.14,2.74]
Subtotal (95% CI) 39 36 100% 0.85[0.24,3.08]
Total events: 6 (Talc slurry), 6 (Other)  
Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
2.1.7 Talc slurry vs tetracycline  
Lynch 1996 9/17 7/15 100% 1.29[0.32,5.17]
Subtotal (95% CI) 17 15 100% 1.29[0.32,5.17]
Total events: 9 (Talc slurry), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.72)  
   
2.1.8 Talc slurry vs silver nitrate  
Paschoalini 2005 1/9 0/16 100% 5.82[0.21,158.82]
Subtotal (95% CI) 9 16 100% 5.82[0.21,158.82]
Total events: 1 (Talc slurry), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
2.1.9 Talc slurry vs thoracoscopic mechanical pleurodesis (TMP)  
Crnjac 2004 11/42 6/45 83.71% 2.31[0.77,6.93]
Hojski 2015 2/18 1/18 16.29% 2.13[0.18,25.78]
Subtotal (95% CI) 60 63 100% 2.28[0.83,6.23]
Total events: 13 (Talc slurry), 7 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=1.6(P=0.11)  
   
2.1.10 Talc slurry vs autologous blood  
Keeratichananont 2018 7/54 10/56 100% 0.69[0.24,1.95]
Subtotal (95% CI) 54 56 100% 0.69[0.24,1.95]
Total events: 7 (Talc slurry), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
2.1.11 Talc slurry vs IPC – daily drainage  
Demmy 2012 4/29 9/26 100% 0.3[0.08,1.14]
Subtotal (95% CI) 29 26 100% 0.3[0.08,1.14]
Favours talc slurry 1000.01 100.1 1 Favours other
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Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 4 (Talc slurry), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.76(P=0.08)  
Test for subgroup differences: Chi2=27.35, df=1 (P=0), I2=63.43%  
Favours talc slurry 1000.01 100.1 1 Favours other
 
 
Analysis 2.2.   Comparison 2 Talc slurry, Outcome 2 Fever.
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 Talc slurry vs talc poudrage  
Dresler 2005 68/196 68/223 83.22% 1.21[0.8,1.82]
Terra 2009 3/30 0/30 16.78% 7.76[0.38,157.14]
Subtotal (95% CI) 226 253 100% 1.65[0.42,6.48]
Total events: 71 (Talc slurry), 68 (Other)  
Heterogeneity: Tau2=0.54; Chi2=1.45, df=1(P=0.23); I2=31.05%  
Test for overall effect: Z=0.72(P=0.47)  
   
2.2.2 Talc slurry vs bleomycin  
Lynch 1996 8/19 6/15 49.67% 1.09[0.28,4.32]
Noppen 1997 5/14 3/12 32.45% 1.67[0.3,9.16]
Ong 2000 1/18 4/20 17.88% 0.24[0.02,2.34]
Subtotal (95% CI) 51 47 100% 0.95[0.36,2.51]
Total events: 14 (Talc slurry), 13 (Other)  
Heterogeneity: Tau2=0; Chi2=1.89, df=2(P=0.39); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
   
2.2.3 Talc slurry vs tetracycline  
Lynch 1996 8/19 6/15 100% 1.09[0.28,4.32]
Subtotal (95% CI) 19 15 100% 1.09[0.28,4.32]
Total events: 8 (Talc slurry), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.12(P=0.9)  
   
2.2.4 Talc slurry vs iodine  
Agarwal 2011 3/18 2/18 39.57% 1.6[0.23,10.94]
Ibrahim 2015 4/21 4/18 60.43% 0.82[0.17,3.9]
Subtotal (95% CI) 39 36 100% 1.07[0.32,3.59]
Total events: 7 (Talc slurry), 6 (Other)  
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
2.2.5 Talc slurry vs silver nitrate  
Paschoalini 2005 3/27 5/33 100% 0.7[0.15,3.24]
Subtotal (95% CI) 27 33 100% 0.7[0.15,3.24]
Total events: 3 (Talc slurry), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.46(P=0.65)  
   
Favours talc slurry 1000.01 100.1 1 Favours other
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.6 Talc slurry vs autologous blood  
Keeratichananont 2018 15/54 5/56 100% 3.92[1.31,11.72]
Subtotal (95% CI) 54 56 100% 3.92[1.31,11.72]
Total events: 15 (Talc slurry), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
Test for subgroup differences: Chi2=5.17, df=1 (P=0.4), I2=3.21%  
Favours talc slurry 1000.01 100.1 1 Favours other
 
 
Analysis 2.3.   Comparison 2 Talc slurry, Outcome 3 Pain.
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Talc slurry vs bleomycin  
Lynch 1996 4/19 4/16 79.42% 0.8[0.16,3.88]
Noppen 1997 0/14 0/12   Not estimable
Ong 2000 0/18 2/20 20.58% 0.2[0.01,4.46]
Subtotal (95% CI) 51 48 100% 0.6[0.15,2.46]
Total events: 4 (Talc slurry), 6 (Other)  
Heterogeneity: Tau2=0; Chi2=0.62, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.71(P=0.48)  
   
2.3.2 Talc slurry vs talc poudrage  
Bhatnagar 2020 6/164 9/166 44.26% 0.66[0.23,1.91]
Dresler 2005 24/240 12/242 55.74% 2.13[1.04,4.36]
Subtotal (95% CI) 404 408 100% 1.27[0.41,3.96]
Total events: 30 (Talc slurry), 21 (Other)  
Heterogeneity: Tau2=0.47; Chi2=3.21, df=1(P=0.07); I2=68.87%  
Test for overall effect: Z=0.41(P=0.68)  
   
2.3.3 Talc slurry vs tetracycline  
Lynch 1996 4/19 7/15 100% 0.3[0.07,1.36]
Subtotal (95% CI) 19 15 100% 0.3[0.07,1.36]
Total events: 4 (Talc slurry), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.55(P=0.12)  
   
2.3.4 Talc slurry vs iodine  
Agarwal 2011 18/18 18/18   Not estimable
Ibrahim 2015 14/21 9/18 100% 2[0.55,7.3]
Subtotal (95% CI) 39 36 100% 2[0.55,7.3]
Total events: 32 (Talc slurry), 27 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
   
2.3.5 Talc slurry vs IPC – not daily drainage  
Boshuizen 2017 1/45 2/43 22.4% 0.47[0.04,5.33]
Thomas 2017 4/71 6/73 77.6% 0.67[0.18,2.47]
Subtotal (95% CI) 116 116 100% 0.62[0.19,1.95]
Favours talc slurry 1000.01 100.1 1 Favours other
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Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 5 (Talc slurry), 8 (Other)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
   
2.3.6 Talc slurry vs placebo  
Sorensen 1984 14/14 17/17   Not estimable
Subtotal (95% CI) 14 17 Not estimable
Total events: 14 (Talc slurry), 17 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.3.7 Talc slurry vs autologous blood  
Keeratichananont 2018 14/54 5/56 100% 3.57[1.19,10.74]
Subtotal (95% CI) 54 56 100% 3.57[1.19,10.74]
Total events: 14 (Talc slurry), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
   
2.3.8 Talc slurry vs IPC – daily drainage  
Demmy 2012 0/29 1/28 100% 0.31[0.01,7.95]
Subtotal (95% CI) 29 28 100% 0.31[0.01,7.95]
Total events: 0 (Talc slurry), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
Test for subgroup differences: Chi2=10.35, df=1 (P=0.11), I2=42.02%  
Favours talc slurry 1000.01 100.1 1 Favours other
 
 
Analysis 2.4.   Comparison 2 Talc slurry, Outcome 4 Breathlessness.
Study or subgroup Talc slurry Other Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
2.4.1 Talc slurry vs IPC (not daily drainage)  
Davies 2012 47 -30.2 (27.9) 49 -37 (27.2) 43.01% 6.8[-4.23,17.83]
Thomas 2017 27 -19 (51.7) 37 -21.1 (57.1) 7.29% 2.1[-24.69,28.89]
Subtotal *** 74   86   50.3% 6.12[-4.08,16.32]
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.18(P=0.24)  
   
2.4.2 Talc slurry vs talc poudrage  
Bhatnagar 2020 93 -29 (36) 91 -25 (35) 49.7% -4[-14.26,6.26]
Subtotal *** 93   91   49.7% -4[-14.26,6.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.44)  
   
Total *** 167   177   100% 1.09[-6.14,8.32]
Heterogeneity: Tau2=0; Chi2=1.98, df=2(P=0.37); I2=0%  
Test for overall effect: Z=0.3(P=0.77)  
Test for subgroup differences: Chi2=1.88, df=1 (P=0.17), I2=46.81%  
Favours talc slurry 10050-100 -50 0 Favours other
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Analysis 2.5.   Comparison 2 Talc slurry, Outcome 5 Mortality.
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Talc slurry vs talc poudrage  
Bhatnagar 2020 68/163 66/165 47.67% 1.07[0.69,1.67]
Dresler 2005 33/163 25/177 37.04% 1.54[0.87,2.73]
Yim 1996 15/29 19/28 15.29% 0.51[0.17,1.49]
Subtotal (95% CI) 355 370 100% 1.1[0.69,1.75]
Total events: 116 (Talc slurry), 110 (Other)  
Heterogeneity: Tau2=0.07; Chi2=3.32, df=2(P=0.19); I2=39.83%  
Test for overall effect: Z=0.38(P=0.7)  
   
2.5.2 Talc slurry vs bleomycin  
Haddad 2004 34/37 30/33 45.36% 1.13[0.21,6.04]
Ong 2000 4/22 4/24 54.64% 1.11[0.24,5.11]
Subtotal (95% CI) 59 57 100% 1.12[0.36,3.46]
Total events: 38 (Talc slurry), 34 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.2(P=0.84)  
   
2.5.3 Talc slurry vs iodine  
Agarwal 2011 0/18 0/18   Not estimable
Ibrahim 2015 1/21 0/18 100% 2.71[0.1,70.65]
Subtotal (95% CI) 39 36 100% 2.71[0.1,70.65]
Total events: 1 (Talc slurry), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
   
2.5.4 Talc slurry vs IPC – not daily drainage  
Boshuizen 2017 19/48 16/46 28.4% 1.23[0.53,2.84]
Davies 2012 20/54 16/52 30.62% 1.32[0.59,2.97]
Thomas 2017 51/71 44/73 40.97% 1.68[0.84,3.38]
Subtotal (95% CI) 173 171 100% 1.43[0.91,2.23]
Total events: 90 (Talc slurry), 76 (Other)  
Heterogeneity: Tau2=0; Chi2=0.37, df=2(P=0.83); I2=0%  
Test for overall effect: Z=1.57(P=0.12)  
   
2.5.5 Talc slurry vs mepacrine  
Ukale 2004 15/48 8/41 100% 1.88[0.7,5.02]
Subtotal (95% CI) 48 41 100% 1.88[0.7,5.02]
Total events: 15 (Talc slurry), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
2.5.6 Talc slurry vs TMP  
Crnjac 2004 4/42 0/45 100% 10.64[0.55,203.85]
Subtotal (95% CI) 42 45 100% 10.64[0.55,203.85]
Total events: 4 (Talc slurry), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.57(P=0.12)  
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Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.7 Talc slurry vs autologous blood  
Keeratichananont 2018 4/58 3/59 100% 1.38[0.3,6.47]
Subtotal (95% CI) 58 59 100% 1.38[0.3,6.47]
Total events: 4 (Talc slurry), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
2.5.8 Talc slurry vs IPC – daily drainage  
Demmy 2012 8/29 11/28 100% 0.59[0.19,1.79]
Subtotal (95% CI) 29 28 100% 0.59[0.19,1.79]
Total events: 8 (Talc slurry), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Test for subgroup differences: Chi2=5.34, df=1 (P=0.62), I2=0%  
Favours talc slurry 1000.01 100.1 1 Favours other
 
 
Analysis 2.6.   Comparison 2 Talc slurry, Outcome 6 Repeat pleural intervention.
Study or subgroup Talc slurry Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.6.1 Talc slurry vs IPC – not daily drainage  
Boshuizen 2017 15/48 7/46 20.25% 2.53[0.92,6.95]
Davies 2012 12/54 3/51 16.09% 4.57[1.21,17.31]
Thomas 2017 16/71 3/73 16.67% 6.79[1.88,24.48]
Subtotal (95% CI) 173 170 53.02% 3.91[1.98,7.72]
Total events: 43 (Talc slurry), 13 (Other)  
Heterogeneity: Tau2=0; Chi2=1.49, df=2(P=0.48); I2=0%  
Test for overall effect: Z=3.92(P<0.0001)  
   
2.6.2 Talc slurry vs talc poudrage  
Bhatnagar 2020 38/159 36/161 27.28% 1.09[0.65,1.83]
Terra 2009 4/30 5/30 15.03% 0.77[0.19,3.2]
Subtotal (95% CI) 189 191 42.31% 1.05[0.64,1.71]
Total events: 42 (Talc slurry), 41 (Other)  
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.18(P=0.85)  
   
2.6.3 Talc slurry vs bleomycin  
Zimmer 1997 0/19 1/14 4.67% 0.23[0.01,6.1]
Subtotal (95% CI) 19 14 4.67% 0.23[0.01,6.1]
Total events: 0 (Talc slurry), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
Total (95% CI) 381 375 100% 1.95[0.9,4.2]
Total events: 85 (Talc slurry), 55 (Other)  
Heterogeneity: Tau2=0.49; Chi2=12.6, df=5(P=0.03); I2=60.31%  
Test for overall effect: Z=1.7(P=0.09)  
Test for subgroup differences: Chi2=10.83, df=1 (P=0), I2=81.53%  
Favours talc slurry 1000.01 100.1 1 Favours other
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Comparison 3.   Talc poudrage





Statistical method Effect size
1 Pleurodesis failure rate 10   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Talc poudrage vs talc slurry 4 919 Odds Ratio (M-H, Random,
95% CI)
0.81 [0.61, 1.08]
1.2 Talc poudrage vs bleomycin 2 57 Odds Ratio (M-H, Random,
95% CI)
0.10 [0.02, 0.48]
1.3 Talc poudrage vs tetracycline 1 33 Odds Ratio (M-H, Random,
95% CI)
0.08 [0.01, 0.76]
1.4 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random,
95% CI)
0.57 [0.08, 3.80]
1.5 Talc poudrage vs mustine 1 37 Odds Ratio (M-H, Random,
95% CI)
0.13 [0.02, 0.71]
1.6 Talc poudrage vs doxycycline 1 31 Odds Ratio (M-H, Random,
95% CI)
0.02 [0.00, 0.47]
2 Fever 4   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Talc poudrage vs talc slurry 2 479 Odds Ratio (M-H, Random,
95% CI)
0.60 [0.15, 2.37]
2.2 Talc poudrage vs bleomycin 1 32 Odds Ratio (M-H, Random,
95% CI)
1.15 [0.14, 9.38]
2.3 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random,
95% CI)
4.22 [0.43, 41.45]
3 Pain 4   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Talc poudrage vs talc slurry 2 812 Odds Ratio (M-H, Random,
95% CI)
0.79 [0.25, 2.45]
3.2 Talc poudrage vs bleomycin 1 32 Odds Ratio (M-H, Random,
95% CI)
3.62 [0.14, 95.78]
3.3 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random,
95% CI)
9.97 [0.50, 198.04]
4 Breathlessness 1 184 Mean Difference (IV, Random,
95% CI)
4.0 [-6.26, 14.26]
4.1 Talc poudrage vs talc slurry 1 184 Mean Difference (IV, Random,
95% CI)
4.0 [-6.26, 14.26]
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Statistical method Effect size
5 Mortality 7   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
5.1 Talc poudrage vs talc slurry 3 725 Odds Ratio (M-H, Random,
95% CI)
0.91 [0.57, 1.46]
5.2 Talc poudrage vs bleomycin 1 32 Odds Ratio (M-H, Random,
95% CI)
1.22 [0.29, 5.13]
5.3 Talc poudrage vs tetracycline 1 41 Odds Ratio (M-H, Random,
95% CI)
5.25 [0.91, 30.22]
5.4 Talc poudrage vs iodine 1 42 Odds Ratio (M-H, Random,
95% CI)
2.64 [0.58, 12.09]
5.5 Talc poudrage vs mustine 1 46 Odds Ratio (M-H, Random,
95% CI)
0.43 [0.09, 1.96]
6 Repeat pleural intervention 2 380 Odds Ratio (M-H, Fixed, 95%
CI)
0.96 [0.59, 1.56]





Analysis 3.1.   Comparison 3 Talc poudrage, Outcome 1 Pleurodesis failure rate.
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Talc poudrage vs talc slurry  
Bhatnagar 2020 36/161 38/159 31.17% 0.92[0.55,1.54]
Dresler 2005 97/242 114/240 64.67% 0.74[0.52,1.06]
Terra 2009 5/30 4/30 4.15% 1.3[0.31,5.4]
Yim 1996 0/28 0/29   Not estimable
Subtotal (95% CI) 461 458 100% 0.81[0.61,1.08]
Total events: 138 (Talc poudrage), 156 (Other)  
Heterogeneity: Tau2=0; Chi2=0.89, df=2(P=0.64); I2=0%  
Test for overall effect: Z=1.43(P=0.15)  
   
3.1.2 Talc poudrage vs bleomycin  
Diacon 2000 2/15 10/17 74.32% 0.11[0.02,0.64]
Hamed 1989 0/10 5/15 25.68% 0.09[0,1.86]
Subtotal (95% CI) 25 32 100% 0.1[0.02,0.48]
Total events: 2 (Talc poudrage), 15 (Other)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=2.91(P=0)  
   
3.1.3 Talc poudrage vs tetracycline  
Fentiman 1986 1/12 11/21 100% 0.08[0.01,0.76]
Subtotal (95% CI) 12 21 100% 0.08[0.01,0.76]
Favours talc poudrage 1000.01 100.1 1 Favours other
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Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 1 (Talc poudrage), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.2(P=0.03)  
   
3.1.4 Talc poudrage vs iodine  
Mohsen 2011 2/22 3/20 100% 0.57[0.08,3.8]
Subtotal (95% CI) 22 20 100% 0.57[0.08,3.8]
Total events: 2 (Talc poudrage), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
3.1.5 Talc poudrage vs mustine  
Fentiman 1983 2/20 8/17 100% 0.13[0.02,0.71]
Subtotal (95% CI) 20 17 100% 0.13[0.02,0.71]
Total events: 2 (Talc poudrage), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.34(P=0.02)  
   
3.1.6 Talc poudrage vs doxycycline  
Kuzdzal 2003 0/18 7/13 100% 0.02[0,0.47]
Subtotal (95% CI) 18 13 100% 0.02[0,0.47]
Total events: 0 (Talc poudrage), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
Test for subgroup differences: Chi2=19.19, df=1 (P=0), I2=73.94%  
Favours talc poudrage 1000.01 100.1 1 Favours other
 
 
Analysis 3.2.   Comparison 3 Talc poudrage, Outcome 2 Fever.
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.2.1 Talc poudrage vs talc slurry  
Dresler 2005 68/223 68/196 83.22% 0.83[0.55,1.24]
Terra 2009 0/30 3/30 16.78% 0.13[0.01,2.61]
Subtotal (95% CI) 253 226 100% 0.6[0.15,2.37]
Total events: 68 (Talc poudrage), 71 (Other)  
Heterogeneity: Tau2=0.54; Chi2=1.45, df=1(P=0.23); I2=31.05%  
Test for overall effect: Z=0.72(P=0.47)  
   
3.2.2 Talc poudrage vs bleomycin  
Diacon 2000 2/15 2/17 100% 1.15[0.14,9.38]
Subtotal (95% CI) 15 17 100% 1.15[0.14,9.38]
Total events: 2 (Talc poudrage), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.89)  
   
3.2.3 Talc poudrage vs iodine  
Mohsen 2011 4/22 1/20 100% 4.22[0.43,41.45]
Subtotal (95% CI) 22 20 100% 4.22[0.43,41.45]
Favours talc poudrage 1000.01 100.1 1 Favours other
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Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 4 (Talc poudrage), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.24(P=0.22)  
Test for subgroup differences: Chi2=2.06, df=1 (P=0.36), I2=2.94%  
Favours talc poudrage 1000.01 100.1 1 Favours other
 
 
Analysis 3.3.   Comparison 3 Talc poudrage, Outcome 3 Pain.
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.3.1 Talc poudrage vs talc slurry  
Bhatnagar 2020 9/166 6/164 44.26% 1.51[0.52,4.34]
Dresler 2005 12/242 24/240 55.74% 0.47[0.23,0.96]
Subtotal (95% CI) 408 404 100% 0.79[0.25,2.45]
Total events: 21 (Talc poudrage), 30 (Other)  
Heterogeneity: Tau2=0.47; Chi2=3.21, df=1(P=0.07); I2=68.87%  
Test for overall effect: Z=0.41(P=0.68)  
   
3.3.2 Talc poudrage vs bleomycin  
Diacon 2000 1/15 0/17 100% 3.62[0.14,95.78]
Subtotal (95% CI) 15 17 100% 3.62[0.14,95.78]
Total events: 1 (Talc poudrage), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
   
3.3.3 Talc poudrage vs iodine  
Mohsen 2011 4/22 0/20 100% 9.97[0.5,198.04]
Subtotal (95% CI) 22 20 100% 9.97[0.5,198.04]
Total events: 4 (Talc poudrage), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Test for subgroup differences: Chi2=2.89, df=1 (P=0.24), I2=30.85%  
Favours talc poudrage 1000.01 100.1 1 Favours other
 
 
Analysis 3.4.   Comparison 3 Talc poudrage, Outcome 4 Breathlessness.
Study or subgroup Talc poudrage Talc slurry Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
3.4.1 Talc poudrage vs talc slurry  
Bhatnagar 2020 91 -25 (35) 93 -29 (36) 100% 4[-6.26,14.26]
Subtotal *** 91   93   100% 4[-6.26,14.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.44)  
   
Total *** 91   93   100% 4[-6.26,14.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.44)  
Favours talc poudrage 10050-100 -50 0 Favours talc slurry
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Analysis 3.5.   Comparison 3 Talc poudrage, Outcome 5 Mortality.
Study or subgroup Talc poudrage Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.5.1 Talc poudrage vs talc slurry  
Bhatnagar 2020 66/165 68/163 47.67% 0.93[0.6,1.45]
Dresler 2005 25/177 33/163 37.04% 0.65[0.37,1.15]
Yim 1996 19/28 15/29 15.29% 1.97[0.67,5.78]
Subtotal (95% CI) 370 355 100% 0.91[0.57,1.46]
Total events: 110 (Talc poudrage), 116 (Other)  
Heterogeneity: Tau2=0.07; Chi2=3.32, df=2(P=0.19); I2=39.83%  
Test for overall effect: Z=0.38(P=0.7)  
   
3.5.2 Talc poudrage vs bleomycin  
Diacon 2000 6/15 6/17 100% 1.22[0.29,5.13]
Subtotal (95% CI) 15 17 100% 1.22[0.29,5.13]
Total events: 6 (Talc poudrage), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.78)  
   
3.5.3 Talc poudrage vs tetracycline  
Fentiman 1986 6/18 2/23 100% 5.25[0.91,30.22]
Subtotal (95% CI) 18 23 100% 5.25[0.91,30.22]
Total events: 6 (Talc poudrage), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
   
3.5.4 Talc poudrage vs iodine  
Mohsen 2011 7/22 3/20 100% 2.64[0.58,12.09]
Subtotal (95% CI) 22 20 100% 2.64[0.58,12.09]
Total events: 7 (Talc poudrage), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
3.5.5 Talc poudrage vs mustine  
Fentiman 1983 3/23 6/23 100% 0.43[0.09,1.96]
Subtotal (95% CI) 23 23 100% 0.43[0.09,1.96]
Total events: 3 (Talc poudrage), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
Test for subgroup differences: Chi2=6.4, df=1 (P=0.17), I2=37.47%  
Favours talc poudrage 1000.01 100.1 1 Favours other
 
 
Analysis 3.6.   Comparison 3 Talc poudrage, Outcome 6 Repeat pleural intervention.
Study or subgroup Talc poudrage Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.6.1 Talc poudrage vs talc slurry  
Bhatnagar 2020 36/161 38/159 89.91% 0.92[0.55,1.54]
Terra 2009 5/30 4/30 10.09% 1.3[0.31,5.4]
Favours talc poudrage 1000.01 100.1 1 Favours talc slurry
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Study or subgroup Talc poudrage Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Subtotal (95% CI) 191 189 100% 0.96[0.59,1.56]
Total events: 41 (Talc poudrage), 42 (Talc slurry)  
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.18(P=0.86)  
   
Total (95% CI) 191 189 100% 0.96[0.59,1.56]
Total events: 41 (Talc poudrage), 42 (Talc slurry)  
Heterogeneity: Tau2=0; Chi2=0.2, df=1(P=0.65); I2=0%  
Test for overall effect: Z=0.18(P=0.86)  
Favours talc poudrage 1000.01 100.1 1 Favours talc slurry
 
 
Comparison 4.   Tetracycline





Statistical method Effect size
1 Pleurodesis failure rate 14   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Tetracycline vs C parvum 1 32 Odds Ratio (M-H, Random,
95% CI)
3.18 [0.52, 19.64]
1.2 Tetracycline vs talc slurry 1 32 Odds Ratio (M-H, Random,
95% CI)
0.78 [0.19, 3.13]
1.3 Tetracycline vs adriamycin 1 21 Odds Ratio (M-H, Random,
95% CI)
0.9 [0.05, 16.59]
1.4 Tetracyclines vs placebo 1 20 Odds Ratio (M-H, Random,
95% CI)
0.3 [0.05, 1.94]
1.5 Tetracycline vs talc poudrage 1 33 Odds Ratio (M-H, Random,
95% CI)
12.1 [1.32, 111.30]
1.6 Tetracycline vs mustine 2 59 Odds Ratio (M-H, Random,
95% CI)
0.37 [0.10, 1.35]
1.7 Tetracycline vs combined tetracycline and
bleomycin
1 38 Odds Ratio (M-H, Random,
95% CI)
8.27 [0.40, 172.05]
1.8 Tetracycline vs bleomycin 5 220 Odds Ratio (M-H, Random,
95% CI)
2.00 [1.07, 3.75]
1.9 Tetracycline vs mepacrine 1 21 Odds Ratio (M-H, Random,
95% CI)
1.6 [0.12, 20.99]
1.10 Tetracycline vs autologous blood 1 48 Odds Ratio (M-H, Random,
95% CI)
0.71 [0.14, 3.60]
1.11 Tetracycline vs silver nitrate 1 50 Odds Ratio (M-H, Random,
95% CI)
0.60 [0.15, 2.47]
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Statistical method Effect size
1.12 Tetracycline poudrage vs tetracycline slur-
ry
1 29 Odds Ratio (M-H, Random,
95% CI)
0.28 [0.04, 1.76]
2 Fever 11   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Tetracycline vs talc slurry 1 34 Odds Ratio (M-H, Random,
95% CI)
0.92 [0.23, 3.63]
2.2 Tetracycline vs bleomycin 5 250 Odds Ratio (M-H, Random,
95% CI)
0.49 [0.16, 1.50]
2.3 Tetracycline vs C parvum 1 36 Odds Ratio (M-H, Random,
95% CI)
0.00 [0.00, 0.06]
2.4 Tetracycline vs mepacrine 1 22 Odds Ratio (M-H, Random,
95% CI)
0.13 [0.02, 0.89]
2.5 Tetracycline vs combination tetracycline
and bleomycin
1 40 Odds Ratio (M-H, Random,
95% CI)
0.47 [0.04, 5.69]
2.6 Tetracycline vs placebo 1 22 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
2.7 Tetracycline vs mustine 1 40 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
2.8 Tetracycline vs autologous blood 1 48 Odds Ratio (M-H, Random,
95% CI)
4.53 [0.83, 24.65]
2.9 Tetracycline vs silver nitrate 1 50 Odds Ratio (M-H, Random,
95% CI)
327.86 [16.05, 6697.61]
3 Pain 10   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Tetracycline vs talc slurry 1 34 Odds Ratio (M-H, Random,
95% CI)
3.28 [0.73, 14.68]
3.2 Tetracycline vs bleomycin 4 220 Odds Ratio (M-H, Random,
95% CI)
1.65 [0.79, 3.43]
3.3 Tetracycline vs C parvum 1 41 Odds Ratio (M-H, Random,
95% CI)
0.41 [0.12, 1.45]
3.4 Tetracycline vs mustine 1 40 Odds Ratio (M-H, Random,
95% CI)
33.87 [1.80, 636.88]
3.5 Tetracycline vs mepacrine 1 22 Odds Ratio (M-H, Random,
95% CI)
0.18 [0.03, 1.23]
3.6 Tetracycline vs placebo 1 22 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
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Statistical method Effect size
3.7 Tetracycline vs autologous blood 1 48 Odds Ratio (M-H, Random,
95% CI)
69.00 [7.61, 625.86]
3.8 Tetracycline vs silver nitrate 1 50 Odds Ratio (M-H, Random,
95% CI)
55.08 [3.02, 1003.70]
4 Mortality 6 300 Odds Ratio (M-H, Random,
95% CI)
0.99 [0.30, 3.26]
4.1 Tetracycline vs talc poudrage 1 41 Odds Ratio (M-H, Random,
95% CI)
0.19 [0.03, 1.10]
4.2 Tetracycline vs bleomycin 2 125 Odds Ratio (M-H, Random,
95% CI)
1.60 [0.69, 3.69]
4.3 Tetracycline vs C parvum 1 36 Odds Ratio (M-H, Random,
95% CI)
3.00 [0.28, 31.99]
4.4 Tetracycline vs silver nitrate 1 50 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]





Analysis 4.1.   Comparison 4 Tetracycline, Outcome 1 Pleurodesis failure rate.
Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Tetracycline vs C parvum  
Leahy 1985 5/16 2/16 100% 3.18[0.52,19.64]
Subtotal (95% CI) 16 16 100% 3.18[0.52,19.64]
Total events: 5 (Tetracyclines), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
4.1.2 Tetracycline vs talc slurry  
Lynch 1996 7/15 9/17 100% 0.78[0.19,3.13]
Subtotal (95% CI) 15 17 100% 0.78[0.19,3.13]
Total events: 7 (Tetracyclines), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.72)  
   
4.1.3 Tetracycline vs adriamycin  
Kefford 1980 9/10 10/11 100% 0.9[0.05,16.59]
Subtotal (95% CI) 10 11 100% 0.9[0.05,16.59]
Total events: 9 (Tetracyclines), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.07(P=0.94)  
   
Favours tetracyclines 2000.005 100.1 1 Favours other
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Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.4 Tetracyclines vs placebo  
Zaloznik 1983 4/12 5/8 100% 0.3[0.05,1.94]
Subtotal (95% CI) 12 8 100% 0.3[0.05,1.94]
Total events: 4 (Tetracyclines), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
   
4.1.5 Tetracycline vs talc poudrage  
Fentiman 1986 11/21 1/12 100% 12.1[1.32,111.3]
Subtotal (95% CI) 21 12 100% 12.1[1.32,111.3]
Total events: 11 (Tetracyclines), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.2(P=0.03)  
   
4.1.6 Tetracycline vs mustine  
Kefford 1980 9/10 9/9 15.33% 0.33[0.01,9.26]
Loutsidis 1994 4/20 8/20 84.67% 0.38[0.09,1.54]
Subtotal (95% CI) 30 29 100% 0.37[0.1,1.35]
Total events: 13 (Tetracyclines), 17 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=1.5(P=0.13)  
   
4.1.7 Tetracycline vs combined tetracycline and bleomycin  
Emad 1996 3/19 0/19 100% 8.27[0.4,172.05]
Subtotal (95% CI) 19 19 100% 8.27[0.4,172.05]
Total events: 3 (Tetracyclines), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.17)  
   
4.1.8 Tetracycline vs bleomycin  
Emad 1996 3/19 2/19 10.7% 1.59[0.23,10.82]
Kessinger 1987 7/18 5/13 18.27% 1.02[0.24,4.41]
Lynch 1996 7/15 4/14 16.53% 2.19[0.47,10.21]
Martinez-Moragon 1997 4/24 2/25 12.11% 2.3[0.38,13.91]
Ruckdeschel 1991 19/36 11/37 42.4% 2.64[1.01,6.91]
Subtotal (95% CI) 112 108 100% 2[1.07,3.75]
Total events: 40 (Tetracyclines), 24 (Other)  
Heterogeneity: Tau2=0; Chi2=1.23, df=4(P=0.87); I2=0%  
Test for overall effect: Z=2.18(P=0.03)  
   
4.1.9 Tetracycline vs mepacrine  
Bayly 1978 2/12 1/9 100% 1.6[0.12,20.99]
Subtotal (95% CI) 12 9 100% 1.6[0.12,20.99]
Total events: 2 (Tetracyclines), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
4.1.10 Tetracycline vs autologous blood  
Keeratichananont 2015 3/24 4/24 100% 0.71[0.14,3.6]
Subtotal (95% CI) 24 24 100% 0.71[0.14,3.6]
Total events: 3 (Tetracyclines), 4 (Other)  
Heterogeneity: Not applicable  
Favours tetracyclines 2000.005 100.1 1 Favours other
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Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.41(P=0.68)  
   
4.1.11 Tetracycline vs silver nitrate  
Tabatabaei  2015 4/25 6/25 100% 0.6[0.15,2.47]
Subtotal (95% CI) 25 25 100% 0.6[0.15,2.47]
Total events: 4 (Tetracyclines), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
   
4.1.12 Tetracycline poudrage vs tetracycline slurry  
Evans 1993 2/15 5/14 100% 0.28[0.04,1.76]
Subtotal (95% CI) 15 14 100% 0.28[0.04,1.76]
Total events: 2 (Tetracyclines), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.17)  
Test for subgroup differences: Chi2=18.87, df=1 (P=0.06), I2=41.71%  
Favours tetracyclines 2000.005 100.1 1 Favours other
 
 
Analysis 4.2.   Comparison 4 Tetracycline, Outcome 2 Fever.
Study or subgroup Tetracycline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.2.1 Tetracycline vs talc slurry  
Lynch 1996 6/15 8/19 100% 0.92[0.23,3.63]
Subtotal (95% CI) 15 19 100% 0.92[0.23,3.63]
Total events: 6 (Tetracycline), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.12(P=0.9)  
   
4.2.2 Tetracycline vs bleomycin  
Emad 1996 1/20 1/20 12.08% 1[0.06,17.18]
Kessinger 1987 2/16 8/16 22.74% 0.14[0.02,0.84]
Lynch 1996 6/15 5/16 27.52% 1.47[0.33,6.43]
Martinez-Moragon 1997 0/31 6/31 11.57% 0.06[0,1.16]
Ruckdeschel 1991 3/41 4/44 26.09% 0.79[0.17,3.76]
Subtotal (95% CI) 123 127 100% 0.49[0.16,1.5]
Total events: 12 (Tetracycline), 24 (Other)  
Heterogeneity: Tau2=0.63; Chi2=6.6, df=4(P=0.16); I2=39.43%  
Test for overall effect: Z=1.25(P=0.21)  
   
4.2.3 Tetracycline vs C parvum  
Leahy 1985 1/19 16/17 100% 0[0,0.06]
Subtotal (95% CI) 19 17 100% 0[0,0.06]
Total events: 1 (Tetracycline), 16 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.89(P<0.0001)  
   
4.2.4 Tetracycline vs mepacrine  
Bayly 1978 4/12 8/10 100% 0.13[0.02,0.89]
Favours tetracycline 1000.01 100.1 1 Favours other
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Study or subgroup Tetracycline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 12 10 100% 0.13[0.02,0.89]
Total events: 4 (Tetracycline), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
   
4.2.5 Tetracycline vs combination tetracycline and bleomycin  
Emad 1996 1/20 2/20 100% 0.47[0.04,5.69]
Subtotal (95% CI) 20 20 100% 0.47[0.04,5.69]
Total events: 1 (Tetracycline), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
4.2.6 Tetracycline vs placebo  
Zaloznik 1983 0/13 0/9   Not estimable
Subtotal (95% CI) 13 9 Not estimable
Total events: 0 (Tetracycline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.2.7 Tetracycline vs mustine  
Loutsidis 1994 0/20 0/20   Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Tetracycline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.2.8 Tetracycline vs autologous blood  
Keeratichananont 2015 7/24 2/24 100% 4.53[0.83,24.65]
Subtotal (95% CI) 24 24 100% 4.53[0.83,24.65]
Total events: 7 (Tetracycline), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
4.2.9 Tetracycline vs silver nitrate  
Tabatabaei  2015 25/25 3/25 100% 327.86[16.05,6697.61]
Subtotal (95% CI) 25 25 100% 327.86[16.05,6697.61]
Total events: 25 (Tetracycline), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
Test for subgroup differences: Chi2=37.53, df=1 (P<0.0001), I2=84.01%  
Favours tetracycline 1000.01 100.1 1 Favours other
 
 
Analysis 4.3.   Comparison 4 Tetracycline, Outcome 3 Pain.
Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.3.1 Tetracycline vs talc slurry  
Lynch 1996 7/15 4/19 100% 3.28[0.73,14.68]
Subtotal (95% CI) 15 19 100% 3.28[0.73,14.68]
Favours tetracycline 1000.01 100.1 1 Favours other
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Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 7 (Tetracyclines), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.55(P=0.12)  
   
4.3.2 Tetracycline vs bleomycin  
Kessinger 1987 16/26 6/16 22.77% 2.67[0.74,9.63]
Lynch 1996 7/15 4/16 17.81% 2.63[0.57,12]
Martinez-Moragon 1997 16/31 10/31 30.23% 2.24[0.8,6.28]
Ruckdeschel 1991 7/41 11/44 29.18% 0.62[0.21,1.79]
Subtotal (95% CI) 113 107 100% 1.65[0.79,3.43]
Total events: 46 (Tetracyclines), 31 (Other)  
Heterogeneity: Tau2=0.19; Chi2=4.51, df=3(P=0.21); I2=33.53%  
Test for overall effect: Z=1.33(P=0.18)  
   
4.3.3 Tetracycline vs C parvum  
Leahy 1985 9/20 14/21 100% 0.41[0.12,1.45]
Subtotal (95% CI) 20 21 100% 0.41[0.12,1.45]
Total events: 9 (Tetracyclines), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.39(P=0.17)  
   
4.3.4 Tetracycline vs mustine  
Loutsidis 1994 9/20 0/20 100% 33.87[1.8,636.88]
Subtotal (95% CI) 20 20 100% 33.87[1.8,636.88]
Total events: 9 (Tetracyclines), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.35(P=0.02)  
   
4.3.5 Tetracycline vs mepacrine  
Bayly 1978 5/12 8/10 100% 0.18[0.03,1.23]
Subtotal (95% CI) 12 10 100% 0.18[0.03,1.23]
Total events: 5 (Tetracyclines), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
4.3.6 Tetracycline vs placebo  
Zaloznik 1983 0/13 0/9   Not estimable
Subtotal (95% CI) 13 9 Not estimable
Total events: 0 (Tetracyclines), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.3.7 Tetracycline vs autologous blood  
Keeratichananont 2015 18/24 1/24 100% 69[7.61,625.86]
Subtotal (95% CI) 24 24 100% 69[7.61,625.86]
Total events: 18 (Tetracyclines), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
   
4.3.8 Tetracycline vs silver nitrate  
Tabatabaei  2015 25/25 12/25 100% 55.08[3.02,1003.7]
Subtotal (95% CI) 25 25 100% 55.08[3.02,1003.7]
Favours tetracycline 1000.01 100.1 1 Favours other
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Study or subgroup Tetracyclines Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 25 (Tetracyclines), 12 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.71(P=0.01)  
Test for subgroup differences: Chi2=31.14, df=1 (P<0.0001), I2=80.73%  
Favours tetracycline 1000.01 100.1 1 Favours other
 
 
Analysis 4.4.   Comparison 4 Tetracycline, Outcome 4 Mortality.
Study or subgroup Tetracycline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.4.1 Tetracycline vs talc poudrage  
Fentiman 1986 2/23 6/18 25.51% 0.19[0.03,1.1]
Subtotal (95% CI) 23 18 25.51% 0.19[0.03,1.1]
Total events: 2 (Tetracycline), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.86(P=0.06)  
   
4.4.2 Tetracycline vs bleomycin  
Emad 1996 1/20 1/20 13.37% 1[0.06,17.18]
Ruckdeschel 1991 19/41 15/44 43.64% 1.67[0.7,4]
Subtotal (95% CI) 61 64 57.01% 1.6[0.69,3.69]
Total events: 20 (Tetracycline), 16 (Other)  
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=1.1(P=0.27)  
   
4.4.3 Tetracycline vs C parvum  
Leahy 1985 3/19 1/17 17.48% 3[0.28,31.99]
Subtotal (95% CI) 19 17 17.48% 3[0.28,31.99]
Total events: 3 (Tetracycline), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
   
4.4.4 Tetracycline vs silver nitrate  
Tabatabaei  2015 0/25 0/25   Not estimable
Subtotal (95% CI) 25 25 Not estimable
Total events: 0 (Tetracycline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.4.5 Tetracycline vs autologous blood  
Keeratichananont 2015 0/24 0/24   Not estimable
Subtotal (95% CI) 24 24 Not estimable
Total events: 0 (Tetracycline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 152 148 100% 0.99[0.3,3.26]
Total events: 25 (Tetracycline), 23 (Other)  
Heterogeneity: Tau2=0.64; Chi2=5.4, df=3(P=0.14); I2=44.46%  
Favours tetracycline 1000.01 100.1 1 Favours other
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Study or subgroup Tetracycline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.01(P=0.99)  
Test for subgroup differences: Chi2=5.27, df=1 (P=0.07), I2=62.05%  
Favours tetracycline 1000.01 100.1 1 Favours other
 
 
Comparison 5.   C parvum





Statistical method Effect size
1 Pleurodesis failure rate 5   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 C parvum vs bleomycin 2 78 Odds Ratio (M-H, Random, 95%
CI)
0.55 [0.01, 57.48]
1.2 C parvum vs tetracycline 1 32 Odds Ratio (M-H, Random, 95%
CI)
0.31 [0.05, 1.94]
1.3 C parvum vs doxycycline 1 35 Odds Ratio (M-H, Random, 95%
CI)
0.52 [0.12, 2.33]
1.4 C parvum vs mustine 1 18 Odds Ratio (M-H, Random, 95%
CI)
0.33 [0.04, 2.52]
2 Fever 5   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 C parvum vs bleomycin 2 80 Odds Ratio (M-H, Random, 95%
CI)
2.30 [0.90, 5.92]
2.2 C parvum vs tetracycline 1 36 Odds Ratio (M-H, Random, 95%
CI)
288.00 [16.62, 4991.05]
2.3 C parvum vs mustine 1 21 Odds Ratio (M-H, Random, 95%
CI)
4.41 [0.16, 121.68]
2.4 C parvum vs doxycycline 1 41 Odds Ratio (M-H, Random, 95%
CI)
7.37 [1.84, 29.55]
3 Pain 4 153 Odds Ratio (M-H, Random, 95%
CI)
2.51 [1.10, 5.75]
3.1 C parvum vs bleomycin 2 71 Odds Ratio (M-H, Random, 95%
CI)
1.42 [0.54, 3.75]
3.2 C parvum vs tetracycline 1 41 Odds Ratio (M-H, Random, 95%
CI)
2.44 [0.69, 8.66]
3.3 C parvum vs doxycycline 1 41 Odds Ratio (M-H, Random, 95%
CI)
7.37 [1.84, 29.55]
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Statistical method Effect size
4 Mortality 3   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
4.1 C parvum vs bleomycin 1 55 Odds Ratio (M-H, Random, 95%
CI)
1.66 [0.51, 5.38]
4.2 C parvum vs tetracycline 1 36 Odds Ratio (M-H, Random, 95%
CI)
0.33 [0.03, 3.55]





Analysis 5.1.   Comparison 5 C parvum, Outcome 1 Pleurodesis failure rate.
Study or subgroup C parvum Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.1.1 C parvum vs bleomycin  
Hillerdal 1986 6/20 17/19 49.39% 0.05[0.01,0.29]
Ostrowski 1989 13/17 8/22 50.61% 5.69[1.38,23.48]
Subtotal (95% CI) 37 41 100% 0.55[0.01,57.48]
Total events: 19 ( C parvum), 25 (Other)  
Heterogeneity: Tau2=10.59; Chi2=17.04, df=1(P<0.0001); I2=94.13%  
Test for overall effect: Z=0.25(P=0.8)  
   
5.1.2 C parvum vs tetracycline  
Leahy 1985 2/16 5/16 100% 0.31[0.05,1.94]
Subtotal (95% CI) 16 16 100% 0.31[0.05,1.94]
Total events: 2 ( C parvum), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
5.1.3 C parvum vs doxycycline  
Salomaa 1995 4/18 6/17 100% 0.52[0.12,2.33]
Subtotal (95% CI) 18 17 100% 0.52[0.12,2.33]
Total events: 4 ( C parvum), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.4)  
   
5.1.4 C parvum vs mustine  
Millar 1980 2/7 6/11 100% 0.33[0.04,2.52]
Subtotal (95% CI) 7 11 100% 0.33[0.04,2.52]
Total events: 2 ( C parvum), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.97), I2=0%  
Favours C parvum 1000.01 100.1 1 Favours other
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Analysis 5.2.   Comparison 5 C parvum, Outcome 2 Fever.
Study or subgroup C. parvum Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.2.1 C parvum vs bleomycin  
Hillerdal 1986 14/20 10/16 46.02% 1.4[0.35,5.63]
Ostrowski 1989 10/19 6/25 53.98% 3.52[0.97,12.73]
Subtotal (95% CI) 39 41 100% 2.3[0.9,5.92]
Total events: 24 ( C. parvum), 16 (Other)  
Heterogeneity: Tau2=0; Chi2=0.91, df=1(P=0.34); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
   
5.2.2 C parvum vs tetracycline  
Leahy 1985 16/17 1/19 100% 288[16.62,4991.05]
Subtotal (95% CI) 17 19 100% 288[16.62,4991.05]
Total events: 16 ( C. parvum), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.89(P<0.0001)  
   
5.2.3 C parvum vs mustine  
Millar 1980 1/9 0/12 100% 4.41[0.16,121.68]
Subtotal (95% CI) 9 12 100% 4.41[0.16,121.68]
Total events: 1 ( C. parvum), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
5.2.4 C parvum vs doxycycline  
Salomaa 1995 13/19 5/22 100% 7.37[1.84,29.55]
Subtotal (95% CI) 19 22 100% 7.37[1.84,29.55]
Total events: 13 ( C. parvum), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.82(P=0)  
Test for subgroup differences: Chi2=10.58, df=1 (P=0.01), I2=71.65%  
Favours C. parvum 1000.01 100.1 1 Favours other
 
 
Analysis 5.3.   Comparison 5 C parvum, Outcome 3 Pain.
Study or subgroup C. parvum Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.3.1 C parvum vs bleomycin  
Hillerdal 1986 8/16 3/11 18.92% 2.67[0.51,13.88]
Ostrowski 1989 10/19 13/25 29.45% 1.03[0.31,3.39]
Subtotal (95% CI) 35 36 48.37% 1.42[0.54,3.75]
Total events: 18 ( C. parvum), 16 (Other)  
Heterogeneity: Tau2=0; Chi2=0.85, df=1(P=0.36); I2=0%  
Test for overall effect: Z=0.72(P=0.47)  
   
5.3.2 C parvum vs tetracycline  
Leahy 1985 14/21 9/20 27.42% 2.44[0.69,8.66]
Subtotal (95% CI) 21 20 27.42% 2.44[0.69,8.66]
Total events: 14 ( C. parvum), 9 (Other)  
Heterogeneity: Not applicable  
Favours C. parvum 1000.01 100.1 1 Favours other
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Study or subgroup C. parvum Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.39(P=0.17)  
   
5.3.3 C parvum vs doxycycline  
Salomaa 1995 13/19 5/22 24.21% 7.37[1.84,29.55]
Subtotal (95% CI) 19 22 24.21% 7.37[1.84,29.55]
Total events: 13 ( C. parvum), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.82(P=0)  
   
Total (95% CI) 75 78 100% 2.51[1.1,5.75]
Total events: 45 ( C. parvum), 30 (Other)  
Heterogeneity: Tau2=0.23; Chi2=4.46, df=3(P=0.22); I2=32.8%  
Test for overall effect: Z=2.18(P=0.03)  
Test for subgroup differences: Chi2=3.62, df=1 (P=0.16), I2=44.73%  
Favours C. parvum 1000.01 100.1 1 Favours other
 
 
Analysis 5.4.   Comparison 5 C parvum, Outcome 4 Mortality.
Study or subgroup C. parvum Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
5.4.1 C parvum vs bleomycin  
Ostrowski 1989 9/26 7/29 100% 1.66[0.51,5.38]
Subtotal (95% CI) 26 29 100% 1.66[0.51,5.38]
Total events: 9 ( C. parvum), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
   
5.4.2 C parvum vs tetracycline  
Leahy 1985 1/17 3/19 100% 0.33[0.03,3.55]
Subtotal (95% CI) 17 19 100% 0.33[0.03,3.55]
Total events: 1 ( C. parvum), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
   
5.4.3 C parvum vs mustine  
Millar 1980 5/9 9/12 100% 0.42[0.07,2.66]
Subtotal (95% CI) 9 12 100% 0.42[0.07,2.66]
Total events: 5 ( C. parvum), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Test for subgroup differences: Chi2=2.39, df=1 (P=0.3), I2=16.22%  
Favours C. parvum 1000.01 100.1 1 Favours other
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Comparison 6.   Indwelling pleural catheter (IPC) – not daily drainage





Statistical method Effect size
1 Pleurodesis failure rate 6   Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 IPC – not daily drainage vs
talc slurry
2 249 Odds Ratio (M-H, Random, 95% CI) 5.46 [2.20, 13.55]
1.2 IPC – not daily drainage vs
talc via IPC
1 139 Odds Ratio (M-H, Random, 95% CI) 2.76 [1.36, 5.60]
1.3 IPC – not daily drainage vs
IPC – daily drainage
2 236 Odds Ratio (M-H, Random, 95% CI) 3.23 [1.79, 5.85]
1.4 IPC – not daily drainage vs
doxycycline
1 119 Odds Ratio (M-H, Random, 95% CI) 4.28 [1.59, 11.54]
2 Fever 1 119 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.07, 2.80]
3 Pain 6   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 IPC – not daily drainage vs
talc slurry
2 232 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.51, 5.15]
3.2 IPC – not daily drainage vs
talc via IPC
1 154 Odds Ratio (M-H, Random, 95% CI) 1.41 [0.47, 4.28]
3.3 IPC – not daily drainage vs
IPC – daily drainage
2 236 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.78, 2.37]
3.4 IPC – not daily drainage vs
doxycycline
1 119 Odds Ratio (M-H, Random, 95% CI) 0.06 [0.00, 1.24]
4 Breathlessness 2 160 Mean Difference (IV, Fixed, 95% CI) -6.12 [-16.32, 4.08]
4.1 IPC – not daily drainage vs
talc slurry
2 160 Mean Difference (IV, Fixed, 95% CI) -6.12 [-16.32, 4.08]
5 Mortality 6 734 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.66, 1.49]
5.1 IPC – not daily drainage vs
talc slurry
3 344 Odds Ratio (M-H, Random, 95% CI) 0.70 [0.45, 1.09]
5.2 IPC – not daily drainage vs
talc via IPC
1 154 Odds Ratio (M-H, Random, 95% CI) 2.29 [0.87, 6.04]
5.3 IPC – not daily drainage vs
IPC – daily drainage
2 236 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.72, 2.32]
6 Repeat pleural procedure 3 343 Odds Ratio (M-H, Fixed, 95% CI) 0.25 [0.13, 0.48]
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Analysis 6.1.   Comparison 6 Indwelling pleural catheter (IPC)
– not daily drainage, Outcome 1 Pleurodesis failure rate.
Study or subgroup IPC – not dai-
ly drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.1.1 IPC – not daily drainage vs talc slurry  
Davies 2012 25/51 12/54 47.79% 3.37[1.45,7.83]
Thomas 2017 52/73 16/71 52.21% 8.51[4.01,18.07]
Subtotal (95% CI) 124 125 100% 5.46[2.2,13.55]
Total events: 77 (IPC – not daily drainage), 28 (Other)  
Heterogeneity: Tau2=0.26; Chi2=2.58, df=1(P=0.11); I2=61.31%  
Test for overall effect: Z=3.66(P=0)  
   
6.1.2 IPC – not daily drainage vs talc via IPC  
Bhatnagar 2018 51/70 34/69 100% 2.76[1.36,5.6]
Subtotal (95% CI) 70 69 100% 2.76[1.36,5.6]
Total events: 51 (IPC – not daily drainage), 34 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.82(P=0)  
   
6.1.3 IPC – not daily drainage vs IPC – daily drainage  
Muruganandan 2018 39/44 27/43 28.22% 4.62[1.51,14.13]
Wahidi 2017 58/76 39/73 71.78% 2.81[1.39,5.66]
Subtotal (95% CI) 120 116 100% 3.23[1.79,5.85]
Total events: 97 (IPC – not daily drainage), 66 (Other)  
Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%  
Test for overall effect: Z=3.87(P=0)  
   
6.1.4 IPC – not daily drainage vs doxycycline  
Putnam 1999 49/91 6/28 100% 4.28[1.59,11.54]
Subtotal (95% CI) 91 28 100% 4.28[1.59,11.54]
Total events: 49 (IPC – not daily drainage), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.87(P=0)  
Test for subgroup differences: Chi2=1.58, df=1 (P=0.66), I2=0%  
Favours IPC -– not daily drainage 1000.01 100.1 1 Favours other
 
 
Analysis 6.2.   Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 2 Fever.
Study or subgroup IPC – not dai-
ly drainage
Doxycycline Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Putnam 1999 3/91 2/28 100% 0.44[0.07,2.8]
   
Total (95% CI) 91 28 100% 0.44[0.07,2.8]
Total events: 3 (IPC – not daily drainage), 2 (Doxycycline)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.39)  
Favours IPC – not daily drainage 1000.01 100.1 1 Favours doxycycline
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Analysis 6.3.   Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 3 Pain.
Study or subgroup IPC – not dai-
ly drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.3.1 IPC – not daily drainage vs talc slurry  
Boshuizen 2017 2/43 1/45 22.4% 2.15[0.19,24.57]
Thomas 2017 6/73 4/71 77.6% 1.5[0.4,5.56]
Subtotal (95% CI) 116 116 100% 1.63[0.51,5.15]
Total events: 8 (IPC – not daily drainage), 5 (Other)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
   
6.3.2 IPC – not daily drainage vs talc via IPC  
Bhatnagar 2018 8/76 6/78 100% 1.41[0.47,4.28]
Subtotal (95% CI) 76 78 100% 1.41[0.47,4.28]
Total events: 8 (IPC – not daily drainage), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
   
6.3.3 IPC – not daily drainage vs IPC – daily drainage  
Muruganandan 2018 13/44 8/43 30.74% 1.83[0.67,5.01]
Wahidi 2017 29/76 25/73 69.26% 1.18[0.61,2.31]
Subtotal (95% CI) 120 116 100% 1.36[0.78,2.37]
Total events: 42 (IPC – not daily drainage), 33 (Other)  
Heterogeneity: Tau2=0; Chi2=0.5, df=1(P=0.48); I2=0%  
Test for overall effect: Z=1.07(P=0.28)  
   
6.3.4 IPC – not daily drainage vs doxycycline  
Putnam 1999 0/91 2/28 100% 0.06[0,1.24]
Subtotal (95% CI) 91 28 100% 0.06[0,1.24]
Total events: 0 (IPC – not daily drainage), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Test for subgroup differences: Chi2=4.14, df=1 (P=0.25), I2=27.5%  
Favours IPC – not daily drainage 1000.01 100.1 1 Favours other
 
 
Analysis 6.4.   Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 4 Breathlessness.
Study or subgroup IPC – not dai-
ly drainage
Talc slurry Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
6.4.1 IPC – not daily drainage vs talc slurry  
Davies 2012 49 -37 (27.2) 47 -30.2 (27.9) 85.51% -6.8[-17.83,4.23]
Thomas 2017 37 -21.1 (57.1) 27 -19 (51.7) 14.49% -2.1[-28.89,24.69]
Subtotal *** 86   74   100% -6.12[-16.32,4.08]
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.18(P=0.24)  
   
Total *** 86   74   100% -6.12[-16.32,4.08]
Heterogeneity: Tau2=0; Chi2=0.1, df=1(P=0.75); I2=0%  
Test for overall effect: Z=1.18(P=0.24)  
Favours IPC – not daily drainage 10050-100 -50 0 Favours talc slurry
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Analysis 6.5.   Comparison 6 Indwelling pleural catheter (IPC) – not daily drainage, Outcome 5 Mortality.
Study or subgroup IPC – not dai-
ly drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.5.1 IPC – not daily drainage vs talc slurry  
Boshuizen 2017 16/46 19/48 16.33% 0.81[0.35,1.88]
Davies 2012 16/52 20/54 17.19% 0.76[0.34,1.69]
Thomas 2017 44/73 51/71 20.72% 0.59[0.3,1.2]
Subtotal (95% CI) 171 173 54.24% 0.7[0.45,1.09]
Total events: 76 (IPC – not daily drainage), 90 (Other)  
Heterogeneity: Tau2=0; Chi2=0.37, df=2(P=0.83); I2=0%  
Test for overall effect: Z=1.57(P=0.12)  
   
6.5.2 IPC – not daily drainage vs talc via IPC  
Bhatnagar 2018 14/76 7/78 13.26% 2.29[0.87,6.04]
Subtotal (95% CI) 76 78 13.26% 2.29[0.87,6.04]
Total events: 14 (IPC – not daily drainage), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
   
6.5.3 IPC – not daily drainage vs IPC – daily drainage  
Muruganandan 2018 9/44 10/43 12.3% 0.85[0.31,2.35]
Wahidi 2017 26/76 18/73 20.2% 1.59[0.78,3.24]
Subtotal (95% CI) 120 116 32.5% 1.29[0.72,2.32]
Total events: 35 (IPC – not daily drainage), 28 (Other)  
Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%  
Test for overall effect: Z=0.86(P=0.39)  
   
Total (95% CI) 367 367 100% 0.99[0.66,1.49]
Total events: 125 (IPC – not daily drainage), 125 (Other)  
Heterogeneity: Tau2=0.08; Chi2=7.34, df=5(P=0.2); I2=31.9%  
Test for overall effect: Z=0.03(P=0.98)  
Test for subgroup differences: Chi2=6, df=1 (P=0.05), I2=66.64%  
Favours IPC – not daily drainage 1000.01 100.1 1 Favours other
 
 
Analysis 6.6.   Comparison 6 Indwelling pleural catheter (IPC)
– not daily drainage, Outcome 6 Repeat pleural procedure.
Study or subgroup IPC – not dai-
ly drainage
Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Boshuizen 2017 7/46 15/48 31.94% 0.39[0.14,1.08]
Davies 2012 3/51 12/54 28.15% 0.22[0.06,0.83]
Thomas 2017 3/73 16/71 39.91% 0.15[0.04,0.53]
   
Total (95% CI) 170 173 100% 0.25[0.13,0.48]
Total events: 13 (IPC – not daily drainage), 43 (Talc slurry)  
Heterogeneity: Tau2=0; Chi2=1.49, df=2(P=0.48); I2=0%  
Test for overall effect: Z=4.09(P<0.0001)  
Favours IPC – not daily drainage 1000.01 100.1 1 Favours talc slurry
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Comparison 7.   Iodine





Statistical method Effect size
1 Pleurodesis failure rate 5   Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 1.76 [0.26, 11.83]
1.2 Iodine vs talc slurry 2 75 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.32, 4.25]
1.3 Iodine vs bleomycin 2 99 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.22, 1.96]
2 Fever 4   Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Iodine vs talc slurry 2 75 Odds Ratio (M-H, Random, 95% CI) 0.93 [0.28, 3.13]
2.2 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.24 [0.02, 2.33]
2.3 Iodine vs bleomycin 1 60 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.60]
3 Pain 4   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Iodine vs talc slurry 2 75 Odds Ratio (M-H, Random, 95% CI) 0.5 [0.14, 1.83]
3.2 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.10 [0.01, 1.99]
3.3 Iodine vs bleomycin 1 60 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.13, 7.60]
4 Mortality 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Iodine vs talc poudrage 1 42 Odds Ratio (M-H, Random, 95% CI) 0.38 [0.08, 1.73]
4.2 Iodine vs talc slurry 1 39 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.01, 9.64]
 
 
Analysis 7.1.   Comparison 7 Iodine, Outcome 1 Pleurodesis failure rate.
Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.1.1 Iodine vs talc poudrage  
Mohsen 2011 3/20 2/22 100% 1.76[0.26,11.83]
Subtotal (95% CI) 20 22 100% 1.76[0.26,11.83]
Total events: 3 (Iodine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
7.1.2 Iodine vs talc slurry  
Agarwal 2011 1/18 2/18 26.54% 0.47[0.04,5.71]
Ibrahim 2015 5/18 4/21 73.46% 1.63[0.36,7.33]
Subtotal (95% CI) 36 39 100% 1.17[0.32,4.25]
Favours iodine 1000.01 100.1 1 Favours other
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Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 6 (Iodine), 6 (Other)  
Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%  
Test for overall effect: Z=0.25(P=0.81)  
   
7.1.3 Iodine vs bleomycin  
Alavi 2011 5/20 4/19 42.55% 1.25[0.28,5.59]
Bagheri 2018 5/30 10/30 57.45% 0.4[0.12,1.36]
Subtotal (95% CI) 50 49 100% 0.65[0.22,1.96]
Total events: 10 (Iodine), 14 (Other)  
Heterogeneity: Tau2=0.16; Chi2=1.33, df=1(P=0.25); I2=25.03%  
Test for overall effect: Z=0.77(P=0.44)  
Test for subgroup differences: Chi2=0.97, df=1 (P=0.62), I2=0%  
Favours iodine 1000.01 100.1 1 Favours other
 
 
Analysis 7.2.   Comparison 7 Iodine, Outcome 2 Fever.
Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.2.1 Iodine vs talc slurry  
Agarwal 2011 2/18 3/18 39.57% 0.63[0.09,4.28]
Ibrahim 2015 4/18 4/21 60.43% 1.21[0.26,5.76]
Subtotal (95% CI) 36 39 100% 0.93[0.28,3.13]
Total events: 6 (Iodine), 7 (Other)  
Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.6); I2=0%  
Test for overall effect: Z=0.11(P=0.91)  
   
7.2.2 Iodine vs talc poudrage  
Mohsen 2011 1/20 4/22 100% 0.24[0.02,2.33]
Subtotal (95% CI) 20 22 100% 0.24[0.02,2.33]
Total events: 1 (Iodine), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.24(P=0.22)  
   
7.2.3 Iodine vs bleomycin  
Bagheri 2018 2/30 2/30 100% 1[0.13,7.6]
Subtotal (95% CI) 30 30 100% 1[0.13,7.6]
Total events: 2 (Iodine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=1.18, df=1 (P=0.55), I2=0%  
Favours iodine 1000.01 100.1 1 Favours other
 
 
Analysis 7.3.   Comparison 7 Iodine, Outcome 3 Pain.
Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.3.1 Iodine vs talc slurry  
Favours iodine 1000.01 100.1 1 Favours other
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Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Agarwal 2011 18/18 18/18   Not estimable
Ibrahim 2015 9/18 14/21 100% 0.5[0.14,1.83]
Subtotal (95% CI) 36 39 100% 0.5[0.14,1.83]
Total events: 27 (Iodine), 32 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
   
7.3.2 Iodine vs talc poudrage  
Mohsen 2011 0/20 4/22 100% 0.1[0.01,1.99]
Subtotal (95% CI) 20 22 100% 0.1[0.01,1.99]
Total events: 0 (Iodine), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
   
7.3.3 Iodine vs bleomycin  
Bagheri 2018 2/30 2/30 100% 1[0.13,7.6]
Subtotal (95% CI) 30 30 100% 1[0.13,7.6]
Total events: 2 (Iodine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Chi2=1.56, df=1 (P=0.46), I2=0%  
Favours iodine 1000.01 100.1 1 Favours other
 
 
Analysis 7.4.   Comparison 7 Iodine, Outcome 4 Mortality.
Study or subgroup Iodine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
7.4.1 Iodine vs talc poudrage  
Mohsen 2011 3/20 7/22 100% 0.38[0.08,1.73]
Subtotal (95% CI) 20 22 100% 0.38[0.08,1.73]
Total events: 3 (Iodine), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
7.4.2 Iodine vs talc slurry  
Ibrahim 2015 0/18 1/21 100% 0.37[0.01,9.64]
Subtotal (95% CI) 18 21 100% 0.37[0.01,9.64]
Total events: 0 (Iodine), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
Test for subgroup differences: Chi2=0, df=1 (P=0.99), I2=0%  
Favours iodine 1000.01 100.1 1 Favours other
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Comparison 8.   Doxycycline





Statistical method Effect size
1 Pleurodesis failure rate 5   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Doxycycline vs talc poudrage 1 31 Odds Ratio (M-H, Random,
95% CI)
42.69 [2.13, 856.61]
1.2 Doxycycline vs bleomycin 2 122 Odds Ratio (M-H, Random,
95% CI)
0.67 [0.24, 1.86]
1.3 Doxycycline vs C parvum 1 35 Odds Ratio (M-H, Random,
95% CI)
1.91 [0.43, 8.48]
1.4 Doxycycline vs IPC – not daily drainage 1 119 Odds Ratio (M-H, Random,
95% CI)
0.23 [0.09, 0.63]
2 Fever 4 308 Odds Ratio (M-H, Random,
95% CI)
0.48 [0.09, 2.59]
2.1 Doxycycline vs bleomycin 2 148 Odds Ratio (M-H, Random,
95% CI)
0.37 [0.01, 12.35]
2.2 Doxycycline vs C parvum 1 41 Odds Ratio (M-H, Random,
95% CI)
0.14 [0.03, 0.54]
2.3 Doxycycline vs IPC – not daily drainage 1 119 Odds Ratio (M-H, Random,
95% CI)
2.26 [0.36, 14.23]
3 Pain 4   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Doxycycline vs bleomycin 2 148 Odds Ratio (M-H, Random,
95% CI)
1.19 [0.37, 3.80]
3.2 Doxycycline vs C parvum 1 41 Odds Ratio (M-H, Random,
95% CI)
0.10 [0.01, 0.96]
3.3 Doxycycline vs IPC – not daily drainage 1 119 Odds Ratio (M-H, Random,
95% CI)
17.26 [0.80, 370.79]
4 Mortality 1   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
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Analysis 8.1.   Comparison 8 Doxycycline, Outcome 1 Pleurodesis failure rate.
Study or subgroup Doxycyline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.1.1 Doxycycline vs talc poudrage  
Kuzdzal 2003 7/13 0/18 100% 42.69[2.13,856.61]
Subtotal (95% CI) 13 18 100% 42.69[2.13,856.61]
Total events: 7 (Doxycyline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
   
8.1.2 Doxycycline vs bleomycin  
Patz 1998 7/38 10/42 90.02% 0.72[0.24,2.14]
Rafiei 2014 0/21 1/21 9.98% 0.32[0.01,8.26]
Subtotal (95% CI) 59 63 100% 0.67[0.24,1.86]
Total events: 7 (Doxycyline), 11 (Other)  
Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
8.1.3 Doxycycline vs C parvum  
Salomaa 1995 6/17 4/18 100% 1.91[0.43,8.48]
Subtotal (95% CI) 17 18 100% 1.91[0.43,8.48]
Total events: 6 (Doxycyline), 4 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.85(P=0.4)  
   
8.1.4 Doxycycline vs IPC – not daily drainage  
Putnam 1999 6/28 49/91 100% 0.23[0.09,0.63]
Subtotal (95% CI) 28 91 100% 0.23[0.09,0.63]
Total events: 6 (Doxycyline), 49 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.87(P=0)  
Test for subgroup differences: Chi2=13.56, df=1 (P=0), I2=77.88%  
Favours doxycycline 1000.01 100.1 1 Favours other
 
 
Analysis 8.2.   Comparison 8 Doxycycline, Outcome 2 Fever.
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.2.1 Doxycycline vs bleomycin  
Patz 1998 0/54 7/52 17.41% 0.06[0,1]
Rafiei 2014 7/21 5/21 28.95% 1.6[0.41,6.19]
Subtotal (95% CI) 75 73 46.36% 0.37[0.01,12.35]
Total events: 7 (Doxycyline), 12 (Others)  
Heterogeneity: Tau2=5.18; Chi2=4.91, df=1(P=0.03); I2=79.62%  
Test for overall effect: Z=0.55(P=0.58)  
   
8.2.2 Doxycycline vs C parvum  
Salomaa 1995 5/22 13/19 28.66% 0.14[0.03,0.54]
Subtotal (95% CI) 22 19 28.66% 0.14[0.03,0.54]
Total events: 5 (Doxycyline), 13 (Others)  
Heterogeneity: Not applicable  
Favours doxycycline 1000.01 100.1 1 Favours other
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Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.82(P=0)  
   
8.2.3 Doxycycline vs IPC – not daily drainage  
Putnam 1999 2/28 3/91 24.98% 2.26[0.36,14.23]
Subtotal (95% CI) 28 91 24.98% 2.26[0.36,14.23]
Total events: 2 (Doxycyline), 3 (Others)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.39)  
   
Total (95% CI) 125 183 100% 0.48[0.09,2.59]
Total events: 14 (Doxycyline), 28 (Others)  
Heterogeneity: Tau2=2.09; Chi2=11.23, df=3(P=0.01); I2=73.28%  
Test for overall effect: Z=0.85(P=0.39)  
Test for subgroup differences: Chi2=5.7, df=1 (P=0.06), I2=64.92%  
Favours doxycycline 1000.01 100.1 1 Favours other
 
 
Analysis 8.3.   Comparison 8 Doxycycline, Outcome 3 Pain.
Study or subgroup Doxycyline Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.3.1 Doxycycline vs bleomycin  
Patz 1998 11/54 6/52 58.26% 1.96[0.67,5.76]
Rafiei 2014 15/21 17/21 41.74% 0.59[0.14,2.49]
Subtotal (95% CI) 75 73 100% 1.19[0.37,3.8]
Total events: 26 (Doxycyline), 23 (Other)  
Heterogeneity: Tau2=0.3; Chi2=1.72, df=1(P=0.19); I2=41.75%  
Test for overall effect: Z=0.29(P=0.77)  
   
8.3.2 Doxycycline vs C parvum  
Salomaa 1995 1/22 6/19 100% 0.1[0.01,0.96]
Subtotal (95% CI) 22 19 100% 0.1[0.01,0.96]
Total events: 1 (Doxycyline), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2(P=0.05)  
   
8.3.3 Doxycycline vs IPC – not daily drainage  
Putnam 1999 2/28 0/91 100% 17.26[0.8,370.79]
Subtotal (95% CI) 28 91 100% 17.26[0.8,370.79]
Total events: 2 (Doxycyline), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Test for subgroup differences: Chi2=7.39, df=1 (P=0.02), I2=72.93%  
Favours doxycyline 1000.01 100.1 1 Favours other
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Analysis 8.4.   Comparison 8 Doxycycline, Outcome 4 Mortality.
Study or subgroup Doxycyline Others Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.4.1 Doxycycline vs bleomycin  
Patz 1998 9/38 13/42 100% 0.69[0.26,1.87]
Subtotal (95% CI) 38 42 100% 0.69[0.26,1.87]
Total events: 9 (Doxycyline), 13 (Others)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
Favours doxycycline 1000.01 100.1 1 Favours other
 
 
Comparison 9.   Duration of drainage aRer pleurodesis administration





Statistical method Effect size
1 Pleurodesis failure rate 3   Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Mortality 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 9.1.   Comparison 9 Duration of drainage aRer
pleurodesis administration, Outcome 1 Pleurodesis failure rate.
Study or subgroup Rapid Standard Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Goodman 2006 2/16 4/19 0% 0.54[0.08,3.4]
Villanueva 1994 2/9 3/15 0% 1.14[0.15,8.59]
Yildirim 2005 0/12 2/8 0% 0.1[0,2.5]
Favours rapid pleurodesis 1000.01 100.1 1 Favours standard
 
 
Analysis 9.2.   Comparison 9 Duration of drainage aRer pleurodesis administration, Outcome 2 Mortality.
Study or subgroup Rapid Standard Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Goodman 2006 3/19 3/22 0% 1.19[0.21,6.72]
Villanueva 1994 9/9 13/15 0% 3.52[0.15,81.92]
Yildirim 2005 3/15 4/12 0% 0.5[0.09,2.86]
Favours rapid pleurodesis 1000.01 100.1 1 Favours standard
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Comparison 10.   OK-432





Statistical method Effect size
1 Pleurodesis failure rate 4   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 OK-432 and mitomycin C 1 53 Odds Ratio (M-H, Random,
95% CI)
0.26 [0.06, 1.11]
1.2 OK-432 vs cisplatin and etoposide 1 67 Odds Ratio (M-H, Random,
95% CI)
0.77 [0.26, 2.27]
1.3 OK-432 and cisplatin 1 34 Odds Ratio (M-H, Random,
95% CI)
0.48 [0.12, 1.92]
1.4 High dose vs low dose 1 38 Odds Ratio (M-H, Random,
95% CI)
1.90 [0.38, 9.44]
1.5 OK-432 vs bleomycin 1 68 Odds Ratio (M-H, Random,
95% CI)
0.70 [0.24, 2.03]
1.6 OK-432 vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random,
95% CI)
12.44 [1.32, 117.03]
2 Fever 3   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random,
95% CI)
256.00 [14.70, 4457.27]
2.2 OK-432 vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random,
95% CI)
14.00 [1.46, 134.25]
2.3 OK-432 vs mitomycin C 1 53 Odds Ratio (M-H, Random,
95% CI)
26.67 [5.91, 120.42]
2.4 OK-432 vs bleomycin 1 67 Odds Ratio (M-H, Random,
95% CI)
1.43 [0.47, 4.35]
2.5 OK-432 vs cisplatin and etoposide 1 66 Odds Ratio (M-H, Random,
95% CI)
3.17 [1.08, 9.30]
3 Pain 3   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random,
95% CI)
6.67 [1.15, 38.60]
3.2 OK-432 vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random,
95% CI)
1.33 [0.33, 5.43]
3.3 OK-432 vs mitomycin C 1 53 Odds Ratio (M-H, Random,
95% CI)
1.04 [0.14, 8.00]
3.4 OK-432 vs bleomycin 1 67 Odds Ratio (M-H, Random,
95% CI)
2.53 [0.89, 7.15]
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Statistical method Effect size
3.5 OK-432 vs cisplatin and etoposide 1 66 Odds Ratio (M-H, Random,
95% CI)
2.1 [0.73, 6.01]
4 Mortality 2   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 OK-432 vs cisplatin 1 34 Odds Ratio (M-H, Random,
95% CI)
1.31 [0.31, 5.53]
4.2 OK-432 vs combined OK-432 and cis-
platin
1 32 Odds Ratio (M-H, Random,
95% CI)
2.18 [0.44, 10.91]
4.3 OK-432 vs bleomycin 1 68 Odds Ratio (M-H, Random,
95% CI)
0.38 [0.14, 1.03]





Analysis 10.1.   Comparison 10 OK-432, Outcome 1 Pleurodesis failure rate.
Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.1.1 OK-432 and mitomycin C  
Luh 1992 3/26 9/27 100% 0.26[0.06,1.11]
Subtotal (95% CI) 26 27 100% 0.26[0.06,1.11]
Total events: 3 (OK-432), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
   
10.1.2 OK-432 vs cisplatin and etoposide  
Yoshida 2007 8/33 10/34 100% 0.77[0.26,2.27]
Subtotal (95% CI) 33 34 100% 0.77[0.26,2.27]
Total events: 8 (OK-432), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
10.1.3 OK-432 and cisplatin  
Ishida 2006 8/17 11/17 100% 0.48[0.12,1.92]
Subtotal (95% CI) 17 17 100% 0.48[0.12,1.92]
Total events: 8 (OK-432), 11 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.03(P=0.3)  
   
10.1.4 High dose vs low dose  
Kasahara 2006 5/19 3/19 100% 1.9[0.38,9.44]
Subtotal (95% CI) 19 19 100% 1.9[0.38,9.44]
Total events: 5 (OK-432), 3 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Favours OK-432 1000.01 100.1 1 Favours other
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Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.79(P=0.43)  
   
10.1.5 OK-432 vs bleomycin  
Yoshida 2007 8/33 11/35 100% 0.7[0.24,2.03]
Subtotal (95% CI) 33 35 100% 0.7[0.24,2.03]
Total events: 8 (OK-432), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
10.1.6 OK-432 vs OK-432 and cisplatin  
Ishida 2006 8/17 1/15 100% 12.44[1.32,117.03]
Subtotal (95% CI) 17 15 100% 12.44[1.32,117.03]
Total events: 8 (OK-432), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.2(P=0.03)  
Test for subgroup differences: Chi2=9.77, df=1 (P=0.08), I2=48.82%  
Favours OK-432 1000.01 100.1 1 Favours other
 
 
Analysis 10.2.   Comparison 10 OK-432, Outcome 2 Fever.
Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.2.1 OK-432 vs cisplatin  
Ishida 2006 16/17 1/17 100% 256[14.7,4457.27]
Subtotal (95% CI) 17 17 100% 256[14.7,4457.27]
Total events: 16 (OK-432), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.8(P=0)  
   
10.2.2 OK-432 vs OK-432 and cisplatin  
Ishida 2006 16/17 8/15 100% 14[1.46,134.25]
Subtotal (95% CI) 17 15 100% 14[1.46,134.25]
Total events: 16 (OK-432), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.29(P=0.02)  
   
10.2.3 OK-432 vs mitomycin C  
Luh 1992 20/26 3/27 100% 26.67[5.91,120.42]
Subtotal (95% CI) 26 27 100% 26.67[5.91,120.42]
Total events: 20 (OK-432), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.27(P<0.0001)  
   
10.2.4 OK-432 vs bleomycin  
Yoshida 2007 25/32 25/35 100% 1.43[0.47,4.35]
Subtotal (95% CI) 32 35 100% 1.43[0.47,4.35]
Total events: 25 (OK-432), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours OK-432 1000.01 100.1 1 Favours other
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Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
10.2.5 OK-432 vs cisplatin and etoposide  
Yoshida 2007 25/32 18/34 100% 3.17[1.08,9.3]
Subtotal (95% CI) 32 34 100% 3.17[1.08,9.3]
Total events: 25 (OK-432), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.11(P=0.04)  
Test for subgroup differences: Chi2=18.37, df=1 (P=0), I2=78.22%  
Favours OK-432 1000.01 100.1 1 Favours other
 
 
Analysis 10.3.   Comparison 10 OK-432, Outcome 3 Pain.
Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.3.1 OK-432 vs cisplatin  
Ishida 2006 8/17 2/17 100% 6.67[1.15,38.6]
Subtotal (95% CI) 17 17 100% 6.67[1.15,38.6]
Total events: 8 (OK-432), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.12(P=0.03)  
   
10.3.2 OK-432 vs OK-432 and cisplatin  
Ishida 2006 8/17 6/15 100% 1.33[0.33,5.43]
Subtotal (95% CI) 17 15 100% 1.33[0.33,5.43]
Total events: 8 (OK-432), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
   
10.3.3 OK-432 vs mitomycin C  
Luh 1992 2/26 2/27 100% 1.04[0.14,8]
Subtotal (95% CI) 26 27 100% 1.04[0.14,8]
Total events: 2 (OK-432), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
10.3.4 OK-432 vs bleomycin  
Yoshida 2007 24/32 19/35 100% 2.53[0.89,7.15]
Subtotal (95% CI) 32 35 100% 2.53[0.89,7.15]
Total events: 24 (OK-432), 19 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
   
10.3.5 OK-432 vs cisplatin and etoposide  
Yoshida 2007 24/32 20/34 100% 2.1[0.73,6.01]
Subtotal (95% CI) 32 34 100% 2.1[0.73,6.01]
Total events: 24 (OK-432), 20 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.38(P=0.17)  
Test for subgroup differences: Chi2=2.61, df=1 (P=0.62), I2=0%  
Favours OK-432 1000.01 100.1 1 Favours other
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Analysis 10.4.   Comparison 10 OK-432, Outcome 4 Mortality.
Study or subgroup OK-432 Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.4.1 OK-432 vs cisplatin  
Ishida 2006 6/17 5/17 100% 1.31[0.31,5.53]
Subtotal (95% CI) 17 17 100% 1.31[0.31,5.53]
Total events: 6 (OK-432), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
   
10.4.2 OK-432 vs combined OK-432 and cisplatin  
Ishida 2006 6/17 3/15 100% 2.18[0.44,10.91]
Subtotal (95% CI) 17 15 100% 2.18[0.44,10.91]
Total events: 6 (OK-432), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.95(P=0.34)  
   
10.4.3 OK-432 vs bleomycin  
Yoshida 2007 16/33 25/35 100% 0.38[0.14,1.03]
Subtotal (95% CI) 33 35 100% 0.38[0.14,1.03]
Total events: 16 (OK-432), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.91(P=0.06)  
   
10.4.4 OK-432 vs cisplatin and etoposide  
Yoshida 2007 16/33 18/34 100% 0.84[0.32,2.18]
Subtotal (95% CI) 33 34 100% 0.84[0.32,2.18]
Total events: 16 (OK-432), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
Test for subgroup differences: Chi2=4.12, df=1 (P=0.25), I2=27.11%  
Favours OK-432 1000.01 100.1 1 Favours other
 
 
Comparison 11.   Mepacrine





Statistical method Effect size
1 Pleurodesis failure rate 5   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Mepacrine vs talc slurry 1 89 Odds Ratio (M-H, Random,
95% CI)
2.08 [0.62, 6.96]
1.2 Mepacrine vs bleomycin 1 36 Odds Ratio (M-H, Random,
95% CI)
0.16 [0.03, 0.89]
1.3 Mepacrine vs tetracycline 1 21 Odds Ratio (M-H, Random,
95% CI)
0.63 [0.05, 8.20]
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Statistical method Effect size
1.4 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random,
95% CI)
0.07 [0.01, 0.73]
1.5 Mepacrine vs mitoxantrone 1 26 Odds Ratio (M-H, Random,
95% CI)
7.61 [0.35, 163.82]
1.6 Mepacrine vs triethylene... 1 29 Odds Ratio (M-H, Random,
95% CI)
0.20 [0.04, 0.98]
2 Fever 3   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Mepacrine vs bleomycin 1 40 Odds Ratio (M-H, Random,
95% CI)
1.91 [0.52, 7.01]
2.2 Mepacrine vs tetracycline 1 22 Odds Ratio (M-H, Random,
95% CI)
8.00 [1.13, 56.79]
2.3 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random,
95% CI)
62.43 [2.85, 1365.52]
2.4 Mepacrine vs triethylene... 1 29 Odds Ratio (M-H, Random,
95% CI)
23.83 [3.35, 169.39]
3 Pain 3 114 Odds Ratio (M-H, Random,
95% CI)
4.56 [1.66, 12.52]
3.1 Mepacrine vs bleomycin 1 40 Odds Ratio (M-H, Random,
95% CI)
2.15 [0.52, 9.00]
3.2 Mepacrine vs tetracycline 1 22 Odds Ratio (M-H, Random,
95% CI)
5.6 [0.81, 38.51]
3.3 Mepacrine vs placebo 1 23 Odds Ratio (M-H, Random,
95% CI)
14.53 [0.71, 298.21]
3.4 Mepacrine vs triethylenethiophospho-
ramide
1 29 Odds Ratio (M-H, Random,
95% CI)
23.71 [1.19, 474.06]
4 Mortality 2   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 Mepacrine vs talc slurry 1 89 Odds Ratio (M-H, Random,
95% CI)
0.53 [0.20, 1.43]
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Analysis 11.1.   Comparison 11 Mepacrine, Outcome 1 Pleurodesis failure rate.
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.1.1 Mepacrine vs talc slurry  
Ukale 2004 8/41 5/48 100% 2.08[0.62,6.96]
Subtotal (95% CI) 41 48 100% 2.08[0.62,6.96]
Total events: 8 (Mepacine), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.19(P=0.23)  
   
11.1.2 Mepacrine vs bleomycin  
Koldsland 1993 2/18 8/18 100% 0.16[0.03,0.89]
Subtotal (95% CI) 18 18 100% 0.16[0.03,0.89]
Total events: 2 (Mepacine), 8 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.09(P=0.04)  
   
11.1.3 Mepacrine vs tetracycline  
Bayly 1978 1/9 2/12 100% 0.63[0.05,8.2]
Subtotal (95% CI) 9 12 100% 0.63[0.05,8.2]
Total events: 1 (Mepacine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
11.1.4 Mepacrine vs placebo  
Mejer 1977 5/14 8/9 100% 0.07[0.01,0.73]
Subtotal (95% CI) 14 9 100% 0.07[0.01,0.73]
Total events: 5 (Mepacine), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.23(P=0.03)  
   
11.1.5 Mepacrine vs mitoxantrone  
Bjermer 1995 3/14 0/12 100% 7.61[0.35,163.82]
Subtotal (95% CI) 14 12 100% 7.61[0.35,163.82]
Total events: 3 (Mepacine), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.2)  
   
11.1.6 Mepacrine vs triethylene...  
Mejer 1977 5/14 11/15 100% 0.2[0.04,0.98]
Subtotal (95% CI) 14 15 100% 0.2[0.04,0.98]
Total events: 5 (Mepacine), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
Test for subgroup differences: Chi2=14.04, df=1 (P=0.02), I2=64.4%  
Favours mepacrine 1000.01 100.1 1 Favours other
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Analysis 11.2.   Comparison 11 Mepacrine, Outcome 2 Fever.
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.2.1 Mepacrine vs bleomycin  
Koldsland 1993 14/20 11/20 100% 1.91[0.52,7.01]
Subtotal (95% CI) 20 20 100% 1.91[0.52,7.01]
Total events: 14 (Mepacine), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
11.2.2 Mepacrine vs tetracycline  
Bayly 1978 8/10 4/12 100% 8[1.13,56.79]
Subtotal (95% CI) 10 12 100% 8[1.13,56.79]
Total events: 8 (Mepacine), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.08(P=0.04)  
   
11.2.3 Mepacrine vs placebo  
Mejer 1977 11/14 0/9 100% 62.43[2.85,1365.52]
Subtotal (95% CI) 14 9 100% 62.43[2.85,1365.52]
Total events: 11 (Mepacine), 0 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.63(P=0.01)  
   
11.2.4 Mepacrine vs triethylene...  
Mejer 1977 11/14 2/15 100% 23.83[3.35,169.39]
Subtotal (95% CI) 14 15 100% 23.83[3.35,169.39]
Total events: 11 (Mepacine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.17(P=0)  
Test for subgroup differences: Chi2=7.18, df=1 (P=0.07), I2=58.2%  
Favours mepacrine 1000.01 100.1 1 Favours other
 
 
Analysis 11.3.   Comparison 11 Mepacrine, Outcome 3 Pain.
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.3.1 Mepacrine vs bleomycin  
Koldsland 1993 16/20 13/20 49.96% 2.15[0.52,9]
Subtotal (95% CI) 20 20 49.96% 2.15[0.52,9]
Total events: 16 (Mepacine), 13 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
   
11.3.2 Mepacrine vs tetracycline  
Bayly 1978 8/10 5/12 27.47% 5.6[0.81,38.51]
Subtotal (95% CI) 10 12 27.47% 5.6[0.81,38.51]
Total events: 8 (Mepacine), 5 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.75(P=0.08)  
   
Favours mepacrine 1000.01 100.1 1 Favours other
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Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.3.3 Mepacrine vs placebo  
Mejer 1977 6/14 0/9 11.19% 14.53[0.71,298.21]
Subtotal (95% CI) 14 9 11.19% 14.53[0.71,298.21]
Total events: 6 (Mepacine), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.74(P=0.08)  
   
11.3.4 Mepacrine vs triethylenethiophosphoramide  
Mejer 1977 6/14 0/15 11.38% 23.71[1.19,474.06]
Subtotal (95% CI) 14 15 11.38% 23.71[1.19,474.06]
Total events: 6 (Mepacine), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.07(P=0.04)  
   
Total (95% CI) 58 56 100% 4.56[1.66,12.52]
Total events: 36 (Mepacine), 18 (Other)  
Heterogeneity: Tau2=0; Chi2=2.93, df=3(P=0.4); I2=0%  
Test for overall effect: Z=2.94(P=0)  
Test for subgroup differences: Chi2=2.83, df=1 (P=0.42), I2=0%  
Favours mepacrine 1000.01 100.1 1 Favours other
 
 
Analysis 11.4.   Comparison 11 Mepacrine, Outcome 4 Mortality.
Study or subgroup Mepacine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.4.1 Mepacrine vs talc slurry  
Ukale 2004 8/41 15/48 100% 0.53[0.2,1.43]
Subtotal (95% CI) 41 48 100% 0.53[0.2,1.43]
Total events: 8 (Mepacine), 15 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
   
11.4.2 Mepacrine vs mitoxantrone  
Bjermer 1995 12/14 11/14 100% 1.64[0.23,11.7]
Subtotal (95% CI) 14 14 100% 1.64[0.23,11.7]
Total events: 12 (Mepacine), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=1, df=1 (P=0.32), I2=0%  
Favours mepacrine 1000.01 100.1 1 Favours other
 
 
Comparison 12.   Interferon (IFN)





Statistical method Effect size
1 Pleurodesis failure rate 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
1.1 IFN vs bleomycin 1 160 Odds Ratio (M-H, Random, 95% CI) 3.25 [1.54, 6.89]
2 Fever 1 160 Odds Ratio (M-H, Random, 95% CI) 0.01 [0.00, 0.11]
3 Pain 1 160 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.53]
3.1 IFN vs bleomycin 1 160 Odds Ratio (M-H, Random, 95% CI) 0.03 [0.00, 0.53]
4 Mortality 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 IFN vs bleomycin 1 160 Odds Ratio (M-H, Random, 95% CI) 2.16 [1.15, 4.07]
 
 
Analysis 12.1.   Comparison 12 Interferon (IFN), Outcome 1 Pleurodesis failure rate.
Study or subgroup IFN Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
12.1.1 IFN vs bleomycin  
Sartori 2004 29/77 13/83 100% 3.25[1.54,6.89]
Subtotal (95% CI) 77 83 100% 3.25[1.54,6.89]
Total events: 29 (IFN), 13 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.08(P=0)  
Favours IFN 1000.01 100.1 1 Favours other
 
 
Analysis 12.2.   Comparison 12 Interferon (IFN), Outcome 2 Fever.
Study or subgroup IFN Bleomycin Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sartori 2004 0/77 41/83 100% 0.01[0,0.11]
   
Total (95% CI) 77 83 100% 0.01[0,0.11]
Total events: 0 (IFN), 41 (Bleomycin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.5(P=0)  
Favours IFN 1000.01 100.1 1 Favours bleomycin ?
 
 
Analysis 12.3.   Comparison 12 Interferon (IFN), Outcome 3 Pain.
Study or subgroup IFN Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
12.3.1 IFN vs bleomycin  
Sartori 2004 0/77 14/83 100% 0.03[0,0.53]
Subtotal (95% CI) 77 83 100% 0.03[0,0.53]
Favours IFN 1000.01 100.1 1 Favours other
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Study or subgroup IFN Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 0 (IFN), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.4(P=0.02)  
   
Total (95% CI) 77 83 100% 0.03[0,0.53]
Total events: 0 (IFN), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.4(P=0.02)  
Favours IFN 1000.01 100.1 1 Favours other
 
 
Analysis 12.4.   Comparison 12 Interferon (IFN), Outcome 4 Mortality.
Study or subgroup IFN Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
12.4.1 IFN vs bleomycin  
Sartori 2004 48/77 36/83 100% 2.16[1.15,4.07]
Subtotal (95% CI) 77 83 100% 2.16[1.15,4.07]
Total events: 48 (IFN), 36 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.39(P=0.02)  
Favours IFN 1000.01 100.1 1 Favours other
 
 
Comparison 13.   Triethylenethiophosphoramide





Statistical method Effect size
1 Pleurodesis failure rate 1   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Triethylene... vs placebo 1 24 Odds Ratio (M-H, Random, 95%
CI)
0.34 [0.03, 3.69]
1.2 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95%
CI)
4.95 [1.02, 24.10]
2 Fever 1 53 Odds Ratio (M-H, Random, 95%
CI)
0.32 [0.00, 26.74]
2.1 Triethylene... vs placebo 1 24 Odds Ratio (M-H, Random, 95%
CI)
3.52 [0.15, 81.92]
2.2 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95%
CI)
0.04 [0.01, 0.30]
3 Pain 1 53 Odds Ratio (M-H, Random, 95%
CI)
1.39 [0.10, 20.15]
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Statistical method Effect size
3.1 Triethylene... vs mepacrine 1 29 Odds Ratio (M-H, Random, 95%
CI)
0.48 [0.10, 2.30]





Analysis 13.1.   Comparison 13 Triethylenethiophosphoramide, Outcome 1 Pleurodesis failure rate.
Study or subgroup Triethylene.... Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
13.1.1 Triethylene... vs placebo  
Mejer 1977 11/15 8/9 100% 0.34[0.03,3.69]
Subtotal (95% CI) 15 9 100% 0.34[0.03,3.69]
Total events: 11 (Triethylene....), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
13.1.2 Triethylene... vs mepacrine  
Mejer 1977 11/15 5/14 100% 4.95[1.02,24.1]
Subtotal (95% CI) 15 14 100% 4.95[1.02,24.1]
Total events: 11 (Triethylene....), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.98(P=0.05)  
Test for subgroup differences: Chi2=3.36, df=1 (P=0.07), I2=70.23%  
Favours triethylene... 1000.01 100.1 1 Favours other
 
 
Analysis 13.2.   Comparison 13 Triethylenethiophosphoramide, Outcome 2 Fever.
Study or subgroup Triethylene.... Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
13.2.1 Triethylene... vs placebo  
Mejer 1977 2/15 0/9 46.13% 3.52[0.15,81.92]
Subtotal (95% CI) 15 9 46.13% 3.52[0.15,81.92]
Total events: 2 (Triethylene....), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.43)  
   
13.2.2 Triethylene... vs mepacrine  
Mejer 1977 2/15 11/14 53.87% 0.04[0.01,0.3]
Subtotal (95% CI) 15 14 53.87% 0.04[0.01,0.3]
Total events: 2 (Triethylene....), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.17(P=0)  
   
Total (95% CI) 30 23 100% 0.32[0,26.74]
Favours triethylene... 1000.01 100.1 1 Favours other
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Study or subgroup Triethylene.... Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 4 (Triethylene....), 11 (Other)  
Heterogeneity: Tau2=8.41; Chi2=5.7, df=1(P=0.02); I2=82.46%  
Test for overall effect: Z=0.5(P=0.62)  
Test for subgroup differences: Chi2=5.48, df=1 (P=0.02), I2=81.75%  
Favours triethylene... 1000.01 100.1 1 Favours other
 
 
Analysis 13.3.   Comparison 13 Triethylenethiophosphoramide, Outcome 3 Pain.
Study or subgroup Triethylene.... Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
13.3.1 Triethylene... vs mepacrine  
Mejer 1977 4/15 6/14 61.36% 0.48[0.1,2.3]
Subtotal (95% CI) 15 14 61.36% 0.48[0.1,2.3]
Total events: 4 (Triethylene....), 6 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.91(P=0.36)  
   
13.3.2 Triethylene... vs placebo  
Mejer 1977 4/15 0/9 38.64% 7.43[0.35,156.28]
Subtotal (95% CI) 15 9 38.64% 7.43[0.35,156.28]
Total events: 4 (Triethylene....), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
   
Total (95% CI) 30 23 100% 1.39[0.1,20.15]
Total events: 8 (Triethylene....), 6 (Other)  
Heterogeneity: Tau2=2.4; Chi2=2.57, df=1(P=0.11); I2=61.14%  
Test for overall effect: Z=0.24(P=0.81)  
Test for subgroup differences: Chi2=2.45, df=1 (P=0.12), I2=59.12%  
Favours triethylene... 1000.01 100.1 1 Favours other
 
 
Comparison 14.   Adriamycin





Statistical method Effect size
1 Pleurodesis failure rate 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Adriamycin vs mustine 1 20 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.01, 10.18]
1.2 Adriamycin vs tetracycline 1 21 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.06, 20.49]
1.3 Adriamycin vs LC9018 and adri-
amycin
1 76 Odds Ratio (M-H, Random, 95% CI) 4.29 [1.62, 11.35]
2 Fever 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
3 Pain 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 14.1.   Comparison 14 Adriamycin, Outcome 1 Pleurodesis failure rate.
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
14.1.1 Adriamycin vs mustine  
Kefford 1980 10/11 9/9 100% 0.37[0.01,10.18]
Subtotal (95% CI) 11 9 100% 0.37[0.01,10.18]
Total events: 10 (Adriamycin), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
14.1.2 Adriamycin vs tetracycline  
Kefford 1980 10/11 9/10 100% 1.11[0.06,20.49]
Subtotal (95% CI) 11 10 100% 1.11[0.06,20.49]
Total events: 10 (Adriamycin), 9 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.07(P=0.94)  
   
14.1.3 Adriamycin vs LC9018 and adriamycin  
Masuno 1991 23/38 10/38 100% 4.29[1.62,11.35]
Subtotal (95% CI) 38 38 100% 4.29[1.62,11.35]
Total events: 23 (Adriamycin), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.94(P=0)  
Test for subgroup differences: Chi2=2.49, df=1 (P=0.29), I2=19.58%  
Favours adriamycin 1000.01 100.1 1 Favours other
 
 
Analysis 14.2.   Comparison 14 Adriamycin, Outcome 2 Fever.
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Masuno 1991 13/45 11/41 0% 1.11[0.43,2.85]
Favours adriamycin 1000.01 100.1 1 Favours other
 
 
Analysis 14.3.   Comparison 14 Adriamycin, Outcome 3 Pain.
Study or subgroup Adriamycin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Masuno 1991 13/45 6/41 0% 2.37[0.81,6.98]
Favours adriamycin 1000.01 100.1 1 Favours other
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Comparison 15.   Placebo





Statistical method Effect size
1 Pleurodesis failure rate 6   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Placebo vs mepacrine 1 23 Odds Ratio (M-H, Random, 95%
CI)
14.40 [1.37, 150.81]
1.2 Placebo vs mitoxantrone 1 95 Odds Ratio (M-H, Random, 95%
CI)
1.33 [0.56, 3.17]
1.3 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95%
CI)
2.91 [0.27, 31.21]
1.4 Placebo vs talc slurry 1 21 Odds Ratio (M-H, Random, 95%
CI)
13.93 [0.66, 293.99]
1.5 Placebo vs tetracycline 1 20 Odds Ratio (M-H, Random, 95%
CI)
3.33 [0.51, 21.58]
1.6 Placebo vs urokinase 1 69 Odds Ratio (M-H, Random, 95%
CI)
0.81 [0.30, 2.19]
1.7 Placebo vs streptokinase 1 40 Odds Ratio (M-H, Random, 95%
CI)
3.00 [0.51, 17.74]
2 Fever 2   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 Placebo vs mepacrine 1 95 Odds Ratio (M-H, Random, 95%
CI)
0.31 [0.12, 0.79]
2.2 Placebo vs mitoxantrone 1 23 Odds Ratio (M-H, Random, 95%
CI)
0.02 [0.00, 0.35]
2.3 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95%
CI)
0.28 [0.01, 6.62]
3 Pain 3 100 Odds Ratio (M-H, Random, 95%
CI)
0.10 [0.01, 0.82]
3.1 Placebo vs talc slurry 1 31 Odds Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
3.2 Placebo vs tetracycline 1 22 Odds Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
3.3 Placebo vs mepacrine 1 23 Odds Ratio (M-H, Random, 95%
CI)
0.07 [0.00, 1.41]
3.4 Placebo vs triethylene... 1 24 Odds Ratio (M-H, Random, 95%
CI)
0.13 [0.01, 2.83]
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Statistical method Effect size
4 Mortality 1 71 Odds Ratio (M-H, Fixed, 95% CI) 12.40 [0.66, 233.22]
 
 
Analysis 15.1.   Comparison 15 Placebo, Outcome 1 Pleurodesis failure rate.
Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.1.1 Placebo vs mepacrine  
Mejer 1977 8/9 5/14 100% 14.4[1.37,150.81]
Subtotal (95% CI) 9 14 100% 14.4[1.37,150.81]
Total events: 8 (Placebo), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.23(P=0.03)  
   
15.1.2 Placebo vs mitoxantrone  
Groth 1991 16/46 14/49 100% 1.33[0.56,3.17]
Subtotal (95% CI) 46 49 100% 1.33[0.56,3.17]
Total events: 16 (Placebo), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
   
15.1.3 Placebo vs triethylene...  
Mejer 1977 8/9 11/15 100% 2.91[0.27,31.21]
Subtotal (95% CI) 9 15 100% 2.91[0.27,31.21]
Total events: 8 (Placebo), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
   
15.1.4 Placebo vs talc slurry  
Sorensen 1984 5/12 0/9 100% 13.93[0.66,293.99]
Subtotal (95% CI) 12 9 100% 13.93[0.66,293.99]
Total events: 5 (Placebo), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.69(P=0.09)  
   
15.1.5 Placebo vs tetracycline  
Zaloznik 1983 5/8 4/12 100% 3.33[0.51,21.58]
Subtotal (95% CI) 8 12 100% 3.33[0.51,21.58]
Total events: 5 (Placebo), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.26(P=0.21)  
   
15.1.6 Placebo vs urokinase  
Mishra 2018 11/34 13/35 100% 0.81[0.3,2.19]
Subtotal (95% CI) 34 35 100% 0.81[0.3,2.19]
Total events: 11 (Placebo), 13 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.68)  
Favours placebo 1000.01 100.1 1 Favours other
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Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
15.1.7 Placebo vs streptokinase  
Saydam 2015 5/20 2/20 100% 3[0.51,17.74]
Subtotal (95% CI) 20 20 100% 3[0.51,17.74]
Total events: 5 (Placebo), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.21(P=0.23)  
Test for subgroup differences: Chi2=8.54, df=1 (P=0.2), I2=29.76%  
Favours placebo 1000.01 100.1 1 Favours other
 
 
Analysis 15.2.   Comparison 15 Placebo, Outcome 2 Fever.
Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.2.1 Placebo vs mepacrine  
Groth 1991 8/46 20/49 100% 0.31[0.12,0.79]
Subtotal (95% CI) 46 49 100% 0.31[0.12,0.79]
Total events: 8 (Placebo), 20 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.44(P=0.01)  
   
15.2.2 Placebo vs mitoxantrone  
Mejer 1977 0/9 11/14 100% 0.02[0,0.35]
Subtotal (95% CI) 9 14 100% 0.02[0,0.35]
Total events: 0 (Placebo), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.63(P=0.01)  
   
15.2.3 Placebo vs triethylene...  
Mejer 1977 0/9 2/15 100% 0.28[0.01,6.62]
Subtotal (95% CI) 9 15 100% 0.28[0.01,6.62]
Total events: 0 (Placebo), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.43)  
Test for subgroup differences: Chi2=3.21, df=1 (P=0.2), I2=37.76%  
Favours placebo 1000.01 100.1 1 Favours other
 
 
Analysis 15.3.   Comparison 15 Placebo, Outcome 3 Pain.
Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.3.1 Placebo vs talc slurry  
Sorensen 1984 17/17 14/14   Not estimable
Subtotal (95% CI) 17 14 Not estimable
Total events: 17 (Placebo), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours placebo 1000.01 100.1 1 Favours other
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Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
   
15.3.2 Placebo vs tetracycline  
Zaloznik 1983 0/9 0/13   Not estimable
Subtotal (95% CI) 9 13 Not estimable
Total events: 0 (Placebo), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.3.3 Placebo vs mepacrine  
Mejer 1977 0/9 6/14 50.39% 0.07[0,1.41]
Subtotal (95% CI) 9 14 50.39% 0.07[0,1.41]
Total events: 0 (Placebo), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.74(P=0.08)  
   
15.3.4 Placebo vs triethylene...  
Mejer 1977 0/9 4/15 49.61% 0.13[0.01,2.83]
Subtotal (95% CI) 9 15 49.61% 0.13[0.01,2.83]
Total events: 0 (Placebo), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
   
Total (95% CI) 44 56 100% 0.1[0.01,0.82]
Total events: 17 (Placebo), 24 (Other)  
Heterogeneity: Tau2=0; Chi2=0.09, df=1(P=0.76); I2=0%  
Test for overall effect: Z=2.14(P=0.03)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favours placebo 1000.01 100.1 1 Favours other
 
 
Analysis 15.4.   Comparison 15 Placebo, Outcome 4 Mortality.
Study or subgroup Placebo Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mishra 2018 35/35 31/36 100% 12.4[0.66,233.22]
   
Total (95% CI) 35 36 100% 12.4[0.66,233.22]
Total events: 35 (Placebo), 31 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
Favours placebo 1000.01 100.1 1 Favours other
 
 
Comparison 16.   Mustine





Statistical method Effect size
1 Pleurodesis failure rate 4   Odds Ratio (M-H, Random, 95% CI) Subtotals only
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Statistical method Effect size
1.1 Mustine vs tetracycline 2 59 Odds Ratio (M-H, Random, 95% CI) 2.72 [0.74, 9.98]
1.2 Mustine vs talc poudrage 1 37 Odds Ratio (M-H, Random, 95% CI) 8.00 [1.40, 45.76]
1.3 Mustine vs C parvum 1 31 Odds Ratio (M-H, Random, 95% CI) 10.8 [1.64, 70.93]
1.4 Mustine vs adriamycin 1 20 Odds Ratio (M-H, Random, 95% CI) 2.71 [0.10, 74.98]
2 Fever 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mustine vs tetracycline 1 40 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Mustine vs C parvum 1 21 Odds Ratio (M-H, Random, 95% CI) 0.23 [0.01, 6.25]
3 Pain 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4 Mortality 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mustine vs talc poudrage 1 46 Odds Ratio (M-H, Random, 95% CI) 2.35 [0.51, 10.86]
4.2 Mustine vs C parvum 1 21 Odds Ratio (M-H, Random, 95% CI) 2.4 [0.38, 15.32]
 
 
Analysis 16.1.   Comparison 16 Mustine, Outcome 1 Pleurodesis failure rate.
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
16.1.1 Mustine vs tetracycline  
Kefford 1980 9/9 9/10 15.33% 3[0.11,83.36]
Loutsidis 1994 8/20 4/20 84.67% 2.67[0.65,10.97]
Subtotal (95% CI) 29 30 100% 2.72[0.74,9.98]
Total events: 17 (Mustine), 13 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=1.5(P=0.13)  
   
16.1.2 Mustine vs talc poudrage  
Fentiman 1983 8/17 2/20 100% 8[1.4,45.76]
Subtotal (95% CI) 17 20 100% 8[1.4,45.76]
Total events: 8 (Mustine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.34(P=0.02)  
   
16.1.3 Mustine vs C parvum  
Millar 1980 6/11 2/20 100% 10.8[1.64,70.93]
Subtotal (95% CI) 11 20 100% 10.8[1.64,70.93]
Total events: 6 (Mustine), 2 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.48(P=0.01)  
   
Favours mustine 1000.01 100.1 1 Favours other
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Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
16.1.4 Mustine vs adriamycin  
Kefford 1980 9/9 10/11 100% 2.71[0.1,74.98]
Subtotal (95% CI) 9 11 100% 2.71[0.1,74.98]
Total events: 9 (Mustine), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
Test for subgroup differences: Chi2=1.89, df=1 (P=0.6), I2=0%  
Favours mustine 1000.01 100.1 1 Favours other
 
 
Analysis 16.2.   Comparison 16 Mustine, Outcome 2 Fever.
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
16.2.1 Mustine vs tetracycline  
Loutsidis 1994 0/20 0/20   Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Mustine), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
16.2.2 Mustine vs C parvum  
Millar 1980 0/12 1/9 100% 0.23[0.01,6.25]
Subtotal (95% CI) 12 9 100% 0.23[0.01,6.25]
Total events: 0 (Mustine), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Test for subgroup differences: Not applicable  
Favours mustine 1000.01 100.1 1 Favours other
 
 
Analysis 16.3.   Comparison 16 Mustine, Outcome 3 Pain.
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Loutsidis 1994 0/20 9/20 0% 0.03[0,0.56]
Favours mustine 1000.01 100.1 1 Favours other
 
 
Analysis 16.4.   Comparison 16 Mustine, Outcome 4 Mortality.
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
16.4.1 Mustine vs talc poudrage  
Fentiman 1983 6/23 3/23 100% 2.35[0.51,10.86]
Subtotal (95% CI) 23 23 100% 2.35[0.51,10.86]
Total events: 6 (Mustine), 3 (Other)  
Favours mustine 1000.01 100.1 1 Favours other
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Mustine Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
16.4.2 Mustine vs C parvum  
Millar 1980 9/12 5/9 100% 2.4[0.38,15.32]
Subtotal (95% CI) 12 9 100% 2.4[0.38,15.32]
Total events: 9 (Mustine), 5 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Test for subgroup differences: Chi2=0, df=1 (P=0.99), I2=0%  
Favours mustine 1000.01 100.1 1 Favours other
 
 
Comparison 17.   Mitoxantrone





Statistical method Effect size
1 Pleurodesis failure rate 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Mitoxantrone vs placebo 1 95 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.32, 1.79]
1.2 Mitoxantrone vs mepacrine 1 26 Odds Ratio (M-H, Random, 95% CI) 7.61 [0.35, 163.82]
1.3 Mitoxantrone vs bleomycin 1 85 Odds Ratio (M-H, Random, 95% CI) 3.18 [1.17, 8.65]
2 Pain 1 96 Odds Ratio (M-H, Random, 95% CI) 2.08 [0.64, 6.76]
3 Fever 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Mitoxantrone vs bleomycin 1 96 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.30, 2.71]
3.2 Mitoxantrone vs placebo 1 95 Odds Ratio (M-H, Random, 95% CI) 3.28 [1.26, 8.49]
4 Mortality 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mitoxantrone vs bleomycin 1 96 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.21, 1.05]
4.2 Mitoxantrone vs mepacrine 1 28 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.09, 4.37]
 
 
Analysis 17.1.   Comparison 17 Mitoxantrone, Outcome 1 Pleurodesis failure rate.
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
17.1.1 Mitoxantrone vs placebo  
Groth 1991 14/49 16/46 100% 0.75[0.32,1.79]
Subtotal (95% CI) 49 46 100% 0.75[0.32,1.79]
Total events: 14 (Mitoxantrone), 16 (Other)  
Favours mitoxantrone 1000.01 100.1 1 Favours other
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Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
   
17.1.2 Mitoxantrone vs mepacrine  
Bjermer 1995 3/14 0/12 100% 7.61[0.35,163.82]
Subtotal (95% CI) 14 12 100% 7.61[0.35,163.82]
Total events: 3 (Mitoxantrone), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.3(P=0.2)  
   
17.1.3 Mitoxantrone vs bleomycin  
Schmidt 1997 15/38 8/47 100% 3.18[1.17,8.65]
Subtotal (95% CI) 38 47 100% 3.18[1.17,8.65]
Total events: 15 (Mitoxantrone), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.27(P=0.02)  
Test for subgroup differences: Chi2=5.69, df=1 (P=0.06), I2=64.87%  
Favours mitoxantrone 1000.01 100.1 1 Favours other
 
 
Analysis 17.2.   Comparison 17 Mitoxantrone, Outcome 2 Pain.
Study or subgroup Mitoxantrone Bleomycin Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Schmidt 1997 9/47 5/49 100% 2.08[0.64,6.76]
   
Total (95% CI) 47 49 100% 2.08[0.64,6.76]
Total events: 9 (Mitoxantrone), 5 (Bleomycin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.22(P=0.22)  
Favours mitoxantrone 1000.01 100.1 1 Favours bleomycin?
 
 
Analysis 17.3.   Comparison 17 Mitoxantrone, Outcome 3 Fever.
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
17.3.1 Mitoxantrone vs bleomycin  
Schmidt 1997 7/47 8/49 100% 0.9[0.3,2.71]
Subtotal (95% CI) 47 49 100% 0.9[0.3,2.71]
Total events: 7 (Mitoxantrone), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.19(P=0.85)  
   
17.3.2 Mitoxantrone vs placebo  
Groth 1991 20/49 8/46 100% 3.28[1.26,8.49]
Subtotal (95% CI) 49 46 100% 3.28[1.26,8.49]
Total events: 20 (Mitoxantrone), 8 (Other)  
Heterogeneity: Not applicable  
Favours mitoxantrone 1000.01 100.1 1 Favours other
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Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=2.44(P=0.01)  
Test for subgroup differences: Chi2=3.03, df=1 (P=0.08), I2=67.04%  
Favours mitoxantrone 1000.01 100.1 1 Favours other
 
 
Analysis 17.4.   Comparison 17 Mitoxantrone, Outcome 4 Mortality.
Study or subgroup Mitoxantrone Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
17.4.1 Mitoxantrone vs bleomycin  
Schmidt 1997 18/47 28/49 100% 0.47[0.21,1.05]
Subtotal (95% CI) 47 49 100% 0.47[0.21,1.05]
Total events: 18 (Mitoxantrone), 28 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.84(P=0.07)  
   
17.4.2 Mitoxantrone vs mepacrine  
Bjermer 1995 11/14 12/14 100% 0.61[0.09,4.37]
Subtotal (95% CI) 14 14 100% 0.61[0.09,4.37]
Total events: 11 (Mitoxantrone), 12 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
Test for subgroup differences: Chi2=0.06, df=1 (P=0.8), I2=0%  
Favours mitoxantrone 1000.01 100.1 1 Favours other
 
 
Comparison 18.   Drain size





Statistical method Effect size
1 Pleurodesis failure rate 2 118 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.53, 2.69]
2 Pain 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3 Mortality 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 18.1.   Comparison 18 Drain size, Outcome 1 Pleurodesis failure rate.
Study or subgroup Small drain Large drain Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Clementsen 1998 2/9 3/9 15.2% 0.57[0.07,4.64]
Rahman 2015 15/50 12/50 84.8% 1.36[0.56,3.3]
   
Total (95% CI) 59 59 100% 1.19[0.53,2.69]
Total events: 17 (Small drain), 15 (Large drain)  
Favours small drain 1000.01 100.1 1 Favours large drain
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Study or subgroup Small drain Large drain Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=0.56, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.42(P=0.68)  
Favours small drain 1000.01 100.1 1 Favours large drain
 
 
Analysis 18.2.   Comparison 18 Drain size, Outcome 2 Pain.
Study or subgroup Small drain Large drain Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Clementsen 1998 2/9 7/9 0% 0.08[0.01,0.75]
Favours small drain 1000.01 100.1 1 Favours large drain
 
 
Analysis 18.3.   Comparison 18 Drain size, Outcome 3 Mortality.
Study or subgroup Small drain Large drain Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Clementsen 1998 3/9 1/9 0% 4[0.33,48.66]
Rahman 2015 40/57 43/57 0% 0.77[0.33,1.75]
Favours small drain 1000.01 100.1 1 Favours large drain
 
 
Comparison 19.   Thoracoscopic mechanical pleurodesis (TMP)





Statistical method Effect size
1 Pleurodesis failure rate 2 123 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.16, 1.20]
2 Mortality 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
 
 
Analysis 19.1.   Comparison 19 Thoracoscopic mechanical pleurodesis (TMP), Outcome 1 Pleurodesis failure rate.
Study or subgroup TMP Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Crnjac 2004 6/45 11/42 83.71% 0.43[0.14,1.3]
Hojski 2015 1/18 2/18 16.29% 0.47[0.04,5.71]
   
Total (95% CI) 63 60 100% 0.44[0.16,1.2]
Total events: 7 (TMP), 13 (Talc slurry)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.95); I2=0%  
Test for overall effect: Z=1.6(P=0.11)  
Favours TMP 1000.01 100.1 1 Favours talc slurry
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Analysis 19.2.   Comparison 19 Thoracoscopic mechanical pleurodesis (TMP), Outcome 2 Mortality.
Study or subgroup TMP Talc slurry Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Crnjac 2004 0/45 4/42 0% 0.09[0,1.8]
Favours TMP 1000.01 100.1 1 Favours talc slurry
 
 
Comparison 20.   Other





Statistical method Effect size
1 Pleurodesis failure rate 4 464 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.76, 1.78]
1.1 Rotation vs no rotation 1 20 Odds Ratio (M-H, Random, 95% CI) 2.25 [0.17, 29.77]
1.2 Mixed particle talc vs graded
talc
1 28 Odds Ratio (M-H, Random, 95% CI) 1.64 [0.23, 11.70]
1.3 Talc pleurodesis vs video-
assisted thoracoscopic surgery
(VATS) parietal pleurectomy
1 122 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.49, 2.09]
1.4 Non-steroidal anti-inflam-
matory drugs (NSAIDs) vs opi-
ates for analgesia
1 294 Odds Ratio (M-H, Random, 95% CI) 1.19 [0.68, 2.08]
2 Fever 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Mixed particle talc vs graded
talc
1 46 Odds Ratio (M-H, Random, 95% CI) 15.92 [1.81, 140.16]
3 Pain 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Streptokinase vs control 1 47 Odds Ratio (M-H, Random, 95% CI) 3.00 [0.12, 77.47]
3.2 NSAID vs opiate (in requiring
rescue analgesia)
1 320 Odds Ratio (M-H, Random, 95% CI) 1.73 [1.08, 2.78]
4 Mortality 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Mixed particle talc vs graded
talc
1 43 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.25, 3.07]
4.2 Talc pleurodesis vs VATS par-
tial pleurectomy
1 175 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.45, 1.90]
4.3 NSAIDs vs opiates for anal-
gesia
1 320 Odds Ratio (M-H, Random, 95% CI) 1.36 [0.87, 2.12]
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Analysis 20.1.   Comparison 20 Other, Outcome 1 Pleurodesis failure rate.
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
20.1.1 Rotation vs no rotation  
Mager 2002 2/10 1/10 2.71% 2.25[0.17,29.77]
Subtotal (95% CI) 10 10 2.71% 2.25[0.17,29.77]
Total events: 2 (Treatment 1), 1 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.62(P=0.54)  
   
20.1.2 Mixed particle talc vs graded talc  
Maskell 2004 3/14 2/14 4.67% 1.64[0.23,11.7]
Subtotal (95% CI) 14 14 4.67% 1.64[0.23,11.7]
Total events: 3 (Treatment 1), 2 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
   
20.1.3 Talc pleurodesis vs video-assisted thoracoscopic surgery (VATS)
parietal pleurectomy
 
Rintoul 2014 25/62 24/60 34.49% 1.01[0.49,2.09]
Subtotal (95% CI) 62 60 34.49% 1.01[0.49,2.09]
Total events: 25 (Treatment 1), 24 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
20.1.4 Non-steroidal anti-inflammatory drugs (NSAIDs) vs opiates for
analgesia
 
Rahman 2015 33/144 30/150 58.13% 1.19[0.68,2.08]
Subtotal (95% CI) 144 150 58.13% 1.19[0.68,2.08]
Total events: 33 (Treatment 1), 30 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
   
Total (95% CI) 230 234 100% 1.16[0.76,1.78]
Total events: 63 (Treatment 1), 57 (Treatment 2)  
Heterogeneity: Tau2=0; Chi2=0.51, df=3(P=0.92); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Test for subgroup differences: Chi2=0.51, df=1 (P=0.92), I2=0%  
Favours treatment 1 1000.01 100.1 1 Favours treatment 2
 
 
Analysis 20.2.   Comparison 20 Other, Outcome 2 Fever.
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
20.2.1 Mixed particle talc vs graded talc  
Maskell 2004 9/22 1/24 100% 15.92[1.81,140.16]
Subtotal (95% CI) 22 24 100% 15.92[1.81,140.16]
Total events: 9 (Treatment 1), 1 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.49(P=0.01)  
Favours treatment 1 1000.01 100.1 1 Favours treatment 2
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Analysis 20.3.   Comparison 20 Other, Outcome 3 Pain.
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
20.3.1 Streptokinase vs control  
Okur 2011 1/24 0/23 100% 3[0.12,77.47]
Subtotal (95% CI) 24 23 100% 3[0.12,77.47]
Total events: 1 (Treatment 1), 0 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
20.3.2 NSAID vs opiate (in requiring rescue analgesia)  
Rahman 2015 61/160 42/160 100% 1.73[1.08,2.78]
Subtotal (95% CI) 160 160 100% 1.73[1.08,2.78]
Total events: 61 (Treatment 1), 42 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
Test for subgroup differences: Chi2=0.11, df=1 (P=0.74), I2=0%  
Favours treatment 1 1000.01 100.1 1 Favours treatment 2
 
 
Analysis 20.4.   Comparison 20 Other, Outcome 4 Mortality.
Study or subgroup Treatment 1 Treatment 2 Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
20.4.1 Mixed particle talc vs graded talc  
Maskell 2004 7/21 8/22 100% 0.88[0.25,3.07]
Subtotal (95% CI) 21 22 100% 0.88[0.25,3.07]
Total events: 7 (Treatment 1), 8 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.83)  
   
20.4.2 Talc pleurodesis vs VATS partial pleurectomy  
Rintoul 2014 18/88 19/87 100% 0.92[0.45,1.9]
Subtotal (95% CI) 88 87 100% 0.92[0.45,1.9]
Total events: 18 (Treatment 1), 19 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.22(P=0.82)  
   
20.4.3 NSAIDs vs opiates for analgesia  
Rahman 2015 98/160 86/160 100% 1.36[0.87,2.12]
Subtotal (95% CI) 160 160 100% 1.36[0.87,2.12]
Total events: 98 (Treatment 1), 86 (Treatment 2)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.18)  
Test for subgroup differences: Chi2=1.06, df=1 (P=0.59), I2=0%  
Favours treatment 1 1000.01 100.1 1 Favours treatment 2
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Comparison 21.   Silver nitrate





Statistical method Effect size
1 Pleurodesis failure rate 2   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
1.1 Silver nitrate vs talc slurry 1 25 Odds Ratio (M-H, Random, 95%
CI)
0.17 [0.01, 4.68]
1.2 Silver nitrate vs tetracycline 1 50 Odds Ratio (M-H, Random, 95%
CI)
1.66 [0.41, 6.78]
2 Fever 2   Odds Ratio (M-H, Random, 95%
CI)
Subtotals only
2.1 Silver nitrate vs talc slurry 1 60 Odds Ratio (M-H, Random, 95%
CI)
1.43 [0.31, 6.61]
2.2 Silver nitrate vs tetracycline 1 50 Odds Ratio (M-H, Random, 95%
CI)
0.00 [0.00, 0.06]
3 Pain 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.33]
3.1 Silver nitrate vs tetracycline 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.33]
4 Mortality 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 21.1.   Comparison 21 Silver nitrate, Outcome 1 Pleurodesis failure rate.
Study or subgroup Silver nitrate Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
21.1.1 Silver nitrate vs talc slurry  
Paschoalini 2005 0/16 1/9 100% 0.17[0.01,4.68]
Subtotal (95% CI) 16 9 100% 0.17[0.01,4.68]
Total events: 0 (Silver nitrate), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.04(P=0.3)  
   
21.1.2 Silver nitrate vs tetracycline  
Tabatabaei  2015 6/25 4/25 100% 1.66[0.41,6.78]
Subtotal (95% CI) 25 25 100% 1.66[0.41,6.78]
Total events: 6 (Silver nitrate), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
Test for subgroup differences: Chi2=1.53, df=1 (P=0.22), I2=34.61%  
Favours silver nitrate 1000.01 100.1 1 Favours control
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Analysis 21.2.   Comparison 21 Silver nitrate, Outcome 2 Fever.
Study or subgroup Silver nitrate Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
21.2.1 Silver nitrate vs talc slurry  
Paschoalini 2005 5/33 3/27 100% 1.43[0.31,6.61]
Subtotal (95% CI) 33 27 100% 1.43[0.31,6.61]
Total events: 5 (Silver nitrate), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.46(P=0.65)  
   
21.2.2 Silver nitrate vs tetracycline  
Tabatabaei  2015 3/25 25/25 100% 0[0,0.06]
Subtotal (95% CI) 25 25 100% 0[0,0.06]
Total events: 3 (Silver nitrate), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
Test for subgroup differences: Chi2=12.69, df=1 (P=0), I2=92.12%  
Favours silver nitrate 1000.01 100.1 1 Favours other
 
 
Analysis 21.3.   Comparison 21 Silver nitrate, Outcome 3 Pain.
Study or subgroup Silver nitrate Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
21.3.1 Silver nitrate vs tetracycline  
Tabatabaei  2015 12/25 25/25 100% 0.02[0,0.33]
Subtotal (95% CI) 25 25 100% 0.02[0,0.33]
Total events: 12 (Silver nitrate), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.71(P=0.01)  
   
Total (95% CI) 25 25 100% 0.02[0,0.33]
Total events: 12 (Silver nitrate), 25 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.71(P=0.01)  
Favours silver nitrate 1000.01 100.1 1 Favours other
 
 
Analysis 21.4.   Comparison 21 Silver nitrate, Outcome 4 Mortality.
Study or subgroup Silver nitrate Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Tabatabaei  2015 0/25 0/25   Not estimable
   
Total (95% CI) 25 25 Not estimable
Total events: 0 (Silver nitrate), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours silver nitrate 1000.01 100.1 1 Favours other
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Comparison 22.   Cisplatin





Statistical method Effect size
1 Pleurodesis failure rate 4   Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Cisplatin vs cisplatin and beva-
cizumab
1 70 Odds Ratio (M-H, Random, 95% CI) 5.00 [1.66, 15.09]
1.2 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 2.06 [0.52, 8.17]
1.3 Cisplatin vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random, 95% CI) 25.67 [2.68, 245.84]
1.4 Cisplatin vs rAd-p53 and cisplatin 1 35 Odds Ratio (M-H, Random, 95% CI) 4.67 [0.99, 22.03]
1.5 Cisplatin vs cisplatin and endo-
statin
1 128 Odds Ratio (M-H, Random, 95% CI) 2.35 [1.07, 5.12]
2 Fever 2   Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.00 [0.00, 0.07]
2.2 Cisplatin vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random, 95% CI) 0.05 [0.01, 0.52]
2.3 Cisplatin vs rAd-p53 and cisplatin 1 35 Odds Ratio (M-H, Random, 95% CI) 0.09 [0.02, 0.51]
3 Pain 1   Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.15 [0.03, 0.87]
3.2 Cisplatin vs OK-432 and cisplatin 1 32 Odds Ratio (M-H, Random, 95% CI) 0.2 [0.03, 1.21]
4 Mortality 3   Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Cisplatin vs OK-432 1 34 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.18, 3.23]
4.2 Cisplatin vs combination OK-432
and cisplatin
1 32 Odds Ratio (M-H, Random, 95% CI) 1.67 [0.32, 8.59]
4.3 Cisplatin vs combination rAd-p53
and cisplatin
1 35 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Cisplatin vs combination cisplatin
and endostatin
1 128 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.57, 2.93]
 
 
Analysis 22.1.   Comparison 22 Cisplatin, Outcome 1 Pleurodesis failure rate.
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
22.1.1 Cisplatin vs cisplatin and bevacizumab  
Du 2013 17/34 6/36 100% 5[1.66,15.09]
Favours cisplatin 1000.01 100.1 1 Favours other
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Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 34 36 100% 5[1.66,15.09]
Total events: 17 (Cisplatin), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.86(P=0)  
   
22.1.2 Cisplatin vs OK-432  
Ishida 2006 11/17 8/17 100% 2.06[0.52,8.17]
Subtotal (95% CI) 17 17 100% 2.06[0.52,8.17]
Total events: 11 (Cisplatin), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.03(P=0.3)  
   
22.1.3 Cisplatin vs OK-432 and cisplatin  
Ishida 2006 11/17 1/15 100% 25.67[2.68,245.84]
Subtotal (95% CI) 17 15 100% 25.67[2.68,245.84]
Total events: 11 (Cisplatin), 1 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.81(P=0)  
   
22.1.4 Cisplatin vs rAd-p53 and cisplatin  
Zhao 2009 9/18 3/17 100% 4.67[0.99,22.03]
Subtotal (95% CI) 18 17 100% 4.67[0.99,22.03]
Total events: 9 (Cisplatin), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.95(P=0.05)  
   
22.1.5 Cisplatin vs cisplatin and endostatin  
Wang 2018 24/62 14/66 100% 2.35[1.07,5.12]
Subtotal (95% CI) 62 66 100% 2.35[1.07,5.12]
Total events: 24 (Cisplatin), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.14(P=0.03)  
Test for subgroup differences: Chi2=5.08, df=1 (P=0.28), I2=21.2%  
Favours cisplatin 1000.01 100.1 1 Favours other
 
 
Analysis 22.2.   Comparison 22 Cisplatin, Outcome 2 Fever.
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
22.2.1 Cisplatin vs OK-432  
Ishida 2006 1/17 16/17 100% 0[0,0.07]
Subtotal (95% CI) 17 17 100% 0[0,0.07]
Total events: 1 (Cisplatin), 16 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.8(P=0)  
   
22.2.2 Cisplatin vs OK-432 and cisplatin  
Ishida 2006 1/17 8/15 100% 0.05[0.01,0.52]
Subtotal (95% CI) 17 15 100% 0.05[0.01,0.52]
Favours silver nitrate 1000.01 100.1 1 Favours other
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Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 1 (Cisplatin), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.52(P=0.01)  
   
22.2.3 Cisplatin vs rAd-p53 and cisplatin  
Zhao 2009 2/18 10/17 100% 0.09[0.02,0.51]
Subtotal (95% CI) 18 17 100% 0.09[0.02,0.51]
Total events: 2 (Cisplatin), 10 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.71(P=0.01)  
Test for subgroup differences: Chi2=3.38, df=1 (P=0.18), I2=40.76%  
Favours silver nitrate 1000.01 100.1 1 Favours other
 
 
Analysis 22.3.   Comparison 22 Cisplatin, Outcome 3 Pain.
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
22.3.1 Cisplatin vs OK-432  
Ishida 2006 2/17 8/17 100% 0.15[0.03,0.87]
Subtotal (95% CI) 17 17 100% 0.15[0.03,0.87]
Total events: 2 (Cisplatin), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.12(P=0.03)  
   
22.3.2 Cisplatin vs OK-432 and cisplatin  
Ishida 2006 2/17 6/15 100% 0.2[0.03,1.21]
Subtotal (95% CI) 17 15 100% 0.2[0.03,1.21]
Total events: 2 (Cisplatin), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%  
Favours cisplatin 1000.01 100.1 1 Favours other
 
 
Analysis 22.4.   Comparison 22 Cisplatin, Outcome 4 Mortality.
Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
22.4.1 Cisplatin vs OK-432  
Ishida 2006 5/17 6/17 100% 0.76[0.18,3.23]
Subtotal (95% CI) 17 17 100% 0.76[0.18,3.23]
Total events: 5 (Cisplatin), 6 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
   
22.4.2 Cisplatin vs combination OK-432 and cisplatin  
Ishida 2006 5/17 3/15 100% 1.67[0.32,8.59]
Subtotal (95% CI) 17 15 100% 1.67[0.32,8.59]
Favours cisplatin 1000.01 100.1 1 Favours other
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Study or subgroup Cisplatin Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 5 (Cisplatin), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
   
22.4.3 Cisplatin vs combination rAd-p53 and cisplatin  
Zhao 2009 0/18 0/17   Not estimable
Subtotal (95% CI) 18 17 Not estimable
Total events: 0 (Cisplatin), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
22.4.4 Cisplatin vs combination cisplatin and endostatin  
Wang 2018 16/62 14/66 100% 1.29[0.57,2.93]
Subtotal (95% CI) 62 66 100% 1.29[0.57,2.93]
Total events: 16 (Cisplatin), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Test for subgroup differences: Chi2=0.56, df=1 (P=0.75), I2=0%  
Favours cisplatin 1000.01 100.1 1 Favours other
 
 
Comparison 23.   Duration of drainage prior to administration of sclerosant




Statistical method Effect size
1 Pleurodesis failure rate 1 79 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.22, 2.82]
 
 
Analysis 23.1.   Comparison 23 Duration of drainage prior to
administration of sclerosant, Outcome 1 Pleurodesis failure rate.
Study or subgroup Rapid drainage Standard
drainage
Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ozkul 2014 5/40 6/39 100% 0.79[0.22,2.82]
   
Total (95% CI) 40 39 100% 0.79[0.22,2.82]
Total events: 5 (Rapid drainage), 6 (Standard drainage)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.37(P=0.71)  
Favours rapid drainage 1000.01 100.1 1 Favours standard drainage
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Comparison 24.   Dose of silver nitrate





Statistical method Effect size
1 Pleurodesis failure rate 1   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
1.1 Silver nitrate 90 mg vs 150 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
0.0 [0.0, 0.0]
1.2 Silver nitrate 90 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
0.18 [0.01, 4.01]
1.3 Silver nitrate 150 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
0.18 [0.01, 4.01]
2 Fever 1   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
2.1 Silver nitrate 90 mg vs 150 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
0.63 [0.09, 4.24]
2.2 Silver nitrate 90 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.89]
2.3 Silver nitrate 150 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
1.59 [0.24, 10.70]
3 Pain 1   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
3.1 Silver nitrate 90 mg vs 150 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.89]
3.2 Silver nitrate 90 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.89]
3.3 Silver nitrate 150 mg vs 180 mg 1 40 Odds Ratio (M-H, Random,
95% CI)
1.0 [0.13, 7.89]
4 Mortality 1   Odds Ratio (M-H, Random,
95% CI)
Subtotals only
4.1 Silver nitrate 90 mg vs 150 mg 1 39 Odds Ratio (M-H, Random,
95% CI)
3.18 [0.30, 33.58]
4.2 Silver nitrate 90 mg vs 180 mg 1 39 Odds Ratio (M-H, Random,
95% CI)
7.80 [0.38, 161.87]
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Analysis 24.1.   Comparison 24 Dose of silver nitrate, Outcome 1 Pleurodesis failure rate.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
24.1.1 Silver nitrate 90 mg vs 150 mg  
Terra 2015 0/20 0/20   Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Experimental), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
24.1.2 Silver nitrate 90 mg vs 180 mg  
Terra 2015 0/20 2/20 100% 0.18[0.01,4.01]
Subtotal (95% CI) 20 20 100% 0.18[0.01,4.01]
Total events: 0 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
   
24.1.3 Silver nitrate 150 mg vs 180 mg  
Terra 2015 0/20 2/20 100% 0.18[0.01,4.01]
Subtotal (95% CI) 20 20 100% 0.18[0.01,4.01]
Total events: 0 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.08(P=0.28)  
Favours lower dose 1000.01 100.1 1 Favours higher dose
 
 
Analysis 24.2.   Comparison 24 Dose of silver nitrate, Outcome 2 Fever.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
24.2.1 Silver nitrate 90 mg vs 150 mg  
Terra 2015 2/20 3/20 100% 0.63[0.09,4.24]
Subtotal (95% CI) 20 20 100% 0.63[0.09,4.24]
Total events: 2 (Experimental), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
   
24.2.2 Silver nitrate 90 mg vs 180 mg  
Terra 2015 2/20 2/20 100% 1[0.13,7.89]
Subtotal (95% CI) 20 20 100% 1[0.13,7.89]
Total events: 2 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
24.2.3 Silver nitrate 150 mg vs 180 mg  
Terra 2015 3/20 2/20 100% 1.59[0.24,10.7]
Subtotal (95% CI) 20 20 100% 1.59[0.24,10.7]
Total events: 3 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=0.45, df=1 (P=0.8), I2=0%  
Favours lower dose 1000.01 100.1 1 Favours higher dose
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Analysis 24.3.   Comparison 24 Dose of silver nitrate, Outcome 3 Pain.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
24.3.1 Silver nitrate 90 mg vs 150 mg  
Terra 2015 2/20 2/20 100% 1[0.13,7.89]
Subtotal (95% CI) 20 20 100% 1[0.13,7.89]
Total events: 2 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
24.3.2 Silver nitrate 90 mg vs 180 mg  
Terra 2015 2/20 2/20 100% 1[0.13,7.89]
Subtotal (95% CI) 20 20 100% 1[0.13,7.89]
Total events: 2 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
24.3.3 Silver nitrate 150 mg vs 180 mg  
Terra 2015 2/20 2/20 100% 1[0.13,7.89]
Subtotal (95% CI) 20 20 100% 1[0.13,7.89]
Total events: 2 (Experimental), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours lower dose 1000.01 100.1 1 Favours higher dose
 
 
Analysis 24.4.   Comparison 24 Dose of silver nitrate, Outcome 4 Mortality.
Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
24.4.1 Silver nitrate 90 mg vs 150 mg  
Terra 2015 3/20 1/19 100% 3.18[0.3,33.58]
Subtotal (95% CI) 20 19 100% 3.18[0.3,33.58]
Total events: 3 (Experimental), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.96(P=0.34)  
   
24.4.2 Silver nitrate 90 mg vs 180 mg  
Terra 2015 3/20 0/19 100% 7.8[0.38,161.87]
Subtotal (95% CI) 20 19 100% 7.8[0.38,161.87]
Total events: 3 (Experimental), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.33(P=0.18)  
   
24.4.3 Silver nitrate 150 mg vs 180 mg  
Terra 2015 1/19 0/19 100% 3.16[0.12,82.64]
Subtotal (95% CI) 19 19 100% 3.16[0.12,82.64]
Total events: 1 (Experimental), 0 (Control)  
Heterogeneity: Not applicable  
Favours lower dose 1000.01 100.1 1 Favours higher dose
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Study or subgroup Experimental Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.69(P=0.49)  
Test for subgroup differences: Chi2=0.24, df=1 (P=0.89), I2=0%  
Favours lower dose 1000.01 100.1 1 Favours higher dose
 
 
Comparison 25.   Talc via indwelling pleural catheter (IPC)





Statistical method Effect size
1 Pleurodesis failure rate 1 139 Odds Ratio (M-H, Random, 95% CI) 0.36 [0.18, 0.73]
2 Pain 1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.15]
3 Mortality 1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.17, 1.15]
3.1 Talc via IPC vs IPC – not daily
drainage
1 154 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.17, 1.15]
 
 
Analysis 25.1.   Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 1 Pleurodesis failure rate.
Study or subgroup Talc via IPC Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Bhatnagar 2018 34/69 51/70 100% 0.36[0.18,0.73]
   
Total (95% CI) 69 70 100% 0.36[0.18,0.73]
Total events: 34 (Talc via IPC), 51 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.82(P=0)  
Favours talc via IPC 1000.01 100.1 1 Favours other
 
 
Analysis 25.2.   Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 2 Pain.
Study or subgroup Talc via IPC Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bhatnagar 2018 6/78 8/76 100% 0.71[0.23,2.15]
   
Total (95% CI) 78 76 100% 0.71[0.23,2.15]
Total events: 6 (Talc via IPC), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours talc via IPC 1000.01 100.1 1 Favours contol
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Analysis 25.3.   Comparison 25 Talc via indwelling pleural catheter (IPC), Outcome 3 Mortality.
Study or subgroup Talc via IPC Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
25.3.1 Talc via IPC vs IPC – not daily drainage  
Bhatnagar 2018 7/78 14/76 100% 0.44[0.17,1.15]
Subtotal (95% CI) 78 76 100% 0.44[0.17,1.15]
Total events: 7 (Talc via IPC), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
   
Total (95% CI) 78 76 100% 0.44[0.17,1.15]
Total events: 7 (Talc via IPC), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
Favours talc via IPC 1000.01 100.1 1 Favours other
 
 
Comparison 26.   Autologous blood





Statistical method Effect size
1 Pleurodesis failure rate 2 158 Odds Ratio (M-H, Random,
95% CI)
1.44 [0.60, 3.47]
1.1 Autologous blood vs talc slurry 1 110 Odds Ratio (M-H, Random,
95% CI)
1.46 [0.51, 4.16]
1.2 Autologous blood vs tetracycline 1 48 Odds Ratio (M-H, Random,
95% CI)
1.4 [0.28, 7.06]
2 Fever 2 158 Odds Ratio (M-H, Fixed, 95%
CI)
0.24 [0.10, 0.61]
2.1 Autologous blood vs talc slurry 1 110 Odds Ratio (M-H, Fixed, 95%
CI)
0.25 [0.09, 0.76]
2.2 Autologous blood vs tetracycline 1 48 Odds Ratio (M-H, Fixed, 95%
CI)
0.22 [0.04, 1.20]
3 Pain 2 158 Odds Ratio (M-H, Fixed, 95%
CI)
0.13 [0.05, 0.32]
3.1 Autologous blood vs talc slurry 1 110 Odds Ratio (M-H, Fixed, 95%
CI)
0.28 [0.09, 0.84]
3.2 Autologous blood vs tetracycline 1 48 Odds Ratio (M-H, Fixed, 95%
CI)
0.01 [0.00, 0.13]
4 Mortality 2 165 Odds Ratio (M-H, Fixed, 95%
CI)
0.72 [0.15, 3.38]
4.1 Autologous blood vs talc slurry 1 117 Odds Ratio (M-H, Fixed, 95%
CI)
0.72 [0.15, 3.38]
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Statistical method Effect size





Analysis 26.1.   Comparison 26 Autologous blood, Outcome 1 Pleurodesis failure rate.
Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
26.1.1 Autologous blood vs talc slurry  
Keeratichananont 2018 10/56 7/54 70.43% 1.46[0.51,4.16]
Subtotal (95% CI) 56 54 70.43% 1.46[0.51,4.16]
Total events: 10 (Autologous blood), 7 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
26.1.2 Autologous blood vs tetracycline  
Keeratichananont 2015 4/24 3/24 29.57% 1.4[0.28,7.06]
Subtotal (95% CI) 24 24 29.57% 1.4[0.28,7.06]
Total events: 4 (Autologous blood), 3 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
   
Total (95% CI) 80 78 100% 1.44[0.6,3.47]
Total events: 14 (Autologous blood), 10 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=0.82(P=0.41)  
Test for subgroup differences: Chi2=0, df=1 (P=0.97), I2=0%  
Favours autologous blood 1000.01 100.1 1 Favours other
 
 
Analysis 26.2.   Comparison 26 Autologous blood, Outcome 2 Fever.
Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
26.2.1 Autologous blood vs talc slurry  
Keeratichananont 2018 5/56 15/54 68.43% 0.25[0.09,0.76]
Subtotal (95% CI) 56 54 68.43% 0.25[0.09,0.76]
Total events: 5 (Autologous blood), 15 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.45(P=0.01)  
   
26.2.2 Autologous blood vs tetracycline  
Keeratichananont 2015 2/24 7/24 31.57% 0.22[0.04,1.2]
Subtotal (95% CI) 24 24 31.57% 0.22[0.04,1.2]
Total events: 2 (Autologous blood), 7 (Other)  
Heterogeneity: Not applicable  
Favours autologous blood 1000.01 100.1 1 Favours other
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Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=1.75(P=0.08)  
   
Total (95% CI) 80 78 100% 0.24[0.1,0.61]
Total events: 7 (Autologous blood), 22 (Other)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=3.01(P=0)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.89), I2=0%  
Favours autologous blood 1000.01 100.1 1 Favours other
 
 
Analysis 26.3.   Comparison 26 Autologous blood, Outcome 3 Pain.
Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
26.3.1 Autologous blood vs talc slurry  
Keeratichananont 2018 5/56 14/54 42.94% 0.28[0.09,0.84]
Subtotal (95% CI) 56 54 42.94% 0.28[0.09,0.84]
Total events: 5 (Autologous blood), 14 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
   
26.3.2 Autologous blood vs tetracycline  
Keeratichananont 2015 1/24 18/24 57.06% 0.01[0,0.13]
Subtotal (95% CI) 24 24 57.06% 0.01[0,0.13]
Total events: 1 (Autologous blood), 18 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
   
Total (95% CI) 80 78 100% 0.13[0.05,0.32]
Total events: 6 (Autologous blood), 32 (Other)  
Heterogeneity: Tau2=0; Chi2=5.68, df=1(P=0.02); I2=82.41%  
Test for overall effect: Z=4.45(P<0.0001)  
Test for subgroup differences: Chi2=5.54, df=1 (P=0.02), I2=81.97%  
Favours autologous blood 1000.01 100.1 1 Favours other
 
 
Analysis 26.4.   Comparison 26 Autologous blood, Outcome 4 Mortality.
Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
26.4.1 Autologous blood vs talc slurry  
Keeratichananont 2018 3/59 4/58 100% 0.72[0.15,3.38]
Subtotal (95% CI) 59 58 100% 0.72[0.15,3.38]
Total events: 3 (Autologous blood), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Favours autologous blood 1000.01 100.1 1 Favours other
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Study or subgroup Autolo-
gous blood
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
26.4.2 Autologous blood vs tetracycline  
Keeratichananont 2015 0/24 0/24   Not estimable
Subtotal (95% CI) 24 24 Not estimable
Total events: 0 (Autologous blood), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 83 82 100% 0.72[0.15,3.38]
Total events: 3 (Autologous blood), 4 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.41(P=0.68)  
Test for subgroup differences: Not applicable  
Favours autologous blood 1000.01 100.1 1 Favours other
 
 
Comparison 27.   Urokinase





Statistical method Effect size
1 Pleurodesis failure rate 1 69 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.46, 3.34]
2 Mortality 1 71 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 1.52]
 
 
Analysis 27.1.   Comparison 27 Urokinase, Outcome 1 Pleurodesis failure rate.
Study or subgroup Urokinase Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mishra 2018 13/35 11/34 100% 1.24[0.46,3.34]
   
Total (95% CI) 35 34 100% 1.24[0.46,3.34]
Total events: 13 (Urokinase), 11 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.68)  
Favours urokinase 1000.01 100.1 1 Favours other
 
 
Analysis 27.2.   Comparison 27 Urokinase, Outcome 2 Mortality.
Study or subgroup Urokinase Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Mishra 2018 31/36 35/35 100% 0.08[0,1.52]
   
Total (95% CI) 36 35 100% 0.08[0,1.52]
Favours urokinase 1000.01 100.1 1 Favours other
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Study or subgroup Urokinase Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 31 (Urokinase), 35 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.68(P=0.09)  
Favours urokinase 1000.01 100.1 1 Favours other
 
 
Comparison 28.   Streptokinase





Statistical method Effect size
1 Pleurodesis failure rate 2 64 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.10, 0.93]
2 Pain 1 47 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.26, 6.74]
 
 
Analysis 28.1.   Comparison 28 Streptokinase, Outcome 1 Pleurodesis failure rate.
Study or subgroup Streptokinase Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Okur 2011 5/19 7/16 50.37% 0.46[0.11,1.9]
Saydam 2015 2/18 5/11 49.63% 0.15[0.02,0.99]
   
Total (95% CI) 37 27 100% 0.31[0.1,0.93]
Total events: 7 (Streptokinase), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.35); I2=0%  
Test for overall effect: Z=2.08(P=0.04)  
Favours streptokinase 1000.01 100.1 1 Favours other
 
 
Analysis 28.2.   Comparison 28 Streptokinase, Outcome 2 Pain.
Study or subgroup Streptokinase Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Okur 2011 4/24 3/23 100% 1.33[0.26,6.74]
   
Total (95% CI) 24 23 100% 1.33[0.26,6.74]
Total events: 4 (Streptokinase), 3 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
Favours streptokinase 1000.01 100.1 1 Favours other
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Comparison 29.   Endostatin




Statistical method Effect size
1 Pleurodesis failure rate 1 128 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.20, 0.93]
2 Mortality 1 128 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.34, 1.76]
 
 
Analysis 29.1.   Comparison 29 Endostatin, Outcome 1 Pleurodesis failure rate.
Study or subgroup Endostatin
+ cisplatin
Cisplatin Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wang 2018 14/66 24/62 100% 0.43[0.2,0.93]
   
Total (95% CI) 66 62 100% 0.43[0.2,0.93]
Total events: 14 (Endostatin + cisplatin), 24 (Cisplatin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.14(P=0.03)  
Favours ndostatin + isplatin 1000.01 100.1 1 Favours cisplatin
 
 
Analysis 29.2.   Comparison 29 Endostatin, Outcome 2 Mortality.
Study or subgroup Endostatin
+ cisplatin 
Cisplatin Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wang 2018 14/66 16/62 100% 0.77[0.34,1.76]
   
Total (95% CI) 66 62 100% 0.77[0.34,1.76]
Total events: 14 (Endostatin + cisplatin ), 16 (Cisplatin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours ndostatin + isplatin 1000.01 100.1 1 Favours cisplatin
 
 
Comparison 30.   Dose of iodine




Statistical method Effect size
1 Pleurodesis failure rate 1 60 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.76]
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Analysis 30.1.   Comparison 30 Dose of iodine, Outcome 1 Pleurodesis failure rate.




Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Neto 2015 1/30 1/30 100% 1[0.06,16.76]
   
Total (95% CI) 30 30 100% 1[0.06,16.76]
Total events: 1 (1% iodine 100ml), 1 (2% iodine 100ml)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 1% iodine 1000.01 100.1 1 Favours 2% iodine
 
 
Comparison 31.   Indwelling pleural catheter (IPC) – daily drainage





Statistical method Effect size
1 Pleurodesis failure rate 3 291 Odds Ratio (M-H, Random, 95% CI) 0.59 [0.15, 2.35]
1.1 IPC – daily drainage vs talc
slurry
1 55 Odds Ratio (M-H, Random, 95% CI) 3.31 [0.88, 12.50]
1.2 IPC – daily drainage vs IPC not
daily drainage
2 236 Odds Ratio (M-H, Random, 95% CI) 0.31 [0.17, 0.56]
2 Pain 3 293 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.45, 1.34]
2.1 IPC – daily drainage vs talc
slurry
1 57 Odds Ratio (M-H, Fixed, 95% CI) 3.22 [0.13, 82.38]
2.2 IPC – daily drainage vs IPC –
not daily drainage
2 236 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.42, 1.28]
3 Mortality 3 293 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.55, 1.53]
3.1 IPC – daily drainage vs talc
slurry
1 57 Odds Ratio (M-H, Fixed, 95% CI) 1.70 [0.56, 5.17]
3.2 IPC – daily drainage vs IPC –
not daily drainage
2 236 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.43, 1.38]
 
 
Analysis 31.1.   Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 1 Pleurodesis failure rate.
Study or subgroup IPC daily
drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
31.1.1 IPC – daily drainage vs talc slurry  
Demmy 2012 9/26 4/29 29.95% 3.31[0.88,12.5]
Subtotal (95% CI) 26 29 29.95% 3.31[0.88,12.5]
Favours IPC daily drainage 1000.01 100.1 1 Favours other
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Study or subgroup IPC daily
drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 9 (IPC daily drainage), 4 (Other)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.76(P=0.08)  
   
31.1.2 IPC – daily drainage vs IPC not daily drainage  
Muruganandan 2018 27/43 39/44 32.6% 0.22[0.07,0.66]
Wahidi 2017 39/73 58/76 37.45% 0.36[0.18,0.72]
Subtotal (95% CI) 116 120 70.05% 0.31[0.17,0.56]
Total events: 66 (IPC daily drainage), 97 (Other)  
Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%  
Test for overall effect: Z=3.87(P=0)  
   
Total (95% CI) 142 149 100% 0.59[0.15,2.35]
Total events: 75 (IPC daily drainage), 101 (Other)  
Heterogeneity: Tau2=1.2; Chi2=10.75, df=2(P=0); I2=81.4%  
Test for overall effect: Z=0.75(P=0.45)  
Test for subgroup differences: Chi2=10.18, df=1 (P=0), I2=90.18%  
Favours IPC daily drainage 1000.01 100.1 1 Favours other
 
 
Analysis 31.2.   Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 2 Pain.
Study or subgroup IPC daily
drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
31.2.1 IPC – daily drainage vs talc slurry  
Demmy 2012 1/28 0/29 1.57% 3.22[0.13,82.38]
Subtotal (95% CI) 28 29 1.57% 3.22[0.13,82.38]
Total events: 1 (IPC daily drainage), 0 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
   
31.2.2 IPC – daily drainage vs IPC – not daily drainage  
Muruganandan 2018 8/43 13/44 35.32% 0.55[0.2,1.49]
Wahidi 2017 25/73 29/76 63.1% 0.84[0.43,1.65]
Subtotal (95% CI) 116 120 98.43% 0.74[0.42,1.28]
Total events: 33 (IPC daily drainage), 42 (Other)  
Heterogeneity: Tau2=0; Chi2=0.5, df=1(P=0.48); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
   
Total (95% CI) 144 149 100% 0.78[0.45,1.34]
Total events: 34 (IPC daily drainage), 42 (Other)  
Heterogeneity: Tau2=0; Chi2=1.27, df=2(P=0.53); I2=0%  
Test for overall effect: Z=0.92(P=0.36)  
Test for subgroup differences: Chi2=0.77, df=1 (P=0.38), I2=0%  
Favours IPC daily drainag 1000.01 100.1 1 Favours other
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Analysis 31.3.   Comparison 31 Indwelling pleural catheter (IPC) – daily drainage, Outcome 3 Mortality.
Study or subgroup IPC daily
drainage
Other Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
31.3.1 IPC – daily drainage vs talc slurry  
Demmy 2012 11/28 8/29 15.5% 1.7[0.56,5.17]
Subtotal (95% CI) 28 29 15.5% 1.7[0.56,5.17]
Total events: 11 (IPC daily drainage), 8 (Other)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
31.3.2 IPC – daily drainage vs IPC – not daily drainage  
Muruganandan 2018 10/43 9/44 22.17% 1.18[0.43,3.26]
Wahidi 2017 18/73 26/76 62.33% 0.63[0.31,1.28]
Subtotal (95% CI) 116 120 84.5% 0.77[0.43,1.38]
Total events: 28 (IPC daily drainage), 35 (Other)  
Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%  
Test for overall effect: Z=0.87(P=0.39)  
   
Total (95% CI) 144 149 100% 0.92[0.55,1.53]
Total events: 39 (IPC daily drainage), 43 (Other)  
Heterogeneity: Tau2=0; Chi2=2.48, df=2(P=0.29); I2=19.47%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=1.51, df=1 (P=0.22), I2=33.76%  
Favours IPC daily drainage 1000.01 100.1 1 Favours other
 
 
Comparison 32.   Mistletoe (viscum)




Statistical method Effect size
1 Pleurodesis failure rate 1 17 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.62]
 
 
Analysis 32.1.   Comparison 32 Mistletoe (viscum), Outcome 1 Pleurodesis failure rate.
Study or subgroup Mistletoe
(viscum)
Bleomycin Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Gaafar 2014 2/10 4/7 100% 0.19[0.02,1.62]
   
Total (95% CI) 10 7 100% 0.19[0.02,1.62]
Total events: 2 (Mistletoe (viscum)), 4 (Bleomycin)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.52(P=0.13)  
Favours istletoe (viscum) 1000.01 100.1 1 Favours bleomycin
 
 
A D D I T I O N A L   T A B L E S
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NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA /
Bleomycin NA NA NA / / / NA NA / / / NA NA NA NA / / NA /
C parvum NA NA 0.55 (0.01 to 57.48); n
= 2; Tau2 = 10.59; I2 =
94%
NA / NA NA NA NA NA NA / NA NA NA NA NA NA /
Doxycycline NA NA 0.67 (0.24 to 1.86); n =






NA NA NA / NA NA NA NA NA NA NA / NA NA NA
IFN NA NA 3.25 (1.54 to 6.89); n
= 1
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
IPC – daily
drainage
NA NA NA NA NA NA NA / NA NA NA NA NA NA NA NA / NA NA
IPC – not dai-
ly drainage















NA NA NA NA NA NA NA NA NA / / NA
Iodine NA NA 0.65 (0.22 to 1.96); n =
2; Tau2 = 0.16; I2 = 25%
NA NA NA NA NA NA NA NA NA NA NA NA / / NA NA
Mepacrine NA NA 0.16 (0.03 to 0.89); n
= 1
NA NA NA NA NA NA NA / NA / NA NA NA / NA /






























































































































































NA NA 0.19 (0.02 to 1.62); n =
1
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Mitoxantrone NA NA 3.18 (1.17 to 8.65); n
= 1
















NA NA NA NA NA NA NA NA NA NA NA / NA NA /











NA NA NA NA NA / NA /
Silver nitrate NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA /
TMP NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA NA
Talc
poudrage
NA NA 0.1 (0.02 to 0.48); n =

















NA NA NA NA / NA /






0.82 (0.37 to 1.82); n =
5; Tau2 = 0.1; I2 = 12%






































































































































































































































2.00 (1.07 to 3.75); n






















































NA NA NA NA NA NA
* Indicates that the comparison included a three-arm study. 
Results that are significant at the conventional level of P ≤ 0.05 are in bold. 
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around.
Table 1.   Direct meta-analysis of pleurodesis failure using the random-eects model showing the odds ratios (95% CI) of the rows compared to the
columns  (Continued)
























































































































































































































































































































































































NA / / / / / / / / /



























































































































































































































































































































































































































































































































































































































































































































































































































































































































Results that are significant at the conventional level of P < 0.05 are in bold. 
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around.
Table 2.   Results of network meta-analysis for pleurodesis failure showing the odds ratios (95% Cr-I) of the agents in the rows compared to the agents
in the columns  (Continued)





















































































OR (95% CI) of agent 1
compared with agent
2***





 6/36 Cisplatin 17/34 0.20 (0.07 to 0.60)
Tetracycline**  3/19 Combined tetracycline
and bleomycin





group Bleomycin**  2/19 Combined tetracycline
and bleomycin
0/19 5.57 (0.25 to 124.19)
OK-432  8/17 Cisplatin  11/17 0.48 (0.12 to 1.92)












High-dose OK-432  5/19 Low-dose OK-432  3/19 1.90 (0.38 to 9.44)
Luh 1992 Lung can-
cer-specific
therapy





Mixed-particle talc  3/14 Graded talc (particles
> 20 µm)





















 25/62 VATS pleurectomy 24/60 0.88 (0.43 to 1.82)
90 mg silver nitrate 0/20 150 mg silver nitrate 0/20 Not estimable







150 mg silver ni-
trate






Cisplatin + 45 mg
endostatin
14/66 Cisplatin 24/62 0.43 (0.2 to 0.93)
Table 3.   Results for pleurodesis failure of the studies evaluating pleurodesis methods which were not included in
the network meta-analysis 
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OK-432  8/33 Bleomycin  11/35 0.70 (0.24 to 2.03)
OK-432  8/33 Cisplatin and etopo-
side






Bleomycin  11/35 Cisplatin and etopo-
side
 10/34 1.10 (0.39 to 3.07)





 3/17 Cisplatin  9/18 0.21 (0.05 to 1.01)
*Three-arm study.
**The results for the pair-wise comparison between tetracycline and bleomycin are included in the network meta-analysis.
***Results that are significant at the conventional level of P ≤ 0.05 are in bold.
Table 3.   Results for pleurodesis failure of the studies evaluating pleurodesis methods which were not included in
the network meta-analysis  (Continued)



























the end of tho-
racoscopy
2/15 Tetracycline pleurodesis
through an intercostal can-
nula






































2/10 No rotation after instillation
of talc






2/16 Drain removed 72 hours after
pleurodesis
4/19 0.54 (0.08 to 3.40)Duration of
drainage af-
ter administra-






2/9 Drain removal when < 150
mL/day output
3/15 1.14 (0.15 to 8.59)
Table 4.   Results for pleurodesis failure of the studies evaluating interventions to optimise pleurodesis which were
not included in the network meta-analysis 
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0/12 Single bedside instillation of
oxytetracycline









tion of talc slur-
ry after drain in-
sertion
5/40 Instillation of talc slurry
when daily drainage from
chest tube < 300 mL/day
6/39 0.79 (0.22 to 2.82)
Okur 2011 Intrapleural
streptokinase












13/35 Placebo 11/34 1.24 (0.46 to 3.34)
*Results that are  significant at the conventional level of P ≤ 0.05 are in bold.
**Studies with more than 2 comparison arms.
Table 4.   Results for pleurodesis failure of the studies evaluating interventions to optimise pleurodesis which were
not included in the network meta-analysis  (Continued)
CI: confidence interval; NSAID: non-steroidal anti-inflammatory drug; OR: odds ratio.
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Bleomycin 11.53 (0.70 to
205.20)







NA / / / / / / / / / /
Doxycy-
cline

















NA / / / / / / / /










NA / / / / / / /






























NA / / / / /




























































































































































































































































































































































Results that are significant at the conventional level of P ≤ 0.05 are in bold. 
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way round.
Table 5.   Results of network meta-analysis for causing fever showing odds ratios (95% CI) of the agents in rows compared to the agents in
columns  (Continued)
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A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (the Cochrane library)
#1           MeSH descriptor: [Pleural E)usion] explode all trees
#2           (pleura* near/5 (e)usion* or fluid*)):ti,ab,kw  (Word variations have been searched)
#3           #1 or #2
#4           MeSH descriptor: [Neoplasms] explode all trees
#5           (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*):ti,ab,kw  (Word variations have been searched)
#6           #4 or #5
#7           #3 and #6
MEDLINE (Ovid)
1     exp Pleural E)usion/
2     (pleura* adj5 (e)usion* or fluid*)).mp.
3     or/1-2
4     exp Neoplasms/
5     (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp.
6     or/4-5
7     randomized controlled trial.pt.
8     controlled clinical trial.pt.
9     randomized.ab.
10     placebo.ab.
11     clinical trials as topic.sh.
12     randomly.ab.
13     trial.ti.
14     7 or 8 or 9 or 10 or 11 or 12 or 13
15     3 and 6 and 14
Embase (Ovid)
1     exp Pleural E)usion/
2     (pleura* adj5 (e)usion* or fluid*)).mp.
3     or/1-2
4     exp neoplasm/
5     (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*).mp.
6     or/4-5
7     random$.tw.
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13     (doubl$ adj blind$).tw.






20     Randomized Controlled Trial/
21     Single Blind Procedure/
22     or/7-21
23     (animal/ or nonhuman/) not human/
24     22 not 23
25     3 and 6 and 24
Web of Science (ISI) SSCI & SCI
#11 #10 AND #2
#10 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3
#9 Topic=(((("random* allocat*") or ("random* assign*"))))
#8 Topic=(((crossover)))
#7 Topic=(((("tripl* blind*") or ("tripl* mask*"))))
#6 Topic=(((("trebl* blind*") or ("trebl* mask*"))))
#5 Topic=(((("doubl* blind*") or ("doubl* mask*"))))
#4 Topic=(((("singl* blind*") or ("singl* mask*"))))
#3 Topic=(((("clin* trial*"))))
#2 Topic=((pleura* near/5 (e)usion* or fluid*))) AND Topic=((cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*))
#1 Topic=((pleura* near/5 (e)usion* or fluid*)))
CINAHL (EBSCO)
S25         S18 AND S21 AND S24  
S24         S22 OR S23        
S23         (cancer* or tumor* or tumour* or neoplas* or carcinom* or malignan*)             
S22         (MH "Neoplasms+")     
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S21         S19 OR S20        
S20         (pleura* N5 (e)usion* or fluid*))          
S19         (MH "Pleural E)usion+")            
S18         S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17              
S17         (allocat* random*)       
S16         (MH "Quantitative Studies")     
S15         (MH "Placebos")            
S14         placebo*           
S13         (random* allocat*)       
S12         (MH "Random Assignment")    
S11         (Randomi?ed control* trial*)    
S10         (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )        
S9           S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 
S8           (allocat* random*)       
S7           (MH "Quantitative Studies")     
S6           (MH "Placebos")            
S5           placebo*           
S4           (random* allocat*)       
S3           (MH "Random Assignment")    
S2           (Randomi?ed control* trial*)    
S1           (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
Appendix 2. Distribution of study population characteristics across all the included studies and within each pair-
wise comparison
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)







































































































































































— 79 2 2 2 2 5 5 2 2 2 4 2 2
All 58 (73) 1 (50) 2 (100) 2
(100)





Only breast 8 (10) 0 0 0 1 (50) 0 0 0 0 0 0 0 2
(100)
Only lung 8 (10) 0 0 0 0 0 0 0 0 0 0 0 0
Cell types
included
Other 5 (6) 1 (50) 0 0 0 0 0 0 0 0 0 0 0
Excluded  37 (47) 0 0 2
(100)




Included 42 (53) 2 (100) 2 (100) 0 1 (50) 2 (40) 4 (80) 1 (50) 1 (50) 2
(100)
1 (25) 0 1 (50)
Unknown 31 (39) 1 (50) 1 (50) 1 (50) 1 (50) 1 (20) 4 (80) NA NA 0 2 (50) 0 2
(100)
Small (< 20-Fr) 14 (18) 1 (50) 1 (50) 0 1 (50) 1 (20) 0 NA NA 1 (50) 0 0 0
















































































































































































22 (28) 0 1 (50) 2
(100)
1 (50) 1 (20) 1 (20) 0 0 0 2 (50) 0 1 (50)
2–4 months 31 (39) 1 (50) 1 (50) 0 1 (50) 1 (20) 2 (40) 2 (100) 0 2
(100)
2 (50) 0 1 (50)
> 4–7 months 3 (4) 0 0 1 (50) 0 0 0 0 0 0 1 (25) 1 (50) 0
> 11–12 months 4 (5) 0 0 0 0 0 0 0 2 (100) 0 0 0 1 (50)






Not stated 7 (9) 0 0 0 1 (50) 2 (40) 0 0 0 0 0 0 0
*If the study reported multiple time points, the one referred to here was that used in our primary analysis (according to our hierarchy of preferences (see Primary out-
comes))
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Appendix 3. Sensitivity analysis of the direct meta-analysis results for pleurodesis failure using the fixed-eect
model showing odds ratios (95% CI) of the rows compared to the columns
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NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA /
Bleomycin NA NA NA / / / NA NA / / / NA NA NA NA / / NA /
C parvum NA NA 0.72 (0.32 to 1.61); n = 2;
Chi2 = 17; I2 = 94%
NA / NA NA NA NA NA NA / NA NA NA NA NA NA /
Doxycycline NA NA 0.66 (0.24 to 1.83); Chi2 =






NA NA NA / NA NA NA NA NA NA NA / NA NA NA
IFN NA NA 3.25 (1.54 to 6.89); n =
1
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
IPC –daily
drainage
NA NA NA NA NA NA NA / NA NA NA NA NA NA NA NA / NA NA
IPC –not dai-
ly drainage
















NA NA NA NA NA NA NA NA NA / / NA
Iodine NA NA 0.63 (0.25 to 1.59); n = 2;
Chi2 = 1.33; I2 = 25%
NA NA NA NA NA NA NA NA NA NA NA NA / / NA NA
Mepacrine NA NA 0.16 (0.03 to 0.89); n =
1






























































































































































NA NA 0.19 (0.02 to 1.62); n = 1 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Mitoxantrone NA NA 3.18 (1.17 to 8.65); n =
1
















NA NA NA NA NA NA NA NA NA NA NA / NA NA /











NA NA NA NA NA / NA /
Silver nitrate NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA /
TMP NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA / NA NA
Talc
poudrage
NA NA 0.1 (0.02 to 0.48); n = 2;

















NA NA NA NA / NA /






0.82 (0.41 to 1.65); n = 5;
Chi2 = 4.53; I2 = 12%










































































































































































































































2.00 (1.07 to 3.73); n =






















































NA NA NA NA NA NA
IFN: interferon; IPC: indwelling pleural catheter; n: the number of studies included in the pair-wise comparison; NA: no direct pair-wise comparison available; TMP: thoraco-
scopic mechanical pleurodesis
* indicates that the comparison included a three-arm study
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 4. Overview of the network meta-analysis results for pleurodesis failure in the secondary endpoints and
sensitivity analyses
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)










































































































































Whole network 21 55 0.70 (0.30 to 1.17) 118 91.3 209.3 0.7 113.9 101 214.9 0.8 No
Fever 14 30 1.67 (1.08 to 1.98) 65.2 56.2 121.5 1.67 64.5 56.7 121.2 1.24 No
Mortality 15 31 0.22 (0.01 to 0.73) 53.8 45.0 98.8 0.22 54.2 49.9 104.0 0.25 No
Pain 14 31 0.69 (0.11 to 1.51) 67.2 51.0 118.2 0.69 60.0 53.4 113.4 0.53 No
Only data collected at 1 month 16 30 0.71 (0.07 to 1.51) 63.7 53 116.8 0.71 63.2 56.9 120.1 0.4 No
Only data collected at 3 months 9 10 0.54 (0.03 to 1.83) 19.9 19 38.8 0.54 19.7 19.2 38.8 0.55 No
Only data collected at 6 months 7 9 0.44 (0.02 to 1.75) 16.9 16.2 33.1 0.44 17.3 16.9 34.2 0.53 No
Trials excluding people with trapped lung 13 23 0.31 (0.01 to 1.19) 47.3 37.2 84.5 0.31 45.5 41.4 86.9 0.45 No
Trials using a clinicoradiological definition of
pleurodesis
19 37 0.89 (0.42 to 1.54) 78.5 66.8 145.3 0.89 78 71.3 149.4 1.09 No
Trials using large-bore chest tubes 12 19 0.73 (0.04 to 1.84) 42.4 33.5 75.9 0.73 39.3 35.1 74.4 0.83 No
Trials with a lower risk of bias (scoring 'high'
risk of bias in maximum 1 domain)
18 27 0.37 (0.02 to 1.47) 56.9 46.2 103.2 0.37 54.1 51.2 105.3 0.59 No
Trials delivering agents by chest tube 16 37 0.87 (0.37 to 1.52) 78.7 63.6 142 0.87 76.6 69.5 146 1.19 No
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Appendix 5. Estimated rank (95% Cr-I) for pleurodesis eicacy in the sensitivity analysis only evaluating those trials
with a lower risk of bias (lower rank confers higher risk of pleurodesis failure)
 
Pleurodesis method Estimated rank (95% Cr-I)
Talc poudrage 2 (1 to 9)
Talc slurry 4 (1 to 9)
C parvum 4 (1 to 12)
Mepacrine 6 (1 to 13)
Iodine 6 (1 to 16)
Doxycycline 7 (1 to 14)
Adriamycin 7 (1 to 18)
Autologous blood 8 (2 to 15)
Tetracycline 9 (4 to 14)
IPC – daily drainage 9 (2 to 15)
Silver nitrate 9 (1 to 17)
Talc via IPC 10 (2 to 17)
Bleomycin 12 (6 to 16)
Mustine 14 (6 to 18)
Triethylenethiophosphoramide 14 (4 to 18)
IPC – not daily drainage 15 (9 to 18)
Mitoxantrone 17 (12 to 18)
Placebo 17 (12 to 18)
Cr-I: credible interval; IPC: indwelling pleural catheter
 
 
Appendix 6. Estimated rank (95% Cr-I) for the subgroup analysis evaluating the network of agents given via a chest
tube (IPC and talc poudrage studies excluded)
 
Pleurodesis agent Estimated rank (95% Cr-I)
Mistletoe 1 (1 to 12)
C parvum 4 (1 to 11)
 
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)









Cochrane Database of Systematic Reviews
Mepacrine 4 (1 to 11)
Talc slurry 5 (2 to 10)
Iodine 6 (1 to 12)
Doxycycline 6 (1 to 13)
Adriamycin 7 (1 to 16)
Bleomycin 8 (5 to 12)
Silver nitrate 8 (1 to 15)
Autologous blood 9 (2 to 15)
Tetracycline 10 (5 to 13)
Triethylenethiophosphoramide 12 (2 to 16)
IFN 13 (4 to 16)
Mustine 13 (5 to 16)
Mitoxantrone 14 (9 to 16)
Placebo 15 (11 to 16)
Cr-I: credible interval; IFN: interferon
  (Continued)
 
Appendix 7. Results of the sensitivity analysis only evaluating those studies with a lower risk of bias. Table of odds
ratios (95% Cr-I) from network meta-analysis (agents in the rows compared to those in the columns)
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)

































































































































































































/ / / / / / / / / / /






























































































































































































































































































































































































































































































































































































































































































































































/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around





































































Cochrane Database of Systematic Reviews
Appendix 8. Results of the sensitivity analysis only evaluating agents given via chest tube. Table of odds ratios (95%
Cr-I) from network meta-analysis (the agents in the rows compared to the agents in the columns) for pleurodesis
success
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NA / / / / / / / / / / / / /
Bleomycin1.22 (0.02 to 82.63) 0.80 (0.13 to
4.81)
NA / / / / / / / / / / / /
C
parvum














NA / / / / / / / / / /










NA / / / / / / / / /











NA / / / / / / / /



















































































































































































































































































































































































































































































Results that are significant at the conventional level of P < 0.05 are in bold
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 9. Direct pair-wise evidence for fever, expressed as odds ratios (95% CI) for the rows compared to the
columns, using random-eects meta-analysis
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Bleomycin NA NA / / NA / / / NA NA NA / / /
C parvum NA 2.30 (0.9 to 5.92); n = 2; Tau2 = 0; I2 =
0%
NA / NA NA NA NA / NA NA NA NA /






NA / NA NA NA NA NA NA NA NA NA
Interferon NA 0.00 (0.00 to 0.11); n = 1 NA NA NA NA NA NA NA NA NA NA NA NA
IPC –not daily
drainage






NA NA NA NA NA NA NA NA NA NA
Iodine NA 1.00 (0.13 to 7.6); n = 1 NA NA NA NA NA NA NA NA NA / / NA
Mepacrine NA 1.91 (0.52 to 7.01); n = 1 NA NA NA NA NA NA NA / NA NA NA /
Mitoxantrone NA 0.90 (0.30 to 2.71); n = 1 NA NA NA NA NA NA NA / NA NA NA NA




NA NA NA NA NA NA NA NA NA NA NA






































































































































































Silver nitrate NA NA NA NA NA NA NA NA NA NA NA NA / /










0.95 (0.36 to 2.51); n = 3: Tau2 = 0; I2 =
0%




= 0; I2 =
0%




















































NA NA NA NA
* indicates that the comparison included a three-arm study
Results that are significant at the conventional level of P ≤ 0.05 are in bold
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 10. Table of the relative chance of pain from direct pair-wise evidence using random-eects model (odds
ratios (95% Cr-I) (rows compared to columns)
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Bleomycin NA NA / / NA NA / / / NA NA NA / / /
C parvum NA 1.42 (0.54 to 3.75); n = 2; Tau2 = 0;
I2 = 0%
NA / NA NA NA NA NA NA NA NA NA NA /
Doxycycline NA 1.19 (0.37 to 3.80); n = 2; Tau2 =






NA NA / NA NA NA NA NA NA NA NA NA
IFN NA 0.03 (0.00 to 0.53); n = 1 NA NA NA NA NA NA NA NA NA NA NA NA NA
IPC –daily
drainage
NA NA NA NA NA / NA NA NA NA NA NA NA / NA
IPC –not daily
drainage








= 2; Tau2 =
0; I2 = 0%
NA NA NA NA NA NA NA NA NA NA
Iodine NA 1.00 (0.13 to 7.60); n = 1 NA NA NA NA NA NA NA NA NA NA / / NA





NA NA NA /
Mitoxantrone NA 2.08 (0.64 to 6.76); n = 1 NA NA NA NA NA NA NA NA NA NA NA NA NA






































































































































































0.60 (0.15 to 2.46); n = 3; Tau2 = 0;
I2 = 0%













NA NA NA NA NA NA NA /
Talc via IPC NA NA NA NA NA 0.71 (0.23
to 2.15); n
= 1






1.65 (0.79 to3.43); n = 4; Tau2 =










































NA NA NA NA
* indicates that the comparison included a three-arm study
Results that are significant at the conventional level of P ≤ 0.05 are in bold
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 11. Table of the relative chances of pain from network meta-analysis (expressed as odds ratios (95% Cr-I)
(rows compared to the columns)
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)






















































































































Bleomycin 19.46 (3.47 to
138.70)
NA / / / / / / / / / / /













NA / / / / / / / / /
IPC – daily
drainage




















NA / / / / / / /










NA / / / / / /































































NA / / /










































































































































































































































































































Results that are significant at the conventional level of P ≤ 0.05 are in bold
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 12. Estimated rank (95% Cr-I) for causing pain (a low rank suggesting more pain)
 
Pleurodesis agent Estimated rank (95% Cr-I)
Autologous blood 1 (1 to 4)
Iodine 2 (1 to 8)
Talc via IPC 4 (1 to 13)
Talc slurry 5 (2 to 8)
IPC –daily drainage 5 (2 to 12)
IPC –not daily drainage 6 (2 to 12)
Talc poudrage 6 (2 to 12)
Bleomycin 8 (4 to 11)
Doxycycline 9 (4 to 13)
Tetracycline 10 (6 to 13)
Mitoxantrone 11 (3 to 14)
Triethylenethiophosphoramide 11 (2 to 14)
C parvum 12 (8 to 14)
Mepacrine 13 (8 to 14)
Cr-I: credible interval; IPC: indwelling pleural catheter
 
 
Appendix 13. Table of the relative chance of mortality from direct evidence using random-eects model (odds ratios
(95% Cr-I) (rows compared to columns)
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)
























































































































Bleomycin NA NA / / / NA NA NA NA / NA / /
C parvum NA 1.66 (0.51 to 5.38); n = 1 NA NA NA NA NA NA NA NA / NA NA
Doxycycline NA 0.69 (0.26 to 1.87); n = 1 NA NA NA NA NA NA NA NA NA NA NA
IFN NA 2.16 (1.15 to 4.07); n = 1 NA NA NA NA NA NA NA NA NA NA NA
IPC –daily
drainage
NA NA NA NA NA NA / NA NA NA NA NA /
IPC –not daily
drainage
NA NA NA NA NA 1.29 (0.72 to
2.32); n = 2;
Tau2 = 0; I2 =
0%
NA NA NA NA NA NA /
Iodine NA NA NA NA NA NA NA NA NA NA NA / /
Mepacrine NA NA NA NA NA NA NA NA NA / NA NA /




NA NA NA NA




NA NA NA NA NA NA NA NA / NA













1.12 (0.36 to 3.46); n = 2;
Tau2 = 0; I2 = 0%
NA NA NA 0.59 (0.19 to
1.79); n = 1
1.43 (0.91 to









NA NA 1.10 (0.69 to



































































































































































Talc via IPC NA NA NA NA NA NA 0.44 (0.17 to
1.15); n = 1
NA NA NA NA NA NA
Tetracycline Not es-
timable
1.60 (0.69 to 3.69); n = 2;





NA NA NA NA NA NA NA NA 0.19 (0.03 to
1.10); n = 1
NA
* indicates that the comparison included a three-arm study
Results that are  significant at the conventional level of P ≤ 0.05 are shaded in grey
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 14. Table of the relative chances of mortality from network meta-analysis (expressed as odds ratios (95%
Cr-I) (rows compared to columns)
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)
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cline
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Results that are significant at the conventional level of P ≤ 0.05 are in bold
/ indicates the odds ratio is already expressed elsewhere in the table comparing the interventions the other way around
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Appendix 15. Estimated rank (95% Cr-I) for mortality (low rank suggesting higher mortality)
 
Pleurodesis agent Estimated rank (95% Cr-I)
Talc via IPC 2 (1 to 11)
Iodine 2 (1 to 11)
Mitoxantrone 3 (1 to 10)
Mepacrine 5 (1 to 12)
Doxycycline 6 (1 to 14)
Autologous blood 6 (1 to 15)
IPC –not daily drainage 7 (3 to 12)
IPC –daily drainage 7 (3 to 13)
Talc Poudrage 8 (4 to 12)
Talc Slurry 9 (6 to 13)
Bleomycin 10 (4 to 13)
C parvum 11 (3 to 15)
IFN 13 (7 to 15)
Tetracycline 14 (10 to 15)
Mustine 14 (6 to 15)
Cr-I: credible interval; IFN: interferon; IPC: indwelling pleural catheter
 
 
W H A T ' S   N E W
 
Date Event Description
10 February 2020 New search has been performed This review has been updated with the results of a new search in
June 2019.
10 February 2020 New citation required and conclusions
have changed
The conclusions have changed due to the inclusion of 18 new
studies (2079 participants). We have more data to be more cer-
tain of the effects of talc slurry, talc poudrage and indwelling
pleural catheters.
 
H I S T O R Y
Protocol first published: Issue 5, 2013
Review first published: Issue 5, 2016
Interventions for the management of malignant pleural eusions: a network meta-analysis (Review)
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Date Event Description
9 April 2019 Amended Comma deleted in ongoing study reference (OPUS Trial).
2 April 2019 Amended Published Notes text amended.
11 January 2018 Review declared as stable See Published notes.
21 August 2014 Amended Updated the authors' Declaration of Interest statements.
 
C O N T R I B U T I O N S   O F   A U T H O R S
The protocol was written collaboratively by AOC, HEJ, RB, NP, NAM.
AD and AOC screened the titles and abstracts and obtained the full-text papers for the 2020 update. Screening of titles and abstracts up
to 2016 was by AOC only.
AD, AOC, NAM assessed the full-text articles for inclusion.
AD, AOC, NP, RB and NAM performed the data extractions.
AD and AOC entered the data into Review Manager (and RevMan Web for 2020 update) and undertook the direct pair-wise comparisons.
HJ performed the network meta-analysis and provided statistical support.
AD and AOC draGed the final report, which was reviewed and amended by all the authors.
AOC and NAM are responsible for future updates.
D E C L A R A T I O N S   O F   I N T E R E S T
AD: none known.
HJ: none known.
RB was  the trial co-ordinator for the TAPPS and IPC-Plus studies (Bhatnagar 2018; Bhatnagar 2020), but did not perform the data
extractions, or any assessments of risk of bias or GRADE, for these studies for the purposes of this review.
NJP: none known.
NM was a member of the trial steering committee for TIME-1 and TIME-3 trials (Mishra 2018; Rahman 2015). NM is a co-author for one of
the included studies (Maskell 2004). However, he did not perform the data extractions, nor any assessments of risk of bias or GRADE, for
these studies for the purposes of this review. North Bristol NHS Trust received unrestricted research funding from CareFusion, to run the
IPC-Plus trial (Bhatnagar 2018) (2012 to 2016) for which NM was the chief investigator. NM also received honoraria from CareFusion for
medical advisory board meetings (2015 to 2019).
AOC was involved in co-ordinating and recruiting to the TIME-3 trial (Mishra 2018). She also recruited to the TAPPS trial (Bhatnagar 2020),
and assisted with the data analysis. She did not perform the data extraction, nor any assessments of risk of bias or GRADE,  for these
studies for the purpose of this review.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health and Care Excellence (NICE), UK.
NIHR Project Reference: NIHR 129794. Cochrane priority reviews for NICE: update commissioned by NICE for completion by March 2020;
relevant guideline: Lung cancer: diagnosis and management, NICE guideline [NG122].
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
2016 review
The wording of the background and methods sections have been improved to make them more concise, minimise repetition and to reflect
the recently published literature.
In the original protocol, we stated we would use risk ratios for dichotomous outcomes; however, we elected to use odds ratios instead,
since network meta-analysis models are more readily available for these.
The protocol stated that the size of the study would be assessed to look for bias associated with small-study e)ects. This was not performed,
as size in itself should not a)ect the study results and inclusion of sample size in 'Risk of bias' tables would be against the advice in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a), and training provided by the Cochrane Bias Methods Group.
The protocol combined blinding of participants and personnel and outcome assessment into a single domain. However, in light of new
guidance from Cochrane, this was separated into 'blinding of participants and personnel' and 'blinding of outcome assessment', as per the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).
The protocol stated we would evaluate mortality in the short, medium and long term. However, due to a paucity of evidence at all these
di)erent time points, an overall assessment was done using the available study data closest to three months aGer the intervention.
The wording of the planned sensitivity analyses has been amended for clarity.
For clarity, we added 'a network meta-analysis' to the title.
Post-hoc, we chose to perform a sensitivity analysis of the main network excluding talc poudrage and IPCs in order to remove the e)ect of
mode of administration to identify which agent may be best delivered via a standard chest tube.
2020 update
We further updated the wording of the background sections to reflect recent literature. We performed a search for ongoing studies on
clinical trial registries, and extracted information on study funding sources and study author conflicts of interest statements, in line with
current Cochrane standards.
We added "methods to optimise IPC use including IPC drainage regimen and combined talc administration via IPC" to the list of types of
interventions because data from newer studies, which have investigated whether daily IPC drainage or talc slurry via IPC may result in
fewer pleurodesis failures in comparison to standard IPC use (with drainage based on symptoms), is included in this review.
We expanded the interventions of direct interest to include 'IPC (both daily drainage and without daily drainage) and talc administered via
IPC' to reflect the di)erent ways in which IPCs are studied in more recent literature.
We included that 'for studies evaluating IPCs, we judged that an e)ective pleurodesis was achieved when there was cessation of pleural
fluid drainage or device removal due to cessation of drainage, or both' to reflect a more specific and clinically relevant definition of
pleurodesis failure relating to IPC use. This was used in preference to the other definitions of pleurodesis failure, listed in the hierarchy of
preferences, in participants receiving an IPC.
In the 'Methods', for unit of analysis issues we added that 'in meta-analysis of continuous outcomes, we pooled di)erences in change from
baseline, rather than di)erences in final values (Higgins 2019)' in keeping with Cochrane Handbook for Systematic Reviews of Interventions
guidance.
In the 'Methods', we added that 'for continuous outcomes, where baseline and final values were reported without a standard deviation
of change score or correlation coe)icient, we imputed correlation coe)icients based on other studies in order to estimate the standard
deviation of change' in keeping with Cochrane Handbook for Systematic Reviews of Interventions guidance.
Although the use of network meta-analysis was mentioned in the published protocol, further details have been included to clarify the
methodology. This includes details on prior distributions and methodology used to quantify heterogeneity and check for inconsistency.
Further, for the main analyses, we plotted the mean residual deviance contributions of each data point under the inconsistency versus
network meta-analysis models. This allows identification of specific data points for which the inconsistency model has improved fit, that
is, data points that are potentially inconsistent with the network (Dias 2018). These changes are based on the protocol template from the
Comparing Multiple Interventions Methods Group, which was not available when we wrote our original protocol.
In 'Sensitivity analyses', we added 'analysis only including studies which administered pleurodesis through a chest tube (any size)', and
slightly amended our criteria for low-risk studies to 'analysis only including studies at a low risk of bias (maximum of one domain assessed
as high risk of bias)' to ensure the sensitivity analysis for studies at low risk of bias included only the most robust data, to give a greater
level of certainty in the estimate of the e)ect.
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We added that 'we performed a post-hoc sensitivity network meta-analysis evaluating only pleurodesis agents delivered via a chest tube (as
opposed to being given at thoracoscopy). We removed the trials evaluating talc poudrage and IPC use from the main network and repeated
the analysis. We performed an additional post-hoc pair-wise meta-analysis comparing ipsilateral repeat invasive pleural intervention rates
(where data were available).'
We performed sensitivity analyses of direct evidence on pleurodesis failure using fixed-e)ect meta-analysis models, since pooled e)ect
estimates from random-e)ects models give relatively more weight to smaller studies, which is oGen considered undesirable.
Within the patient acceptability secondary outcome, we considered that the risk of requiring a repeat invasive pleural procedure for
symptomatic re-accumulation of pleural fluid is an important factor when selecting an initial management strategy for MPE. Therefore,
we performed a post-hoc direct meta-analysis of requirement for a repeat ipsilateral invasive pleural intervention.
We added an assessment of the certainty of the body of evidence and include 'Summary of findings' tables, which present outcomes from
the main network meta-analysis for pleurodesis failure, adverse events (fever and pain) and mortality. Where su)icient data enabled direct
meta-analysis of breathlessness improvement and repeat invasive pleural intervention for the most commonly used interventions, we also
included this information in the summary tables.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Bleomycin  [therapeutic use];  Doxycycline  [therapeutic use];  Fever  [etiology];  Iodine  [therapeutic use];  Pleural E)usion, Malignant
 [etiology]  [*therapy];  Pleurodesis  [*methods];  Quinacrine  [therapeutic use];  Randomized Controlled Trials as Topic;  Talc
 [therapeutic use];  Treatment Failure
MeSH check words
Adult; Humans
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